学术周报 · IF≥10
肿瘤领域文献阅读汇编
2026年第39周 (2026-09-23) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| Blood | 11 | IF 23.9 |
| Cancer letters | 10 | IF 11.8 |
| Advanced healthcare materials | 9 | IF 11.0 |
| Journal for immunotherapy of cancer | 9 | IF 11.7 |
| Pharmacological research | 7 | IF 12.2 |
| Molecular biomedicine | 7 | IF 13.0 |
| Cancer research | 7 | IF 22.6 |
| European heart journal | 7 | IF 45.3 |
| Nature medicine | 6 | IF 52.5 |
| Signal transduction and targeted therapy | 6 | IF 81.2 |
1血液肿瘤 (83篇)
临床研究 (26篇)
Regular physical activity offers numerous benefits to children's health and well-being and is essential for reducing cardiovascular risk in children with cardiovascular disease. Despite increasing evidence supporting its benefits, many young patients remain insufficiently active because of concerns regarding exercise related risks, limited expertise. This clinical consensus statement provides practical guidance for the prescription of exercise and physical activity in children and adolescents aged 6 to 17 years with cardiovascular disease. The document aims to bridge the gap between evidence supporting the benefits of physical activity and its implementation in daily clinical practice, promoting safe participation in sport and exercise across a broad spectrum of cardiovascular conditions. This consensus statement outlines an individualised, patient-centred approach to exercise prescription based on clinical assessment, cardiovascular risk stratification, and the FITT principle: frequency, intensity, time, and type. Specific recommendations are provided for congenital and acquired heart disease, cardiomyopathies, arrhythmias, pulmonary hypertension, cardio-oncology patients, and children with physical disabilities or syndromes. The document emphasises the importance of multidisciplinary care, periodic follow up, exercise testing when indicated, and tailored programs adapted to the child's clinical condition, developmental stage, and personal preferences. The overarching goal is to encourage safe and enjoyable participation in physical activity, improve quality of life and functional capacity, and foster lifelong healthy behaviours in children with cardiovascular disease.
中文摘要:规律的身体活动为儿童的健康与福祉带来诸多益处,并且对于降低患有心血管疾病儿童的心血管风险至关重要。尽管支持其益处的证据不断增加,许多年轻患者仍因对运动相关风险的担忧以及专业知识有限而活动不足。本临床共识声明为6至17岁患有心血管疾病的儿童和青少年提供了运动与身体活动处方的实用指导。本文旨在弥合支持身体活动益处的证据与其在日常临床实践中实施之间的差距,促进在广泛心血管疾病范围内安全参与体育运动和锻炼。本共识声明概述了一种个体化、以患者为中心的运动处方方法,该方法基于临床评估、心血管风险分层以及FITT原则:频率、强度、时间和类型。针对先天性和获得性心脏病、心肌病、心律失常、肺动脉高压、心脏肿瘤学患者以及身体残疾或综合征儿童,提供了具体建议。本文强调多学科照护、定期随访、在适当时进行运动测试,以及根据儿童临床状况、发育阶段和个人偏好量身定制项目的重要性。总体目标是鼓励患有心血管疾病的儿童安全且愉快地参与身体活动,改善生活质量和功能能力,并培养终身健康行为。
Congenital anomalies of the kidney and urinary tract (CAKUT) are a heterogeneous group of structural defects that arise from disordered nephrogenesis. CAKUT accounts for 20%-30% of all prenatal anomalies, with a pooled birth prevalence of 3.83 per 1000. The pathogenesis reflects disrupted ureteric bud-metanephric mesenchyme signalling and early transcriptional programs. Genetic disorders underlie approximately one-fifth of cases, with monogenic causes (notably HNF1β and PAX2) and copy number variants being particularly prevalent in syndromic presentations. The broad phenotypic expression underscores the value of genetic testing in cases of severe or syndromic disease, familial dysplasia, bilateral dysplasia (often cystic), and idiopathic chronic kidney disease/kidney replacement therapy (KRT). We will focus on two defects, being the most common causes of pediatric CKD: kidney dysplasia/hypoplasia and lower urinary tract obstruction. Chronic kidney damage associated with CAKUT progresses slowly, while the peak need for KRT occurs in adolescence, the average commencement is around 31 years of age. These patients carry a heightened risk of cardiovascular and metabolic disease, neurocognitive impairment and a small increased risk of malignancy. A life-course model of care, integrating targeted genetic diagnosis with proactive management of CKD and its extrarenal sequelae, is essential to improve outcomes.
中文摘要:先天性肾脏和尿路畸形(CAKUT)是一组由肾发生紊乱引起的异质性结构缺陷。CAKUT占所有产前畸形的20%-30%,合并出生患病率为每1000例3.83例。其发病机制反映了输尿管芽-后肾间充质信号传导及早期转录程序的中断。遗传性疾病约占病例的五分之一,其中单基因病因(尤其是HNF1β和PAX2)和拷贝数变异在综合征表现中尤为普遍。广泛的表型表达凸显了在严重或综合征性疾病、家族性发育不良、双侧发育不良(常为囊性)以及特发性慢性肾脏病/肾脏替代治疗(KRT)病例中进行遗传检测的价值。我们将聚焦于两种缺陷,它们是儿童慢性肾脏病最常见的原因:肾发育不良/发育不全和下尿路梗阻。与CAKUT相关的慢性肾损伤进展缓慢,而KRT需求高峰出现在青春期,平均开始时间约为31岁。这些患者心血管和代谢疾病、神经认知障碍的风险升高,恶性肿瘤风险略有增加。全生命周期照护模式,将靶向遗传诊断与慢性肾脏病及其肾外后遗症的主动管理相结合,对于改善结局至关重要。
In multiple myeloma (MM), defining tumor burden is difficult because systemic bone marrow disease and focal lesions often show different levels of activity. We analyzed 352 newly diagnosed patients. We used bone marrow plasma cell percentage (BMPC) quantified from whole slide images, MRI-total diffusion volume (TDV), PET-metabolic tumor volume (TMTV), and serum sBCMA levels. In patients with complete datasets, Principal Component Analysis (PCA) and unsupervised clustering were used to classify patients into four phenotypes based on two factors: physical tumor volume (based on BMPC, TDV and TMTV) and sBCMA levels. Among all markers evaluated, sBCMA showed the strongest and most consistent prognostic association, independent of imaging-defined tumor volume. The four phenotypes were: Dual-High (high volume / high sBCMA), Sero-dominant (low volume / high sBCMA), Macro-dominant (high volume / low sBCMA), and Dual-Low (low volume / low sBCMA). Elevated sBCMA, rather than tumor volume, was the primary determinant of early treatment failure; the Sero-dominant and Dual-High groups showed similar 12-month progression-free survival despite markedly different tumor volumes. The Macro-dominant phenotype represented a state of "spatial sequestration," characterized by extensive imaging-defined tumor burden that remained anatomically confined without hematogenous dissemination or extramedullary spread. In this phenotype, the prognostic impact of Gain(1q21) was not significant, whereas it was strongly associated with inferior survival in the Sero-dominant phenotype. MM outcomes are determined by the interaction between physical tumor volume and sBCMA levels. This multimodal classification provides a rational framework for risk stratification.
中文摘要:在多发性骨髓瘤(MM)中,由于全身性骨髓病变和局灶性病变常表现出不同程度的活性,因此界定肿瘤负荷较为困难。我们分析了352例新诊断患者。我们使用了从全切片图像量化的骨髓浆细胞百分比(BMPC)、MRI总扩散体积(TDV)、PET代谢肿瘤体积(TMTV)以及血清sBCMA水平。在具有完整数据集的患者中,采用主成分分析(PCA)和无监督聚类,根据两个因素将患者分为四种表型:物理肿瘤体积(基于BMPC、TDV和TMTV)和sBCMA水平。在所有评估的标志物中,sBCMA显示出最强且最一致的预后相关性,且独立于影像学定义的肿瘤体积。四种表型为:双高型(高体积/高sBCMA)、血清主导型(低体积/高sBCMA)、大体积主导型(高体积/低sBCMA)和双低型(低体积/低sBCMA)。sBCMA升高而非肿瘤体积,是早期治疗失败的主要决定因素;尽管肿瘤体积差异显著,血清主导型和双高型组的12个月无进展生存期相似。大体积主导型表型代表一种「空间隔离」状态,其特征为广泛的影像学定义肿瘤负荷在解剖上保持局限,而无血行播散或髓外扩散。在该表型中,Gain(1q21)的预后影响不显著,而在血清主导型表型中,它与更差的生存期强烈相关。MM的结局由物理肿瘤体积与sBCMA水平之间的相互作用决定。这种多模式分类为风险分层提供了合理的框架。
Allogeneic hematopoietic cell transplantation (allo-HCT) is long established as the only curative option for many patients with acute myeloid leukemia (AML). Recent evidence demonstrates that measurable residual disease (MRD) testing, known to help stratify patients with AML in remission based on their risk for post-HCT relapse and mortality, can provide opportunities for patient-specific allo-HCT personalization. This includes patient selection for transplantation, guiding conditioning regimen intensity, surveillance for early identification of relapse during post-transplant remission, and, in some cases, selecting patients predicted to benefit from post-transplant maintenance or pre-emptive therapy. Just as therapy for AML is not yet perfected, MRD testing for AML currently still has many caveats but is emerging as a useful tool in specific contexts for the clinical management of those undergoing allo-HCT. As with all emerging technologies, physicians continue to face uncertainty regarding how to appropriately interpret or intervene upon such results. As we move forward, it will be important to distinguish promising translational research claims and theoretical aspirations from the practical testing realities in order to provide robust, reproducible, and actionable results to better guide therapeutic decisions. In four representative cases, we describe how we currently use MRD testing for adult patients with AML undergoing allo-HCT.
中文摘要:异基因造血细胞移植(allo-HCT)早已被确立为许多急性髓系白血病(AML)患者唯一的治愈性选择。近期证据表明,可测量残留病(MRD)检测有助于根据移植后复发和死亡风险对处于缓解期的AML患者进行分层,并可为患者个体化的allo-HCT提供机会。这包括选择适合移植的患者、指导预处理方案强度、在移植后缓解期进行监测以早期识别复发,以及在某些情况下筛选预计可从移植后维持治疗或抢先治疗中获益的患者。正如AML治疗尚未臻完善,目前AML的MRD检测仍存在许多注意事项,但正在成为特定情境下管理接受allo-HCT患者的有用工具。与所有新兴技术一样,医生在如何恰当解读此类结果或据此干预方面仍面临不确定性。展望未来,重要的是将有前景的转化研究主张和理论设想与实际检测现实区分开来,以提供稳健、可重复且可操作的结果,更好地指导治疗决策。通过四个代表性病例,我们描述了目前如何将MRD检测用于接受allo-HCT的成人AML患者。
Acute leukemia is a hematologic malignancy that affects people of all ages. Immunotherapies, including T-cell engagers, antibody-drug conjugates, and chimeric antigen receptor T-cell therapies have contributed to a paradigm shift in the treatment of patients with acute leukemia. Combined with advancements in allogeneic hematopoietic stem cell transplant and targeted therapy development, patients with acute leukemia have additional effective treatment options, providing the possibility of long-term remission. However, these advances have resulted in a complex and dynamic treatment landscape for clinicians to navigate. To guide the oncology community and provide a framework for patient care, the Society for Immunotherapy of Cancer convened a panel of experts to develop this clinical practice guideline on immunotherapy for the treatment of acute leukemia. Drawing from published data and clinical experience, the Expert Panel developed evidence-based and consensus-based recommendations relating to diagnostics; immunotherapies for the treatment of acute lymphoblastic leukemia, acute myeloid leukemia, and blastic plasmacytoid dendritic cell neoplasm; toxicity and safety management; treatment sequencing; and patient education and quality of life.
中文摘要:急性白血病是一种影响所有年龄段人群的血液系统恶性肿瘤。免疫疗法,包括T细胞衔接器、抗体药物偶联物和嵌合抗原受体T细胞疗法,已促使急性白血病患者的治疗发生范式转变。结合异基因造血干细胞移植和靶向治疗开发方面的进展,急性白血病患者有了更多有效治疗选择,为长期缓解提供了可能。然而,这些进展也导致临床医生需要应对复杂且不断变化的治疗格局。为了指导肿瘤学界并为患者照护提供框架,癌症免疫治疗学会召集了一个专家小组,制定了这部关于急性白血病免疫治疗临床实践指南。专家小组根据已发表数据和临床经验,制定了基于证据和共识的建议,涉及诊断;急性淋巴细胞白血病、急性髓系白血病和母细胞性浆细胞样树突状细胞肿瘤的免疫治疗;毒性和安全性管理;治疗排序;以及患者教育和生活质量。
Cytopathology is central to cancer screening and diagnosis but remains labor-intensive, motivating the development of scalable computational solutions. Here, we present CROWN (Cytology visual foundation netwoRk Optimized With self-supervised learNing), a universal visual foundation model for computational cytopathology. CROWN was pretrained on more than 10 million cytology image patches using a DINOv2-based self-supervised framework, without requiring manual annotations during pretraining. We evaluated CROWN in 202 task-setting combinations spanning classification, segmentation, detection, retrieval and slide-level prediction across private institutional cohorts and public datasets. CROWN achieved the best overall performance among established pretrained encoders across diverse benchmark settings, with accuracy exceeding 95% in 48 patch-level classification evaluations and 98% in 22 of them. These findings support CROWN as a scalable visual backbone for general-purpose computational cytopathology across heterogeneous datasets and task settings.
中文摘要:细胞病理学在癌症筛查和诊断中处于核心地位,但仍高度依赖人力,这促使人们开发可扩展的计算解决方案。在此,我们提出 CROWN(Cytology visual foundation netwoRk Optimized With self-supervised learNing),一个用于计算细胞病理学的通用视觉基础模型。CROWN 在超过 1000 万个细胞病理学图像块上,使用基于 DINOv2 的自监督框架进行预训练,预训练期间无需人工标注。我们在 202 种任务设置组合中评估了 CROWN,涵盖分类、分割、检测、检索和切片级预测,涉及私人机构队列和公共数据集。在不同基准设置中,CROWN 在已有预训练编码器中取得了最佳总体性能,在 48 项图像块级分类评估中准确率超过 95%,其中 22 项达到 98%以上。这些发现支持 CROWN 作为可扩展的视觉骨干,适用于跨异质数据集和任务设置的通用计算细胞病理学。
Accurate non-invasive tools for bladder cancer detection and preoperative assessment of muscle invasion remain limited. We developed a plasma cell-free DNA (cfDNA) fragmentomics assay to support two clinically related tasks: detection of bladder cancer and preoperative estimation of muscle-invasive risk. Using low-pass whole-genome sequencing, we extracted fragment size coverage, copy-number variation, and nucleosome positioning features. The multicenter cohort included 656 participants and an external extension of 31 cancer cases (total, 687). An integrated classifier was first trained for cancer detection. Subsequently, a separate non-muscle-invasive bladder cancer (NMIBC) versus muscle-invasive bladder cancer (MIBC) classifier was developed using definitively staged cases from the training cohort with internal threshold selection and independent external validation. For cancer detection, the model achieved AUCs of 0.9484 (training), 0.9446 (internal validation), and 0.9390 (external validation). At the locked threshold of 0.592, selected in the internal validation cohort, sensitivities were 81.0%, 80.0%, and 84.3%, with specificities of 95.0%, 94.7%, and 91.8% against healthy controls and 93.3% and 91.1% against benign disease controls in internal and external validation, respectively. For invasion stratification, the NMIBC/MIBC classifier achieved AUCs of 0.9254, 0.9004, and 0.8845 in the training, internal validation, and expanded external validation cohorts, respectively, with 90.3% sensitivity and 77.4% specificity for MIBC detection externally. The assay demonstrated high reproducibility across storage conditions and sequencing batches. This blood-based framework supports multicenter bladder cancer detection and preoperative stratification of muscle invasion as an adjunctive translational approach, while prospective validation in defined clinical use settings remains necessary.
中文摘要:用于膀胱癌检测及术前肌层浸润评估的准确无创工具仍然有限。我们开发了一种血浆游离DNA(cfDNA)片段组学检测方法,以支持两项临床相关任务:膀胱癌检测和术前肌层浸润风险评估。利用低深度全基因组测序,我们提取了片段大小覆盖度、拷贝数变异和核小体定位特征。多中心队列共纳入656名参与者,并额外扩展了31例癌症病例(总计687例)。首先训练了一个整合分类器用于癌症检测。随后,在训练队列中具有明确分期的病例上开发了一个独立的非肌层浸润性膀胱癌(NMIBC)与肌层浸润性膀胱癌(MIBC)分类器,并进行了内部阈值选择和独立外部验证。在癌症检测方面,该模型在训练、内部验证和外部验证中分别达到AUC 0.9484、0.9446和0.9390。在内部验证队列中选择的锁定阈值0.592下,对健康对照的敏感性分别为81.0%、80.0%和84.3%,特异性分别为95.0%、94.7%和91.8%;在内部和外部验证中,对良性疾病对照的特异性分别为93.3%和91.1%。在浸润分层方面,NMIBC/MIBC分类器在训练、内部验证和扩展外部验证队列中分别达到AUC 0.9254、0.9004和0.8845;在外部验证中检测MIBC的敏感性为90.3%,特异性为77.4%。该检测在不同储存条件和测序批次间表现出高重复性。这一基于血液的框架支持多中心膀胱癌检测及术前肌层浸润分层,作为一种辅助性转化方法;但仍需在明确的临床使用场景中进行前瞻性验证。
Retinoblastoma (RB) outcomes in low- and middle-income countries remain inferior to those achieved in high-income countries, largely due to delayed diagnosis, limited access to specialized care, and fragmented treatment systems. The aim of this study is to evaluate the long-term impact of a two-decade strategy based on centralized multidisciplinary care, structured capacity building, and a telemedicine-supported international twinning partnership in reducing disparities in retinoblastoma (RB) outcomes in a resource-limited setting. Retrospective, single-center cohort study. 601 children with RB (1000 affected eyes) treated at King Hussein Cancer Center (KHCC) between March 2003 and December 2025. Demographic characteristics, tumor classification, treatment modalities, globe salvage, metastasis, secondary malignancies, and survival outcomes were reviewed. Overall survival was estimated using the Kaplan-Meier method. Globe salvage rate, rates of metastasis and secondary malignancy, and 5-year overall survival. Of 601 children, 314 (52%) were male, 399 (66%) had bilateral disease, and 346 (58%) were non-Jordanian, referred from 15 countries. Of 1000 affected eyes, 120 (12%) were enucleated before referral; among the remaining eyes, 7 (0.7%) had extraocular disease, and by International Classification, 52 (5.2%) were Group A, 134 (13%) Group B, 204 (20%) Group C, 391 (39%) Group D, and 92 (9.2%) Group E. Of 880 eyes treated at KHCC, primary enucleation was performed in 157 (18%), and conservative eye-salvage therapy was attempted in 723 (82%). Among the 723 eyes that underwent eye-salvaging treatment, systemic chemotherapy was administered in 713 (99%), transpupillary thermo therapy (TTT) in all 723 (100%), cryotherapy in 248 (34%), intra-arterial chemotherapy in 34 (4.7%; 11 primary and 23 secondary), intravitreal chemotherapy in 43 (5.9%), subtenon chemotherapy in 24 (3.3%), and iodine-125 plaque brachytherapy in 23 (3.2%). Ten Group A eyes in 10 patients were treated with TTT and/or cryotherapy alone without systemic chemotherapy. Overall eye salvage rate was 61% (538/880); among conservatively treated eyes, salvage rate was 74.4% (538/723), ranging from 98% (Group A) to 17% (Group E). At median follow-up of 120 months, metastasis occurred in 26 patients (4.3%) and secondary malignancy in 7 (1.2%). Estimated 5-year overall survival was 96% (95% CI, 94%-98%). A centralized multidisciplinary RB program integrating telemedicine, international collaboration, and advanced globe-salvage therapies achieved survival and eye-preservation outcomes comparable to high-income settings despite resource constraints. Over two decades, KHCC evolved into a major regional referral center, offering a scalable model for reducing global disparities in RB care. None.
中文摘要:视网膜母细胞瘤(RB)在低收入和中等收入国家的结局仍低于高收入国家,主要原因是诊断延迟、获得专科医疗的机会有限以及治疗体系碎片化。本研究旨在评估基于集中化多学科照护、结构化能力建设以及远程医疗支持的国际结对合作、为期二十年的策略,在资源有限环境下缩小视网膜母细胞瘤(RB)结局差异方面的长期影响。回顾性单中心队列研究。纳入2003年3月至2025年12月在侯赛因国王癌症中心(KHCC)接受治疗的601例RB患儿(1000只患眼)。回顾人口学特征、肿瘤分类、治疗方式、眼球保留、转移、第二恶性肿瘤和生存结局。总生存采用Kaplan-Meier法估计。主要结局为眼球保留率、转移率和第二恶性肿瘤发生率以及5年总生存率。601例患儿中,314例(52%)为男性,399例(66%)为双侧病变,346例(58%)为非约旦籍,来自15个国家转诊。1000只患眼中,120只(12%)在转诊前已行眼球摘除;在剩余患眼中,7只(0.7%)有眼外疾病,按国际分类,52只(5.2%)为A组,134只(13%)为B组,204只(20%)为C组,391只(39%)为D组,92只(9.2%)为E组。在KHCC接受治疗的880只患眼中,157只(18%)行初次眼球摘除,723只(82%)尝试保守保眼治疗。在723只接受保眼治疗的患眼中,713只(99%)接受全身化疗,723只(100%)接受经瞳孔温热疗法(TTT),248只(34%)接受冷冻治疗,34只(4.7%;其中11只初次、23只再次)接受动脉内化疗,43只(5.9%)接受玻璃体腔化疗,24只(3.3%)接受球筋膜下化疗,23只(3.2%)接受碘-125敷贴器近距离放疗。10例患者的10只A组患眼仅接受TTT和/或冷冻治疗,未接受全身化疗。总体眼球保留率为61%(538/880);在保守治疗患眼中,保留率为74.4%(538/723),范围从A组的98%到E组的17%。中位随访120个月时,26例(4.3%)发生转移,7例(1.2%)发生第二恶性肿瘤。估计5年总生存率为96%(95% CI,94%-98%)。一个整合远程医疗、国际合作和先进保眼治疗的集中化多学科RB项目,尽管资源受限,仍取得了与高收入地区相当的生存和保眼结局。二十年间,KHCC已发展为主要的区域转诊中心,为缩小全球RB照护差异提供了可扩展的模式。无。
Adolescents and young adults (AYAs, aged 15-39 years at cancer diagnosis) are recognized as a distinct patient group with specific clinical and psychosocial needs requiring tailored care. This article presents the Network of Expertise (NoE) on AYAs with cancer developed through the Joint Action on Network of Expertise to strengthen AYA research and care across Europe. The NoE adopts a structured, collaborative approach aligning national and European Union-level goals, creating a platform for professionals, patient groups, and stakeholders to advance AYA cancer care, influence policy, and reduce disparities among member states. It also promotes cooperation between pediatric and adult oncology services to improve care throughout the cancer continuum. The article highlights the main challenges ahead and emphasizes that their successful resolution depends on shared commitment to collaboration-ultimately aiming to enhance outcomes and quality of life for AYAs with cancer.
中文摘要:青少年和年轻成人(AYAs,诊断癌症时年龄为15-39岁)被认为是一个具有特定临床和心理社会需求、需要量身定制照护的独特患者群体。本文介绍了通过「欧洲专家网络联合行动」建立的癌症AYA专家网络(NoE),旨在加强欧洲范围内的AYA研究与照护。该NoE采取结构化协作方式,协调国家与欧盟层面的目标,为专业人员、患者团体和利益相关者创建一个平台,以推进AYA癌症照护、影响政策并减少成员国之间的差异。它还促进儿科与成人肿瘤服务之间的合作,以改善整个癌症连续过程中的照护。本文强调了未来面临的主要挑战,并强调其成功解决取决于对协作的共同承诺,最终目标是改善AYA癌症患者的结局和生活质量。
Imaging is increasingly essential for the diagnosis, prognostication, and management of cancer patients. It is a field in rapid evolution and has the potential to provide noninvasive characterization of malignancy, which remains an important Holy Grail of medicine. Radiomics, which involves the high-throughput assessment of imaging features, aims to transform images into structured phenotypic data. By correlating imaging-derived data with clinical and molecular information, radiomics offers the potential to relate tumor biology to imaging phenotype to improve patient prognostication and management. This review surveys the principles and applications of classical and deep learning-based radiomic approaches in oncology, and it highlights key challenges in robustness and reproducibility that must be addressed to realize the potential of radiomics in clinical practice.
中文摘要:影像学在癌症患者的诊断、预后判断和管理中日益不可或缺。该领域正快速演进,并有望对恶性肿瘤进行无创表征,而这仍是医学领域一项重要的「圣杯」。放射组学涉及对影像特征的高通量评估,旨在将图像转化为结构化的表型数据。通过将影像衍生数据与临床和分子信息相关联,放射组学有望将肿瘤生物学与影像表型联系起来,从而改善患者预后判断和管理。本综述梳理了肿瘤学中经典放射组学方法和基于深度学习的放射组学方法的原理与应用,并强调了在稳健性和可重复性方面必须解决的关键挑战,以实现在临床实践中发挥放射组学的潜力。
To describe the impact of adding a tyrosine kinase inhibitor (TKI) to intensive chemotherapy (IC) on the outcome of de novo BCR::ABL1+ acute myeloid leukemia (AML), we retrospectively analyzed the data of 212 adult AML with ≥20% bone marrow blasts, BCR::ABL1+ or t(9;22)(q34.1;q11.2), no history of previous chronic myeloid leukemia and no prior exposure to BCR-ABL1 TKI. Eighty-nine patients were treated with IC alone and 123 with IC+TKI between 1999 and 2024. Complete remission (CR) or CR with incomplete hematologic recovery (CRi) was achieved in 52/77 patients (68%) with IC and 110/123 patients (89%) with IC+TKI (P<0.0001). With a median follow-up of 66.7 months, the median overall survival (OS) was 20.5 months with IC and not reached with IC+TKI. The 3-year and 5-year OS rates were 42.1% and 38.5% with IC and 70.9% and 62.9% with IC+TKI (P<0.0001) respectively. In multivariate analyses, the addition of TKI to IC was significantly and independently associated with an improved CR/CRi rate (odds ratio: 4.74 [95% confidence interval: 2.17-10.35]; P<0.001) and OS (hazard ratio: 0.40 [0.27-0.62]; P<0.001). Also, adding TKI to IC and alloHSCT in CR1 were independent prognostic factors for relapse-free survival (HR: 0.42; 95% CI: 0.23-0.75; P=0.004 and HR: 0.31; 95% CI: 0.17-0.55; P<0.0001). The outcome of de novo BCR::ABL1+ AML is strongly improved by the addition of a TKI to IC and should become the standard of care. The classification as adverse-risk should be reconsidered in the future ELN classification.
中文摘要:为了描述在强化化疗(IC)基础上加用酪氨酸激酶抑制剂(TKI)对新发BCR::ABL1阳性急性髓系白血病(AML)结局的影响,我们回顾性分析了212例成人AML患者的数据,这些患者骨髓原始细胞≥20%,BCR::ABL1阳性或t(9;22)(q34.1;q11.2),无既往慢性髓性白血病病史,且既往未暴露于BCR-ABL1 TKI。1999年至2024年间,89例单用IC治疗,123例接受IC+TKI治疗。IC组52/77例(68%)达到完全缓解(CR)或伴血液学恢复不全的CR(CRi),IC+TKI组110/123例(89%)达到CR/CRi(P<0.0001)。中位随访66.7个月,IC组中位总生存期(OS)为20.5个月,IC+TKI组未达到。IC组3年和5年OS率分别为42.1%和38.5%,IC+TKI组分别为70.9%和62.9%(P<0.0001)。在多变量分析中,IC基础上加用TKI与CR/CRi率提高(比值比:4.74 [95%置信区间:2.17-10.35];P<0.001)和OS改善(风险比:0.40 [0.27-0.62];P<0.001)显著且独立相关。此外,IC基础上加用TKI和CR1期异基因造血干细胞移植(alloHSCT)是无复发生存的独立预后因素(HR:0.42;95% CI:0.23-0.75;P=0.004和HR:0.31;95% CI:0.17-0.55;P<0.0001)。在IC基础上加用TKI可显著改善新发BCR::ABL1阳性AML的结局,应成为标准治疗。未来ELN分类中应重新考虑将其归为不良风险。
Clustered regularly interspaced short palindromic repeats (CRISPR)/Cas-associated systems have emerged as powerful tools for next-generation molecular diagnostics, particularly for nucleic acid detection. However, ultrasensitive protein detection is equally critical across diverse applications in biology and medicine, especially for diagnosing and prognosing diseases such as cancer, traumatic brain injury (TBI), Alzheimer's disease, and cardiovascular diseases. Despite recent efforts to adapt CRISPR/Cas systems for protein detection, these methods have typically achieved sensitivity in the femtomolar to picomolar range, underscoring the need for enhanced detection capabilities. Here, we developed CRISPR-AMPED, a CRISPR/Cas-based immunoassay enhanced by magnetic proximity extension and detection. This approach combines proximity extension assay (PEA) with magnetic beads to convert protein targets into DNA barcodes while enabling effective washing to reduce background noise. The resulting DNA barcodes are detected through recombinase polymerase amplification (RPA) coupled with CRISPR/Cas12a, eliminating thermocycling and providing simultaneous target and signal amplification. CRISPR-AMPED achieves attomolar-level sensitivity, surpassing ELISA by over three orders of magnitude and outperforming existing immunoassays and CRISPR/Cas-based protein detection systems. As an initial demonstration of clinical utility, we applied CRISPR-AMPED to detect the inflammatory biomarker interleukin-8 (IL-8) in serum samples from patients with TBI and healthy controls. Further integration with a smartphone-based detection device demonstrates its potential for portable testing, while the digital format extends the dynamic range and enhances quantitation precision. Together, these results establish CRISPR-AMPED as a sensitive protein detection approach using IL-8 as an initial model target and provide a framework for future adaptation to additional protein biomarkers.
中文摘要:成簇规律间隔短回文重复序列(CRISPR)/Cas相关系统已成为下一代分子诊断的有力工具,尤其用于核酸检测。然而,在生物学和医学的多种应用中,超灵敏蛋白检测同样至关重要,特别是用于癌症、创伤性脑损伤(TBI)、阿尔茨海默病和心血管疾病等疾病的诊断与预后。尽管近期已有将CRISPR/Cas系统用于蛋白检测的尝试,但这些方法通常仅达到飞摩尔至皮摩尔级灵敏度,凸显出提升检测能力的必要性。在此,我们开发了CRISPR-AMPED,一种基于CRISPR/Cas并借助磁性邻近延伸与检测增强的免疫分析方法。该策略将邻近延伸分析(PEA)与磁珠结合,将蛋白靶标转化为DNA条形码,同时可实现有效洗涤以降低背景噪声。所得DNA条形码通过重组酶聚合酶扩增(RPA)结合CRISPR/Cas12a进行检测,无需热循环,并可同时实现靶标扩增与信号放大。CRISPR-AMPED达到阿托摩尔级灵敏度,超过ELISA三个数量级以上,并优于现有免疫分析和基于CRISPR/Cas的蛋白检测系统。作为临床应用的初步展示,我们将CRISPR-AMPED用于检测TBI患者和健康对照血清样本中的炎症生物标志物白细胞介素-8(IL-8)。进一步与基于智能手机的检测设备整合,展示了其便携式检测潜力,而数字化模式则扩展了动态范围并提高了定量精度。总之,这些结果确立了CRISPR-AMPED作为一种灵敏蛋白检测方法,并以IL-8作为初始模型靶标,为未来适配其他蛋白生物标志物提供了框架。
Targeted therapies have improved outcomes for patients with chronic lymphocytic leukemia (CLL); yet, not all achieve durable responses. Existing prognostic models, developed for chemoimmunotherapy, have limited predictive value for newer targeted combinations. Here, we used data from a randomized phase II clinical trial to identify predictors of progression-free survival (PFS) in response to Bruton tyrosine kinase (BTK) + B-cell lymphoma 2 (Bcl-2) inhibitor combination therapy. We studied the functional, genetic, and clinical characteristics of patients with relapsed/refractory (R/R) CLL treated with ibrutinib + venetoclax in the VISION/HO141 clinical trial (NCT03226301). Ex vivo drug sensitivity testing, (phospho)protein profiling, and immunophenotyping were performed on baseline peripheral blood mononuclear cells from 177 patients. Ex vivo drug sensitivity correlated with clinical responses to single-agent therapies. (Phospho)protein patterns reflected intracellular pathway activity and predicted ex vivo drug sensitivity. Using stringent feature selection and regularized ridge regression to prevent overfitting, we integrated functional, genetic, and clinical data sets and identified six features-sensitivity to VEGFR-2-, JAK1/2 + Bcl-2-, and BTK + PI3K-inhibitors; phosphorylation ratios of Bcl-2:BTK and p90RSK:PLCγ2; and frequency of CD8+ T cells-that together outperformed the International Prognostic Index for CLL (CLL-IPI) and other clinical scores in predicting PFS. These findings demonstrate that a prognostic model based on the functional features of CLL cell signaling and interaction with the microenvironment has the potential to improve upon conventional prognostic scores, warranting further clinical validation also in the frontline setting.
中文摘要:靶向治疗改善了慢性淋巴细胞白血病(CLL)患者的结局;然而,并非所有患者都能获得持久缓解。为化学免疫治疗开发的现有预后模型对较新的靶向联合方案的预测价值有限。在此,我们利用一项随机II期临床试验的数据,识别对布鲁顿酪氨酸激酶(BTK)+ B细胞淋巴瘤2(Bcl-2)抑制剂联合治疗应答中无进展生存期(PFS)的预测因素。我们研究了在VISION/HO141临床试验(NCT03226301)中接受伊布替尼+维奈克拉治疗的复发/难治性(R/R)CLL患者的功能、遗传和临床特征。对177例患者的基线外周血单个核细胞进行了离体药物敏感性检测、(磷酸化)蛋白谱分析和免疫表型分析。离体药物敏感性与单药治疗的临床应答相关。(磷酸化)蛋白模式反映了细胞内通路活性,并预测离体药物敏感性。采用严格的特征选择和正则化岭回归以防止过拟合,我们整合了功能、遗传和临床数据集,并识别出六个特征——对VEGFR-2、JAK1/2 + Bcl-2和BTK + PI3K抑制剂的敏感性;Bcl-2:BTK和p90RSK:PLCγ2的磷酸化比值;以及CD8+ T细胞频率——这些特征共同在预测PFS方面优于CLL国际预后指数(CLL-IPI)和其他临床评分。这些发现表明,基于CLL细胞信号传导功能特征及其与微环境相互作用的预后模型,有潜力改进传统预后评分,值得在前线治疗场景中进一步进行临床验证。
Metabolic risk in type 2 diabetes is not fully captured by standard clinical measures. Use of NMR-based metabolomic indices may enhance risk prediction, but their role in individuals with type 2 diabetes is unresolved. We analysed data from 9550 adults with type 2 diabetes who were followed for 5 years in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. The composite index MVX (metabolic vulnerability), and its components IVX (inflammation vulnerability index) and MMX (metabolic malnutrition index), were derived from baseline plasma NMR. Associations with mortality and non-fatal events were assessed using Cox models adjusted for clinical variables and treatment allocation. Predictive performance was assessed using C statistics and variable contribution analysis. All three indices were associated with total mortality. Participants in the highest MVX quintile (Q5) had an over fourfold greater unadjusted mortality risk, and more than double the risk after adjustment (HR 2.31; 95% CI 1.71, 3.12). Each standard deviation increase in MVX showed a 75% higher mortality risk (95% CI 62, 89; p<0.001). MVX was associated with cardiovascular and cancer mortality separately, and independently predicted non-fatal cardiovascular events and new incident cancer. MMX and IVX showed weaker and less consistent associations. MVX improved risk model discrimination (C statistic 0.725 to 0.737; p=0.0003) and outperformed prior CVD history as a predictor. MVX independently predicts total and cardiovascular mortality in type 2 diabetes, offering prognostic value beyond traditional risk factors. The absolute event rates reflect the treatment standards of the FIELD recruitment period (1997-2000), prior to widespread use of several contemporary cardioprotective therapies. The results support further investigation of the clinical utility of MVX for determination of personalised risk.
中文摘要:2型糖尿病的代谢风险并未被标准临床指标完全反映。基于核磁共振的代谢组学指数可能增强风险预测,但其在2型糖尿病患者中的作用尚未明确。我们分析了Fenofibrate Intervention and Event Lowering in Diabetes(FIELD)研究中9550例2型糖尿病成人患者的数据,随访5年。综合指数MVX(代谢脆弱性)及其组成部分IVX(炎症脆弱指数)和MMX(代谢营养不良指数)由基线血浆核磁共振推导得出。采用Cox模型评估其与死亡和非致死性事件的关联,并校正临床变量和治疗分配。采用C统计量和变量贡献分析评估预测性能。三个指数均与全因死亡相关。MVX最高五分位(Q5)参与者的未校正死亡风险增加超过四倍,校正后风险增加超过一倍(HR 2.31;95% CI 1.71, 3.12)。MVX每增加一个标准差,死亡风险增加75%(95% CI 62, 89;p<0.001)。MVX分别与心血管死亡和癌症死亡相关,并可独立预测非致死性心血管事件和新发癌症。MMX和IVX的关联较弱且较不一致。MVX改善了风险模型的区分度(C统计量从0.725提高至0.737;p=0.0003),并且优于既往心血管疾病史作为预测因素。MVX可独立预测2型糖尿病患者的全因死亡和心血管死亡,提供超越传统风险因素的预后价值。绝对事件发生率反映了FIELD招募时期(1997-2000年)的治疗标准,当时若干当代心脏保护疗法尚未广泛使用。结果支持进一步研究MVX用于确定个体化风险的临床效用。
Large B cell lymphomas (LBCLs) exhibit significant heterogeneity which leads to disparate treatment response, with up to 40% of patients developing refractory disease or relapsing within the first two years. To understand the cellular and molecular basis of this heterogeneity, we performed single-cell RNA-seq, BCR-seq, and TCR-seq on LBCL tumor biopsies, generating an atlas of 63 LBCL cases, mostly classified as diffuse LBCL, not otherwise specified (DLBCL NOS). We identified five conserved transcriptional archetypes of malignant B cells that co-occur within individual tumors, with varying proportions across patients. Notably, high abundance of Archetype 4, characterized by memory B cell features and quiescence markers, correlated with poor event-free survival following standard immunochemotherapy, a finding which was validated in independent cohorts through deconvolution of bulk RNA-seq data. Our study provides a novel framework for patient stratification based on the quantification of malignant cellular states, with implications for precision therapy of LBCLs.
中文摘要:大B细胞淋巴瘤(LBCL)具有显著异质性,导致治疗反应差异很大,高达40%的患者在最初两年内出现难治性疾病或复发。为理解这种异质性的细胞和分子基础,我们对LBCL肿瘤活检样本进行了单细胞RNA测序、BCR测序和TCR测序,构建了包含63例LBCL病例的图谱,其中大多数被分类为弥漫性大B细胞淋巴瘤,非特指型(DLBCL NOS)。我们鉴定出恶性B细胞的五种保守转录原型,它们在同一肿瘤内共存,且在不同患者中比例各异。值得注意的是,以记忆B细胞特征和静息标志物为特征的原型4丰度高,与标准免疫化疗后较差的无事件生存期相关,这一发现通过bulk RNA-seq数据的解卷积在独立队列中得到验证。我们的研究提供了一种基于恶性细胞状态定量的患者分层新框架,对LBCL的精准治疗具有重要意义。
Cancer management remains fragmented across its continuum, from late-stage diagnosis and salvage therapies to non-personalized surveillance. Here, we present Oncoformer, a unified multimodal transformer model trained on the China Oncology Multimodal Prediction and Surveillance Study (COMPASS) cohort (3.67 million individuals, 17.7 million clinical visits) and validated on independent external cohorts, including the UK Biobank. Oncoformer integrates longitudinal electronic health records with chest X-ray imaging to address multiple clinical tasks: pan-cancer diagnosis (area under the receiver operating characteristic curve [AUROC] = 0.956), future cancer prediction up to 1 year before diagnosis (AUROC = 0.869), tumor stage inference (mean AUROC > 0.90), patient-specific treatment-response forecasting, and recurrence-free survival stratification across ten cancer types (all p < 0.01). Staging predictions were independently validated against postoperative pathological endpoints and shown to converge on core cancer genomic pathways. By translating routine clinical data into a dynamic view of cancer evolution, Oncoformer provides a framework for risk-informed cancer prediction and treatment stratification using routine clinical data.
中文摘要:癌症管理在其连续过程中仍然呈碎片化,从晚期诊断和挽救性治疗到非个体化监测均如此。在此,我们提出Oncoformer,一个统一的多模态Transformer模型,基于中国肿瘤多模态预测与监测研究(COMPASS)队列(367万人、1770万次临床就诊)训练,并在独立外部队列(包括英国生物银行)中验证。Oncoformer整合纵向电子健康记录与胸部X线影像,以处理多项临床任务:泛癌诊断(受试者工作特征曲线下面积[AUROC]=0.956)、诊断前最长1年的未来癌症预测(AUROC=0.869)、肿瘤分期推断(平均AUROC>0.90)、患者特异性治疗反应预测,以及跨十种癌症类型的无复发生存分层(所有p<0.01)。分期预测经术后病理终点独立验证,并显示其收敛于核心癌症基因组通路。通过将常规临床数据转化为癌症演变的动态视图,Oncoformer为利用常规临床数据开展风险信息驱动的癌症预测和治疗分层提供了框架。
The phase 3 SYMPATICO study included an open-label cohort to evaluate first-line ibrutinib plus venetoclax in patients with nonblastoid mantle cell lymphoma (MCL) aged ≥65 years (n = 65) or ≥18 years with a TP53 mutation (TP53m; n = 11). Eligible patients received oral ibrutinib 560 mg once daily and venetoclax (5-week ramp-up to 400 mg once daily) for 2 years, then single-agent ibrutinib 560 mg until disease progression or unacceptable toxicity. In total, 78 patients were enrolled. With a median time on study of 40.5 months, the complete response (CR) rate was 69% (95% confidence interval [CI], 58-79), and the overall response rate was 95% (95% CI, 87-99). The median duration of response was 37.1 months (95% CI, 30.3 to not estimable [NE]). The median progression-free survival (mPFS) was 40.2 months (95% CI, 29.4 to NE); median overall survival (OS) was not reached (3-year OS rate, 79% [95% CI, 68-86]). In patients aged ≥65 years, CR rates were 76% (no TP53m) and 44% (with TP53m), mPFS was 40.2 and 22.0 months, and 3-year OS was 85% and 66%, respectively. In adult patients aged <65 years (with TP53m), the CR rate was 73%, mPFS was 15.4 months, and 3-year OS was 73%. The most common treatment-emergent adverse events were diarrhea (49%), fatigue (37%), neutropenia (35%), and COVID-19 (32%). First-line ibrutinib plus venetoclax showed promising efficacy, with high CR rates and durable remissions, in patients with previously untreated nonblastoid MCL and may be an option for patients aged ≥65 years or patients of any age with TP53m. The trial was registered at www.clinicaltrials.gov as NCT03112174.
中文摘要:3期SYMPATICO研究纳入一个开放标签队列,评估一线伊布替尼联合维奈克拉治疗非母细胞样套细胞淋巴瘤(MCL)患者,这些患者年龄≥65岁(n=65)或年龄≥18岁且伴TP53突变(TP53m;n=11)。合格患者接受口服伊布替尼560 mg每日一次和维奈克拉(5周递增至400 mg每日一次)治疗2年,随后单药伊布替尼560 mg直至疾病进展或不可接受毒性。共入组78例患者。中位研究时间40.5个月,完全缓解(CR)率为69%(95%置信区间[CI],58-79),总缓解率为95%(95% CI,87-99)。中位缓解持续时间为37.1个月(95% CI,30.3至不可估计[NE])。中位无进展生存期(mPFS)为40.2个月(95% CI,29.4至NE);中位总生存期(OS)未达到(3年OS率,79%[95% CI,68-86])。在年龄≥65岁患者中,CR率分别为76%(无TP53m)和44%(伴TP53m),mPFS分别为40.2和22.0个月,3年OS分别为85%和66%。在年龄<65岁的成人患者(伴TP53m)中,CR率为73%,mPFS为15.4个月,3年OS为73%。最常见的治疗中出现的不良事件为腹泻(49%)、疲乏(37%)、中性粒细胞减少(35%)和COVID-19(32%)。一线伊布替尼联合维奈克拉在既往未经治疗的非母细胞样MCL患者中显示出有前景的疗效,具有高CR率和持久缓解,可能成为年龄≥65岁或任何年龄伴TP53m患者的一种选择。该试验注册于www.clinicaltrials.gov,编号NCT03112174。
Chemotherapy-induced thrombocytopenia (CIT) is a common complication of cancer therapy that may result in major bleeding events and reduction of chemotherapy relative dose intensity. Although there remain no widely available licensed therapies to manage CIT, major studies, including global pivotal phase 3 clinical trials of the thrombopoietin receptor agonists (TPO-RAs) romiplostim and avatrombopag in CIT, have been completed, along with additional supporting evidence from other clinical trials and observational studies. As with patients with chemotherapy-induced neutropenia, not all patients with CIT require treatment, but for those who do, it can have a major impact on a patient's oncologic care and outcomes. Proper management of CIT requires an understanding of the 2 clinical subtypes of CIT (persistent and nadir), the limited role of platelet transfusions and antifibrinolytics, and when and how to appropriately use TPO-RA support. In this article, 4 patient cases of CIT are used to illustrate common and challenging scenarios occurring in clinical practice. Built on a framework of published studies and supported by extensive clinical experience, appropriate treatment strategies for CIT are described in detail, with emphasis on proper selection of patient, dosing, titration, and monitoring for the use of TPO-RAs in CIT.
中文摘要:化疗所致血小板减少症(CIT)是癌症治疗中常见的并发症,可能导致严重出血事件并降低化疗相对剂量强度。尽管目前尚无广泛可及且获批用于管理CIT的疗法,但包括促血小板生成素受体激动剂(TPO-RAs)罗米司亭和阿伐曲泊帕在CIT中的全球关键性3期临床试验在内的主要研究已经完成,并得到其他临床试验和观察性研究的额外支持证据。与化疗所致中性粒细胞减少症患者一样,并非所有CIT患者都需要治疗,但对于需要治疗的患者,治疗可能对患者的肿瘤治疗及结局产生重大影响。CIT的规范管理需要理解CIT的2种临床亚型(持续性和最低点性)、血小板输注和抗纤溶药物的有限作用,以及何时及如何恰当地使用TPO-RA支持。本文通过4例CIT患者病例来说明临床实践中常见且具有挑战性的情景。基于已发表研究的框架,并得到广泛临床经验的支持,本文详细描述了CIT的适当治疗策略,重点强调在CIT中使用TPO-RAs时对患者的正确选择、给药、剂量调整和监测。
Bulk sequencing of relapsed tumors reveals mutations associated with resistance to cancer therapy but is insufficient to fully assess all causes of relapse. Because of inherent tumor heterogeneity, on-treatment tumor evolution may select genetically distinct clones or shifts in malignant transcriptional states not resolvable by bulk sequencing. We performed multiomic single-cell DNA/protein and RNA/protein profiling of a clinical trial cohort of patients with acute myeloid leukemia (AML) treated on the phase 1b clinical trial of the BCL2 inhibitor venetoclax and the FLT3 inhibitor gilteritinib (Ven/Gilt) to characterize immunophenotypic, transcriptional, and genetic clonal evolution driving resistance. We found that although Ven/Gilt effectively eliminated FLT3-mutant clones, resistance was associated with RAS activation through multiple mechanisms, including selection for RAS-mutant clones, nonmutational upregulation of RAS transcriptional programs, and a shift to RAS-associated monocytic AML differentiation. Using an in vitro model of monocytic differentiation associated with nonmutational RAS transcriptional activation, we demonstrated that RAS-pathway inhibition resensitized to Ven/Gilt. These data illustrate that convergent resistance pathways in patients can be activated via diverse genetic and nongenetic mechanisms. These results underscore that RAS signaling is central to FLT3 and BCL2 inhibitor resistance, is tightly coupled with AML monocytic differentiation, and highlights the potential of RAS-pathway inhibition as a viable clinical strategy to combat resistance. This trial was registered at www.ClinicalTrials.gov as NCT03625505.
中文摘要:对复发肿瘤进行bulk测序可揭示与癌症治疗耐药相关的突变,但不足以全面评估所有复发原因。由于肿瘤固有的异质性,治疗过程中的肿瘤演化可能选择遗传学上不同的克隆,或导致恶性转录状态的转变,而这些无法通过bulk测序解析。我们对一项临床试验队列中的急性髓系白血病(AML)患者进行了多组学单细胞DNA/蛋白质和RNA/蛋白质分析,这些患者接受了BCL2抑制剂维奈克拉(venetoclax)和FLT3抑制剂吉瑞替尼(gilteritinib)(Ven/Gilt)的1b期临床试验治疗,以刻画驱动耐药的免疫表型、转录和遗传克隆演化。我们发现,尽管Ven/Gilt有效清除了FLT3突变克隆,耐药仍与通过多种机制发生的RAS激活相关,包括选择RAS突变克隆、非突变性的RAS转录程序上调,以及向与RAS相关的单核细胞型AML分化的转变。利用与未突变RAS转录激活相关的单核细胞分化体外模型,我们证明抑制RAS通路可恢复对Ven/Gilt的敏感性。这些数据表明,患者体内汇聚的耐药通路可通过多种遗传和非遗传机制被激活。这些结果强调,RAS信号是FLT3和BCL2抑制剂耐药的核心,与AML单核细胞分化紧密耦合,并凸显了将RAS通路抑制作为对抗耐药的可行临床策略的潜力。该试验注册于www.ClinicalTrials.gov,编号NCT03625505。
The prognostic heterogeneity of early-stage natural killer/T-cell lymphoma (NKTCL) remains inadequately defined. This study aimed to investigate the prognostic value and potential biological relevance of the metabolic-inflammatory biomarkers in early-stage NKTCL. We conducted a secondary analysis on 166 patients with early-stage NKTCL from a multicenter clinical trial (NCT02631239). C-reactive protein-triglyceride-glucose Index (CTI) was calculated as: 0.412* Ln (CRP [mg/L]) + Ln (TG [mg/dL] × FPG [mg/dL])/2. Cox proportional hazards models and restricted cubic spline analyses were applied to assess the association and dose-response relationship between CTI and overall survival (OS). Mechanistic insights were explored through animal experiments and clinical lymphocyte-subset analyses. Independent prognostic factors were identified using multivariable Cox regression, and a composite prognostic model incorporating CTI, body mass index (BMI), and albumin (ALB) was subsequently developed and internally evaluated. High CTI was independently associated with inferior OS in patients with early-stage NKTCL, with a significant linear dose-response relationship. Patients with high CTI had a higher incidence of B symptoms and elevated lactate dehydrogenase and β2-microglobulin levels. A simplified CTI-BMI-ALB prognostic model demonstrated moderate predictive performance for 1-, 3-, and 5-year OS, with AUCs of 0.71, 0.71, and 0.69, respectively, and an overall C-index of 0.69 (95% CI: 0.59-0.79). In the present cohort, the CTI-BMI-ALB model showed improved discriminative performance compared with conventional prognostic indices and provided additional survival stratification among patients classified as low-risk or favorable-risk by these indices within this cohort. In vivo experiments showed that the Gubra-Amylin NASH diet-induced metabolic-inflammatory state with elevated CTI levels was associated with accelerated lymphoma progression, reduced intratumoral CD8+ T-cell infiltration, and increased proportions of Tregs and M2 macrophages. Consistently, clinical lymphocyte-subset analysis confirmed Treg enrichment in patients with high CTI and a positive association between CTI and the proportion of Tregs. CTI is an independent prognostic biomarker in early-stage NKTCL, reflecting systemic metabolic-inflammatory and immune dysregulation. The CTI-BMI-ALB model, which integrates inflammatory, nutritional, and metabolic dimensions, showed potential for complementary risk stratification beyond conventional prognostic indices and warrants further validation before broader clinical application.
中文摘要:早期自然杀伤/T细胞淋巴瘤(NKTCL)的预后异质性仍未得到充分界定。本研究旨在探讨代谢炎症生物标志物在早期NKTCL中的预后价值及潜在生物学相关性。我们对一项多中心临床试验(NCT02631239)中的166例早期NKTCL患者进行了二次分析。C反应蛋白-甘油三酯-葡萄糖指数(CTI)的计算公式为:0.412×Ln(CRP [mg/L])+Ln(TG [mg/dL]×FPG [mg/dL])/2。采用Cox比例风险模型和限制性立方样条分析评估CTI与总生存期(OS)之间的关联及剂量-反应关系。通过动物实验和临床淋巴细胞亚群分析探索机制。使用多变量Cox回归识别独立预后因素,随后构建包含CTI、体重指数(BMI)和白蛋白(ALB)的复合预后模型并进行内部评价。高CTI与早期NKTCL患者较差的OS独立相关,且呈显著线性剂量-反应关系。高CTI患者B症状发生率更高,乳酸脱氢酶和β2-微球蛋白水平升高。简化的CTI-BMI-ALB预后模型对1年、3年和5年OS显示出中等预测效能,AUC分别为0.71、0.71和0.69,总体C指数为0.69(95% CI:0.59-0.79)。在本队列中,CTI-BMI-ALB模型较传统预后指数表现出更好的区分能力,并在本队列内对这些指数判定为低危或有利危的患者提供了额外的生存分层。体内实验显示,Gubra-Amylin NASH饮食诱导的代谢炎症状态伴CTI水平升高与淋巴瘤进展加速、瘤内CD8+ T细胞浸润减少以及Treg和M2巨噬细胞比例增加相关。一致地,临床淋巴细胞亚群分析证实高CTI患者存在Treg富集,且CTI与Treg比例呈正相关。CTI是早期NKTCL的独立预后生物标志物,反映全身代谢炎症和免疫失调。整合炎症、营养和代谢维度的CTI-BMI-ALB模型显示出超越传统预后指数的补充风险分层潜力,在广泛临床应用前需要进一步验证。
The cardiotoxic effects of cancer therapies are well established, and the most clinically relevant consequences include heart failure and cardiomyopathy. As such, efforts have been focused on developing strategies to attenuate the risk of cardiovascular dysfunction in patients receiving potentially cardiotoxic therapies. Randomized trials to identify cardioprotective approaches have largely selected patients on the basis of cancer type and treatment regimen, regardless of baseline or dynamic changes in cardiovascular risk. However, contemporary evidence suggests that this approach results in modest to no significant benefit on subclinical or clinical measures of cardiotoxicity. We hypothesize that a risk-guided cardioprotection approach can enable the delivery of targeted therapy to those who may derive the greatest cardiovascular benefit, avoiding unnecessary treatment of lower-risk populations. Here, we review the contemporary literature on primary cardioprotection and present recent studies in cardio-oncology focused on risk-guided cardioprotection to support the implementation of more tailored strategies.
中文摘要:癌症治疗的心脏毒性效应已得到充分证实,最具临床相关性的后果包括心力衰竭和心肌病。因此,相关努力集中于制定策略,以降低接受潜在心脏毒性治疗患者发生心血管功能障碍的风险。旨在识别心脏保护方法的随机试验大多根据癌症类型和治疗方案选择患者,而未考虑心血管风险的基线水平或动态变化。然而,当代证据提示,这种方法对亚临床或临床心脏毒性指标的获益有限甚至无显著获益。我们假设,风险指导的心脏保护方法能够将靶向治疗提供给可能获得最大心血管获益的人群,同时避免对较低风险人群进行不必要的治疗。在此,我们回顾关于一级心脏保护的当代文献,并介绍肿瘤心脏病学中聚焦于风险指导的心脏保护的最新研究,以支持实施更具个体化的策略。
γδ T cells are becoming increasingly appreciated for their antitumour capacity and role in mediating responses to immune checkpoint blockade1-3. Unlike classical αβ T cells, the degree to which γδ T cells rely on their T cell receptors (TCRs) to induce antitumour responses remains unclear. The challenge of distinguishing γδ T cells with tumour-reactive TCRs from bystander γδ T cells limits our understanding of tumour-reactive γδ T cell biology and the translation of their TCRs into immunotherapeutics. Here we present PreGame, a machine-learning algorithm capable of identifying tumour-reactive γδ T cells from single-cell CITE sequencing data. We use PreGame to identify tumour-reactive γδ T cells from patients with multiple myeloma or other solid cancers, and confirm the specificity of their TCRs to tumour cells. Clinically, we demonstrate that expansion of tumour-reactive γδ T cells is an early biomarker of response in patients with multiple myeloma receiving combination therapy with belantamab mafodotin. We also identify a γδ TCR epitope in the ubiquitously expressed HLA-C protein and a logic gate that enables tumour immunosurveillance. Thus, PreGame is a versatile tool that can accelerate our understanding of γδ T cell biology and facilitate the translation of γδ TCRs into universal therapeutics.
中文摘要:γδ T细胞因其抗肿瘤能力以及在介导免疫检查点阻断应答中的作用而日益受到重视1-3。与经典αβ T细胞不同,γδ T细胞在诱导抗肿瘤应答时依赖其T细胞受体(TCR)的程度仍不清楚。将有肿瘤反应性TCR的γδ T细胞与旁观者γδ T细胞区分开来这一挑战,限制了我们对肿瘤反应性γδ T细胞生物学的理解,以及将其TCR转化为免疫治疗药物的进程。在此,我们提出PreGame,一种能够从单细胞CITE测序数据中识别肿瘤反应性γδ T细胞的机器学习算法。我们使用PreGame从多发性骨髓瘤或其他实体癌患者中识别肿瘤反应性γδ T细胞,并确认其TCR对肿瘤细胞的特异性。在临床上,我们证明肿瘤反应性γδ T细胞的扩增是多发性骨髓瘤患者接受belantamab mafodotin联合治疗时应答的早期生物标志物。我们还鉴定出普遍表达的HLA-C蛋白中的一个γδ TCR表位,以及一个能够实现肿瘤免疫监视的逻辑门。因此,PreGame是一种多功能工具,可加速我们对γδ T细胞生物学的理解,并促进将γδ TCR转化为通用治疗药物。
Children on post-filter hemodiafiltration (post-HDF) have reduced cardiovascular damage and improved growth compared to conventional hemodialysis. High convection volumes in post-HDF are associated with improved outcomes. Even higher convection volumes can be reached with pre-filter HDF (pre-HDF). However, data is limited. Here, we compare the effect of pre- vs post-HDF on solute removal, inflammation, nutrition markers and blood pressure in a randomized, multicenter cross-over trial. After a four-week wash-out period in post-HDF, 24 children on maintenance dialysis were randomized either to four-weeks pre- then four-weeks post-HDF, or vice-versa, keeping all other dialysis related parameters constant. The primary outcome measure was reduction in α1-microglobulin, a large-middle molecular weight (MW) uremic retention solute. Twenty-one patients completed the study. The median age was 15.1 years, with 15(71%) girls. Median convection volumes were 36.2 (inter quartile range 32;40) vs 14.3 (12.9;15.8) l/m2 body surface area per session in pre-HDF and post-HDF respectively. Pre-dialysis α1- microglobulin [median difference -17.0 ng/ml (95% confidence interval (CI) -27.0;-3.5)], ß2-microglobulin [-5.19 mg/l (95%CI -9.34;-1.76)] and myoglobin [-76.0 ng/ml (95%CI-100;-44.5)] concentrations were significantly lower, and reduction ratios (RR) were significantly higher in pre-HDF compared with post-HDF. Interleukin-10, tumor necrosis factor-α and high sensitivity C-reactive protein were significantly lower in pre-HDF. Pre-HDF achieved significantly higher RRs of total indoxyl sulfate and p-cresyl sulfate. The RR for small MW solutes, Kt/V and serum albumin did not differ meaningfully between modalities. Diastolic blood pressure was significantly higher in pre-HDF, correlating with higher replacement volume and higher post-dialysis serum sodium concentration. Pre-HDF achieves superior removal of middle and larger-middle MW uraemic retention solutes and was associated with a more favorable inflammatory profile, without compromising small MW retention solute removal or albumin levels, compared to post-HDF. Pre-HDF may be associated with higher blood pressure in a sub-set of patients, potentially due to greater sodium load from higher replacement volumes.
中文摘要:与常规血液透析相比,接受后稀释血液透析滤过(post-HDF)的儿童心血管损伤减轻且生长改善。post-HDF中的高对流容量与预后改善相关。前稀释HDF(pre-HDF)可达到更高的对流容量。然而,相关数据有限。在此,我们在一项随机、多中心交叉试验中比较pre-HDF与post-HDF对溶质清除、炎症、营养标志物和血压的影响。在post-HDF下经过四周洗脱期后,24名维持性透析儿童被随机分配至先接受四周pre-HDF再接受四周post-HDF,或相反顺序,同时保持所有其他透析相关参数不变。主要结局指标是α1-微球蛋白的下降,其是一种大中分子量尿毒症潴留溶质。21名患者完成了研究。中位年龄为15.1岁,其中15名(71%)为女孩。pre-HDF和post-HDF每次治疗的中位对流容量分别为36.2(四分位距32;40)和14.3(12.9;15.8)l/m2体表面积。与post-HDF相比,pre-HDF透析前α1-微球蛋白[中位差-17.0 ng/ml(95%置信区间(CI)-27.0;-3.5)]、β2-微球蛋白[-5.19 mg/l(95%CI -9.34;-1.76)]和肌红蛋白[-76.0 ng/ml(95%CI -100;-44.5)]浓度显著更低,下降率(RR)显著更高。pre-HDF中白细胞介素-10、肿瘤坏死因子-α和高敏C反应蛋白显著更低。pre-HDF对总硫酸吲哚酚和对甲酚硫酸盐的RR显著更高。小分子量溶质的RR、Kt/V和血清白蛋白在两种模式之间无有意义的差异。pre-HDF中舒张压显著更高,与更高的置换液量和更高的透析后血清钠浓度相关。与post-HDF相比,pre-HDF对中分子及较大中分子量尿毒症潴留溶质的清除更优,并与更有利的炎症谱相关,且不损害小分子量潴留溶质清除或白蛋白水平。pre-HDF可能与部分患者血压升高相关,可能归因于更高置换液量带来的更大钠负荷。
Integrating multiple bioanalytical functions onto a single chip for point-of-care protein detection remains challenging. Here, we introduce a biological detection system-on-chip (BDSoC) that merges the purification capabilities of microfluidic chips with the detection sensitivity of carbon nanotube (CNT) field-effect transistor (FET) biosensors, achieving ultrasensitive analysis of trace protein biomarkers in complex samples. The BDSoC device allows direct and precise detection of tumor biomarkers in undiluted serum across an exceptionally low concentration range from 2 fg/mL to 1 pg/mL and correctly classified all 24 clinical serum samples tested in this study, corresponding to an observed diagnostic accuracy of 100% in this preliminary cohort. The platform is highly scalable, allowing for the future integration of biosensor arrays for multiplexing, advanced fluidic control, and versatile sample processing modules. This work marks a significant advance toward the ultimate vision of the "single-drop blood test" SoC, accelerating the practical deployment of FET biosensors and their evolution in point-of-care diagnostic technologies.
中文摘要:将多种生物分析功能集成到单个芯片上以实现即时蛋白质检测仍然具有挑战性。在此,我们介绍一种生物检测系统级芯片(BDSoC),它将微流控芯片的纯化能力与碳纳米管(CNT)场效应晶体管(FET)生物传感器的检测灵敏度相结合,实现了对复杂样本中痕量蛋白质生物标志物的超灵敏分析。BDSoC器件能够直接、精确地检测未稀释血清中的肿瘤生物标志物,浓度范围极低,从2 fg/mL至1 pg/mL,并正确分类了本研究中测试的全部24份临床血清样本,在本初步队列中对应的观察诊断准确率为100%。该平台高度可扩展,未来可集成用于多重检测的生物传感器阵列、先进的流体控制和多功能样本处理模块。这项工作朝着「单滴血检测」SoC的最终愿景迈出了重要一步,加速了FET生物传感器的实际部署及其在即时诊断技术中的发展。
Antiresorptive therapy represents a cornerstone in the management of osteoporosis and cancer-related bone disease through suppression of osteoclast-mediated bone resorption. As implant therapy becomes more common in aging populations, clinicians increasingly encounter patients receiving these medications, thus making their impact on peri-implant tissues clinically relevant. This narrative review critically examines clinical evidence on implant survival, peri-implant bone stability, peri-implantitis progression, and treatment considerations in patients receiving antiresorptive therapy, while integrating mechanistic insights. Evidence suggests that implant survival and marginal bone loss in osteoporotic patients are generally comparable to untreated individuals, indicating that suppression of bone resorption does not inherently compromise osseointegration. However, these outcomes may not fully reflect peri-implant tissue dynamics. Antiresorptives alter osteoclast functions and bone remodeling, potentially affecting the osteoimmune balance required to adapt to mechanical and oral microbial challenges. While these effects may remain subclinical under healthy conditions, they may become relevant during chronic peri-implant inflammation or repeated surgical interventions, where remodeling demands are increased. Altered remodeling may result in lesion persistence, impaired structural recovery, and late complications. Although medication-related osteonecrosis of the jaw remains rare, antiresorptives may modify osteoimmune interactions within inflamed tissues. Therefore, peri-implantitis may act as a contextual modifier influencing healing outcomes. Antiresorptive therapy should not be regarded as an absolute contraindication to implant therapy in appropriately selected patients, particularly those receiving osteoporosis-dose regimens. However, chronic peri-implant inflammation, repeated surgical intervention, and high-dose oncologic antiresorptive exposure may impair osteoimmune adaptation and increase susceptibility to delayed healing and MRONJ-related complications. Early control of peri-implant inflammation, individualized risk stratification, and strict supportive maintenance should be considered central components of clinical management in antiresorptive-exposed patients.
中文摘要:抗骨吸收治疗通过抑制破骨细胞介导的骨吸收,是骨质疏松症和癌症相关骨病管理的基石。随着种植治疗在老龄化人群中越来越普遍,临床医生越来越多地遇到接受这些药物的患者,因此这些药物对种植体周围组织的影响具有临床意义。本叙述性综述批判性地审视了接受抗骨吸收治疗患者的种植体存留率、种植体周围骨稳定性、种植体周围炎进展及治疗考虑方面的临床证据,同时整合了机制性见解。证据提示,骨质疏松症患者的种植体存留率和边缘骨丢失通常与未治疗者相当,表明抑制骨吸收本身不会损害骨结合。然而,这些结局可能无法完全反映种植体周围组织动态。抗骨吸收药物改变破骨细胞功能和骨重塑,可能影响适应机械和口腔微生物挑战所需的骨免疫平衡。虽然这些效应在健康条件下可能保持亚临床状态,但在慢性种植体周围炎症或反复手术干预导致重塑需求增加时,可能变得相关。重塑改变可能导致病变持续、结构恢复受损和晚期并发症。尽管药物相关性颌骨坏死仍然罕见,但抗骨吸收药物可能改变炎症组织内的骨免疫相互作用。因此,种植体周围炎可能作为一种情境调节因素影响愈合结局。对于适当选择的患者,尤其是接受骨质疏松症剂量方案的患者,抗骨吸收治疗不应被视为种植治疗的绝对禁忌证。然而,慢性种植体周围炎症、反复手术干预和高剂量肿瘤学抗骨吸收暴露可能损害骨免疫适应,并增加延迟愈合和MRONJ相关并发症的易感性。在抗骨吸收暴露患者中,早期控制种植体周围炎症、个体化风险分层和严格的支持性维护应被视为临床管理的核心组成部分。
Recent analyses raise concerns regarding the safety and cost of robotic cholecystectomy (RC) relative to laparoscopic cholecystectomy (LC); however, the analyses were limited by varied surgeon experience and inadequate adjustment for procedure difficulty. To compare clinical outcomes and cost between RC and LC across a multihospital health system by surgeons routinely performing both surgeries, and develop a preoperative risk calculator. This retrospective study of minimally invasive cholecystectomy (MIC) took place at 8 hospitals within a large health care system between 2020 and 2021. Cholecystectomy difficulty was stratified using the Nassar preoperative scoring (low/intermediate risk, ≤6; high risk, ≥7). Operative outcomes for 90-day follow-up and total variable cost of encounter were compared. Participants included adult patients undergoing LC or RC. Participants with planned open cholecystectomy, malignancy, or MIC performed as part of other procedures were excluded. Analysis was completed in December 2024 and submitted in March 2026. Surgical approach (RC vs LC) based on initial operative intent. Primary outcomes were adverse event (conversion and/or Clavien-Dindo grade ≥3 complication) and total variable cost. Multivariable models identified detectors of adverse outcome. Inverse probability-weighted estimators predicted average treatment effects (ATE) on cost. Data were used to develop a calculator to estimate the risk of adverse outcomes by operative approach. Among 1828 patients (mean [SD] age, 52.9 [17.8] years; 65.9% female and 34.1% male), 806 (44.1%) underwent RC and 1022 (55.9%) underwent LC. RC was associated with shorter length of stay and lower rates of adverse outcome compared with LC (3.3%; 95% CI, 2.2%-4.8% vs 8.7%; 95% CI, 7.0%-10.5%; P < .001). On multivariable analysis, operative approach interacted significantly with Nassar risk level and body mass index (BMI). In high-risk patients with a BMI of 30 (calculated as weight in kilograms divided by height in meters squared), LC was associated with adverse outcome (odds ratio [OR], 3.69; 95% CI, 2.04-6.69; P < .001). In low/intermediate-risk patients, outcomes were comparable for low BMI, but among those with elevated BMI (35) LC was associated with adverse outcomes (OR, 3.19; 95% CI, 1.62-6.29; P = .001). RC was associated with higher total variable cost in both low/intermediate-risk (ATE, $2211.60; 95% CI, $1521.49-$2901.72; P < .001) and high-risk cohorts (ATE, $2417.05; 95% CI, $1675.62-$3158.48; P < .001). A predictive risk calculator demonstrated strong discrimination (AUC, 0.744; 95% CI, 0.685-0.803 for training cohort; AUC, 0.750; 95% CI, 0.659-0.842 for validation cohort). In this study, RC was associated with fewer adverse outcomes in select patients compared with LC, with the greatest benefit observed in high-risk cholecystectomy and patients with elevated BMI. However, RC was associated with higher cost across all risk strata. A validated risk calculator may assist surgeons in selecting the appropriate operative modality, optimizing outcomes and resource utilization.
中文摘要:近期分析对机器人胆囊切除术(RC)相较腹腔镜胆囊切除术(LC)的安全性和成本提出担忧;然而,这些分析受限于外科医生经验差异以及未充分校正手术难度。旨在比较由常规开展两种手术的外科医生在多医院医疗系统中实施的RC与LC的临床结局和成本,并开发术前风险计算器。这项关于微创胆囊切除术(MIC)的回顾性研究于2020年至2021年在一个大型医疗系统内的8家医院开展。胆囊切除术难度采用Nassar术前评分进行分层(低/中风险,≤6;高风险,≥7)。比较90天随访的手术结局以及本次就诊的总可变成本。纳入接受LC或RC的成年患者。排除计划开腹胆囊切除术、恶性肿瘤或作为其他手术一部分实施的MIC患者。分析于2024年12月完成,并于2026年3月提交。手术方式(RC vs LC)基于初始手术意向。主要结局为不良事件(中转开腹和/或Clavien-Dindo分级≥3的并发症)和总可变成本。多变量模型识别不良结局的预测因素。逆概率加权估计量预测对成本的平均治疗效应(ATE)。使用数据开发计算器,以按手术方式估计不良结局风险。在1828例患者中(平均[SD]年龄52.9[17.8]岁;女性65.9%,男性34.1%),806例(44.1%)接受RC,1022例(55.9%)接受LC。与LC相比,RC与较短住院时间和较低不良结局率相关(3.3%;95%CI,2.2%-4.8% vs 8.7%;95%CI,7.0%-10.5%;P<0.001)。在多变量分析中,手术方式与Nassar风险水平和体重指数(BMI)存在显著交互作用。在BMI为30(按体重公斤数除以身高米数的平方计算)的高风险患者中,LC与不良结局相关(比值比[OR],3.69;95%CI,2.04-6.69;P<0.001)。在低/中风险患者中,低BMI者结局相当,但在BMI升高(35)者中,LC与不良结局相关(OR,3.19;95%CI,1.62-6.29;P=0.001)。RC在低/中风险队列(ATE,2211.60美元;95%CI,1521.49-2901.72美元;P<0.001)和高风险队列(ATE,2417.05美元;95%CI,1675.62-3158.48美元;P<0.001)中均与更高的总可变成本相关。预测风险计算器显示出较强的区分度(训练队列AUC,0.744;95%CI,0.685-0.803;验证队列AUC,0.750;95%CI,0.659-0.842)。在本研究中,与LC相比,RC在部分患者中与更少的不良结局相关,在高风险胆囊切除术和BMI升高的患者中获益最大。然而,RC在所有风险分层中均与更高成本相关。一个经过验证的风险计算器可能帮助外科医生选择合适的手术方式,优化结局和资源利用。
基础研究 (57篇)
Natural killer (NK) cells are innate lymphocytes that defend the host by directly killing virus-infected, stressed, and tumor cells. Their direct cytotoxic mechanisms include the release of cytotoxic granules, engagement of death receptor pathways, and mediation of antibody-dependent cellular cytotoxicity (ADCC). They can also eliminate targets indirectly via the secretion of proinflammatory cytokines. Importantly, recent studies show NK cells help limit autoimmunity by targeting autoreactive immune cells, highlighting their broader role in maintaining tissue homeostasis, including within the immune-privileged central nervous system (CNS). Both preclinical and clinical studies support the therapeutic potential of NK cell-based immunotherapies for neuroinflammatory, neurodegenerative, and neuro-oncologic diseases. A key challenge remains achieving sufficient specificity and efficacy within the CNS, which necessitates a more profound understanding of NK cell biology in the unique brain microenvironment. This review summarizes the fundamental biology of NK cells and their roles in CNS pathologies, with a focus on their interactions with the CNS niche. We also discuss recent advances, such as immune-engager strategies and adoptive NK cell therapies, aiming to provide insights to guide future therapeutic development for CNS disorders.
中文摘要:自然杀伤(NK)细胞是固有淋巴细胞,通过直接杀伤病毒感染细胞、应激细胞和肿瘤细胞来防御宿主。其直接细胞毒性机制包括释放细胞毒性颗粒、启动死亡受体通路以及介导抗体依赖细胞介导的细胞毒性作用(ADCC)。它们还可通过分泌促炎细胞因子间接清除靶细胞。重要的是,近期研究表明NK细胞可通过靶向自身反应性免疫细胞帮助限制自身免疫,这凸显了其在维持组织稳态中的更广泛作用,包括在免疫豁免的中枢神经系统(CNS)内。临床前和临床研究均支持基于NK细胞的免疫疗法对神经炎症性、神经退行性和神经肿瘤性疾病具有治疗潜力。一个关键挑战仍是在CNS内实现足够的特异性和疗效,这需要更深入地理解NK细胞在独特脑微环境中的生物学。本综述总结了NK细胞的基础生物学及其在CNS病理中的作用,重点是其与CNS微环境的相互作用。我们还讨论了近期进展,例如免疫衔接策略和过继性NK细胞疗法,旨在为未来CNS疾病治疗开发提供见解。
A major limitation in preventing cancer relapse is our incomplete understanding of therapy resistance and tumor dormancy, including the role of therapy-induced polyploidy in generating rapidly proliferating progeny that repopulate the tumor. In this context, polyploid giant cancer cells (PGCCs) are a unique subpopulation traditionally considered terminally senescent due to large size, abnormal DNA content, and inability to undergo mitosis. However, compelling evidence shows that PGCCs generate progeny via amitotic mechanisms (neosis), producing highly proliferative, chemo-resistant tumor-initiating cells that drive cancer relapse. Although metabolic adaptations and autophagy support PGCC formation and survival, the mechanisms underlying these processes and their contribution to tumor relapse remain poorly understood. This review explores the complex interplay between autophagy and metabolic adaptations in PGCCs, emphasizing their role in PGCC formation, long-term survival and dormancy, and in the generation of amitotic progeny that drive tumor regrowth and cancer relapse. Mechanistic insights into how autophagy and metabolic plasticity enable PGCCs to withstand stress, maintain energy homeostasis, and escape therapy are highlighted. Additionally, we discuss therapeutic approaches targeting PGCCs by disruption of autophagy and metabolic pathways, evaluating their potential to impair progeny formation, overcome therapy resistance, and prevent cancer recurrence.
中文摘要:预防癌症复发的一个主要限制是我们对治疗耐药性和肿瘤休眠的理解不完整,包括治疗诱导的多倍体在产生可快速增殖并重新填充肿瘤的后代中的作用。在此背景下,多倍体巨癌细胞(PGCCs)是一个独特的亚群,传统上因其体积大、DNA含量异常以及无法进行有丝分裂而被认为是终末衰老的。然而,有有力证据表明,PGCCs通过无丝分裂机制(neosis)产生后代,生成高度增殖、耐化疗的肿瘤起始细胞,从而驱动癌症复发。尽管代谢适应和自噬支持PGCC的形成和存活,但这些过程背后的机制及其对肿瘤复发的贡献仍知之甚少。本综述探讨了PGCC中自噬与代谢适应之间复杂的相互作用,强调它们在PGCC形成、长期存活和休眠以及产生驱动肿瘤再生长和癌症复发的无丝分裂后代中的作用。文中重点介绍了关于自噬和代谢可塑性如何使PGCCs承受应激、维持能量稳态并逃避治疗的机制性见解。此外,我们讨论了通过破坏自噬和代谢途径来靶向PGCCs的治疗方法,评估其损害后代形成、克服治疗耐药性和预防癌症复发的潜力。
Antigen release is a critical step in initiating antitumor immune responses, yet its regulation during metastasis is not well understood. Here we show that circulating tumor cells undergoing vascular migration produce migrasomes that serve as a metastasis-specific mechanism of antigen release. These migrasomes are enriched in tumor-associated antigens, including cancer-testis and mutated antigens, and are captured efficiently by antigen-presenting cells in secondary lymphoid organs, where they undergo cross-presentation to elicit CD8+ T cell-mediated immune responses that constrain metastatic progression. Genetic inhibition of migrasome formation enhances metastasis, while administration of purified cancer-derived migrasomes restores immune-mediated suppression of metastatic growth. These findings show paradoxically that metastasis can enhance tumor immunogenicity through migrasome-mediated antigen release, highlighting a link between cancer dissemination and immune activation and establishing migrasomes as a distinct and potent platform for endogenous tumor antigen delivery.
中文摘要:抗原释放是启动抗肿瘤免疫应答的关键步骤,但其在转移过程中的调控尚不清楚。在此,我们表明,经历血管迁移的循环肿瘤细胞会产生迁移体,后者作为转移特异性的抗原释放机制。这些迁移体富含肿瘤相关抗原,包括癌-睾丸抗原和突变抗原,并能被次级淋巴器官中的抗原提呈细胞高效捕获,在那里发生交叉提呈,从而引发CD8+ T细胞介导的免疫应答,限制转移进展。对迁移体形成的遗传抑制会增强转移,而给予纯化的肿瘤来源迁移体则可恢复免疫介导的转移生长抑制。这些发现悖论性地表明,转移可通过迁移体介导的抗原释放增强肿瘤免疫原性,突显了癌症播散与免疫激活之间的联系,并将迁移体确立为一种独特且强效的内源性肿瘤抗原递送平台。
Adipose browning and atrophy are early events of cachexia, a lethal metabolic disorder affecting nearly half of the population with cancer. Here, using individual-derived specimens and mouse models, we identified an iron-dependent pathway that initiates adipose browning in both physiological and cachectic settings. Upon adrenergic stimulation of adipocytes, an influx of iron induces the activity of methionine sulfoxide reductase A (MSRA), an enzyme that reverses the oxidation of proteinaceous methionine residues. Mechanistically, iron coordination by the conserved iron-binding EXXH motif of two MSRA polypeptides serves to dimerize, stabilize and elevate its reductase activity. Iron-bound MSRA dimers in turn promote adipose browning by maintaining the reduced state of select substrates, including the catalytic subunit of protein kinase A. Remarkably, in mouse models, MsrA deletion impairs adipose browning, mitigates cachexia and prolongs the survival of tumor-bearing animals. Thus, as a key nexus of cancer-associated cachexia, the β3 adrenergic receptor-iron-MSRA axis is a promising target for clinical intervention.
中文摘要:脂肪棕色化和萎缩是恶病质的早期事件,恶病质是一种致死性代谢紊乱,影响近半数癌症人群。在此,我们利用个体来源标本和小鼠模型,鉴定出一条依赖铁的途径,该途径在生理和恶病质状态下均可启动脂肪棕色化。当脂肪细胞受到肾上腺素能刺激时,铁内流诱导甲硫氨酸亚砜还原酶A(MSRA)的活性,该酶可逆转蛋白质甲硫氨酸残基的氧化。机制上,两条MSRA多肽中保守的铁结合EXXH基序通过配位铁,促进其二聚化、稳定并提高其还原酶活性。结合铁的MSRA二聚体进而通过维持特定底物的还原状态来促进脂肪棕色化,这些底物包括蛋白激酶A的催化亚基。值得注意的是,在小鼠模型中,MsrA缺失会损害脂肪棕色化、减轻恶病质并延长荷瘤动物的生存期。因此,作为癌症相关恶病质的关键枢纽,β3肾上腺素能受体-铁-MSRA轴是临床干预的有前景靶点。
Retinoic acid, the active metabolite of vitamin A, is a pleiotropic signaling molecule that integrates developmental, homeostatic, and pathological processes across multiple organ systems. During embryogenesis, RA gradients regulate tissue patterning and lineage commitment, while in adult tissues, RA contributes to epithelial integrity, stem-cell regulation, immune homeostasis, and metabolic balance. Disruption of retinoic acid synthesis, degradation, receptor signaling, or pathway crosstalk underlies a broad spectrum of diseases, including congenital malformations, autoimmune and inflammatory conditions, neurodegenerative disorders, cardiovascular disease, pulmonary and ophthalmic pathologies, and cancer. In the tumor, RA signaling exhibits remarkable plasticity, acting as either a differentiation inducer or a stemness-maintaining factor, depending on genetic, metabolic, and microenvironmental cues. Therapeutically, retinoid-based interventions have revolutionized the treatment of acute promyelocytic leukemia. Still, their broader application has been constrained by resistance mechanisms, pharmacokinetic limitations, tissue-specific effects, and the dual nature of retinoic acid signaling across different disease states. Advances in organoid systems, single-cell and spatial transcriptomics, and multimodal epigenomics are revealing highly localized and cell-type specific retinoid responses, supporting a systems-level model of RA signaling. This framework defines "retinoid endotypes" as tissue- and stage-specific states shaped by retinoid metabolic niches, chromatin state, and microenvironmental organization, with potential to guide patient stratification and precision retinoid therapy.
中文摘要:维甲酸是维生素A的活性代谢产物,是一种多效性信号分子,整合多个器官系统中的发育、稳态和病理过程。在胚胎发生过程中,RA梯度调控组织图式形成和谱系定向;在成体组织中,RA有助于上皮完整性、干细胞调控、免疫稳态和代谢平衡。维甲酸合成、降解、受体信号或通路串扰的紊乱是多种疾病的基础,包括先天畸形、自身免疫和炎症性疾病、神经退行性疾病、心血管疾病、肺部和眼科病理以及癌症。在肿瘤中,RA信号表现出显著的可塑性,根据遗传、代谢和微环境线索,既可作为分化诱导因子,也可作为维持干性的因子。在治疗方面,基于类视黄醇的干预已彻底改变了急性早幼粒细胞白血病的治疗。然而,其更广泛应用仍受到耐药机制、药代动力学限制、组织特异性效应以及维甲酸信号在不同疾病状态中双重性质的制约。类器官系统、单细胞和空间转录组学以及多模态表观基因组学的进展正在揭示高度局部化和细胞类型特异性的类视黄醇反应,支持RA信号的系统级模型。该框架将「类视黄醇内型」定义为由类视黄醇代谢生态位、染色质状态和微环境组织塑造的组织和阶段特异性状态,具有指导患者分层和精准类视黄醇治疗的潜力。
The composition and functional activity of the gut microbiome are important host-associated factors that influence the efficacy and responsiveness of cancer immunotherapy. Traditional microbiome modulation methods lack precision, consistency, and extensive clinical applicability. Engineered nanoparticles (NPs) represent an emerging platform for investigating more controllable approaches to microbiome-associated therapeutic modulation. NPs possess physicochemical characteristics that can influence the gut microbial ecosystem. This review introduces the concept of "nanoparticle pharmacomicrobiomics" as an emerging framework that links NP design to defined microbial shifts and their potential pharmacological and immunological consequences. Through integrated literature synthesis, bibliometric co-occurrence analysis, clinical trial synthesis, and mechanistic interpretation, we develop a conceptual framework that describes potential relationships among NP properties, microbial ecology, metabolite signalling, immune modulation, and cancer immunotherapy. We emphasize the integration of nanomaterials, microbiome science, and immunology as an emerging interdisciplinary direction in oncology. This framework provides a conceptual basis that may facilitate the development of future strategies that integrate nanotechnology with microbiome and immune modulation to improve precision cancer immunotherapy.
中文摘要:肠道微生物组的组成和功能活性是影响癌症免疫治疗疗效与反应性的重要宿主相关因素。传统微生物组调控方法缺乏精准性、一致性以及广泛的临床适用性。工程化纳米颗粒(NPs)代表了一种新兴平台,可用于探索更可控的微生物组相关治疗调控方法。NPs具有可影响肠道微生物生态系统的理化特性。本综述提出「纳米颗粒药物微生物组学」这一概念,作为一个新兴框架,将NP设计与明确的微生物改变及其潜在药理学和免疫学后果联系起来。通过整合文献综述、文献计量共现分析、临床试验综合以及机制阐释,我们构建了一个概念框架,描述NP特性、微生物生态学、代谢物信号传导、免疫调节与癌症免疫治疗之间的潜在关系。我们强调纳米材料、微生物组科学与免疫学的整合是肿瘤学中一个新兴的跨学科方向。该框架提供了一个概念基础,可能有助于促进未来将纳米技术与微生物组和免疫调节相整合的策略开发,以改善精准癌症免疫治疗。
While dietary therapies targeting individual amino acids in cancer show promise in modulating tumor metabolism, the issue of nutrient competition between tumors and the immune system remains unresolved. The current approaches face significant challenges, particularly in the context of metabolic adaptability and immune responses. Here, we demonstrate that the combined modulation of lysine (Lys) and arginine (Arg) balances tumor suppression and host fitness. Using a cross-species approach combining Drosophila and mouse models, we define a narrow therapeutic window for Lys and Arg. A balanced combination (0.5% Lys/0.5% Arg) reduces tumor burden, extends survival, and preserves host fitness in tumor-bearing mice, whereas an imbalanced formulation (0.25% Lys/1% Arg, LLHA) paradoxically accelerates tumor progression. Single-cell RNA sequencing revealed that LLHA was associated with increased B cells, M1-annotated macrophages and reduced T cells, consistent with systemic immune remodeling that may favor tumor progression, accompanied by decreased Rps6 and Rps29 and increased Hba-a1 and Hbb-bt expression, suggesting alterations in mechanistic target of rapamycin (mTOR), hemoglobin, and ribosomal/translational pathways in immune cells. By defining biphasic thresholds and identifying optimal Lys/Arg combinations, this work provides a preclinical framework for investigating how balanced Lys/Arg modulation may influence tumor control and host fitness. This represents a step towards potential future synergy with immunotherapies, contingent upon further validation of immune dependency.
中文摘要:尽管针对癌症中单一氨基酸的饮食疗法在调节肿瘤代谢方面显示出前景,但肿瘤与免疫系统之间的营养竞争问题仍未解决。当前方法面临重大挑战,尤其是在代谢适应性和免疫反应方面。在此,我们证明赖氨酸(Lys)和精氨酸(Arg)的联合调节可平衡肿瘤抑制与宿主健康。采用结合果蝇和小鼠模型的跨物种方法,我们确定了Lys和Arg的狭窄治疗窗。平衡组合(0.5% Lys/0.5% Arg)可降低肿瘤负荷、延长生存期并维持荷瘤小鼠的宿主健康,而不平衡配方(0.25% Lys/1% Arg,LLHA)却矛盾地加速肿瘤进展。单细胞RNA测序显示,LLHA与B细胞增加、M1注释巨噬细胞增加和T细胞减少相关,这与可能有利于肿瘤进展的全身免疫重塑一致,并伴随Rps6和Rps29表达降低以及Hba-a1和Hbb-bt表达升高,提示免疫细胞中雷帕霉素机制靶点(mTOR)、血红蛋白和核糖体/翻译通路发生改变。通过定义双相阈值并确定最佳Lys/Arg组合,这项工作为研究平衡的Lys/Arg调节如何影响肿瘤控制和宿主健康提供了临床前框架。这代表朝着未来可能与免疫疗法产生协同作用迈出的一步,但取决于对免疫依赖性的进一步验证。
The development of simple, efficient, and actively targeted drug delivery systems remains a significant challenge for clinical translation. Here, we propose a carrier-free nanodrug platform based on polyphenol-modified prodrugs with self-assembly and ligand-adsorption capabilities. Specifically, two gallic acid-modified Cabazitaxel (CTX) prodrugs were synthesized: a reduction-responsive prodrug (CSG) and a non-responsive control (CCG). These prodrugs spontaneously assembled into nanocomplexes, and transferrin (Tf) was non-covalently adsorbed onto their surfaces via polyphenol-protein interactions, forming Tf-functionalized nanocomplexes (Tf NCs). This ligand-anchoring strategy endowed the system with Tf receptor (TfR)-mediated active targeting and enhanced colloidal stability. Notably, the CSG@Tf NCs exhibited a cascade targeting effect: prolonged circulation, tumor-specific accumulation via TfR recognition, and glutathione (GSH)-triggered CTX release in the tumor microenvironment. In vitro and in vivo studies confirmed that CSG@Tf NCs significantly improved antitumor efficacy while reducing systemic toxicity. This work presents a novel, carrier-free, and dual-functional strategy for constructing targeted prodrug nanomedicines with strong translational potential.
中文摘要:开发简单、高效且具有主动靶向能力的药物递送系统仍然是临床转化面临的重大挑战。在此,我们提出了一种基于多酚修饰前药的载体递送平台,该平台具有自组装和配体吸附能力。具体而言,合成了两种没食子酸修饰的卡巴他赛(CTX)前药:一种还原响应型前药(CSG)和一种非响应型对照(CCG)。这些前药可自发组装成纳米复合物,并且转铁蛋白(Tf)通过多酚-蛋白相互作用非共价吸附到其表面,形成Tf功能化纳米复合物(Tf NCs)。这种配体锚定策略赋予系统转铁蛋白受体(TfR)介导的主动靶向能力并增强了胶体稳定性。值得注意的是,CSG@Tf NCs表现出级联靶向效应:延长循环时间、通过TfR识别实现肿瘤特异性蓄积,以及在肿瘤微环境中由谷胱甘肽(GSH)触发CTX释放。体外和体内研究证实,CSG@Tf NCs显著提高了抗肿瘤疗效,同时降低了全身毒性。这项工作为构建具有强大转化潜力的靶向前药纳米药物提供了一种新型、无载体且双功能的策略。
Neuronal innervation plays a pivotal role in controlling tissue function during homeostasis and regeneration, as well as in pathological contexts such as inflammation, autoimmune disorders, fibrosis and cancer. A major obstacle in understanding neuron-tissue interactions at the molecular level is that neuronal cell bodies reside in peripheral ganglia often far outside the organ of interest and are therefore typically excluded in common single-cell datasets of tissues. Here we developed Trace-n-Seq to address this issue-a method that combines retrograde tracing with fluorescence-activated cell sorting and single-cell sequencing to molecularly profile individual neurons innervating healthy or diseased tissues. Trace-n-Seq can be used to explore the specific gene expression signatures of peripheral neurons at single-cell resolution. The method utilizes retrograde axonal tracing using Fast Blue, ganglia dissociation and fluorescence-activated cell sorting followed by single-cell RNA sequencing to enable the isolation and transcriptomic analysis of ganglia. Unlike bulk or whole-ganglia single-cell RNA sequencing without retrograde labeling, Trace-n-Seq allows the characterization of organ-specific neurons with single-cell resolution, eliminating background from uninvolved neurons and unrelated cell types located in the same ganglion. The procedure allows researchers to obtain molecular transcriptomes of tissue-innervating neurons and to study their plasticity, subtype identity and potential interactions with the tissue microenvironment. The complete Trace-n-Seq workflow can be performed in 2 weeks and is suitable for researchers with experience in molecular biology, neuronal tissue handling, sequencing techniques and bioinformatic analysis.
中文摘要:神经元支配在维持稳态和再生过程中对组织功能的控制起着关键作用,也在炎症、自身免疫性疾病、纤维化和癌症等病理情境中发挥重要作用。在分子水平理解神经元-组织相互作用的一个主要障碍是,神经元胞体位于外周神经节,通常远离目标器官,因此在常见的组织单细胞数据集中通常被排除。在此,我们开发了Trace-n-Seq来解决这一问题——一种将逆行示踪与荧光激活细胞分选和单细胞测序相结合的方法,用于对支配健康或患病组织的单个神经元进行分子谱分析。Trace-n-Seq可用于在单细胞分辨率下探索外周神经元的特异性基因表达特征。该方法利用Fast Blue进行逆行轴突示踪、神经节解离和荧光激活细胞分选,随后进行单细胞RNA测序,从而能够分离神经节并进行转录组分析。与未进行逆行标记的批式或全神经节单细胞RNA测序不同,Trace-n-Seq能够以单细胞分辨率表征器官特异性神经元,消除来自同一神经节中未参与支配的神经元和无关细胞类型的背景。该流程使研究人员能够获得支配组织的神经元的分子转录组,并研究其可塑性、亚型身份以及与组织微环境的潜在相互作用。完整的Trace-n-Seq工作流程可在2周内完成,适合具有分子生物学、神经元组织处理、测序技术和生物信息学分析经验的研究人员。
Living donor valves for valve replacement in pediatric patients, come with the risk of immune rejection of the implanted tissue. To address this, and increase the options for living implants in pediatric patients, we previously developed a lentiviral immune-shielding strategy that leverages viral immune evasion mechanisms to downregulate surface HLA expression (via US2) and suppress natural killer (NK) cell activation (via Serpin b9). In this study, we comprehensively evaluated the impact of delivery of immune-shielding genes in donor valve cells and whole donor valves on immune responses in vitro using host peripheral blood mononuclear cells (PBMCs). Our results demonstrate that this approach prevents immune cell-mediated death of donor heart valve cells and reduces PBMC clustering around the allogeneic valve cells. Transcriptomic analysis of immune-shielded donor valves via bulk RNA sequencing revealed upregulation of genes associated with immune tolerance pathways commonly observed in viral infections, cancer, and placental development. These findings support the impact of immune-shielding technology as a strategy to protect allograft heart valves from immune-mediated degeneration, advancing the path toward durable, immunologically compatible implants for pediatric patients.
中文摘要:用于儿科患者瓣膜置换的活体供体瓣膜存在植入组织免疫排斥风险。为解决这一问题并增加儿科患者活体植入物的选择,我们此前开发了一种慢病毒免疫屏蔽策略,利用病毒免疫逃逸机制下调表面HLA表达(通过US2)并抑制自然杀伤(NK)细胞活化(通过Serpin b9)。在本研究中,我们使用宿主外周血单核细胞(PBMC),在体外全面评估了将免疫屏蔽基因递送至供体瓣膜细胞和完整供体瓣膜后对免疫应答的影响。我们的结果表明,该方法可防止免疫细胞介导的供体心脏瓣膜细胞死亡,并减少PBMC在同种异体瓣膜细胞周围的聚集。通过bulk RNA测序对免疫屏蔽供体瓣膜进行转录组分析显示,与免疫耐受通路相关的基因上调,这些通路常见于病毒感染、癌症和胎盘发育中。这些发现支持免疫屏蔽技术作为一种保护同种移植心脏瓣膜免受免疫介导退化的策略所发挥的作用,并推动为儿科患者实现持久、免疫相容植入物的进程。
The Regulator of Cullins 1 (ROC1) or RING box protein-1 (RBX1) is an essential component of the largest multiunit Cullin-RING ubiquitin ligase (CRL). Previous studies demonstrated that ROC1 is frequently overexpressed in multiple malignancies, which predicts advanced cancer stages and poor prognosis. However, the molecular mechanisms driving ROC1 overexpression in cancers remain largely unknown. Herein, we reveal that HSP90 binds to ROC1 with its N-Terminus, thus promoting ROC1 stabilization. HSP90 inhibition with the N-Terminal, but not the C-Terminal inhibitors accelerate ROC1 destabilization by facilitating its ubiquitination and subsequent degradation by CHIP E3 ligase. CHIP specifically interacts with ROC1 at its CC domain, thus promoting the K48-linked-ubiquitin-mediated degradation of ROC1 at the K26 residue. Indeed, deletion of CHIP markedly blocks HSP90-inactivation-induced ROC1 reduction. Function exploration reveals that HSP90 inhibition suppresses lung adenocarcinoma (LUAD) cell growth substantially by decreasing ROC1 abundance. In clinic, HSP90β and ROC1 are overexpressed in LUAD samples, which have positive correlation and predict poor prognosis of LUAD patients. LUAD organoids analysis reveals that HSP90 blockage promotes ROC1 destabilization and inhibits the growth of organoid cells. Taken together, the present results demonstrate the regulatory mechanism of ROC1 in malignancies and suggest a novel mechanism of the oncogenic role of HSP90 to promote lung tumorigenesis.
中文摘要:Cullin 调节因子1(ROC1)或称 RING box 蛋白-1(RBX1)是最大的多亚基 Cullin-RING 泛素连接酶(CRL)复合体的必需组分。既往研究表明,ROC1 在多种恶性肿瘤中频繁过表达,并预示癌症分期较晚和预后不良。然而,驱动癌症中 ROC1 过表达的分子机制在很大程度上仍不清楚。在此,我们发现 HSP90 通过其 N 端与 ROC1 结合,从而促进 ROC1 稳定。使用 N 端抑制剂而非 C 端抑制剂抑制 HSP90,可通过促进 ROC1 泛素化及其随后被 CHIP E3 连接酶降解而加速 ROC1 失稳。CHIP 通过其 CC 结构域与 ROC1 特异性相互作用,从而促进 K48 连接泛素介导的 ROC1 在 K26 残基处降解。事实上,敲除 CHIP 可显著阻断 HSP90 失活诱导的 ROC1 减少。功能探索显示,HSP90 抑制通过降低 ROC1 丰度显著抑制肺腺癌(LUAD)细胞生长。在临床中,HSP90β 和 ROC1 在 LUAD 样本中过表达,二者呈正相关,并预示 LUAD 患者预后不良。LUAD 类器官分析显示,阻断 HSP90 可促进 ROC1 失稳并抑制类器官细胞生长。综上,本研究结果阐明了 ROC1 在恶性肿瘤中的调控机制,并提示 HSP90 通过促进肺肿瘤发生发挥致癌作用的新机制。
The intrinsic heterogeneity of solid tumors remains a crucial barrier to understanding cancer biology and predicting therapeutic outcomes. Here, we introduce a scalable and versatile biofabrication platform that enables the controlled assembly of multitype spheroid arrays (MSA) within standard culture microplates. By performing programmable bioprinting within soft, microstructured culture devices, we achieve the precise spatial deposition of multiple cell types into defined microwells, yielding reproducible arrays of heterogeneous 3D tumor spheroids that collectively recapitulate the macro- and micro-heterogeneity of solid cancers. We demonstrate that this approach permits the fine-tuning of spheroid size, composition, and arrangement. It also supports the delayed secondary programmed seeding of cells on pre-grown spheroids, mimicking biological processes such as the invasion of immune cells. These methods enable quantitative drug-response profiling within a single assay. They overcome some critical limitations of current 3D cancer models, introducing the concept of the "cancer-in-a-well" technology. This technology provides a simple-to-use, cost-effective, high-throughput, and highly reproducible platform to recreate the complexity of tumors in vitro using methods and instruments that can be potentially used by any researcher in any cell culture lab. We can foresee a positive impact on cancer biology studies, drug screening, and personalized oncology.
中文摘要:实体瘤的内在异质性仍是理解癌症生物学和预测治疗结局的关键障碍。在此,我们介绍一种可扩展且多功能的生物制造平台,能够在标准培养微孔板内可控组装多类型球状体阵列(MSA)。通过在柔软、微结构化的培养装置中进行可编程生物打印,我们实现了将多种细胞类型精确空间沉积到限定微孔中,产生可重复的异质性3D肿瘤球状体阵列,这些阵列共同再现了实体癌的宏观和微观异质性。我们证明,该方法允许对球状体大小、组成和排列进行精细调节。它还支持在已生长的球状体上进行延迟的二次程序化细胞接种,从而模拟免疫细胞侵袭等生物过程。这些方法能够在单次检测中实现定量药物反应分析。它们克服了当前3D癌症模型的一些关键局限性,引入了「cancer-in-a-well」技术的概念。该技术提供了一种简单易用、成本效益高、高通量且高度可重复的平台,可使用任何研究人员在任何细胞培养实验室中潜在可用的方法和仪器,在体外重建肿瘤的复杂性。我们可以预见其对癌症生物学研究、药物筛选和个性化肿瘤学产生积极影响。
Radiotherapy (RT) remains a cornerstone in cancer treatment; however, its therapeutic efficacy is often limited by tumor fibrosis and radioresistance, primarily driven by transforming growth factor-β (TGF-β) upregulation. To address these challenges, we developed a tris(bipyridyl)ruthenium(II)-based metal-organic layer (RuMOL) for siRNA delivery, designed to simultaneously elicit efficient radiosensitization and silence TGF-β expression, thereby improving tumor response to RT. RuMOL/siRNA demonstrates robust antitumor effects both in vitro and in vivo by reversing fibrosis and potentiating RT-induced DNA damage. Detailed mechanistic studies reveal that TGF-β downregulation effectively suppresses fibrosis, enhances tumor perfusion and oxygenation, and mitigates hypoxia-driven radioresistance, ultimately improving the therapeutic effect of x-ray irradiation. This innovative platform holds promise as a dual-functional agent for siRNA-based gene silencing and RT enhancement in cancer therapy.
中文摘要:放射治疗(RT)仍是癌症治疗的基石;然而,其疗效常受到肿瘤纤维化和放射抗性的限制,而后者主要由转化生长因子-β(TGF-β)上调驱动。为应对这些挑战,我们开发了一种基于三(联吡啶)钌(II)的金属有机层(RuMOL)用于siRNA递送,旨在同时引发有效的放射增敏并沉默TGF-β表达,从而改善肿瘤对RT的应答。RuMOL/siRNA在体外和体内均通过逆转纤维化和增强RT诱导的DNA损伤而表现出强大的抗肿瘤作用。详细的机制研究显示,TGF-β下调可有效抑制纤维化,增强肿瘤灌注和氧合,并减轻缺氧驱动的放射抗性,最终提高x射线照射的治疗效果。这一创新平台有望作为基于siRNA的基因沉默和癌症治疗中RT增强的双功能试剂。
Acute Myeloid Leukemia (AML) is a prevalent and aggressive hematologic cancer driven by leukemic stem cells and immune evasion. Among its subtypes, Mixed Lineage Leukemia-AF9 (MLL-AF9)- rearranged AML is exceptionally lethal, with B-cell lymphoma 2 (Bcl2), a key anti-apoptotic protein, supporting leukemic survival and immune dysfunction. Targeting Bcl2 in this context is crucial for dismantling oncogenic circuits and restoring immune activity. Here, we have synthesized, de novo, IL-3 receptor alpha chain (IL-3Rα, commonly known as cluster of differentiation 123 or CD123) targeted aptamer-tethered liposomal nanocarriers (CD123-si-Bcl2@LNPs) encapsulating Bcl2 siRNA (CD123-si-Bcl2@LNPs) for selective AML targeting, survival disruption, and immune restoration. Mechanistic studies established a previously uncharacterized signaling axis wherein the MLL-AF9 fusion oncoprotein induces the overexpression of the transcription factor c-Myb. This induced c-Myb binds directly to the Bcl2 promoter, upregulating Bcl2 expression and enhancing both STAT3 expression and its Ser727 autophosphorylation. Consequently, this pathway amplifies IL-6-driven immunosuppression and dampens NK and CD8⁺ T cell responses. Nanocomposite-mediated disruption of this specific axis successfully reversed these oncogenic and immunosuppressive signals. Therapeutic efficacy was evaluated using a patient-derived xenograft (PDX) model, generated by retroviral MLL-AF9 overexpression in CD34⁺/CD38⁻ sorted leukemic stem cells from AML patients and engraftment into NOD/SCID mice. CD123-si-Bcl2@LNPs significantly reduced leukemic burden in vivo. Bcl2 siRNA encapsulated liposomal nanoparticles demonstrated robust Bcl2 knockdown, apoptosis induction, and impaired leukemic self-renewal across in vitro and in vivo models. Post-treatment immune profiling revealed enhanced NK cell (CD56⁺) expression and reversal of T cell exhaustion, with CD8⁺ T cell activation marked by downregulation of CTLA-4. Differentiation marker analysis revealed decreased CD45+ and c-KIT+ expression, accompanied by an upregulation of the myeloid monocyte differentiation marker CD11b, indicating myeloid maturation and a reduction in leukemic stemness. This dual-action therapeutic strategy simultaneously targets survival and immune evasion pathways in MLL-AF9-positive AML cells by the treatment of CD123-si-Bcl2@LNPs, offering a promising, precision-guided nano-immunotherapeutic strategy for future translational potential for MLL-AF9-positive acute myeloid leukemia. STATEMENT OF SIGNIFICANCE: •The CD123 aptamer-targeted liposomal nanocarrier facilitates precise siRNA delivery in acute myeloid leukemia (AML), significantly enhancing the transfection efficiency and stability of Bcl2 siRNA. •siRNA nanotherapy reveals a novel immune-evasion axis involving c-Myb, Bcl2, and STAT3 axis which is critical for the progression of AML. •Targeted silencing of Bcl2 disrupts the survival networks of leukemic stem cells. •Nano-immunotherapy revitalizes the antitumor activity of natural killer (NK) cells and CD8⁺ T-cells. •Liposomal siRNA therapy effectively suppresses MLL-AF9 leukemia in NOD/SCID patient-derived xenograft (PDX) mouse models.
中文摘要:急性髓系白血病(AML)是一种常见且侵袭性强的血液系统恶性肿瘤,由白血病干细胞和免疫逃逸驱动。在其亚型中,混合谱系白血病-AF9(MLL-AF9)重排的AML格外致命,而关键抗凋亡蛋白B细胞淋巴瘤2(Bcl2)支持白血病细胞存活并导致免疫功能障碍。在此背景下靶向Bcl2对于拆解致癌环路和恢复免疫活性至关重要。在此,我们从头合成了IL-3受体α链(IL-3Rα,通常称为分化簇123或CD123)靶向的、适配体连接的脂质体纳米载体(CD123-si-Bcl2@LNPs),其包封Bcl2 siRNA,用于选择性靶向AML、破坏存活并恢复免疫。机制研究确立了一条此前未被表征的信号轴,其中MLL-AF9融合癌蛋白诱导转录因子c-Myb过表达。这种诱导的c-Myb直接结合Bcl2启动子,上调Bcl2表达,并增强STAT3表达及其Ser727自磷酸化。因此,该通路放大IL-6驱动的免疫抑制并削弱NK和CD8⁺ T细胞反应。纳米复合物介导的该特定信号轴破坏成功逆转了这些致癌和免疫抑制信号。使用患者来源异种移植(PDX)模型评估治疗效果,该模型通过逆转录病毒在来自AML患者的CD34⁺/CD38⁻分选白血病干细胞中过表达MLL-AF9,并植入NOD/SCID小鼠而生成。CD123-si-Bcl2@LNPs在体内显著降低白血病负荷。包封Bcl2 siRNA的脂质体纳米颗粒在体外和体内模型中表现出强效的Bcl2敲低、凋亡诱导和白血病自我更新受损。治疗后免疫分析显示NK细胞(CD56⁺)表达增强,T细胞耗竭逆转,CD8⁺ T细胞活化以CTLA-4下调为标志。分化标志物分析显示CD45+和c-KIT+表达降低,同时髓系单核细胞分化标志物CD11b上调,表明髓系成熟和白血病干性降低。这种双重作用治疗策略通过CD123-si-Bcl2@LNPs治疗同时靶向MLL-AF9阳性AML细胞中的存活和免疫逃逸通路,为MLL-AF9阳性急性髓系白血病未来的转化潜力提供了一种有前景的精准引导纳米免疫治疗策略。意义声明:CD123适配体靶向的脂质体纳米载体促进急性髓系白血病(AML)中的精确siRNA递送,显著提高Bcl2 siRNA的转染效率和稳定性。siRNA纳米疗法揭示了一条涉及c-Myb、Bcl2和STAT3轴的新型免疫逃逸轴,该轴对AML进展至关重要。靶向沉默Bcl2破坏白血病干细胞的存活网络。纳米免疫疗法重振自然杀伤(NK)细胞和CD8⁺ T细胞的抗肿瘤活性。脂质体siRNA疗法在NOD/SCID患者来源异种移植(PDX)小鼠模型中有效抑制MLL-AF9白血病。
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide, yet approved pharmacotherapies remain limited. The ovarian tumor domain-containing protein 1 (OTUD1) has been implicated in metabolic regulation, but its role in MASLD remains unclear. OTUD1 expression was significantly elevated in liver samples from patients with MASLD and in high-fat diet (HFD)-fed mice, a finding further supported by two independent Gene Expression Omnibus (GEO) cohorts (GSE24807 and GSE126848). Studies using systemic Otud1-knockout mice showed that Otud1 deficiency markedly alleviated insulin resistance and inflammation under HFD and high-fat, methionine-restricted, choline-deficient (HFMCD) diet conditions. To assess the hepatocyte-specific and therapeutic relevance of OTUD1, Otud1 was silenced in hepatocytes using AAV8-TBG-shOtud1, which significantly ameliorated HFMCD-induced steatohepatitis. Mechanistically, integrated interactome analyses identified heat shock protein 90α (HSP90α) as a direct substrate of OTUD1. OTUD1 bound to HSP90α and removed its K48-linked polyubiquitin chains at K283, thereby preventing its proteasomal degradation and enhancing its stability. This effect was required for OTUD1-driven lipid accumulation in hepatocytes, as the catalytically inactive OTUD1-C320S mutant failed to stabilize HSP90α or promote lipid deposition. Transcriptomic profiling further revealed that OTUD1 overexpression activated lipid metabolism and inflammatory pathways in OA/PA-treated LO2 cells. Together, these findings identify OTUD1 as a previously unrecognized driver of MASLD progression through the OTUD1-HSP90α axis and suggest that OTUD1 may serve as a potential therapeutic target for metabolic liver disease.
中文摘要:代谢功能障碍相关脂肪性肝病(MASLD)是全球最常见的慢性肝病,但获批的药物治疗仍有限。含卵巢肿瘤结构域蛋白1(OTUD1)已被认为参与代谢调控,但其在MASLD中的作用仍不清楚。OTUD1表达在MASLD患者肝样本和高脂饮食(HFD)喂养小鼠中显著升高,两个独立的基因表达综合数据库(GEO)队列(GSE24807和GSE126848)进一步支持这一发现。使用全身性Otud1敲除小鼠的研究显示,Otud1缺失显著减轻HFD及高脂、甲硫氨酸限制、胆碱缺乏(HFMCD)饮食条件下的胰岛素抵抗和炎症。为评估OTUD1的肝细胞特异性和治疗相关性,使用AAV8-TBG-shOtud1在肝细胞中沉默Otud1,可显著改善HFMCD诱导的脂肪性肝炎。机制上,整合相互作用组分析确定热休克蛋白90α(HSP90α)是OTUD1的直接底物。OTUD1与HSP90α结合,并去除其K283位点的K48连接多泛素链,从而阻止其蛋白酶体降解并增强其稳定性。该效应是OTUD1驱动肝细胞脂质积累所必需的,因为催化失活的OTUD1-C320S突变体未能稳定HSP90α或促进脂质沉积。转录组分析进一步显示,在OA/PA处理的LO2细胞中,OTUD1过表达激活了脂质代谢和炎症通路。总之,这些发现确定OTUD1是通过OTUD1-HSP90α轴驱动MASLD进展的先前未被识别的因素,并提示OTUD1可能作为代谢性肝病的潜在治疗靶点。
Metabolism and autophagy are closely interconnected, but whether metabolic alterations can chemically modify proteins and influence their selective autophagic degradation remains poorly understood. Our recent findings show that increased S-nitrosylation resulting from the loss of the denitrosylase AKR1A1/SCoR impairs glycolysis and promotes methylglyoxal accumulation, leading to carbonyl modification and selective autophagic degradation of KEAP1. These findings suggest that metabolic rewiring can influence the fate of specific proteins. In particular, we discuss whether glycation may act as a metabolic "mark" for selective autophagy and how the removal of metabolically modified proteins may, in turn, sustain signaling pathways involved in tumor progression and therapy resistance.
中文摘要:代谢与自噬密切相关,但代谢改变能否通过化学修饰蛋白质并影响其选择性自噬降解,仍知之甚少。我们近期的研究结果显示,去亚硝基化酶AKR1A1/SCoR缺失导致S-亚硝基化增加,会损害糖酵解并促进甲基乙二醛积累,进而引起羰基化修饰和KEAP1的选择性自噬降解。这些发现提示,代谢重编程可以影响特定蛋白质的命运。我们尤其讨论了糖化是否可能作为选择性自噬的一种代谢「标记」,以及代谢修饰蛋白的清除又如何反过来维持参与肿瘤进展和治疗耐药的信号通路。
Despite the emergence of immunotherapies, the treatment of diffuse large B-cell lymphoma (DLBCL) remains challenging. This is mainly attributed to the immunosuppressive properties of the tumor microenvironment (TME), which limit the achievement of durable therapeutic responses. High expression of Polo-like kinase 4 (PLK4), a mitotic kinase, is associated with significantly poorer survival outcomes in DLBCL patients receiving CHOP-based chemotherapy. Moreover, the combination of mitotic kinase inhibitors and the microtubules-targeting agent vincristine (VCR) exhibit synergistic anti-tumor effects in B-cell lymphoma mouse models. In this study, we found that PLK4 was up-regulated in DLBCL, and its silencing significantly inhibited tumor growth. Furthermore, the combination of si-PLK4 and VCR exerted stronger anti-tumor effects than either treatment alone, which was mediated by activating cGAS-STING pathway. Based on these findings, we developed a nanomedicine-based therapeutic strategy for DLBCL using zeolite imidazole framework (ZIF)-90 as carrier for co-delivery of VCR and si-PLK4. To enhance targeting specificity toward CD20+ lymphoma cells, rituximab (RTX) was conjugated onto the nanomedicine, named VCR/siPLK4@ZIF-90-RTX. The VCR/siPLK4@ZIF-90-RTX showed minimal premature release of VCR and siPLK4, with a pH-responsive release profile. Compared with the combination of VCR and RTX, VCR/siPLK4@ZIF-90-RTX showed enhanced anti-tumor effects in vitro, and exhibited high biocompatibility and low toxic side effects in vivo. Moreover, VCR/siPLK4@ZIF-90-RTX could promote the maturation of dendritic cells and subsequent tumor infiltration of CD8+ T and CD4+ T cells by activating cGAS-STING pathway. Collectively, this work provides a potential synergistic chemo-immunotherapeutic strategy that effectively remodels the immunosuppressive TME and improves therapeutic efficacy.
中文摘要:尽管免疫疗法不断涌现,弥漫性大B细胞淋巴瘤(DLBCL)的治疗仍然具有挑战性。这主要归因于肿瘤微环境(TME)的免疫抑制特性,其限制了持久治疗反应的实现。有丝分裂激酶Polo样激酶4(PLK4)的高表达与接受CHOP为基础化疗的DLBCL患者显著更差的生存结局相关。此外,有丝分裂激酶抑制剂与微管靶向药物长春新碱(VCR)联合在B细胞淋巴瘤小鼠模型中表现出协同抗肿瘤作用。在本研究中,我们发现PLK4在DLBCL中上调,沉默PLK4可显著抑制肿瘤生长。进一步,si-PLK4与VCR联合比任一单独治疗产生更强的抗肿瘤作用,该作用由激活cGAS-STING通路介导。基于这些发现,我们利用沸石咪唑酯骨架(ZIF)-90作为载体共递送VCR和si-PLK4,开发了一种基于纳米药物的DLBCL治疗策略。为增强对CD20+淋巴瘤细胞的靶向特异性,将利妥昔单抗(RTX)偶联到纳米药物上,命名为VCR/siPLK4@ZIF-90-RTX。VCR/siPLK4@ZIF-90-RTX显示出VCR和siPLK4的提前释放极少,并具有pH响应性释放特征。与VCR和RTX联合相比,VCR/siPLK4@ZIF-90-RTX在体外显示出增强的抗肿瘤作用,并在体内表现出高生物相容性和低毒副作用。此外,VCR/siPLK4@ZIF-90-RTX可通过激活cGAS-STING通路促进树突状细胞成熟以及随后CD8+ T细胞和CD4+ T细胞的肿瘤浸润。总之,这项工作提供了一种潜在协同化疗-免疫治疗策略,可有效重塑免疫抑制性TME并提高治疗效果。
In relapsed/refractory multiple myeloma, the approved B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR)-T cell product ciltacabtagene autoleucel (cilta-cel) shows higher response rates than idecabtagene vicleucel (ide-cel) in pivotal trials and real-world comparisons. This advantage has been attributed to the biparatopic dual-VHH (dVHH) binder of cilta-cel. However, the products also differ in the gene regulatory elements driving CAR expression: cilta-cel uses a human elongation factor α (EF1α) promoter in conjunction with a woodchuck hepatitis post-transcriptional regulatory element (EF1α+WPRE), whereas ide-cel uses a myeloproliferative sarcoma virus enhancer (MND) promoter without WPRE (MMD-WPRE). The role of these elements in CAR-T cell efficacy remains unexplored.We generated lentiviral vectors where the CAR transgene was composed of either a dVHH-based or a single-chain variable fragment (scFv)-based BCMA-CAR with a 4-1BB costimulatory and a CD3ζ signaling domain, expressed either by EF1α+WPRE or MND-WPRE Primary human T cells or a nuclear factor of activated T cells (NFAT)-GFP Jurkat reporter line were compared at matched vector copy numbers (VCN) or CAR surface expression. Antitumor efficacy was assessed in MM.1S-engrafted NSG mice.When transduced at the same multiplicities of infection, MND-WPRE CAR-T cells reached higher VCN and transduction rates than EF1α+WPRE regardless of the binder type. In an NFAT-GFP reporter assay, unstimulated MND-WPRE-driven cells showed higher NFAT and CD69 expression, consistent with greater tonic signaling compared with EF1α+WPRE In vivo, independently of the BCMA binder moiety, EF1α+WPRE-driven CAR-T cells demonstrated superior cytokine secretion and tumor control along with greater survival of mice treated with EF1α+WPREcompared with MND-WPRE-driven CAR-T cells.CAR-T cells expressing the CAR under MND-WPRE showed greater gene transfer during manufacturing, but this did not translate into superior function in vivo. The advantage attributed to cilta-cel's dual VHH binder was lost when expressed under MND-WPRE and, conversely, ide-cel's scFv binder achieved better antitumor activity when expressed under EF1α+WPRE than under MND-WPRE The efficacy difference between our CAR constructs in xenograft models therefore tracked with the choice of regulatory elements driving CAR expression independently of the binder. It may be better to choose gene regulatory elements based on the CAR-T cell function they confer rather than on expression strength alone.
中文摘要:在复发/难治性多发性骨髓瘤中,已获批的B细胞成熟抗原(BCMA)靶向嵌合抗原受体(CAR)-T细胞产品ciltacabtagene autoleucel(cilta-cel)在关键试验和真实世界比较中显示出高于idecabtagene vicleucel(ide-cel)的缓解率。这一优势被归因于cilta-cel的双表位双VHH(dVHH)结合域。然而,这些产品在驱动CAR表达的基因调控元件上也存在差异:cilta-cel使用人延伸因子α(EF1α)启动子联合土拨鼠肝炎病毒转录后调控元件(EF1α+WPRE),而ide-cel使用骨髓增殖性肉瘤病毒增强子(MND)启动子且不含WPRE(MND-WPRE)。这些元件在CAR-T细胞疗效中的作用尚未被探索。我们构建了慢病毒载体,其中CAR转基因由基于dVHH或基于单链可变区片段(scFv)的BCMA-CAR组成,带有4-1BB共刺激域和CD3ζ信号域,分别由EF1α+WPRE或MND-WPRE表达。在匹配的载体拷贝数(VCN)或CAR表面表达水平下,比较了原代人T细胞或活化T细胞核因子(NFAT)-GFP Jurkat报告细胞系。在MM.1S移植的NSG小鼠中评估了抗肿瘤疗效。当以相同感染复数转导时,无论结合域类型如何,MND-WPRE CAR-T细胞达到的VCN和转导率均高于EF1α+WPRE。在NFAT-GFP报告实验中,未刺激的MND-WPRE驱动细胞显示更高的NFAT和CD69表达,与相比EF1α+WPRE更强的紧张性信号一致。在体内,独立于BCMA结合域部分,EF1α+WPRE驱动的CAR-T细胞表现出更优的细胞因子分泌和肿瘤控制,并且接受EF1α+WPRE治疗的小鼠生存期长于MND-WPRE驱动的CAR-T细胞。在MND-WPRE下表达CAR的CAR-T细胞在生产过程中显示出更高的基因转移,但这并未转化为体内更优的功能。cilta-cel双VHH结合域所归因的优势在MND-WPRE下表达时消失;相反,ide-cel的scFv结合域在EF1α+WPRE下表达时比在MND-WPRE下表达获得更好的抗肿瘤活性。因此,我们的CAR构建体在异种移植模型中的疗效差异与驱动CAR表达的调控元件选择相关,而不依赖于结合域。可能更好的做法是根据CAR-T细胞所获得的功能,而不是仅根据表达强度,来选择基因调控元件。
Ubiquitin receptor-mediated, ubiquitin-independent targeted protein degradation via 26S proteasomes.
The 26S proteasome engages with ubiquitinated substrates primarily through its constituent ubiquitin (Ub) receptors, which initiates a cascade of proteolytic processes. Leveraging this recognition mechanism, we developed a targeted protein degradation (TPD) strategy that recruits substrates directly to the proteasome, thereby bypassing the ubiquitination step. Our proteasome-targeting chimera, Protea-Tac, is a heterobifunctional protein degrader composed of a Ub receptor and an intracellular antibody. This chimera integrates into 26S proteasomes without altering their structural or functional integrity. Protea-Tac with cognate antibodies degraded various target proteins, including c-Fos, BRD4, FlagTDP43, HAtau, and GFPODC. We mechanistically demonstrated that this platform is (i) modular, allowing facile target switching, (ii) Ub independent, and (iii) highly target specific. Furthermore, Protea-Tac exhibited potent in vivo antitumor efficacy, posttranslationally inducing c-Fos degradation and substantially delaying tumor progression through both viral and nonviral delivery systems. These findings identify Protea-Tac as a distinct TPD platform capable of directly degrading intracellular proteins via engineered 26S proteasomes.
中文摘要:26S蛋白酶体主要通过其组成型泛素(Ub)受体与泛素化底物结合,从而启动一系列蛋白水解过程。利用这一识别机制,我们开发了一种靶向蛋白降解(TPD)策略,可将底物直接招募至蛋白酶体,从而绕过泛素化步骤。我们的蛋白酶体靶向嵌合体Protea-Tac是一种异源双功能蛋白降解剂,由Ub受体和胞内抗体组成。该嵌合体可整合入26S蛋白酶体,而不改变其结构或功能的完整性。携带同源抗体的Protea-Tac可降解多种靶蛋白,包括c-Fos、BRD4、FlagTDP43、HAtau和GFPODC。我们从机制上证明,该平台(i)具有模块化特征,可简便地切换靶点,(ii)不依赖Ub,且(iii)具有高度靶标特异性。此外,Protea-Tac在体内表现出强效抗肿瘤活性,可通过病毒和非病毒递送系统在翻译后诱导c-Fos降解,并显著延缓肿瘤进展。这些发现表明,Protea-Tac是一种独特的TPD平台,能够通过工程化26S蛋白酶体直接降解细胞内蛋白。
CRISPR activation (CRISPRa) enables precise up-regulation of gene expression for ex vivo and in vivo applications. However, a lack of scalable, high-coverage tools has limited comprehensive genetic screening in murine models. Here, we introduce Partita, a next-generation mouse whole-genome CRISPRa sgRNA platform, designed for unparalleled efficiency in gene activation studies. Partita uses a high-density targeting strategy, deploying 10 sgRNAs per transcriptional start site, structured into five gene class-specific sublibraries to maximize transcriptional induction. To demonstrate the capabilities of Partita, we performed a series of large-scale screens: an in vitro enrichment/depletion screen, whole-genome CRISPRa screens in a double-hit lymphoma model to uncover resistance factors to proapoptotic drugs (venetoclax, nutlin-3a, and etoposide) and an in vivo screen to identify accelerators of MYC-driven lymphomagenesis. Each experiment revealed both expected and unexpected regulators, with high validation rates. By enabling robust gain-of-function screening, Partita unlocks new avenues for functional genomics and expands the toolkit for discovering key drivers of biological processes across diverse research fields.
中文摘要:CRISPR激活(CRISPRa)能够精确上调基因表达,适用于离体和在体应用。然而,缺乏可扩展、高覆盖度的工具限制了在小鼠模型中进行全面的遗传筛选。在此,我们推出Partita,一种新一代小鼠全基因组CRISPRa sgRNA平台,旨在为基因激活研究提供前所未有的效率。Partita采用高密度靶向策略,每个转录起始位点部署10条sgRNA,并组织为五个基因类别特异性亚文库,以最大化转录诱导。为展示Partita的能力,我们进行了一系列大规模筛选:一项体外富集/耗竭筛选,在双打击淋巴瘤模型中进行全基因组CRISPRa筛选以发现促凋亡药物(维奈克拉、nutlin-3a和依托泊苷)的耐药因子,以及一项体内筛选以鉴定MYC驱动淋巴瘤发生的促进因子。每个实验都揭示了预期和非预期的调控因子,且验证率很高。通过实现稳健的功能获得性筛选,Partita为功能基因组学开辟了新途径,并扩展了用于发现多种研究领域中生物过程关键驱动因子的工具包。
While the genetic paradigm of cancer is powerful, it remains incomplete. For example, high mutational burdens are commonplace in homeostatically-stable epithelia, but the presence of driver mutations alone does not result in cancer. Here, we revealed additional factors contributing to the eco-evolutionary dynamics of carcinogenesis. The dynamics of carcinogenesis were tracked from initiation to emergence using a UV-driven model of squamous cell carcinoma, via in vivo serial 3D reconstruction of >25,000 fluorescently labeled keratinocyte clades (cells expressing a single fluorophore and related by descent). While median and mean clade sizes (8-16 cells) differed little with UV exposure, UV exposure resulted in large goliath clades (>~4.2×106 µm3; >500 cells). Of note, goliath formation preceded the acquisition of established driver mutations, and only a subset of goliaths exhibited both greater mutational loads and dense aggregations of cells (micro-lumps). Of 21 randomly selected goliath clades in macroscopically normal-appearing skin tracked weekly, 2 developed into visible lesions, while an adaptation of the Drake equation placed the probability of this occurring at less than 10-6. The earliest molecular signatures based on single-cell RNA-sequencing of irradiated skin reflected epidermal de-differentiation and immunosuppression. Overall, this study documents skin cancer initiation due to UV exposure from changes in clade distribution through macroscopic lesion development arising from goliath clades. These data highlight these transitions in relation to known driver mutations and transcriptomic changes, suggesting a possible explanation for why cancers are rare relative to the degree of somatic mosaicism present.
中文摘要:尽管癌症的遗传范式很有力,但它仍不完整。例如,高突变负荷在稳态稳定的上皮中很常见,但仅有驱动突变的存在并不会导致癌症。在此,我们揭示了促成癌变生态演化动力学的其他因素。我们利用紫外线驱动的鳞状细胞癌模型,通过对超过25,000个荧光标记的角质形成细胞克隆支系(表达单一荧光基团并通过谱系关系相关联的细胞)进行体内连续三维重建,追踪了癌变从起始到出现的动力学。尽管克隆支系大小的中位数和平均值(8-16个细胞)随紫外线暴露差异很小,但紫外线暴露导致了大型「歌利亚」克隆支系(大于约4.2×10^6 µm^3;超过500个细胞)。值得注意的是,「歌利亚」的形成先于已确定驱动突变的获得,并且只有一部分「歌利亚」同时表现出更高的突变负荷和密集的细胞聚集(微团块)。在肉眼外观正常的皮肤中随机选取的21个「歌利亚」克隆支系被每周追踪,其中2个发展为可见病变,而根据对德雷克方程的一种改编,估计这种情况发生的概率小于10^-6。基于受照射皮肤的单细胞RNA测序的最早分子特征反映了表皮去分化和免疫抑制。总体而言,本研究记录了紫外线暴露导致的皮肤癌起始过程:从克隆支系分布的变化,到由「歌利亚」克隆支系引起的肉眼可见病变发展。这些数据强调了这些转变与已知驱动突变和转录组变化之间的关系,并提示了为何相对于所存在的体细胞嵌合程度而言癌症较为罕见的一种可能解释。
Improving outcomes for patients with brain tumors remains a formidable challenge. Patient survival is often considered very poor even though standard first line treatments include surgery, radiotherapy, and chemotherapy. These therapies often have detrimental side effects on brain functions and do not suffice when tumors advance and metastasize, prompting the need for new treatment modalities. Recent innovations in antibody-based immunotherapies may complement brain cancer treatment. Biotechnical engineering platforms yield new antibody-inspired biomolecules for optimal engagement of specific and tumor-associated antigens, which also recruit and elicit immune effector cell functions. Here, we review current advances on multi-specific immune cell engagers for brain tumor treatment and provide novel insights into overcoming existing challenges.
中文摘要:改善脑肿瘤患者的结局仍然是一项艰巨挑战。尽管标准一线治疗包括手术、放疗和化疗,患者的生存率常被认为极低。这些治疗往往对脑功能产生有害副作用,并且当肿瘤进展和转移时并不足够,从而促使人们需要新的治疗方式。近期基于抗体的免疫疗法创新可能补充脑癌治疗。生物技术工程平台可产生新的抗体启发型生物分子,以最佳方式结合特定抗原和肿瘤相关抗原,同时招募并激发免疫效应细胞功能。在此,我们综述用于脑肿瘤治疗的多特异性免疫细胞衔接器的当前进展,并为克服现有挑战提供新的见解。
CD19-directed chimeric antigen receptor (CAR)-T cells are breakthrough therapies for large B-cell lymphomas, but fewer than half of patients achieve durable responses. We previously showed RHOA deletions are enriched in progressing cases, but the role of RHOA deficiency is poorly defined despite frequent occurrence in newly diagnosed disease. Here we show RHOA loss downregulates CD19, promoting cell-intrinsic resistance to CAR-19 in vitro and in vivo. CD19 decline, however, provides an incomplete explanation of resistance and would not explain high frequency of the deletion in newly diagnosed cases. We therefore performed single-cell assessments of immunocompetent RHOA-deficient lymphoma microenvironments, revealing remarkable concordance with features in CAR-19-resistant patients. Despite increased microenvironmental production of interferon gamma (IFNγ), RHOA-deficient tumor cells themselves show impaired response to the cytokine including failed induction of Class I MHC molecules. Overall, we describe for the first time how a single-gene alteration recurrent in CAR-19-resistant lymphoma contributes to treatment failures.
中文摘要:靶向CD19的嵌合抗原受体(CAR)T细胞是大B细胞淋巴瘤的突破性疗法,但不到一半的患者能获得持久缓解。我们此前表明,RHOA缺失在疾病进展病例中富集,但尽管该缺失在新诊断疾病中频繁出现,RHOA缺陷的作用仍不明确。在此,我们显示RHOA缺失会下调CD19,从而在体外和体内促进对CAR-19的细胞内在耐药。然而,CD19下降只能部分解释耐药,且无法解释该缺失在新诊断病例中的高频率。因此,我们对具有免疫能力的RHOA缺陷淋巴瘤微环境进行了单细胞评估,发现其与CAR-19耐药患者中的特征高度一致。尽管微环境中干扰素γ(IFNγ)产生增加,但RHOA缺陷的肿瘤细胞本身对该细胞因子的反应受损,包括未能诱导I类MHC分子。总体而言,我们首次描述了一种在CAR-19耐药淋巴瘤中反复出现的单基因改变如何导致治疗失败。
Castration-resistant prostate cancer (CRPC) progression despite treatment with potent androgen receptor (AR) antagonists such as enzalutamide is a major clinical challenge. The mitotic kinase BUB1B is a central member of an oncogenic seven-gene network that drives CRPC. Here, we characterized BUB1B as an actionable therapeutic target for treatment-resistant PC. High BUB1B expression correlated with PC progression and aggressiveness. BUB1B depletion blocked CRPC cell proliferation through accumulation in G2/M and mitotic delay. Conversely, ectopic expression of BUB1B conferred castration and enzalutamide resistance to androgen-dependent PC cells in vitro and in vivo. BUB1B promotion of CRPC was not dependent on AR canonical signaling as assessed through AR knockdown and PROTAC-mediated AR degradation. BUB1B kinase activity was necessary for CRPC progression, as only wild type (WT), but not two kinase-dead mutants, promoted castration-resistant growth, and BUB1B kinase activity was required to maintain castration resistance. Expression of the primary substrate of BUB1B, CENP-E, also promoted CRPC progression, while a phosphodeficient mutant of the BUB1B phosphorylation site was ineffective. Moreover, only a phosphomimic mutant of CENP-E rescued growth after BUB1B depletion in CRPC cells, indicating that BUB1B-dependent phosphorylation of CENP-E was sufficient for progression and necessary to sustain CRPC growth. Targeting CENP-E with the clinically tested, small-molecule GSK923295 phenocopied BUB1B knockdown, sensitized resistant cells to enzalutamide and suppressed growth of enzalutamide-resistant xenografts in vivo. These data support BUB1B kinase as a driver of castration and enzalutamide resistance, positioning CENP-E inhibition as an attainable approach for treatment-resistant disease.
中文摘要:去势抵抗性前列腺癌(CRPC)在强效雄激素受体(AR)拮抗剂如恩杂鲁胺治疗后仍进展,是重大临床挑战。有丝分裂激酶BUB1B是驱动CRPC的致癌七基因网络的核心成员。在此,我们将BUB1B表征为治疗抵抗性前列腺癌的可干预治疗靶点。BUB1B高表达与前列腺癌进展和侵袭性相关。敲低BUB1B通过使细胞积累于G2/M期并造成有丝分裂延迟而阻断CRPC细胞增殖。相反,BUB1B异位表达在体外和体内赋予雄激素依赖性前列腺癌细胞去势和恩杂鲁胺抵抗。通过AR敲低和PROTAC介导的AR降解评估,BUB1B促进CRPC并不依赖AR经典信号。BUB1B激酶活性是CRPC进展所必需的,因为只有野生型(WT)而非两个激酶失活突变体可促进去势抵抗性生长,并且BUB1B激酶活性是维持去势抵抗所必需的。BUB1B主要底物CENP-E的表达也促进CRPC进展,而BUB1B磷酸化位点的磷酸缺陷突变体无效。此外,在CRPC细胞中,只有CENP-E的磷酸模拟突变体可在BUB1B敲低后挽救生长,表明BUB1B依赖性的CENP-E磷酸化足以促进进展,并且是维持CRPC生长所必需的。使用经临床测试的小分子GSK923295靶向CENP-E可表型模拟BUB1B敲低,使抵抗细胞对恩杂鲁胺敏感,并在体内抑制恩杂鲁胺抵抗性异种移植瘤生长。这些数据支持BUB1B激酶是去势和恩杂鲁胺抵抗的驱动因素,将CENP-E抑制定位为治疗抵抗性疾病的一种可及方法。
High-density lipoproteins (HDL) are essential to alleviate the progression of atherosclerosis by mediating reverse-cholesterol transport, antioxidant and anti-inflammatory effects. We aimed to enhance the expression of endogenous HDL components, apolipoprotein A1 (APOA1) and antioxidant enzyme paraoxonase 1 (PON1), and to investigate their athero-protective effects. The CRISPR/dCas9 technology was used to activate the transcription of endogenous APOA1/PON1 in human hepatocytes (Huh7 line) and Apoa1/Pon1 in apoE-/- mice. The expression of APOA1/PON1 genes was successfully upregulated in hepatocytes, and their proteins were secreted in the culture medium in the presence/absence of tumor necrosis factor-α (TNFα). APOA1-rich Huh7-derived conditioned medium exerted antioxidant and anti-inflammatory effects in TNFα-activated EA.hy926 endothelial cells. A single dose of the CRISPR/dCas9 plasmids i.v. injected in apoE-/- mice increased the expression of hepatic Apoa1/Pon1 and their serum levels up to four weeks. FPLC analysis showed that increased serum APOA1 was distributed between HDL, LDL, and in lipid-free form. These mice also exhibited high levels of hepatic, gallbladder and feces cholesterol, in part due to the upregulation of hepatic scavenger receptor class-B1, cholesterol 7-alpha-hydroxylase, and ATP-binding cassette sub-family-G-member-8 transporter. In apoE-/- mice with upregulated Apoa1/Pon1, no increased inflammatory stress or innate immune activation were detected, while lipid peroxides were decreased in PON1 mice. Of major interest, the area of aortic lipid deposits was halved in the treated mice. Our findings demonstrate the successful upregulation of endogenous Apoa1/Pon1 in apoE-/- mice by using the CRISPR/dCas9 system, and highlight new mechanisms for APO1/PON1 anti-atherosclerotic action, explaining the reduction of aortic lipid deposits.
中文摘要:高密度脂蛋白(HDL)通过介导胆固醇逆向转运、抗氧化和抗炎作用,对于缓解动脉粥样硬化进展至关重要。我们旨在增强内源性HDL组分载脂蛋白A1(APOA1)和抗氧化酶对氧磷酶1(PON1)的表达,并研究其抗动脉粥样硬化保护作用。采用CRISPR/dCas9技术激活人肝细胞(Huh7细胞系)中内源性APOA1/PON1以及apoE-/-小鼠中Apoa1/Pon1的转录。APOA1/PON1基因在肝细胞中成功上调,并且在有/无肿瘤坏死因子-α(TNFα)存在时,其蛋白分泌到培养基中。富含APOA1的Huh7来源条件培养基在TNFα激活的EA.hy926内皮细胞中发挥抗氧化和抗炎作用。向apoE-/-小鼠静脉注射单剂CRISPR/dCas9质粒后,肝脏Apoa1/Pon1表达及其血清水平升高持续至四周。FPLC分析显示,升高的血清APOA1分布于HDL、LDL以及无脂质形式中。这些小鼠还表现出肝脏、胆囊和粪便胆固醇水平升高,部分原因是肝脏B类清道夫受体1、胆固醇7α-羟化酶和ATP结合盒亚家族G成员8转运体上调。在Apoa1/Pon1上调的apoE-/-小鼠中,未检测到炎症应激或固有免疫激活增加,而PON1小鼠中脂质过氧化物降低。最引人关注的是,治疗小鼠的主动脉脂质沉积面积减少了一半。我们的研究结果表明,使用CRISPR/dCas9系统成功上调了apoE-/-小鼠内源性Apoa1/Pon1,并揭示了APO1/PON1抗动脉粥样硬化作用的新机制,解释了主动脉脂质沉积减少。
High-iodine groundwater is a widespread hydrogeochemical anomaly and an important environmental and health concern worldwide. It is commonly distributed in arid and semi-arid inland basins, alluvial plains, and coastal zones influenced by seawater intrusion. Its formation is governed by coupled hydrogeochemical and biogeochemical processes. Long-term exposure to high-iodine groundwater is associated with adverse health outcomes, particularly thyroid dysfunction and increased risks of goiter and thyroid cancer. Because in situ remediation alone is often insufficient to ensure sustained reduction of iodine to levels suitable for safe drinking water, engineered water treatment remains the most direct and reliable option. Among them adsorption is widely studied and practically relevant treatment approach. This review critically evaluates the adsorbent materials relevant to high-iodine groundwater remediation, including metal-based materials, carbonaceous adsorbents and functionalized organic materials. These materials target the dominant groundwater iodine species through distinct mechanisms such as ion exchange, strong metal-iodine interactions, moderate oxidation-adsorption coupling, and multi-site binding enabled by tailored functional groups or pore environments. Current evidence shows that adsorbent performance depends not only on adsorption capacity, but also on species selectivity, matrix tolerance, and practical applicability under trace-level and chemically complex groundwater conditions. However, most existing adsorbents remain limited by narrow iodine-species selectivity, interference from competing anions and natural organic matter, and insufficient evidence for regeneration and field applicability. This review highlights the key material classes, mechanistic foundations, critical limitations, and design principles that should guide the development of selective, robust, and practically usable adsorbents for high-iodine groundwater remediation.
中文摘要:高碘地下水是一种广泛分布的水文地球化学异常现象,也是全球重要的环境与健康问题。它通常分布于干旱和半干旱内陆盆地、冲积平原以及受海水入侵影响的沿海地区。其形成受水文地球化学和生物地球化学过程的耦合控制。长期暴露于高碘地下水与不良健康结局相关,尤其是甲状腺功能障碍以及甲状腺肿和甲状腺癌风险增加。由于仅靠原位修复往往不足以确保将碘持续降低至适合安全饮用的水平,工程水处理仍是最直接且可靠的选择。其中,吸附是被广泛研究且具有实际相关性的处理方法。本综述批判性评估了与高碘地下水修复相关的吸附剂材料,包括金属基材料、碳质吸附剂和功能化有机材料。这些材料通过不同机制靶向地下水中的主要碘形态,例如离子交换、强金属-碘相互作用、适度氧化-吸附耦合,以及由定制官能团或多孔环境实现的多位点结合。当前证据表明,吸附剂性能不仅取决于吸附容量,还取决于形态选择性、基质耐受性以及在痕量水平和化学复杂地下水条件下的实际适用性。然而,大多数现有吸附剂仍受限于碘形态选择性窄、竞争性阴离子和天然有机物的干扰,以及再生和现场适用性证据不足。本综述强调了关键材料类别、机制基础、主要局限性和设计原则,以指导开发用于高碘地下水修复的选择性强、稳健且实际可用的吸附剂。
Immunotherapy has emerged as a revolutionary therapeutic approach to treat cancer showing remarkable clinical responses. However, its efficacy in solid tumours such as prostate cancer (PCa) remains very limited due to a highly immunosuppressive tumour immune microenvironment (TIME) that hampers cytotoxic T cell infiltration and activity. Here, we show that lysine methyltransferase 9 (KMT9) governs the formation of an immunosuppressive TIME in PCa. KMT9 regulates the expression of tumour-secreted myeloid-attracting C-X-C motif chemokine receptor 2 (CXCR2) ligands such as C-X-C motif chemokine ligand 5 (CXCL5) thereby promoting the infiltration of immunosuppressive polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) within tumours. These changes collectively result in decreased activation and exclusion of cytotoxic T cells from tumour glands. Furthermore, we demonstrate that KMT9 confers tumour cell-resistance to T cell cytotoxicity by regulating expression of arginase 1 (ARG1). Accordingly, KMT9α ablation results in inhibition of prostate tumour growth accompanied by a massive reduction of PMN-MDSC recruitment and a significant increase in cytotoxic T cell activation and infiltration of the prostate tumour glands. Together, we uncovered KMT9 as a regulator of immune evasion that promotes an immune-excluded TIME in prostate tumours. Furthermore, our findings establish KMT9 as a therapeutic target to reprogram the immunosuppressive landscape and potentially improve the clinical efficacy of current immunotherapies.
中文摘要:免疫治疗已成为一种革命性的癌症治疗方法,显示出显著的临床反应。然而,其在实体瘤如前列腺癌(PCa)中的疗效仍然非常有限,因为高度免疫抑制的肿瘤免疫微环境(TIME)阻碍了细胞毒性T细胞的浸润和活性。在此,我们表明赖氨酸甲基转移酶9(KMT9)调控前列腺癌中免疫抑制性TIME的形成。KMT9调节肿瘤分泌的髓系招募性C-X-C趋化因子受体2(CXCR2)配体如C-X-C趋化因子配体5(CXCL5)的表达,从而促进免疫抑制性多形核髓源性抑制细胞(PMN-MDSCs)在肿瘤内的浸润。这些变化共同导致细胞毒性T细胞活化降低并被排除于肿瘤腺体之外。此外,我们证明KMT9通过调节精氨酸酶1(ARG1)的表达赋予肿瘤细胞对T细胞细胞毒性的抵抗。相应地,KMT9α缺失导致前列腺肿瘤生长抑制,同时伴随PMN-MDSC招募大幅减少以及细胞毒性T细胞活化和浸润前列腺肿瘤腺体显著增加。总之,我们揭示了KMT9作为免疫逃逸调节因子,促进前列腺肿瘤中免疫排斥型TIME。此外,我们的发现确立KMT9作为治疗靶点,可重编程免疫抑制格局,并可能提高当前免疫治疗的临床疗效。
Ferroptosis, an iron-dependent cell death, emerged as a new therapeutic approach to treat diseases such as cancer or diabetes. Several pathological conditions are characterized by the appearance of chronic hypoxia, which is known to attract immune cells, especially monocytes and macrophages. Therefore, we investigated how chronic hypoxia affects ferroptosis in primary human macrophages and THP-1 cells. Chronic but not acute hypoxia sensitized cells towards ferroptosis, in line with elevated cellular as well as mitochondrial lipid peroxides, and mitochondrial ROS. Time kinetics revealed an earlier increase in lipid peroxidation under chronic hypoxia compared to normoxia, which was followed by mitochondrial lipid peroxidation and mitochondrial ROS. Mechanistically, and in contrast to normoxia and/or acute hypoxia, chronic hypoxia diminished nuclear abundance and activity of the antioxidant transcription factor NRF2. Consequently, NRF2 target gene expression, including ferroptosis suppressor protein 1 (FSP1), decreased. Inhibition or knockdown of FSP1 mimicked the ferroptosis-sensitizing effect of chronic hypoxia. To causatively link decreased NRF2 activity to increased ferroptosis under hypoxia, we inhibited KEAP1, which preserved NRF2 activity, increased FSP1 expression, and decreased ferroptosis. Our data provides novel insights into NRF2 regulation under chronic hypoxia linked to FSP1 expression and ferroptosis sensitivity of primary human macrophages.
中文摘要:铁死亡是一种铁依赖性细胞死亡,已成为治疗癌症或糖尿病等疾病的新治疗策略。多种病理状态以慢性缺氧为特征,已知慢性缺氧会招募免疫细胞,尤其是单核细胞和巨噬细胞。因此,我们研究了慢性缺氧如何影响原代人巨噬细胞和 THP-1 细胞中的铁死亡。慢性缺氧而非急性缺氧使细胞对铁死亡敏感,这与细胞及线粒体脂质过氧化物和线粒体 ROS 升高一致。时间动力学显示,与常氧相比,慢性缺氧下脂质过氧化增加更早出现,随后是线粒体脂质过氧化和线粒体 ROS。在机制上,与常氧和/或急性缺氧相比,慢性缺氧降低了抗氧化转录因子 NRF2 的核内丰度和活性。因此,包括铁死亡抑制蛋白 1(FSP1)在内的 NRF2 靶基因表达下降。抑制或敲低 FSP1 模拟了慢性缺氧的铁死亡增敏效应。为了将 NRF2 活性降低与缺氧下铁死亡增加建立因果联系,我们抑制了 KEAP1,这保留了 NRF2 活性,增加了 FSP1 表达,并减少了铁死亡。我们的数据为慢性缺氧下 NRF2 调控及其与 FSP1 表达和原代人巨噬细胞铁死亡敏感性的联系提供了新见解。
Gallium (Ga) is an iron-mimetic metal with broad-spectrum antimicrobial activity and emerging potential in bone regeneration and localized cancer therapy. However, its biomedical translation is limited by unfavorable pharmacokinetics, systemic exposure, and hydrolytic instability of free Ga3 + under physiological conditions. Hydrogels offer a versatile strategy by stabilizing gallium species, enhancing local retention, regulating release, and providing tissue-compatible interfaces and microenvironmental modulation. This review focuses on how hydrogel design can stabilize different gallium species, control their local availability, and improve therapeutic performance across distinct pathological microenvironments. We summarize gallium bioactivity and speciation, classify gallium-containing hydrogels according to gallium incorporation and network interactions, and analyze how network architecture, coordination chemistry, degradation, and external stimuli govern retention and release. Emerging applications include infected wound and biofilm treatment, bone repair, localized cancer therapy, and other site-specific interventions. We further discuss iron competition, immune regulation, cytotoxicity, liquid-metal stability, and translational barriers, and outline directions for mechanism-guided and quantitatively standardized gallium-hydrogel design.
中文摘要:镓(Ga)是一种铁模拟金属,具有广谱抗菌活性,并在骨再生和局部癌症治疗中展现出新兴潜力。然而,其生物医学转化受到不良药代动力学、全身暴露以及生理条件下游离Ga3+水解不稳定的限制。水凝胶通过稳定镓物种、增强局部滞留、调节释放,并提供组织相容性界面和微环境调控,提供了一种多用途策略。本综述聚焦水凝胶设计如何稳定不同镓物种、控制其局部可利用性,并改善在不同病理微环境中的治疗性能。我们总结镓的生物活性和形态分布,根据镓的引入方式和网络相互作用对含镓水凝胶进行分类,并分析网络结构、配位化学、降解和外部刺激如何调控滞留与释放。新兴应用包括感染伤口和生物膜治疗、骨修复、局部癌症治疗以及其他部位特异性干预。我们进一步讨论铁竞争、免疫调节、细胞毒性、液态金属稳定性及转化障碍,并概述机制指导且定量标准化的镓-水凝胶设计方向。
Antiseizure medications, such as levetiracetam, are commonly used in glioma patients. Retrospective analyses evaluating effects of antiseizure medications on glioma patient survival have yielded inconsistent results, probably due to confounding factors of glioma subtype and drug class. Here we present retrospective real-world clinical data that demonstrate longer overall survival for children with diffuse midline glioma (DMG) who were taking levetiracetam, which was not evident in pediatric patients with hemispheric high-grade glioma. In preclinical models, levetiracetam reduces glioma proliferation and tumor burden, extending survival of mice bearing DMG orthotopic xenografts. These beneficial effects were not found in hemispheric high-grade glioma patient-derived orthotopic xenograft models. The subtype-specificity of this antiproliferative effect of levetiracetam is congruent with recent findings that GABAergic neuron-to-glioma synapses promote glioma growth in DMG but not hemispheric high-grade glioma. We demonstrate here that levetiracetam attenuates low-frequency GABAergic synaptic transmission in a glioma-specific manner, reducing GABAergic synaptic currents in DMG but not in healthy neurons. This effect is independent of action on SV2A, the chief mechanism by which levetiracetam functions to prevent and treat seizures. Taken together, these findings indicate a promising approach to target GABAergic synapses in DMG and suggest that use of levetiracetam in DMG should be further studied in future prospective clinical studies.
中文摘要:抗癫痫发作药物,如左乙拉西坦,常用于胶质瘤患者。评估抗癫痫发作药物对胶质瘤患者生存影响的回顾性分析结果不一致,可能由于胶质瘤亚型和药物类别的混杂因素所致。在此,我们提供回顾性真实世界临床数据,显示服用左乙拉西坦的弥漫中线胶质瘤(DMG)患儿总生存期更长,而在半球高级别胶质瘤患儿中未观察到这一现象。在临床前模型中,左乙拉西坦减少胶质瘤增殖和肿瘤负荷,延长携带DMG原位异种移植瘤小鼠的生存期。这些有益效应在半球高级别胶质瘤患者来源的原位异种移植瘤模型中未发现。左乙拉西坦这种抗增殖效应的亚型特异性与近期发现一致:GABA能神经元到胶质瘤的突触促进DMG中的胶质瘤生长,但不促进半球高级别胶质瘤生长。我们在此证明,左乙拉西坦以胶质瘤特异性方式减弱低频GABA能突触传递,降低DMG中的GABA能突触电流,但不降低健康神经元中的GABA能突触电流。该效应独立于其对SV2A的作用,而SV2A是左乙拉西坦预防和治疗癫痫发作的主要作用机制。综上所述,这些发现提示了一种靶向DMG中GABA能突触的有前景的方法,并提示左乙拉西坦在DMG中的应用应在未来前瞻性临床研究中进一步研究。
PPARγ coactivator 1 alpha (PGC1α) is a master transcriptional coregulator of metabolism, and its activity mirrors many of the effects of hypoxia signaling in prostate cancer (PCa). Whereas PGC1α restrains PCa progression through its association with the estrogen-related receptor alpha (ERRα) and is a predictor of better patient outcome, hypoxia signaling is associated with poor prognosis. However, their interplay in PCa remains poorly understood. Here we show that the PGC1α/ERRα complex reduces the protein levels of Hypoxia Inducible transcription Factor alpha (HIFα). Moreover, loss of PGC1α is associated with the establishment of an autocrine pseudohypoxic state. Mechanistically, the transcriptional complex formed by PGC1α and ERRα binds to the EGLN1 promoter, induces PHD2 expression, and triggers canonical HIFα proteasomal degradation. This mechanism is oxygen-dependent and thus is prevented under severe hypoxia. Importantly, this regulatory axis provides a new component to the tumor-suppressive activity of the PGC1α/ERRα complex. Specifically, EGLN1 silencing partially reverts PGC1α-mediated PCa tumor suppressive properties both in cellulo and in vivo. Our findings are reinforced by a positive correlation between PGC1α/ERRα activity and EGLN1 expression levels in human PCa datasets. Altogether, these results support that PHD2-regulated degradation of HIFα contributes to PGC1α/ERRα-mediated PCa suppression.
中文摘要:PPARγ辅激活因子1α(PGC1α)是代谢的主转录辅调节因子,其活性反映了前列腺癌(PCa)中缺氧信号通路的诸多效应。PGC1α通过与雌激素相关受体α(ERRα)结合抑制PCa进展,并可预测患者预后较好,而缺氧信号则与不良预后相关。然而,二者在PCa中的相互作用仍知之甚少。本研究表明,PGC1α/ERRα复合物可降低缺氧诱导转录因子α(HIFα)的蛋白水平。此外,PGC1α缺失与自分泌假性缺氧状态的建立相关。机制上,PGC1α与ERRα形成的转录复合物结合EGLN1启动子,诱导PHD2表达,并触发经典的HIFα蛋白酶体降解。该机制依赖于氧气,因此在严重缺氧条件下受到抑制。重要的是,该调控轴为PGC1α/ERRα复合物的抑瘤活性提供了新组分。具体而言,EGLN1沉默可部分逆转PGC1α介导的PCa抑瘤特性,这在细胞水平和体内均得到验证。我们在人PCa数据集中发现PGC1α/ERRα活性与EGLN1表达水平呈正相关,进一步支持上述发现。总之,这些结果支持PHD2调控的HIFα降解参与PGC1α/ERRα介导的PCa抑制。
Synthetic chemistry within living systems offers a transformative strategy for precision medicine by enabling the targeted generation of therapeutic agents directly at disease sites. Carbon monoxide (CO), an endogenous gasotransmitter upregulated in many cancer phenotypes, represents a unique yet underexploited chemical feedstock for such intracellular synthesis. However, the intrinsically low reactivity of CO necessitates transition-metal mediation, which is typically compromised by rapid deactivation by intracellular thiols such as glutathione (GSH). Here, we present a biocompatible albumin-palladacycle complex (APC) platform that harnesses endogenous CO for two distinct functions: the detection of CO levels and the in situ synthesis of cytotoxic phenanthridinone derivatives-a privileged scaffold found in potent poly(ADP-ribose) polymerase (PARP) and topoisomerase inhibitors. Central to this design is a coumarin anchor that directs the palladium center into the hydrophobic binding pocket of albumin, shielding it from thiol-mediated poisoning while facilitating cellular uptake via endocytosis. We demonstrate that this system effectively detects elevated CO in cancer cells and, in a parallel application, enables the in situ synthesis of pharmacologically active agents. Although the associated cytotoxicity is modest, the approach nonetheless suppresses cancer cell growth. This study considerably advances the proof of concept for "therapeutic in vivo synthetic chemistry," in which disease-associated metabolites are repurposed as structural building blocks for both diagnostic and therapeutic applications.
中文摘要:在活体系统内进行合成化学为精准医学提供了一种变革性策略,能够在疾病部位直接靶向生成治疗药物。一氧化碳(CO)是一种内源性气体信号分子,在许多癌症表型中上调,代表了一种独特但尚未被充分利用的化学原料,可用于此类细胞内合成。然而,CO固有的低反应性需要过渡金属介导,而过渡金属通常会因细胞内硫醇如谷胱甘肽(GSH)的快速失活而受到损害。在此,我们提出了一种生物相容的白蛋白-钯环配合物(APC)平台,该平台利用内源性CO实现两种不同的功能:检测CO水平以及原位合成细胞毒性菲啶酮衍生物——这是一种在强效聚(ADP-核糖)聚合酶(PARP)和拓扑异构酶抑制剂中存在的优势骨架。该设计的核心是一个香豆素锚,它将钯中心引导进入白蛋白的疏水结合口袋,保护其免受硫醇介导的毒化,同时通过内吞作用促进细胞摄取。我们证明,该系统能有效检测癌细胞中升高的CO,并在平行应用中实现药理活性剂的原位合成。尽管相关细胞毒性较为温和,但该方法仍能抑制癌细胞生长。这项研究显著推进了「治疗性体内合成化学」的概念验证,其中疾病相关代谢物被重新利用为诊断和治疗应用的结构砌块。
Head and neck cancer (HNC) exhibits significant heterogeneity, leading to variable treatment responses and unstable efficacy of non-coding RNA (ncRNA) therapies, which presents a major challenge in clinical management. ncRNAs, including miRNAs, lncRNAs, and circRNAs, play pivotal roles in regulating tumor initiation, progression, and drug resistance. However, their expression and function are dynamically reshaped by tumor heterogeneity, thereby compromising the stability and predictability of ncRNA-based therapies. This article first systematically reviews the current research landscape of different ncRNAs in HNC at the molecular level. It further explores the challenges posed by heterogeneity in ncRNA therapy concerning delivery, target selection, and microenvironmental interference. Subsequently, it summarizes various countermeasures and future directions, including those based on precision diagnostics, novel delivery systems, gene editing technologies, and multimodal combination strategies. Finally, the article prospects the application potential of individualized ncRNA treatment strategies that integrate heterogeneity information in the future of precision medicine for HNC.
中文摘要:头颈癌(HNC)表现出显著的异质性,导致治疗反应差异以及非编码RNA(ncRNA)疗法疗效不稳定,这给临床管理带来了重大挑战。包括miRNA、lncRNA和circRNA在内的ncRNA在调控肿瘤发生、进展和耐药中发挥关键作用。然而,其表达和功能受到肿瘤异质性的动态重塑,从而削弱了基于ncRNA疗法的稳定性和可预测性。本文首先在分子层面系统综述了不同ncRNA在HNC中的研究现状。随后探讨了异质性在ncRNA疗法的递送、靶点选择及微环境干扰方面带来的挑战。接着总结了多种应对策略和未来方向,包括基于精准诊断、新型递送系统、基因编辑技术以及多模式联合策略等。最后,展望了整合异质性信息的个体化ncRNA治疗策略在HNC精准医学未来中的应用潜力。
TP53 mutations occur early in malignant transformation as truncal events in tumor evolution and are therefore generally present in all descendant tumor cells, creating an immunological vulnerability. Here, we examined the immunogenicity and antigenicity of p53 neoantigens emerging from these truncal mutations. Comprehensive immunopeptidomics revealed that hotspot mutations in human tumors preferentially localize to p53 regions resistant to antigen processing, thereby avoiding display altogether. Moreover, for neoantigens presentable by HLA-A∗02:01 or HLA-B∗07:02 and structurally divergent from corresponding wild-type p53 peptide-HLA complexes, clinical tumors commonly lacked the relevant presenting HLA allele. Tumor cells further resisted T cell killing through increased activity of the aminopeptidase ERAP1, preventing display of high-affinity HLA-A∗02:01 complexes containing an immunogenic p53I195F-derived 11-mer, or by expressing low-affinity HLA-A∗02:01 complexes containing a p53R175H-derived 9-mer with poor antigenicity despite high-quality human TCRs. These findings define mechanisms by which tumors restrict targetable truncal neoantigen display and suggest immunopeptidome shift strategies to circumvent immune escape.
中文摘要:TP53突变在恶性转化早期作为肿瘤演化中的主干事件发生,因此通常存在于所有子代肿瘤细胞中,形成了一种免疫学上的易感性。在此,我们研究了由这些主干突变产生的p53新抗原的免疫原性和抗原性。全面的免疫肽组学显示,人类肿瘤中的热点突变优先定位于p53中对抗原加工具有抗性的区域,从而完全避免展示。此外,对于可由HLA-A∗02:01或HLA-B∗07:02呈递、且与相应野生型p53肽-HLA复合物结构不同的新抗原,临床肿瘤通常缺乏相关呈递HLA等位基因。肿瘤细胞还通过增强氨肽酶ERAP1活性来抵抗T细胞杀伤,阻止含有免疫原性p53I195F衍生11聚体的高亲和力HLA-A∗02:01复合物展示,或通过表达含有p53R175H衍生9聚体的低亲和力HLA-A∗02:01复合物,尽管存在高质量的人类TCR,其抗原性仍较差。这些发现明确了肿瘤限制可靶向主干新抗原展示的机制,并提示可通过免疫肽组转变策略来规避免疫逃逸。
Interpreting the biological and clinical significance of somatic mutations in cancer genomes remains challenging. In this issue of Cancer Cell, Hyeon et al. identify and map significantly mutated regions to protein domains and structural features, establishing a proteo-genomics framework for interpreting cancer mutations beyond genes and hotspots.
中文摘要:解读癌症基因组中体细胞突变的生物学与临床意义仍具挑战性。在本期《Cancer Cell》中,Hyeon等人识别并将显著突变区域定位到蛋白质结构域及结构特征,建立了一个蛋白质组-基因组学框架,用于在基因和热点之外解读癌症突变。
We present Tahoe-100M, a giga-scale single-cell perturbation atlas comprising 100 million transcriptomes from 50 diverse cancer cell lines treated with 1,100 drug-dose conditions. This parallel profiling of thousands of perturbations at single-cell resolution with minimal batch effects is enabled by the Mosaic platform, which multiplexes genetically distinct cell models into balanced "cell villages." Beyond cataloging transcriptomic shifts, Tahoe-100M systematically quantifies cellular phenotypes, including proliferation, cytotoxicity, lineage-specific vulnerabilities, and cell-cycle changes. It captures population-level transcriptomic heterogeneity, characterizing whether drug responses drive cells toward divergent fates or convergent states. Pathway-based signatures define drug-induced expression programs, classify mechanisms of action, reveal off-target activities, and expose adaptive stress responses associated with resistance. By unifying cellular and molecular readouts, this broadly applicable perturbation atlas advances our ability to model gene regulation, drug response, and network dynamics. Its public release enables the training of AI frameworks to advance predictive models of cell behavior.
中文摘要:我们提出 Tahoe-100M,一个超大规模单细胞扰动图谱,包含来自 50 种不同癌细胞系的 1 亿个转录组,这些细胞系接受了 1,100 种药物-剂量条件处理。Mosaic 平台通过将遗传上不同的细胞模型多重化并平衡为「细胞村落」,实现了在单细胞分辨率下对数千种扰动的并行分析,且批次效应极小。除编目转录组变化外,Tahoe-100M 系统量化细胞表型,包括增殖、细胞毒性、谱系特异性易感性和细胞周期变化。它捕获群体水平的转录组异质性,表征药物反应是驱使细胞走向分歧命运还是趋同状态。基于通路的特征定义了药物诱导的表达程序,对作用机制进行分类,揭示脱靶活性,并暴露与耐药相关的适应性应激反应。通过统一细胞和分子读数,这一广泛适用的扰动图谱提升了我们建模基因调控、药物反应和网络动态的能力。其公开发布使得能够训练 AI 框架,以推进细胞行为的预测模型。
Targeting metabolic dependencies of leukemic stem cells (LSC) may open avenues to improve outcomes of patients suffering from acute myeloid leukemia (AML). LSCs rely heavily on an active tricarboxylic acid (TCA) cycle and mitochondrial oxidative phosphorylation whereas healthy hematopoietic stem and progenitor cells (HSPCs) possess more metabolic flexibility. Here, we identify the TCA cycle enzyme isocitrate dehydrogenase 3 (IDH3) as a critical and selective regulator of LSC maintenance. IDH3 is more abundant in LSCs compared to healthy HSPCs, and TCA cycle activity correlates with inferior clinical outcomes of AML patients. Knockdown of IDH3A, the catalytic subunit of the complex, impairs colony-forming potential and bone marrow organoid as well as in vivo engraftment of AML, while sparing healthy hematopoiesis. Mechanistically, IDH3A downregulation reduces TCA cycle flux and leads to accumulation of intracellular citrate, impairing both glycolysis and oxidative phosphorylation. The resulting bioenergetic crisis activates AMPK and suppresses mTORC1, leading to reduced translational activity and an imbalance of anti-apoptotic proteins. Consequently, IDH3A-KD cells show enhanced susceptibility to BCL2 inhibition by venetoclax in vitro and in vivo. In a clinical cohort, LSCs from patients resistant to venetoclax/azacitidine (Ven/Aza) exhibit transcriptomic programs indicative of active TCA cycle and glycolysis. We demonstrate that downregulation of IDH3A activity and subsequent citrate accumulation directly affect these pathways and shift AML stem cells towards a metabolic state of increased vulnerability. In summary, we establish IDH3 as a metabolic rheostat in LSCs and suggest targeting the IDH3A-citrate axis to overcome Ven/Aza resistance of AML patients.
中文摘要:靶向白血病干细胞(LSC)的代谢依赖可能为改善急性髓系白血病(AML)患者结局开辟途径。LSC高度依赖活跃的三羧酸(TCA)循环和线粒体氧化磷酸化,而健康造血干/祖细胞(HSPC)具有更强的代谢灵活性。在此,我们将TCA循环酶异柠檬酸脱氢酶3(IDH3)鉴定为LSC维持的关键且选择性调节因子。与健康HSPC相比,IDH3在LSC中更丰富,且TCA循环活性与AML患者较差的临床结局相关。敲低该复合物的催化亚基IDH3A会损害AML的集落形成潜力、骨髓类器官以及体内植入能力,同时不损害健康造血。机制上,IDH3A下调降低TCA循环通量并导致细胞内柠檬酸积累,从而损害糖酵解和氧化磷酸化。由此产生的生物能量危机激活AMPK并抑制mTORC1,导致翻译活性降低和抗凋亡蛋白失衡。因此,IDH3A敲低细胞在体外和体内对维奈克拉抑制BCL2更为敏感。在一个临床队列中,对维奈克拉/阿扎胞苷(Ven/Aza)耐药患者的LSC表现出提示TCA循环和糖酵解活跃的转录组程序。我们证明,下调IDH3A活性及随后的柠檬酸积累直接影响这些通路,并将AML干细胞转向更易受损的代谢状态。总之,我们确立IDH3作为LSC中的代谢变阻器,并提出靶向IDH3A-柠檬酸轴以克服AML患者的Ven/Aza耐药。
Genomic integrity in transcriptionally active regions is pivotal for suppressing oncogenic mutations, yet the mechanisms that govern precise homologous recombination (HR) repair within these regions remain elusive. Here, we report that the IRAK1-spliceosome axis operates with small nuclear RNA (snRNA) as a central hub, potently promoting accurate repair at DNA double-strand break (DSB) sites within active chromatin in human cancer cells. Mechanistically, IRAK1 phosphorylates spliceosomal serine/arginine (SR)-rich proteins to recruit snRNA to DSBs, inducing robust condensation of the MRE11-RAD50-NBS1 (MRN) complex near transcriptionally active regions to create an ATM activation platform. Collectively, our findings define a prevalent mechanism governing region-specific precise repair in transcriptionally active domains, where snRNA acts as a "transcription repair bridge" to link transcriptional processes to HR repair and ultimately preserves genomic stability. Inhibiting IRAK1 axis impairs HR repair in transcriptionally active regions, causing a marked increase in mutation rates specific to these regions and cancer-cell chemosensitivity.
中文摘要:转录活跃区域的基因组完整性对于抑制致癌突变至关重要,然而,调控这些区域内精确同源重组(HR)修复的机制仍不清楚。在此,我们报道,IRAK1-剪接体轴以小核RNA(snRNA)为中心枢纽发挥作用,在人类癌细胞中有效促进活跃染色质内DNA双链断裂(DSB)位点的精确修复。机制上,IRAK1磷酸化剪接体富含丝氨酸/精氨酸(SR)的蛋白,将snRNA招募至DSB,诱导MRE11-RAD50-NBS1(MRN)复合物在转录活跃区域附近强烈凝聚,从而形成ATM激活平台。总体而言,我们的发现定义了一种在转录活跃结构域中调控区域特异性精确修复的普遍机制,其中snRNA充当「转录修复桥」,将转录过程与HR修复连接起来,最终维持基因组稳定性。抑制IRAK1轴会损害转录活跃区域的HR修复,导致这些区域特异性突变率显著升高,并增加癌细胞的化疗敏感性。
Generative AI (Gen-AI) has shown a remarkable impact in several biological research areas, from protein folding and de novo design to pathogenic mutation prediction. However, it remains unclear whether these molecular-level successes can translate to cellular and multicellular insights relevant to fields ranging from immunology to cancer and neurodegeneration. This arises from the intricate nature of the molecular mechanisms that determine cellular and organismal behavior, the lack of sufficient training data, and the multicellular nature of most pathophysiologic phenotypes. Novel Gen-AI frameworks are likely needed to integrate prior biological knowledge, such as molecular interaction networks, as well as guiding principles focusing the community's attention on solving biologically and translationally relevant problems. Drawing inspiration from Hilbert's list of 23 mathematical problems that have focused the mathematical community's attention for more than a century, we propose fifteen grand AI challenges to focus the biomedical community's attention on critically relevant questions, most of which still lack effective predictive methodologies.
中文摘要:生成式人工智能(Gen-AI)在多个生物学研究领域已展现出显著影响,从蛋白质折叠和从头设计到致病突变预测。然而,这些分子层面的成功能否转化为与免疫学、癌症和神经退行性变等领域相关的细胞及多细胞层面的见解,仍不清楚。其原因在于决定细胞和机体行为的分子机制错综复杂、缺乏充足的训练数据,以及大多数病理生理表型具有多细胞特性。可能需要新的Gen-AI框架来整合先验生物学知识,例如分子相互作用网络,以及指导原则,使社区关注解决具有生物学和转化相关性的问题。受希尔伯特提出的23个数学问题一个多世纪以来一直聚焦数学界注意力的启发,我们提出十五项宏大的人工智能挑战,以使生物医学界关注关键相关问题,其中大多数问题仍缺乏有效的预测方法。
Immunosuppressed patients with non-melanoma skin cancer experience worse clinical outcomes, yet the tumor immune microenvironment associated with systemic immunosuppression remains incompletely defined. Using integrated single-cell, spatial transcriptomic, multiplex immunofluorescence, and spatial epigenomic profiling across immunocompetent and immunosuppressed tumors, we found that overall immune-cell composition was largely preserved despite differences in immune-cell distribution, spatial organization, and T cell clonality. Immunosuppressed tumors demonstrated reduced intratumoral macrophage densities, decreased T cell clonal diversity, altered antigen-presenting cell and T cell spatial interactions, and distinct fibroblast- and macrophage-associated spatial niches. Multi-cohort validation across complementary spatial and single-cell platforms identified consistent alterations in innate-adaptive immune organization in immunosuppressed tumors. Together, these findings define spatial and functional remodeling of the tumor immune microenvironment under systemic immunosuppression and provide a framework for future therapeutic investigation in high-risk patients.
中文摘要:患有非黑色素瘤皮肤癌的免疫抑制患者临床结局更差,但全身性免疫抑制相关的肿瘤免疫微环境仍未被充分阐明。我们综合运用单细胞、空间转录组、多重免疫荧光和空间表观基因组分析,对免疫健全与免疫抑制肿瘤进行比较,发现尽管免疫细胞分布、空间组织和T细胞克隆性存在差异,总体免疫细胞组成基本保持不变。免疫抑制肿瘤表现为瘤内巨噬细胞密度降低、T细胞克隆多样性下降、抗原呈递细胞与T细胞的空间相互作用改变,以及成纤维细胞和巨噬细胞相关的独特空间生态位。跨互补空间和单细胞平台的多队列验证发现,免疫抑制肿瘤中固有免疫—适应性免疫组织存在一致的改变。总之,这些发现界定了全身性免疫抑制下肿瘤免疫微环境的空间和功能重塑,并为高危患者的未来治疗研究提供了框架。
Amino acid levels fluctuate across diverse pathological conditions. Whether such amino acid modulations directly shape pathophysiology by regulating host gene expression remains unknown. We found that extracellular arginine restriction, observed in cancer and infection, represses specific arginine tRNAs-directly suppressing translation of major histocompatibility complex I (MHC class I) and antigen presentation. Arginine regulation of MHC class I was codon-usage dependent, as synonymous codon mutations prevented MHC class I modulation. Dietary arginine restriction impaired anti-viral immunity against influenza and SARS-CoV-2 and increased colon tumorigenesis. Conversely, increasing arginine availability via dietary supplementation or myeloid-specific arginase 1 deletion enhanced MHC class I protein levels, suppressed colon tumorigenesis, and improved viral infection outcomes. These disease-modulating effects were abolished in β2-microglobulin (B2m)-deficient mice. Thus, dietary modulation of a single amino acid critically influences codon-biased translation and MHC class I-mediated immunity to respiratory viral infections and cancer, revealing an unexpected mechanism and disease hazard for arginine deficiency and highlighting potential for amino acid-based translation modulation therapy.
中文摘要:在不同病理状态下,氨基酸水平会发生波动。这种氨基酸变化是否通过调控宿主基因表达直接塑造病理生理过程,尚不清楚。我们发现,在癌症和感染中观察到的细胞外精氨酸限制会抑制特定的精氨酸tRNA,从而直接抑制主要组织相容性复合体I类(MHC I类)分子和抗原呈递的翻译。精氨酸对MHC I类的调控依赖于密码子使用,因为同义密码子突变可阻止MHC I类受到调控。膳食精氨酸限制损害了针对流感和SARS-CoV-2的抗病毒免疫,并增加了结肠肿瘤发生。相反,通过膳食补充或髓系特异性精氨酸酶1缺失来提高精氨酸可利用性,可增强MHC I类蛋白水平,抑制结肠肿瘤发生,并改善病毒感染结局。这些疾病调节效应在β2微球蛋白(B2m)缺陷小鼠中消失。因此,单一氨基酸的膳食调节关键性影响密码子偏倚翻译以及MHC I类介导的针对呼吸道病毒感染和癌症的免疫,揭示了精氨酸缺乏的一种意外机制和疾病危害,并凸显了基于氨基酸的翻译调节疗法的潜力。
Homologous recombination (HR) is an important DNA repair pathway that safeguards genome integrity. During HR, the Rad51 nucleoprotein filaments catalyze strand invasion into a homologous duplex DNA. Filament formation requires a conserved family of Rad51 paralogs that act as tumor suppressors in humans. By capturing six distinct states using cryo-electron microscopy, we reveal that the Saccharomyces cerevisiae Rad51 paralog complex, composed of the Rad55-Rad57 heterodimer and the SHU (Psy3-Csm2-Shu1-Shu2) complex, selectively brings Rad51 to single-stranded DNA to seed filament formation. Rad51 itself is a transient yet integral component of this machinery which binds along the Rad57 subunit to complete a high-affinity DNA-binding site. We also uncover a dual-nucleotide regulatory mechanism: a structural ADP molecule stabilizes the complex, while a second, catalytic ATPase site at the Rad57-Rad51 interface promotes the release of the paralog complex. These structural and mechanistic features provide a blueprint for understanding the function of Rad51 paralogs across eukaryotes.
中文摘要:同源重组(HR)是一条重要的DNA修复途径,可维护基因组完整性。在HR过程中,Rad51核蛋白丝催化链侵入同源双链DNA。丝状体形成需要保守的Rad51旁系同源蛋白家族,这些蛋白在人类中作为抑癌因子发挥作用。通过冷冻电镜捕获六种不同状态,我们揭示酿酒酵母Rad51旁系同源复合物,由Rad55-Rad57异二聚体和SHU(Psy3-Csm2-Shu1-Shu2)复合物组成,选择性将Rad51带到单链DNA上以启动丝状体形成。Rad51本身是该机器的一个瞬时但不可或缺的组分,它沿Rad57亚基结合以完成一个高亲和力DNA结合位点。我们还揭示了一种双核苷酸调控机制:一个结构性ADP分子稳定该复合物,而位于Rad57-Rad51界面的第二个催化性ATP酶位点促进旁系同源复合物的释放。这些结构和机制特征为理解真核生物中Rad51旁系同源蛋白的功能提供了蓝图。
Spatial profiling of proteins and protein interactions facilitates understanding of cell functions within tissues and is essential for studies in signaling, immunity, and cancer. We present spatial proximity sequencing (Sprox-seq) for simultaneous profiling of surface proteins, protein complexes, and mRNAs, recording the tissue location of each molecule. Sprox-seq profiled 32 proteins, 528 pairwise interactions, and thousands of mRNAs with spatial resolution across human tonsils and germinal centers. Mapping tissue-wide protein interactions recapitulated RNA-defined tissue architecture but also revealed higher interaction complexity in the light zone. Protein-interaction trajectories uncovered a B cell state transition distinct from that inferred by RNA. Integrated protein-complex and mRNA analysis related spatially enriched complexes with mitotic pathways. Sprox-seq captured cell-cell interactions, such as B cell-follicular dendritic cell interactions mediated by the receptor complex VLA-4-VCAM1. Sprox-seq provides a spatially resolved multi-modal view of cell states and an integrated study of protein and cellular interactions across tissues.
中文摘要:对蛋白质及蛋白质相互作用进行空间分析有助于理解组织内细胞功能,并且对信号传导、免疫和癌症研究至关重要。我们提出了空间邻近测序(Sprox-seq),可同时分析表面蛋白、蛋白复合物和mRNA,并记录每个分子的组织位置。Sprox-seq以空间分辨率在人类扁桃体和生发中心中分析了32种蛋白、528对相互作用以及数千种mRNA。绘制组织范围的蛋白质相互作用图谱重现了RNA定义的组织结构,但也揭示了明区中更高的相互作用复杂性。蛋白质相互作用轨迹揭示了不同于RNA推断的B细胞状态转变。整合蛋白质复合物与mRNA分析将空间富集的复合物与有丝分裂通路联系起来。Sprox-seq捕获了细胞间相互作用,例如由受体复合物VLA-4-VCAM1介导的B细胞与滤泡树突状细胞相互作用。Sprox-seq提供了细胞状态的空间分辨多模态视图,并实现了跨组织的蛋白质与细胞相互作用的整合研究。
Deletion of chromosome 17p [del(17p)] is among the most adverse cytogenetic abnormalities in multiple myeloma (MM). By integrating RNA sequencing data from cells of patients with MM with genetic dependency data from MM cell lines, we identified protein kinase membrane-associated tyrosine/threonine 1 (PKMYT1), a member of the WEE family, as a potential therapeutic target in MM cells harboring del(17p). Genetic suppression or pharmacological inhibition of PKMYT1 activity with the selective inhibitor RP-6306 triggered accumulation of DNA damage, micronucleus formation, and mitotic catastrophe, resulting in preferential cell death in del(17p) MM cells while largely sparing del(17p)- MM cells and healthy cells. RP-6306 also reduced tumor burden and extended survival in vivo in both xenograft and TP53-deficient syngeneic models. Collectively, our findings nominate PKMYT1 as an actionable target and support PKMYT1 inhibition as a biomarker-driven therapeutic strategy for patients with del(17p) or TP53-deficient MM.
中文摘要:17p染色体缺失[del(17p)]是多发性骨髓瘤(MM)中最不利的细胞遗传学异常之一。通过整合MM患者细胞的RNA测序数据与MM细胞系的遗传依赖性数据,我们鉴定出蛋白激酶膜相关酪氨酸/苏氨酸1(PKMYT1)——WEE家族成员——是携带del(17p)的MM细胞中的潜在治疗靶点。通过遗传抑制或用选择性抑制剂RP-6306药理学抑制PKMYT1活性,可引发DNA损伤积累、微核形成和有丝分裂灾难,导致del(17p) MM细胞优先死亡,同时在很大程度上不伤害del(17p)阴性MM细胞和健康细胞。RP-6306还在异种移植和TP53缺陷同基因模型中降低肿瘤负荷并延长体内生存。总之,我们的发现将PKMYT1列为可操作靶点,并支持将PKMYT1抑制作为针对del(17p)或TP53缺陷MM患者的生物标志物驱动治疗策略。
Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatric myelodysplastic syndrome or myeloproliferative disorder for which hematopoietic stem cell transplantation remains the only curative option; however, outcomes are particularly poor in patients harboring PTPN11 (encodes SHP2 phosphatase) mutations. Using a Shp2E76K/+ JMML mouse model, we identified a pathogenic interleukin-17A (IL-17A)/PTGS2/NLRP3 signaling axis that drives bone marrow inflammation, suppresses antitumor immunity, and promotes leukemic progression. Shp2E76K/+ mice exhibited profound immune dysregulation, characterized by expansion of regulatory T cells, increased T-cell exhaustion, and impaired cytotoxic function with reduced CD4+ and CD8+ T-cell frequencies. Mechanistically, mutant macrophages upregulated IL-17A, triggering NLRP3 inflammasome activation, PTGS2 induction, caspase-1 cleavage, and IL-1β maturation, thereby amplifying inflammatory signaling within the marrow niche. Therapeutically, IL-17A neutralization suppressed inflammasome activity, whereas the combined inhibition of NLRP3 and PTGS2 restored cytotoxic T-cell function, reduced systemic and marrow inflammation, reversed myeloproliferation, and significantly prolonged survival in Shp2E76K/+ mice. Importantly, ex vivo treatment of primary samples from patients with JMML with dual NLRP3/PTGS2 inhibition combined with mitogen-activated protein kinase kinase (MEK) blockade significantly reduced leukemic progenitor colony formation, supporting translational relevance. In patient-derived xenograft models of PTPN11-mutant JMML, dual NLRP3/PTGS2 inhibition combined with MEK blockade most effectively reduced leukemic burden, decreased human CD45+ engraftment, and depleted leukemic CD34+CD38+ progenitors and granulocyte-macrophage progenitors while restoring megakaryocyte-erythroid progenitor populations, resulting in significantly improved overall survival. Together, these findings establish IL-17A/PTGS2/NLRP3 signaling as a central driver of immune suppression and myeloid expansion in PTPN11-mutant JMML and highlight combinatorial anti-inflammatory targeting as a promising therapeutic strategy for this high-risk disease.
中文摘要:幼年型粒单核细胞白血病(JMML)是一种侵袭性儿童骨髓增生异常综合征或骨髓增殖性疾病,造血干细胞移植仍是唯一治愈选择;然而,携带PTPN11(编码SHP2磷酸酶)突变的患者结局尤其差。我们利用Shp2E76K/+ JMML小鼠模型,鉴定出一条致病性白介素-17A(IL-17A)/PTGS2/NLRP3信号轴,其驱动骨髓炎症、抑制抗肿瘤免疫并促进白血病进展。Shp2E76K/+小鼠表现出显著免疫失调,特征为调节性T细胞扩增、T细胞耗竭增加以及细胞毒性功能受损,同时CD4+和CD8+ T细胞频率降低。机制上,突变巨噬细胞上调IL-17A,触发NLRP3炎症小体活化、PTGS2诱导、caspase-1裂解和IL-1β成熟,从而放大骨髓微环境内的炎症信号。在治疗上,IL-17A中和可抑制炎症小体活性,而联合抑制NLRP3和PTGS2可恢复细胞毒性T细胞功能、减轻全身和骨髓炎症、逆转骨髓增殖,并显著延长Shp2E76K/+小鼠生存期。重要的是,对JMML患者原代样本进行离体双重NLRP3/PTGS2抑制联合丝裂原活化蛋白激酶激酶(MEK)阻断,可显著减少白血病祖细胞集落形成,支持其转化相关性。在PTPN11突变JMML患者来源异种移植模型中,双重NLRP3/PTGS2抑制联合MEK阻断最有效地降低白血病负荷、减少人CD45+植入、耗竭白血病CD34+CD38+祖细胞和粒-巨噬祖细胞,同时恢复巨核-红系祖细胞群体,从而显著改善总生存期。总之,这些发现确立IL-17A/PTGS2/NLRP3信号是PTPN11突变JMML中免疫抑制和髓系扩增的核心驱动因素,并强调联合抗炎靶向是这种高风险疾病有前景的治疗策略。
Peripheral T-cell lymphoma (PTCL) represents a highly heterogeneous and aggressive lymphoid neoplasm that lacks pathogenic biomarkers of RNA modification with therapeutic potential. IGF2BP2 is recognized as an N6-methyladenosine reader critically involved in oncogenesis. In this study, we observed consistently high expression of IGF2BP2 across common nodal PTCL subtypes in 3 independent external cohorts, which was further confirmed in our RNA-sequencing (RNA-seq) data set of 196 patients with newly diagnosed PTCL. Both in vitro and in vivo, IGF2BP2 promoted tumor cell growth and inhibited CD8+ T-cell infiltration within the tumor microenvironment. Mechanistically, IGF2BP2 bound to endosome-related genes (RAB4, VPS35, RAB9, and STAM) to maintain their stability, which resulted in enhanced endocytic activity and increased internalization of membrane proteins, and ultimately induced tumor cell proliferation and inhibition of CD8+ T-cell-mediated tumor cytotoxicity. The relationship between IGF2BP2 and endocytosis-associated genes was confirmed using RNA-seq data from patients with PTCL. IGF2BP2 as an upstream regulator of both tumor growth and immune suppression was further demonstrated in patient-derived xenograft models and a coculture system established using tumor samples from patients with PTCL and peripheral blood mononuclear cells. Notably, therapeutic targeting of IGF2BP2 with CWI1-2 suppressed endocytosis and impeded tumor growth in both cell lines and patient-derived xenograft models. Collectively, our findings highlight IGF2BP2 as a clinically relevant oncogenic driver in PTCL that integrates tumor-intrinsic growth signals with immune evasion through endocytosis-centered regulation, providing a novel therapeutic rationale for RNA modification-based strategies that concurrently target tumor cells and the tumor microenvironment.
中文摘要:外周T细胞淋巴瘤(PTCL)是一种高度异质性和侵袭性的淋巴系统肿瘤,缺乏具有治疗潜力的RNA修饰致病生物标志物。IGF2BP2被认为是关键参与肿瘤发生的N6-甲基腺苷阅读蛋白。在本研究中,我们在3个独立外部队列中观察到IGF2BP2在常见结内PTCL亚型中持续高表达,并在我们196例新诊断PTCL患者的RNA测序(RNA-seq)数据集中得到进一步证实。在体外和体内,IGF2BP2均促进肿瘤细胞生长并抑制肿瘤微环境中的CD8+ T细胞浸润。机制上,IGF2BP2结合内体相关基因(RAB4、VPS35、RAB9和STAM)以维持其稳定性,导致内吞活性增强和膜蛋白内化增加,并最终诱导肿瘤细胞增殖和抑制CD8+ T细胞介导的肿瘤细胞毒性。使用PTCL患者的RNA-seq数据证实了IGF2BP2与内吞相关基因之间的关系。在患者来源异种移植模型和使用PTCL患者肿瘤样本与外周血单个核细胞建立的共培养系统中,进一步证明了IGF2BP2是肿瘤生长和免疫抑制的上游调节因子。值得注意的是,使用CWI1-2治疗性靶向IGF2BP2可抑制内吞并阻碍细胞系和患者来源异种移植模型中的肿瘤生长。总之,我们的研究结果强调IGF2BP2是PTCL中具有临床相关性的致癌驱动因子,其通过以内吞为中心的调控将肿瘤内在生长信号与免疫逃逸整合,为同时靶向肿瘤细胞和肿瘤微环境的RNA修饰策略提供了新的治疗依据。
Transcription factor NRF2 (encoded by the NFE2L2 gene) is a central signalling hub that coordinates antioxidant, detoxification, anti-inflammatory and metabolic programmes to maintain cellular homeostasis, with broad relevance to degenerative diseases, chronic inflammation and cancer. NFE2L2 is transcribed from two promoters: the canonical promoter (P1) and an alternative promoter (P2), generating transcripts that differ solely in their first exon. Exon 1 of P1-derived transcripts contains the AUG start codon, whereas the considerably longer exon 1' of P2-derived transcripts forms an extended 5' untranslated region (5'UTR). Consequently, the P1-derived NRF2 isoform 1 contains 16 additional N-terminal amino acids relative to the P2-derived isoform 2. Although transcripts from both promoters are expressed in human tissues, the existence of isoform 2 protein and the functional significance of alternative promoter usage have remained unresolved. Here, we identify an endogenous NRF2 protein species consistent with isoform 2 using an isoform-specific siRNA strategy. Isoform 2 is negatively regulated by KEAP1 and retains the ability to activate canonical NRF2 target genes. Despite similar stability of the two isoforms, isoform 2 accumulates at substantially lower basal levels, which is associated with reduced translational engagement of P2-derived transcripts. Polysome profiling revealed that P1-derived transcripts are predominantly associated with polysomes, whereas P2-derived transcripts are distributed between polysomal and subpolysomal fractions. The extended P2-specific 5'UTR contains evolutionarily conserved structural features that may contribute to translational regulation. Finally, the electrophilic NRF2 activator omaveloxolone (RTA-408) induced translation of transcripts from both promoters, demonstrating that NRF2 stress response is coordinated through the combined regulation of mRNA translation and protein stability.
中文摘要:转录因子NRF2(由NFE2L2基因编码)是一个核心信号枢纽,协调抗氧化、解毒、抗炎和代谢程序以维持细胞稳态,与退行性疾病、慢性炎症和癌症广泛相关。NFE2L2由两个启动子转录:经典启动子P1和替代启动子P2,产生仅第一个外显子不同的转录本。P1来源转录本的外显子1包含AUG起始密码子,而P2来源转录本的外显子1'明显更长,形成延长的5'非翻译区(5'UTR)。因此,P1来源的NRF2异构体1比P2来源的异构体2多含16个N端氨基酸。尽管来自两个启动子的转录本均在人组织中表达,但异构体2蛋白的存在以及替代启动子使用的功能意义仍未解决。在此,我们使用异构体特异性siRNA策略鉴定出一种与异构体2一致的内源性NRF2蛋白种类。异构体2受KEAP1负调控,并保留激活经典NRF2靶基因的能力。尽管两种异构体稳定性相似,异构体2的基线积累水平显著更低,这与P2来源转录本的翻译参与减少相关。多聚核糖体分析显示,P1来源转录本主要与多聚核糖体结合,而P2来源转录本分布于多聚核糖体组分和亚多聚核糖体组分之间。延长的P2特异性5'UTR含有进化上保守的结构特征,可能有助于翻译调控。最后,亲电性NRF2激活剂omaveloxolone(RTA-408)诱导两个启动子来源转录本的翻译,表明NRF2应激反应通过mRNA翻译和蛋白稳定性的联合调控进行协调。
MicroRNAs (miRNAs) have emerged as important biomarkers for cancer diagnosis and prognosis, yet their accurate detection remains challenging due to low abundance, short sequences, and sequence homology. Herein, we report a novel biosensing platform based on a cascade cis-cleavage-triggered split activator assembly strategy by integrating catalytic hairpin assembly (CHA) with dual CRISPR/Cas12a amplification for ultrasensitive and selective miRNA detection. In contrast to conventional CHA-CRISPR assays that directly couple CHA products with Cas12a activation and suffer from crRNA-induced leakage and elevated background signals, the proposed system decouples target recognition from signal output through a split activator architecture. Target miRNA initiates CHA to generate a duplex intermediate, which is first processed by Cas12a/crRNA1 via cis-cleavage to release a fragmentary DNA trigger. This fragment subsequently assembles with a predesigned auxiliary strand to form a complete activator, enabling secondary activation of Cas12a/crRNA2 and leading to amplified trans-cleavage signals. This cascade design significantly suppresses nonspecific background while enabling sequential signal amplification, resulting in substantially improved signal-to-noise ratios and enhanced analytical performance. The developed biosensor achieves sensitive miRNA detection with a low detection limit and excellent specificity. Furthermore, the practical applicability of the platform was demonstrated in cell lysates and human plasma samples with satisfactory accuracy and recovery. Owing to its modular and programmable design, this split activator-mediated CHA-CRISPR strategy provides a general and versatile framework for constructing low-background CRISPR biosensors and may facilitate the development of sensitive miRNA sensing platforms.
中文摘要:微小RNA(miRNA)已成为癌症诊断和预后评估的重要生物标志物,然而由于其丰度低、序列短且存在序列同源性,其准确检测仍面临挑战。在此,我们报道了一种基于级联顺式切割触发的分裂激活剂组装策略的新型生物传感平台,通过将催化发夹组装(CHA)与双CRISPR/Cas12a放大相整合,实现对miRNA的超灵敏和选择性检测。与传统的CHA-CRISPR检测方法不同,后者将CHA产物直接与Cas12a激活相偶联,并受到crRNA诱导的泄漏和高背景信号的困扰,所提出的系统通过分裂激活剂架构将靶标识别与信号输出解耦。靶标miRNA启动CHA生成双链中间体,该中间体首先被Cas12a/crRNA1通过顺式切割加工,释放出一个片段化DNA触发物。该片段随后与预先设计的辅助链组装形成完整的激活剂,从而实现Cas12a/crRNA2的二次激活,并导致放大的反式切割信号。这种级联设计显著抑制了非特异性背景,同时实现顺序信号放大,从而大幅提高信噪比并增强分析性能。所开发的生物传感器实现了灵敏的miRNA检测,具有低检测限和优异的特异性。此外,该平台在实际应用中的适用性在细胞裂解液和人血浆样本中得到验证,具有令人满意的准确度和回收率。由于其模块化和可编程设计,这种分裂激活剂介导的CHA-CRISPR策略为构建低背景CRISPR生物传感器提供了一个通用且多功能的框架,并可能促进灵敏miRNA传感平台的开发。
Nanoparticles derived from various animals, plants, and microorganisms demonstrate potent application potential in the construction of functionalized pharmaceutic preparations, owing to their special in vivo behavioral and immune-stimulating effects. Yeast cell wall-derived nanoparticles (Ycws) can reverse the tumor immunosuppressive microenvironment via activating various cells related to anti-tumor immunity, while it is difficult to ensure the complete elimination of the treated tumors. Meanwhile, photothermal therapy (PTT) can effectively ablate the irradiated tumors with cell pyroptosis induction, while it has limited effect on the distant unirradiated tumors. Herein, Ycws and near-infrared light II photothermal agent IR1061 had been encapsulated by liposome to obtain Lipo@Ycws/IR1061 (LYI) for the local ablation of superficial lymphoma and efficient inhibition of the growth of distant tumors. LYI exhibited uniform morphology, good biological stability and outstanding photothermal conversion performance. Furthermore, LYI-mediated PTT triggered cell pyroptosis and eliminated the exposure tumors. Moreover, Ycws together with PTT-induced pyroptosis could reduce the growth of distant tumors via optimizing the tumor immune microenvironment, especially the maturation of DC cells and the anti-tumor polarization of macrophages. This study integrates the efficient local tumor ablation of PTT with the powerful immune adjuvant function of Ycws, providing a biocompatible photothermal-immunotherapy platform for malignant lymphoma.
中文摘要:源自多种动物、植物和微生物的纳米颗粒因其特殊的体内行为和免疫刺激作用,在构建功能化药物制剂方面展现出强大的应用潜力。酵母细胞壁来源纳米颗粒(Ycws)可通过激活多种与抗肿瘤免疫相关的细胞来逆转肿瘤免疫抑制微环境,但难以确保完全消除所治疗的肿瘤。同时,光热治疗(PTT)可通过诱导细胞焦亡有效消融照射肿瘤,而对远处未照射肿瘤的作用有限。在此,本研究利用脂质体包裹Ycws和近红外光II光热剂IR1061,获得Lipo@Ycws/IR1061(LYI),用于局部消融浅表淋巴瘤并有效抑制远处肿瘤生长。LYI表现出均匀的形态、良好的生物稳定性和出色的光热转换性能。此外,LYI介导的PTT触发细胞焦亡并消除暴露的肿瘤。而且,Ycws与PTT诱导的细胞焦亡可通过优化肿瘤免疫微环境,特别是DC细胞成熟和巨噬细胞的抗肿瘤极化,抑制远处肿瘤生长。本研究将PTT高效的局部肿瘤消融与Ycws强大的免疫佐剂功能相结合,为恶性淋巴瘤提供了一种生物相容性良好的光热-免疫治疗平台。
Central nervous system (CNS) leukemia remains a major clinical challenge in acute lymphoblastic leukemia, largely due to the restrictive nature of the blood-brain barrier (BBB), which severely limits therapeutic delivery and contributes to high relapse rates and poor prognosis. Here, we report ALB-phage, a bioengineered anti-leukemia backpack-phage system designed for active BBB navigation and intracranial drug delivery. M13 bacteriophages were genetically engineered to display BBB-homing ligands, forming a high-aspect-ratio biological transport platform (BTP). A leukemia-targeting therapeutic backpack (L-Pak) was constructed by encapsulating methotrexate within lipid nanoparticles fused with leukemia cell membranes, enabling homotypic targeting. The L-Pak was conjugated to the BTP via a matrix metalloproteinase-responsive PLGVR linker, allowing selective cleavage within the cerebrospinal fluid. Owing to its filamentous morphology, ALB-phage achieved efficient BBB translocation predominantly through energy-dependent macropinocytosis with an additional contribution from clathrin-mediated endocytosis. Both in vitro and in vivo studies demonstrate that ALB-phage effectively penetrates the BBB and selectively eradicates leukemia blasts, resulting in marked tumor suppression and a significant extension of median survival from 29 to 40 days in cell-line-derived xenograft models. Collectively, this M13 bacteriophage-based all-in-one platform integrates targeted BBB penetration with homology-mediated cytotoxicity, offering a promising strategy for the treatment of CNS leukemia and other central nervous system malignancies.
中文摘要:中枢神经系统(CNS)白血病仍是急性淋巴细胞白血病的主要临床挑战,很大程度上由于血脑屏障(BBB)的限制性,严重限制治疗药物递送,并导致高复发率和不良预后。在此,我们报道 ALB-phage,一种为主动穿越BBB和颅内药物递送而设计的生物工程化抗白血病背包噬菌体系统。M13噬菌体经基因工程改造以展示BBB归巢配体,形成高纵横比的生物运输平台(BTP)。通过将甲氨蝶呤包封于与白血病细胞膜融合的脂质纳米颗粒中,构建白血病靶向治疗背包(L-Pak),从而实现同型靶向。L-Pak通过基质金属蛋白酶响应性PLGVR连接子与BTP偶联,使其可在脑脊液中选择性裂解。由于其丝状形态,ALB-phage主要经能量依赖性巨胞饮作用,并额外借助网格蛋白介导的内吞作用,实现高效BBB转运。体外和体内研究均表明,ALB-phage可有效穿透BBB并选择性清除白血病原始细胞,从而显著抑制肿瘤,并将细胞系来源异种移植模型的中位生存期从29天延长至40天。总体而言,这种基于M13噬菌体的一体化平台将靶向BBB穿透与同源介导的细胞毒性整合,为中枢神经系统白血病及其他中枢神经系统恶性肿瘤的治疗提供了一种有前景的策略。
DNA replication forks can be challenged by cancer chemotherapeutic treatments, leading to accumulation of single-stranded DNA and slowdown of DNA synthesis. The marked plasticity of replication forks under replication stress ensures fork stability, damage tolerance and complete genome duplication1. Initiation and progression of replication forks occur in a three-dimensionally organized genome. DNA loop extrusion by the cohesin complex organizes the genome2 and regulates the initiation and positioning of DNA replication origins3,4. Although transient interaction of sister forks was recently reported during unperturbed replication5, the functional relevance of fork contacts during replication stress and the role of cohesin in this context remain unknown. Here we show that cohesin-mediated loop extrusion rearranges nascent DNA contacts at stressed replication forks to promote genome stability. Using auxin-inducible degron6, separation-of-function mutants7-9 and a newly developed Micro-C-based technique to capture chromatin contacts at nascent DNA (Repli-C), we found that loop-extruding cohesin accumulates at stalled replication forks, limiting sister-fork coupling in favour of inter-replicon contacts. This process promotes active fork slowing and reversal by preventing PRIMPOL action on single-stranded DNA1. These findings show that the replication stress response is not merely an accumulation of individual regulatory events, but is topologically integrated across the genome through cohesin loop extrusion. While providing a new function for loop-extruding cohesin, our results indicate the potential impact on cancer therapy of frequent cohesin mutations in tumours10.
中文摘要:DNA复制叉可受到癌症化疗处理的挑战,导致单链DNA积累和DNA合成减慢。复制应激下复制叉显著的可塑性确保了复制叉稳定性、损伤耐受和完整基因组复制1。复制叉的起始和推进发生在三维组织的基因组中。黏连蛋白复合物介导的DNA环挤出组织基因组2,并调控DNA复制起点的起始和定位3,4。尽管最近报道在未受扰动的复制过程中姐妹复制叉存在瞬时相互作用5,但复制应激期间复制叉接触的功能相关性以及黏连蛋白在此背景下的作用仍不清楚。我们在此表明,黏连蛋白介导的环挤出重排应激复制叉处新生DNA接触,以促进基因组稳定性。利用生长素诱导型降解子6、功能分离突变体7-9以及新开发的基于Micro-C的捕获新生DNA处染色质接触的技术(Repli-C),我们发现执行环挤出的黏连蛋白在停滞的复制叉处积累,限制姐妹复制叉偶联,而有利于复制子间接触。该过程通过阻止PRIMPOL对单链DNA的作用1,促进主动的复制叉减慢和逆转。这些发现表明,复制应激反应不仅仅是单个调控事件的累积,而是通过黏连蛋白环挤出在基因组范围内进行拓扑整合。在赋予执行环挤出的黏连蛋白新功能的同时,我们的结果提示肿瘤中频繁出现的黏连蛋白突变对癌症治疗可能产生影响10。
Poly(rC)-binding protein 1 (PCBP1), a splicing factor and key member of the hnRNP E family, was initially characterized for its tumor suppressive properties. More recently, its role in gene regulation in the brain and nervous system has attracted growing interest. Through an international multicenter collaboration, we identified 16 de novo pathogenic variants in PCBP1 across 17 subjects from 16 unrelated families. All affected individuals exhibited intellectual disability (ID), with autism spectrum disorder (ASD) as a prominent feature. Functional analysis in primary hippocampal mouse neuron cultures indicated that PCBP1 variants impair dendritic arborization, underscoring their deleterious effects. Transcriptomic profiling by RNA sequencing of subject-derived T cells showed a distinctive signature characterized by significantly increased exon skipping. These results highlight the contribution of PCBP1 in neurogenesis and neuritogenesis, which is impacted by loss-of-function variants expressed in neuronal cells, thereby supporting the link between splicing defects and neurodevelopmental disorders. Collectively, our findings demonstrate the prominent role of PCBP1 in neurodevelopment, reaffirming the importance of splicing regulation in mammalian neurodevelopment.
中文摘要:多聚(rC)结合蛋白1(PCBP1)是一种剪接因子,也是hnRNP E家族的关键成员,最初因其肿瘤抑制特性而受到关注。近年来,其在脑和神经系统基因调控中的作用日益引起兴趣。通过一项国际多中心合作,我们在来自16个无亲缘关系家庭的17名受试者中发现了16个PCBP1新生致病性变异。所有受累个体均表现出智力障碍(ID),其中孤独症谱系障碍(ASD)是突出特征。对原代小鼠海马神经元培养物的功能分析表明,PCBP1变异损害树突分枝,突显其有害效应。对受试者来源T细胞进行RNA测序的转录组分析显示,一种以显著增加外显子跳跃为特征的独特特征。这些结果强调了PCBP1在神经发生和神经突生长中的贡献,而神经元细胞中表达的功能丧失变异会影响这一过程,从而支持剪接缺陷与神经发育障碍之间的联系。总之,我们的发现证明PCBP1在神经发育中的重要作用,并再次强调剪接调控在哺乳动物神经发育中的重要性。
Faithful gene expression requires coordination between RNA polymerase II elongation and co-transcriptional RNA processing, yet the chromatin-associated assemblies supporting this coupling remain incompletely defined. Using native chromatin proteomics in human cells, we identify ECAS (elongation complex associated with splicing), a bipartite assembly linking an elongation module (AFF4-ELL2-EAF1) to a U2 snRNP-associated intron binding complex. ECAS occupies promoter-proximal chromatin and is molecularly distinct from canonical P-TEFb-containing super elongation complex (SEC). Acute perturbation of Aquarius (AQR)/XAB2-dependent ECAS functions impairs productive gene-body elongation without altering pause release, increases intron retention, and preferentially affects long genes. AQR loss also reduces capping-factor recruitment and nascent 5' capping and increases promoter-proximal accumulation of cleavage/polyadenylation and RNA exosome factors. In mouse hematopoietic cells, Aqr is highly expressed, and its perturbation profoundly impairs leukemia initiation, maintenance, and leukemia stem cell function in MLL-rearranged leukemia. Together, these findings establish ECAS as a chromatin-associated assembly that couples productive elongation with RNA processing.
中文摘要:忠实基因表达需要RNA聚合酶II延伸与共转录RNA加工之间的协调,然而支持这种偶联的染色质相关组装体仍未完全明确。我们利用人类细胞中的天然染色质蛋白质组学鉴定出ECAS(与剪接相关的延伸复合物),这是一个二分组装体,将延伸模块(AFF4-ELL2-EAF1)与U2 snRNP相关的内含子结合复合物连接起来。ECAS占据启动子近端染色质,并且在分子上与含经典P-TEFb的超级延伸复合物(SEC)不同。急性扰动Aquarius(AQR)/XAB2依赖的ECAS功能会损害有效基因体延伸,而不改变暂停释放,增加内含子保留,并优先影响长基因。AQR缺失还会减少加帽因子招募和新生的5'加帽,并增加切割/多聚腺苷酸化因子和RNA外泌体因子在启动子近端的积累。在小鼠造血细胞中,Aqr高表达,并且其扰动会深刻损害MLL重排白血病中的白血病起始、维持和白血病干细胞功能。总之,这些发现确立了ECAS是一个偶联有效延伸与RNA加工的染色质相关组装体。
Metastatic cancer cells must adapt to the physical properties of distant tissues, yet the consequences of such mechanical adaptation for immune surveillance remain poorly understood. In Immunity, Elbanna and colleagues reveal an unexpected trade-off between mechanical fitness and immune vulnerability: Environmental rigidity induces cancer-cell stiffening, enabling robust colonization of rigid bone in the absence of effective cytotoxic immunity. However, this mechanically adapted state also increases susceptibility to cytotoxic lymphocytes, allowing immunosurveillance to preferentially eliminate stiffened cancer cells and suppress bone metastasis in immunocompetent hosts. SPP1 contributes to this environmentally induced mechanical adaptation and its associated immune vulnerability. This study also highlights a broader mechanical dialogue between the metastatic niche, cancer cells, and the immune system, in which adaptation to one physical constraint may create vulnerability to another. Mechanistically, cancer-cell mechanics may represent more than a consequence of tumor progression-it may constitute an actionable determinant of immune susceptibility. Manipulating the mechanical state of cancer cells could therefore complement strategies aimed at enhancing immune-cell function. The study raises the intriguing possibility that the very adaptation that enables cancer cells to establish themselves within a rigid metastatic niche may simultaneously expose a therapeutically exploitable mechanical vulnerability to immune surveillance.
中文摘要:转移性癌细胞必须适应远处组织的物理特性,但这种机械适应对免疫监视的后果仍知之甚少。在《Immunity》中,Elbanna及其同事揭示了机械适应性与免疫脆弱性之间出乎意料的权衡:环境硬度诱导癌细胞变硬,使其在缺乏有效细胞毒性免疫的情况下能够稳固定植于坚硬的骨组织。然而,这种机械适应状态也增加了对细胞毒性淋巴细胞的易感性,使免疫监视能够优先清除变硬的癌细胞,并在免疫功能正常宿主体内抑制骨转移。SPP1参与这种环境诱导的机械适应及其相关的免疫脆弱性。该研究还强调了转移微环境、癌细胞与免疫系统之间更广泛的机械对话,其中对一种物理限制的适应可能造成对另一种物理限制的脆弱性。从机制上看,癌细胞力学可能不仅是肿瘤进展的结果,还可能是免疫易感性的可干预决定因素。因此,操控癌细胞的机械状态可能补充旨在增强免疫细胞功能的策略。该研究提出一个引人入胜的可能性:使癌细胞能够在坚硬转移微环境中立足的适应本身,可能同时暴露出一处可治疗利用的、对免疫监视的机械脆弱性。
Achieving precise and efficient targeting represents a major challenge in drug delivery to overcome the limitations of conventional therapies. Surface functionalization of extracellular vesicles (EVs)-nanosized membranous particles released by all cell types- has emerged as a promising strategy to enhance targeted drug delivery. EVs are naturally involved in intercellular communication by transferring bioactive molecules from donor to recipient cells, and their biologically active interface confers inherent targeting properties and a favorable safety profile, making them attractive vehicles compared to synthetic nanoparticles. However, the naїve use of EVs is often limited by nonspecific biodistribution and off-target accumulation, reducing their therapeutic efficacy. To overcome these limitations, increasing efforts have focused on engineering EVs through cargo loading and surface functionalization strategies, enabling enhanced targeting and improved delivery of therapeutic molecules. In this review, we first describe the biological features of EVs, including their biogenesis, heterogeneity, and molecular composition, which underlie their potential as drug delivery systems. We then discuss the main determinants of EV-mediated drug delivery and present current engineering strategies, including cargo loading and surface functionalization approaches, highlighting their advantages and limitations. Finally, we summarize the application of engineered EVs in the treatment of several pathological conditions, including cardiovascular, neurological, autoimmune, and cancer diseases, and discuss the major challenges in clinical translation and future perspectives for EV-based targeted therapies.
中文摘要:实现精准高效的靶向递送是药物递送领域的一项重大挑战,旨在克服传统疗法的局限性。细胞外囊泡(EVs)是由所有细胞类型释放的纳米级膜性颗粒,对其表面进行功能化已成为增强靶向药物递送的一种有前景的策略。EVs天然参与细胞间通讯,通过将生物活性分子从供体细胞转移到受体细胞,其具有生物活性的界面赋予其固有的靶向特性和良好的安全性,使其相较合成纳米颗粒成为有吸引力的载体。然而,未经改造的EVs常受限于非特异性生物分布和脱靶蓄积,从而降低其治疗效力。为克服这些局限,越来越多的研究致力于通过货物装载和表面功能化策略对EVs进行工程化改造,以实现增强靶向并改善治疗分子的递送。在这篇综述中,我们首先描述EVs的生物学特征,包括其生物发生、异质性和分子组成,这些特征构成了其作为药物递送系统的潜力基础。随后,我们讨论EV介导药物递送的主要决定因素,并介绍当前的工程化策略,包括货物装载和表面功能化方法,强调其优势和局限。最后,我们总结工程化EVs在多种病理状况治疗中的应用,包括心血管、神经系统、自身免疫和癌症疾病,并讨论临床转化中的主要挑战以及基于EVs的靶向治疗未来前景。
Growth and differentiation factor 15 (GDF-15) is a stress-responsive hormone secreted by various cell types in response to cellular stress. To regulate ingestive behaviour, suppress food intake, and induce nausea and vomiting during cellular stress, GDF-15 signals via a brainstem-restricted receptor, GFRAL. Elevated circulating GDF-15 levels serve as a biomarker of cellular stress and are increased in a wide range of diseases. GDF-15 has recently been established as a causal factor in cancer cachexia and GDF15-GFRAL antagonism is being pursued as a therapeutic strategy. Recent studies have highlighted a dynamic interplay between GDF-15 and the hypothalamus-pituitary-adrenal (HPA) axis, suggesting that GDF-15 acts as a sentinel hormone in stress responses. Here, we review the canonical role of GDF-15 in stress-related conditions and its potential impact on circadian regulation and HPA axis dysregulation. The review explores the potential activation of the HPA axis by GDF-15 and discuss the hypothesis that downstream glucocorticoid signalling may contribute to some of the cardiovascular, metabolic, immune, and musculoskeletal changes reported for GDF-15. Additionally, the review discusses the potential role of GDF-15 in adrenal insufficiency and its treatment and in adrenocortical carcinoma. In summary, this review aims to elucidate the role of GDF-15 in glucocorticoid homeostasis and adrenal disease in the context of the stress response.
中文摘要:生长与分化因子15(GDF-15)是一种应激反应性激素,由多种细胞类型在细胞应激时分泌。为了在细胞应激期间调节摄食行为、抑制食物摄入并诱导恶心和呕吐,GDF-15通过脑干限制性受体GFRAL传递信号。循环GDF-15水平升高可作为细胞应激的生物标志物,并在多种疾病中升高。GDF-15最近已被确立为癌症恶病质的因果因素,并且GDF15-GFRAL拮抗正被作为治疗策略进行探索。近期研究强调了GDF-15与下丘脑-垂体-肾上腺(HPA)轴之间的动态相互作用,提示GDF-15在应激反应中充当哨兵激素。在此,我们综述GDF-15在应激相关状况中的经典作用及其对昼夜节律调节和HPA轴失调的潜在影响。本综述探讨GDF-15对HPA轴的潜在激活,并讨论以下假说:下游糖皮质激素信号可能促成已报道的GDF-15相关心血管、代谢、免疫和肌肉骨骼改变中的一部分。此外,本综述讨论GDF-15在肾上腺功能不全及其治疗中以及在肾上腺皮质癌中的潜在作用。总之,本综述旨在阐明GDF-15在应激反应背景下对糖皮质激素稳态和肾上腺疾病的作用。
Tumor innervation (TIN) and perineural invasion (PNI) are well-established pathological features of pancreatic ductal adenocarcinoma (PDAC) that drive its aggressiveness and associated pain. Here, we reveal that regenerating islet-derived (Reg) proteins, secreted by peritumoral exocrine acinar cells, facilitate TIN and PNI through two paracrine mechanisms. In PDAC cells, Reg proteins drive cancer invasiveness along nerves via autocrine transforming growth factor β (TGF-β) signaling. In neurons, Reg proteins are neurotrophic and potentiate neuronal excitability, resulting in hyperinnervation and pain. Interleukin-22, primarily produced by CD4+ T cells, triggers Reg expression. Exostosin-like glycosyltransferase 3 (EXTL3) is the functional receptor for Reg proteins in both cell types. Genetic silencing of Reg or EXTL3 reduces TIN, nerve-cancer proximity, PDAC progression, and pain behavior in mice. Clinically, the Reg-EXTL3-TGF-β axis correlates with increased TIN and PNI severity, poor prognosis, and greater pain. Thus, targeting the Reg-EXTL3 axis may be an attractive strategy for mitigating neural-associated adverse consequences in PDAC.
中文摘要:肿瘤神经支配(TIN)和神经周围侵犯(PNI)是胰腺导管腺癌(PDAC)已确立的病理特征,驱动其侵袭性和相关疼痛。在此,我们揭示,由瘤周外分泌腺泡细胞分泌的再生胰岛衍生(Reg)蛋白通过两种旁分泌机制促进TIN和PNI。在PDAC细胞中,Reg蛋白通过自分泌转化生长因子β(TGF-β)信号驱动癌症沿神经侵袭。在神经元中,Reg蛋白具有神经营养作用并增强神经元兴奋性,导致过度神经支配和疼痛。白细胞介素-22主要由CD4+ T细胞产生,可触发Reg表达。外泌素样糖基转移酶3(EXTL3)是两种细胞类型中Reg蛋白的功能性受体。基因沉默Reg或EXTL3可减少小鼠中的TIN、神经-癌症邻近、PDAC进展和疼痛行为。临床上,Reg-EXTL3-TGF-β轴与TIN和PNI严重程度增加、预后不良和更严重的疼痛相关。因此,靶向Reg-EXTL3轴可能是减轻PDAC中神经相关不良后果的有吸引力的策略。
2肿瘤免疫/微环境 (49篇)
临床研究 (19篇)
Biliary tract cancers (BTCs) are associated with poor outcomes despite recent incorporation of immune checkpoint inhibitors into first-line chemotherapy. Human epidermal growth factor receptor 2 (HER2) overexpression or amplification defines a therapeutically targetable subset of BTC but its integration into first-line chemoimmunotherapy has not been prospectively evaluated. This multi-institutional, open-label, phase 1b/2 HERBOT study (KCSG-HB23-05) aimed to evaluate first-line HER2-targeted quadruplet regimen consisting of trastuzumab, nivolumab, gemcitabine and cisplatin in participants with HER2-positive advanced BTC. Here the primary endpoint was met with an objective response rate of 55% (95% confidence interval (CI) 38.5-70.7; one complete response and 21 partial responses among 40 participants) and a disease control rate of 95% (95% CI 83.5-99.4); the median duration of response was 12.6 months (95% CI 5.7-not reached). With a median follow-up of 17.0 months, the median progression-free survival was 10.6 months (95% CI 7.8-17.4) and median overall survival was not reached. Two participants (5.0%) underwent curative-intent conversion surgery. Common grade ≥3 treatment-related adverse events included neutropenia (57.5%), anemia (30.0%) and thrombocytopenia (22.5%). Preplanned artificial-intelligence-powered whole-slide image analyses suggested that tumors with higher proportions of HER2 3+ cells were associated with greater clinical benefit. These findings suggest that upfront HER2-targeted therapeutic intensification in BTC may represent a promising direction for future first-line treatment strategies, with relevance to ongoing phase 3 studies. ClinicalTrials.gov identifier: NCT05749900 .
中文摘要:胆道癌(BTC)尽管近期将免疫检查点抑制剂纳入一线化疗,但结局仍然较差。人表皮生长因子受体2(HER2)过表达或扩增定义了BTC中一个可治疗靶向的亚群,但其整合到一线化学免疫治疗中尚未被前瞻性评估。这项多机构、开放标签的1b/2期HERBOT研究(KCSG-HB23-05)旨在评估由曲妥珠单抗、纳武利尤单抗、吉西他滨和顺铂组成的一线HER2靶向四药方案在HER2阳性晚期BTC参与者中的疗效。此处主要终点已达到,客观缓解率为55%(95%置信区间(CI)38.5-70.7;40名参与者中1例完全缓解和21例部分缓解),疾病控制率为95%(95%CI 83.5-99.4);中位缓解持续时间为12.6个月(95%CI 5.7-未达到)。中位随访17.0个月时,中位无进展生存期为10.6个月(95%CI 7.8-17.4),中位总生存期未达到。2名参与者(5.0%)接受了根治性意向的转化手术。常见的≥3级治疗相关不良事件包括中性粒细胞减少(57.5%)、贫血(30.0%)和血小板减少(22.5%)。预先计划的人工智能驱动的全切片图像分析提示,HER2 3+细胞比例较高的肿瘤与更大的临床获益相关。这些发现提示,BTC中初始HER2靶向治疗强化可能代表未来一线治疗策略的一个有前景的方向,并与正在进行的3期研究相关。ClinicalTrials.gov注册号:NCT05749900。
Steatohepatitic hepatocellular carcinoma (SH-HCC) is a distinct subtype of hepatocellular carcinoma with poorly defined molecular features and limited diagnostic and therapeutic strategies. This study aimed to delineate its multi-omics landscape, develop non-invasive diagnostic tools and identify actionable therapeutic targets. We integrated multimodal clinical and omics datasets from an overall cohort of 156 patients, including RNA-seq (n=69), spatial transcriptomics (n=36), spatial metabolomics (n=6), lipidomics (n=125) and serum proteomics (n=152), for comprehensive molecular profiling and diagnostic model construction. FABP4 was functionally validated in Sleeping Beauty-induced HCC mouse models. An SH-HCC index was established to reliably differentiate SH-HCC from conventional HCC. Drug response analysis suggested a potential reduction in responsiveness to sorafenib and immunotherapy-based regimens in SH-HCC, whereas transarterial chemoembolisation may remain an effective therapeutic option. Spatial transcriptomics revealed increased immune cell infiltration, a reinforced immune barrier and reduced tumour-immune cell communication. SH-HCC is characterised by a lipid-rich phenotype, and a diagnostic model based on 12 lipid species showed good performance in an independent cohort (area under the curve (AUC)=0.909). Serum proteomic model demonstrated good performance in the test cohort (AUC=0.828). Importantly, our preliminary findings suggest a potential therapeutic role for FABP4, as its genetic deletion suppressed tumour growth, reshaped the tumour immune microenvironment and enhanced the response to PD-1 blockade. This study provides the first multi-omics characterisation of SH-HCC, highlighting the SH-HCC index and non-invasive diagnostic models, with FABP4 as a potential target.
中文摘要:脂肪性肝炎型肝细胞癌(SH-HCC)是肝细胞癌的一种独特亚型,其分子特征尚不明确,诊断和治疗策略有限。本研究旨在描绘其多组学全景,开发无创诊断工具并确定可干预的治疗靶点。我们整合了总队列156例患者的多模态临床与组学数据集,包括RNA测序(n=69)、空间转录组学(n=36)、空间代谢组学(n=6)、脂质组学(n=125)和血清蛋白质组学(n=152),用于全面分子分型和诊断模型构建。在Sleeping Beauty诱导的HCC小鼠模型中对FABP4进行了功能验证。建立了SH-HCC指数,可可靠区分SH-HCC与传统HCC。药物反应分析提示,SH-HCC对索拉非尼和免疫治疗方案的反应性可能降低,而经导管动脉化疗栓塞可能仍是有效治疗选择。空间转录组学显示免疫细胞浸润增加、免疫屏障增强以及肿瘤-免疫细胞通讯减少。SH-HCC以富含脂质表型为特征,基于12种脂质物种的诊断模型在独立队列中表现良好(曲线下面积(AUC)=0.909)。血清蛋白质组模型在测试队列中表现良好(AUC=0.828)。重要的是,我们的初步发现提示FABP4具有潜在治疗作用,因为其基因缺失抑制了肿瘤生长、重塑了肿瘤免疫微环境并增强了对PD-1阻断的应答。本研究首次对SH-HCC进行了多组学表征,突出SH-HCC指数和无创诊断模型,并将FABP4作为潜在靶点。
Tumor-agnostic drug development reframes oncology around shared molecular dependencies rather than tissue origin, enabling efficient development for rare, actionable drivers across tumors. Since the first tumor-agnostic approval in 2017 for immunotherapy in microsatellite instability-high or mismatch repair-deficient tumors, the regulatory paradigm has expanded to high tumor mutation burden (TMB-H) cancers, oncogene-directed kinase inhibitors, such as NTRK, rearranged during transfection (RET), BRAF valine-to-glutamic acid substitution at codon 600 (BRAF V600E), and antibody-drug conjugate targeting Her2 overexpression, establishing proof of principle across modalities. In this review, we examine current tumor-agnostic approvals and emerging targets with pan-cancer potential: Kirsten rat sarcoma viral oncogene homolog (KRAS) variants [glycine-to-cysteine substitution at codon 12 (G12C), glycine-to-aspartic acid substitution at codon 12 (G12D), and active GTP-bound RAS (RAS(ON)) inhibitors; degraders; and chimeric antigen receptor T-cell (CAR-T)], methylthioadenosine phosphorylase (MTAP) loss (methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) and methionine adenosyltransferase 2A (MAT2A) inhibition), tumor protein p53 (TP53) tyrosine-to-cysteine substitution at codon 220 (Y220C) allele-specific reactivation, and fibroblast growth factor receptor 2 (FGFR2) and neuregulin (NRG) fusions. We explore critical challenges including standardized assays, endpoints, infrastructure, and access limitations. Finally, we outline features shaping next-generation programs: novel basket-trial designs, real-world evidence integration, and international collaborative frameworks. With molecules, infrastructure, and trial designs advancing in parallel, tumor-agnostic strategies are poised to deliver equitable benefit across cancers, realizing precision medicine without borders.
中文摘要:肿瘤不可知论式的药物研发将肿瘤学重新聚焦于共有的分子依赖,而非组织来源,从而能够针对跨瘤种中罕见但可干预的驱动因素进行高效开发。自2017年首个肿瘤不可知论适应证获批(用于微卫星高度不稳定或错配修复缺陷肿瘤的免疫治疗)以来,监管范式已扩展至高肿瘤突变负荷(TMB-H)癌症、靶向癌基因的激酶抑制剂(如NTRK、转染重排基因RET、BRAF第600位密码子缬氨酸至谷氨酸替换即BRAF V600E)以及靶向Her2过表达的抗体药物偶联物,在多种治疗模态上建立了原理验证。在本综述中,我们梳理了当前的肿瘤不可知论获批药物以及具有泛癌种潜力的新兴靶点:KRAS变异(第12位密码子甘氨酸至半胱氨酸替换即G12C、第12位密码子甘氨酸至天冬氨酸替换即G12D,以及活性GTP结合型RAS即RAS(ON)抑制剂;降解剂;以及嵌合抗原受体T细胞即CAR-T)、甲硫腺苷磷酸化酶(MTAP)缺失(甲硫腺苷即MTA协同的蛋白精氨酸甲基转移酶5即PRMT5与甲硫氨酸腺苷转移酶2A即MAT2A抑制)、肿瘤蛋白p53(TP53)第220位密码子酪氨酸至半胱氨酸替换即Y220C的等位基因特异性再激活,以及成纤维细胞生长因子受体2(FGFR2)与神经调节蛋白(NRG)融合。我们探讨了关键挑战,包括检测方法标准化、终点、基础设施与可及性限制。最后,我们概述了塑造下一代研发项目的特征:新型篮式试验设计、真实世界证据整合以及国际合作框架。随着分子、基础设施与试验设计并行推进,肿瘤不可知论策略有望在不同癌症中带来公平获益,实现无国界的精准医学。
Dual inhibition of indoleamine 2,3-dioxygenase 1 (IDO1) and programmed death-ligand 1 (PD-L1) may alleviate suppression of antitumor immune responses by overcoming redundant immunosuppressive pathways. This study evaluated the combination of KHK2455, a novel and selective, long-lasting, and potent oral IDO1 inhibitor, with avelumab, a PD-L1 inhibitor, in adults with locally advanced or metastatic urothelial carcinoma. This multicenter, open-label Phase 1 study evaluated the safety and tolerability of oral daily KHK2455 (30, 100, and 200 mg) plus intravenous avelumab (800 mg biweekly), the safety of KHK2455 200 mg monotherapy, KHK2455 and avelumab antitumor activity, avelumab antidrug antibodies, and combination therapy pharmacokinetics. 16 subjects were enrolled (n=4, 4, and 8 in the 30, 100 and 200 mg cohorts, respectively). No dose-dependency was observed for KHK2455-only related treatment-emergent adverse events (TEAEs). No TEAEs were considered related to KHK2455 or avelumab. Four subjects had fatal TEAEs considered not related to treatment.One subject in the KHK2455 30 mg cohort achieved a complete response (CR) and one in the KHK2455 200 mg cohort achieved a partial response (PR), both with avelumab.PD-L1 expression was evaluated in the 13 available baseline tumor biopsy samples. All biopsies expressed PD-L1 in at least one compartment; 31% (4/13) were positive on tumor cells and 69.2% (9/13) were positive on tumor-associated immune cells. Over half (53.8%, 7/13) expressed PD-L1 at high levels and within the disease control group consisting of CR (n=1), PR (n=1) and stable disease (n=5), 57.1% (4/7) were PD-L1 high. Baseline expression profiles showed significantly higher immune activation in the subject with CR compared with the subject with PR and those with progressive disease. The subject with CR had the highest baseline Tumor Inflammation Signature (TIS) score (9.06) compared with 4.8 in the subject with PR and lower TIS score values in subjects with progressive disease. Changes in gene expression were observed, including upregulation of CXCL12, CCND2, and MMRN2, and downregulation of HLA-DRB5, CRABP2, and VEGFA in responders versus progressive disease comparisons. The favorable safety profile and preliminary efficacy results of KHK2455 in combination with avelumab, along with the translational biomarker findings, warrant further investigation.
中文摘要:吲哚胺2,3-双加氧酶1(IDO1)与程序性死亡配体1(PD-L1)的双重抑制可能通过克服冗余的免疫抑制通路,减轻对抗肿瘤免疫应答的抑制。本研究在局部晚期或转移性尿路上皮癌成人患者中评估了KHK2455(一种新型、选择性、长效且强效的口服IDO1抑制剂)与avelumab(一种PD-L1抑制剂)的联合治疗。这项多中心、开放标签的1期研究评估了口服每日KHK2455(30、100和200 mg)联合静脉注射avelumab(800 mg,每两周一次)的安全性和耐受性、KHK2455 200 mg单药治疗的安全性、KHK2455与avelumab的抗肿瘤活性、avelumab的抗药抗体以及联合治疗的药代动力学。共入组16例受试者(30、100和200 mg队列分别为4、4和8例)。仅与KHK2455相关的治疗中出现的不良事件(TEAE)未观察到剂量依赖性。没有TEAE被认为与KHK2455或avelumab相关。4例受试者发生致死性TEAE,被认为与治疗无关。KHK2455 30 mg队列中1例受试者达到完全缓解(CR),KHK2455 200 mg队列中1例受试者达到部分缓解(PR),两者均联合avelumab。对13份可获得的基线肿瘤活检样本进行了PD-L1表达评估。所有活检样本至少在一个区室中表达PD-L1;31%(4/13)在肿瘤细胞上为阳性,69.2%(9/13)在肿瘤相关免疫细胞上为阳性。超过半数(53.8%,7/13)高表达PD-L1,在由CR(n=1)、PR(n=1)和疾病稳定(n=5)组成的疾病控制组中,57.1%(4/7)为PD-L1高表达。基线表达谱显示,与PR受试者和疾病进展受试者相比,CR受试者的免疫激活显著更高。CR受试者的基线肿瘤炎症特征(TIS)评分最高(9.06),而PR受试者为4.8,疾病进展受试者的TIS评分更低。在缓解者与疾病进展者的比较中观察到基因表达变化,包括CXCL12、CCND2和MMRN2上调,以及HLA-DRB5、CRABP2和VEGFA下调。KHK2455联合avelumab的良好安全性特征和初步疗效结果,以及转化生物标志物发现,值得进一步研究。
Colorectal cancers (CRC) with microsatellite stability (MSS) and instability (MSI) differ in tumor microenvironment (TME) composition and clinical treatment and outcomes. While MSI CRC is considered to be sensitive to immune checkpoint blockade therapy, MSS tumors are largely resistant. Characterizing the spatial TME differences between MSS and MSI tumors could provide insights to improve immunotherapy efficacy. Here, we profiled an integrated single-cell and spatial transcriptomic atlas of MSS and MSI CRC across independent cohorts and platforms. Spatial mapping revealed subtype-specific boundary microenvironments coupled to distinct malignant epithelial states. Cancer cells in a fully mesenchymal epithelial-mesenchymal-transition (EMT) state (EMT-II subtype) were enriched near the tumor boundary in MSS, while cancer cells with metabolically active EMT programs (EMT-III subtype) and interferon states were enriched in MSI and displayed a more dispersed distribution. A boundary-proximal interaction network selectively enriched in MSS was characterized by the accumulation of glial-like and tip-like cells around tumor boundary, which preferentially co-localized with EMT-II state tumor cells. The network was linked to extracellular matrix remodeling and EMT malignant cell states. Further, development of a cross-platform classifier TiGELR, a machine learning-derived tip cell-glial cell-EMT II tumor cell ligand-receptor signature, accurately distinguished MSS from MSI and stratified immunotherapy outcomes. Together, this study characterizes the spatial heterogeneity of tumor states and TME programs in CRC and provides a translational framework for improved CRC stratification and immunotherapy guidance.
中文摘要:微卫星稳定(MSS)和微卫星不稳定(MSI)的结直肠癌(CRC)在肿瘤微环境(TME)组成以及临床治疗和结局方面存在差异。MSI CRC被认为对免疫检查点阻断治疗敏感,而MSS肿瘤大多耐药。刻画MSS与MSI肿瘤之间的空间TME差异,可为提高免疫治疗疗效提供见解。在此,我们通过独立队列和平台,绘制了MSS和MSI CRC整合的单细胞和空间转录组图谱。空间定位揭示,亚型特异性的边界微环境与不同的恶性上皮状态相耦合。处于完全间质性上皮-间质转化(EMT)状态的癌细胞(EMT-II亚型)在MSS中富集于肿瘤边界附近,而具有代谢活跃EMT程序(EMT-III亚型)和干扰素状态的癌细胞则在MSI中富集,并呈现更分散的分布。一个在MSS中选择性富集的近边界相互作用网络,其特征是胶质样细胞和尖端样细胞在肿瘤边界周围积聚,并优先与EMT-II状态肿瘤细胞共定位。该网络与细胞外基质重塑及EMT恶性细胞状态相关。此外,开发了一种跨平台分类器TiGELR,这是一种由机器学习得到的尖端细胞-胶质细胞-EMT II肿瘤细胞配体-受体特征,能够准确区分MSS与MSI,并对免疫治疗结局进行分层。总之,本研究刻画了CRC中肿瘤状态和TME程序的空间异质性,并为改进CRC分层和免疫治疗指导提供了转化框架。
Gastrointestinal (GI) cancers remain a leading cause of cancer mortality, with durable benefit from current therapies limited to a subset of patients. Precision oncology is expanding options by targeting recurrent, actionable alterations, most notably in cholangiocarcinoma (CCA), in genes such as FGFR2, IDH1, KRAS, BRAF and ERBB2. Here, we review the evolving therapeutic landscape, emphasizing clinical efficacy, and indications for various treatment modalities. Key therapies include FGFR inhibitors (first and next-generation; both covalent and FGFR2-selective agents), IDH1 inhibitors, KRAS and BRAF inhibitors combined with EGFR blockade and/or chemotherapy, and HER2-targeted monoclonal antibodies, tyrosine kinase inhibitors (TKIs), and antibody-drug conjugates (ADCs). Central mechanisms of both primary and secondary resistance are detailed, with a focus on on-target mutations and convergent off-target MAPK signaling pathways. Finally, we discuss drug-tolerant persister cells, residual tumor cell states that survive therapy without canonical genetic resistance alterations and may contribute to relapse and secondary resistance.
中文摘要:胃肠道(GI)癌症仍然是癌症死亡的主要原因之一,当前疗法带来的持久获益仅局限于部分患者。精准肿瘤学通过靶向反复出现的可操作改变正在扩展治疗选择,最显著的是在胆管癌(CCA)中,涉及FGFR2、IDH1、KRAS、BRAF和ERBB2等基因。在此,我们综述不断演变的治疗格局,强调不同治疗方式的临床疗效和适应证。关键疗法包括FGFR抑制剂(第一代和下一代;共价和FGFR2选择性药物)、IDH1抑制剂、KRAS和BRAF抑制剂联合EGFR阻断和/或化疗,以及HER2靶向单克隆抗体、酪氨酸激酶抑制剂(TKI)和抗体-药物偶联物(ADC)。详细阐述了原发性和继发性耐药的核心机制,重点关注靶点突变和汇聚性的脱靶MAPK信号通路。最后,我们讨论药物耐受持留细胞,即在没有经典遗传性耐药改变的情况下存活下来的残余肿瘤细胞状态,它们可能促进复发和继发性耐药。
Programmed death ligand 1 (PD-L1) blockade offers new therapeutic options for oesophageal squamous cell carcinoma (ESCC); however, the underlying mechanisms and associated biomarkers that determine treatment response remain unclear. We delineate the mechanisms underlying the response and resistance, and elucidate the immune features that enhance neoadjuvant PD-L1 blockade efficacy in ESCC. Here, we characterise the cellular dynamics following neoadjuvant PD-L1 blockade via analysing the single-cell transcriptomes of 210 978 cells and spatial transcriptomes of 20 tissue sections. We identify coordinated cellular programmes centred on CXCL13+ CD8+ exhausted T cells, TNFRSF9+ CD4+ regulatory T cells, atypical memory B cells and APOE+ macrophages, which coordinate the responses to neoadjuvant PD-L1 blockade at baseline. In post-treatment non-responder ESCCs, the cellular programmes exhibit an immunosuppressive phenotype, leading to the failure of therapeutic benefits. Furthermore, we reveal that lymphocyte activation gene 3 serves as a potential target and can potentiate the response via perturbation of the coordinated cellular programmes. Overall, our findings unravel the coordinated cellular programmes associated with treatment response, providing insights for prioritising individualised immunotherapy strategies in ESCC. ChiCTR2400083452.
中文摘要:程序性死亡配体1(PD-L1)阻断为食管鳞状细胞癌(ESCC)提供了新的治疗选择;然而,决定治疗反应的潜在机制和相关生物标志物仍不清楚。我们阐明了ESCC中新辅助PD-L1阻断反应与耐药的机制,并阐明了增强其疗效的免疫特征。在此,我们通过分析210,978个细胞的单细胞转录组和20个组织切片的空间转录组,表征了新辅助PD-L1阻断后的细胞动态。我们识别出以CXCL13+ CD8+耗竭T细胞、TNFRSF9+ CD4+调节性T细胞、非典型记忆B细胞和APOE+巨噬细胞为中心的协调细胞程序,这些程序在基线时协调对新辅助PD-L1阻断的反应。在治疗后无反应的ESCC中,这些细胞程序表现出免疫抑制表型,导致治疗获益失败。此外,我们揭示淋巴细胞活化基因3(LAG3)可作为潜在靶点,并可通过扰动协调的细胞程序增强反应。总体而言,我们的发现揭示了与治疗反应相关的协调细胞程序,为ESCC中优先采用个体化免疫治疗策略提供了见解。ChiCTR2400083452。
Older adults with frailty demonstrate systemic immunosenescence, including T-cell exhaustion and reduced immune diversity, yet maintain immune checkpoint blockade (ICB) efficacy comparable to that of younger patients. Baseline immune cell composition in both the tumor microenvironment (TME) and peripheral blood has been linked to ICB response in melanoma. To address this paradox, we investigated whether frailty is associated with alterations in the TME immune composition in melanoma.We applied imaging mass cytometry with a 40-marker panel to comprehensively characterize the pretreatment immune TME in formalin-fixed, paraffin-embedded tissue from 23 patients with melanoma, stratified by age, frailty status (as determined by the Clinical Frailty Scale), and clinical benefit from ICB. 33 immune cell phenotypes were identified and compared across patient groups.Frail patients exhibited significantly higher densities of CD4+CD45RO+ memory T cells compared with non-frail older patients. No other differences in the immune TME were observed between frail and non-frail patients, and overall survival was comparable between these groups. In contrast, multiple age-related differences were observed, including reduced naive T-cell densities and increased myeloid cell infiltration in older patients, consistent with features of immunologic aging. Clinical benefit from ICB was associated with greater overall immune infiltration and lower granulocyte densities, independent of age or frailty status.Despite previously demonstrated systemic immunosenescence, the melanoma immune TME preserved in older adults with frailty, consistent with observed preservation of ICB efficacy.
中文摘要:衰弱老年患者表现出系统性免疫衰老,包括T细胞耗竭和免疫多样性降低,但其免疫检查点阻断(ICB)疗效却与较年轻患者相当。黑色素瘤中,肿瘤微环境(TME)和外周血的基线免疫细胞组成均与ICB应答相关。为解释这一矛盾,我们研究了衰弱是否与黑色素瘤TME免疫组成的改变相关。我们应用40标志物组合的成像质谱流式技术,对23例黑色素瘤患者经福尔马林固定、石蜡包埋的治疗前组织中的免疫TME进行全面表征,并按年龄、衰弱状态(由临床衰弱量表确定)和ICB临床获益进行分层。共鉴定出33种免疫细胞表型,并在各组患者间进行比较。与非衰弱老年患者相比,衰弱患者CD4+CD45RO+记忆T细胞密度显著更高。衰弱与非衰弱患者之间未观察到免疫TME的其他差异,且两组总生存期相当。相比之下,观察到多项与年龄相关的差异,包括老年患者初始T细胞密度降低和髓系细胞浸润增加,与免疫衰老特征一致。ICB临床获益与总体免疫浸润更高和粒细胞密度更低相关,且独立于年龄或衰弱状态。尽管既往已证实存在系统性免疫衰老,但衰弱老年人的黑色素瘤免疫TME仍得以保留,这与观察到的ICB疗效保留一致。
Small cell lung cancer (SCLC) is a highly aggressive neoplasm with limited sensitivity to anti-PD-(L)1 blockade, which is likely caused by the epigenetic silencing of MHC-I. Elucidating MHC-I-independent immune recognition mechanisms is therefore crucial for enhancing treatment responses and improving clinical outcomes in a greater number of patients. Leveraging single-cell approaches, we discovered γδ T cell infiltration in biospecimens from patients with SCLC. Despite PD-1 expression, γδ T cells maintained a cytotoxic transcriptional profile, suggesting an anti-tumor role. Indeed, high γδ T cell infiltration in two practice-changing clinical trials predicted improved response to anti-PD-L1 immunotherapy in patients with SCLC. Moreover, using preclinical models, we demonstrated that γδ T cells are effective at tarlatamab (delta-like ligand 3 [DLL3]-CD3 bispecific T cell engager [BiTE])-redirected SCLC killing and that zoledronate, an FDA-approved compound, can sensitize SCLC cells to γδ T cell-mediated killing. Thus, our findings suggest that engaged γδ T cells are potentially valuable targets for SCLC therapy.
中文摘要:小细胞肺癌(SCLC)是一种高度侵袭性的肿瘤,对抗PD-(L)1阻断治疗的敏感性有限,这可能是由MHC-I的表观遗传沉默所致。因此,阐明不依赖MHC-I的免疫识别机制对于提高治疗反应和改善更多患者的临床结局至关重要。利用单细胞方法,我们在SCLC患者的生物标本中发现了γδ T细胞浸润。尽管表达PD-1,γδ T细胞仍维持细胞毒性转录谱,提示其具有抗肿瘤作用。事实上,在两项改变临床实践的临床试验中,高γδ T细胞浸润预示SCLC患者对抗PD-L1免疫治疗的反应改善。此外,利用临床前模型,我们证明γδ T细胞能有效介导tarlatamab(δ样配体3 [DLL3]-CD3双特异性T细胞衔接器 [BiTE])重定向的SCLC杀伤,并且FDA批准的化合物唑来膦酸可使SCLC细胞对γδ T细胞介导的杀伤敏感。因此,我们的发现提示,被激活的γδ T细胞可能是SCLC治疗中有价值的靶点。
Type 2 diabetes (T2D) and cancer frequently coexist and are connected by hyperinsulinemia, hyperglycemia, obesity, chronic inflammation, and multiorgan metabolic dysfunction. These alterations activate insulin/insulin-like growth factor 1, PI3K/AKT/mTOR, MAPK, JAK/STAT, and NF-κB signaling while reshaping the tumor microenvironment through endocrine, immune, and metabolic pathways. This review synthesizes epidemiological and mechanistic evidence linking T2D with cancer and evaluates the oncological implications of major antidiabetic therapies. We discuss how dysfunction of skeletal muscle, adipose tissue, liver, pancreas, and hormonal axes may converge on tumor growth, immune evasion, and treatment resistance. We then critically examine metformin, insulin analogs, sulfonylureas, sodium-glucose cotransporter 2 inhibitors, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and dual GIP/GLP-1 receptor agonists. Metformin has demonstrated extensive preclinical antitumor activity, whereas randomized clinical studies have generally yielded neutral cancer-specific outcomes. Human findings for other agents vary according to cancer type, metabolic phenotype, treatment duration, and study design, with observational estimates particularly sensitive to diabetes severity, obesity, treatment selection, and reverse causality. In clinical practice, glucose-lowering therapy is therefore best guided by glycemic efficacy, cardiovascular and renal protection, body-weight effects, safety, cancer-treatment context, and prognosis. Integrating pharmacological mechanisms with clinically achievable exposure and human outcome data may enable more precise metabolic management at the diabetes-cancer interface.
中文摘要:2型糖尿病(T2D)与癌症常共存,并通过高胰岛素血症、高血糖、肥胖、慢性炎症和多器官代谢功能障碍相互关联。这些改变激活胰岛素/胰岛素样生长因子1、PI3K/AKT/mTOR、MAPK、JAK/STAT和NF-κB信号通路,同时通过内分泌、免疫和代谢途径重塑肿瘤微环境。本综述综合了将T2D与癌症联系起来的流行病学和机制证据,并评估主要降糖治疗的肿瘤学意义。我们讨论骨骼肌、脂肪组织、肝脏、胰腺和激素轴的功能障碍如何可能共同促进肿瘤生长、免疫逃逸和治疗耐药。随后,我们批判性审视二甲双胍、胰岛素类似物、磺脲类、钠-葡萄糖协同转运蛋白2抑制剂、噻唑烷二酮类、二肽基肽酶-4抑制剂、胰高血糖素样肽-1受体激动剂以及GIP/GLP-1双受体激动剂。二甲双胍已显示出广泛的临床前抗肿瘤活性,而随机临床研究通常得出癌症特异性结局为中性的结果。其他药物的人体研究结果因癌症类型、代谢表型、治疗持续时间和研究设计而异,观察性估计尤其对糖尿病严重程度、肥胖、治疗选择和反向因果关系敏感。因此,在临床实践中,降糖治疗最好根据血糖疗效、心血管和肾脏保护、对体重的影响、安全性、癌症治疗背景和预后进行指导。将药理学机制与临床可达到的暴露量和人体结局数据相结合,可能有助于在糖尿病-癌症交界处实现更精准的代谢管理。
Nasopharyngeal carcinoma (NPC) is a distinctive epithelial malignancy characterized by marked geographic and ethnic clustering, with the greatest burden concentrated in East and Southeast Asia despite declining age-standardized incidence and mortality rates in many regions. NPC arises from a complex interaction among persistent Epstein-Barr virus (EBV) infection, inherited susceptibility, and environmental exposures. Among these factors, EBV plays a central role in endemic NPC through latent gene products, particularly latent membrane protein 1 (LMP1), latent membrane protein 2A (LMP2A), and Epstein-Barr nuclear antigen 1 (EBNA1), which sustain oncogenic signaling, remodel the tumor microenvironment, and reinforce malignant progression. Clinically, NPC is often diagnosed at a locoregionally advanced stage because of its deep anatomical location and nonspecific early symptoms, making accurate detection, risk stratification, and treatment selection particularly important. Although previous reviews have addressed individual aspects of NPC biology or management, an integrated framework linking epidemiological determinants, viral oncogenesis, host molecular dysregulation, and therapeutic evolution remains needed. This review therefore synthesizes current evidence on NPC epidemiology, risk factors, EBV-associated molecular mechanisms, major signaling pathways and their crosstalk, genetic and epigenetic alterations, clinical features, diagnosis, staging, and management. Particular emphasis is placed on the clinical roles and limitations of plasma EBV DNA, the distinction between established standards and investigational strategies, and emerging molecular and immune-based therapies. By linking mechanistic insights with their clinical and translational implications, this review provides a biologically informed framework for understanding NPC and highlights priorities for biomarker standardization, risk-adapted treatment, and future therapeutic development.
中文摘要:鼻咽癌(NPC)是一种具有独特特征的上皮性恶性肿瘤,表现出明显的地理和族群聚集性,尽管许多地区的年龄标化发病率和死亡率呈下降趋势,但疾病负担仍主要集中在东亚和东南亚。鼻咽癌由持续性EBV感染、遗传易感性和环境暴露之间复杂的相互作用引起。在这些因素中,EBV通过潜伏基因产物,尤其是潜伏膜蛋白1(LMP1)、潜伏膜蛋白2A(LMP2A)和EBV核抗原1(EBNA1),在地方性鼻咽癌中发挥核心作用,这些产物维持致癌信号、重塑肿瘤微环境并促进恶性进展。临床上,由于鼻咽部解剖位置深且早期症状非特异,鼻咽癌常在局部区域晚期才被诊断,因此准确检测、风险分层和治疗选择尤为重要。尽管既往综述已涉及鼻咽癌生物学或管理的个别方面,但仍需要一个将流行病学决定因素、病毒致癌、宿主分子失调和治疗演变联系起来的整合框架。因此,本综述综合了关于鼻咽癌流行病学、危险因素、EBV相关分子机制、主要信号通路及其交互作用、遗传和表观遗传改变、临床特征、诊断、分期和管理的现有证据。重点阐述了血浆EBV DNA的临床作用与局限性、已确立标准与在研策略之间的区别,以及新兴的分子与免疫治疗策略。通过将机制性见解与其临床和转化意义相联系,本综述为理解鼻咽癌提供了一个基于生物学的框架,并强调了生物标志物标准化、风险适应治疗和未来治疗开发的重点。
Immune checkpoint inhibitors (ICIs) are recommended for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), including patients with tumors with a programmed cell death 1 ligand 1 (PD-L1) combined positive score (CPS) of less than 1. However, the benefit of ICIs in this population remains uncertain. To quantify the probability that ICIs are associated with improved or reduced survival in HNSCC with a PD-L1 CPS of less than 1 compared with standard non-ICI therapy. Systematic search of PubMed, Embase, Web of Science, and ClinicalTrials.gov from database inception to January 11, 2026. Phase 3 randomized clinical trials comparing ICI-based regimens vs standard non-ICI control in HNSCC reporting outcomes in the subgroup with a PD-L1 CPS of less than 1. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) reporting guideline was followed. Bayesian random-effects meta-analysis estimated hazard ratios (HRs) with 95% credible intervals (CrIs) and the posterior probability of HR being greater than 1.0 (favoring control), a continuous measure of evidence. Frequentist random-effects meta-analysis also estimated HRs with 95% CIs and P values to assess statistical significance. All processes were performed independently by at least 2 reviewers, with discrepancies resolved through discussion or adjudication by a senior investigator. The primary outcome was overall survival (OS), and the secondary outcome was a composite of disease-free survival (DFS), progression-free survival (PFS), and event-free survival (EFS). The meta-analysis included 7 randomized clinical trials from 2018 to 2025 involving 630 patients with tumors with a PD-L1 CPS of less than 1. In the recurrent/metastatic setting (3 trials), the bayesian HR for OS was 1.42 (95% CrI, 0.93-2.06), with a posterior probability of an HR exceeding 1.0 of 95.6%. The frequentist HR was 1.46 (95% CI, 1.17-1.83; P < .001). In the locally advanced setting (4 trials), the bayesian HR for the composite of DFS, PFS, and EFS was 1.19 (95% CrI, 0.72-2.06), with posterior probability of an HR exceeding 1.0 of 76.8%. Across all trials, the bayesian HR was 1.43 (95% CrI, 0.97-2.07) for OS (4 trials) and 1.30 (95% CrI, 0.94-1.75) for the composite of DFS, PFS, and EFS (6 trials), with posterior probability of an HR exceeding 1.0 of 96.2% and 95.5%, respectively. The frequentist HRs were 1.47 (95% CI, 1.18-1.83) for OS and 1.31 (95% CI, 1.02-1.69) for the composite of DFS, PFS, and EFS. This systematic review and meta-analysis found a high bayesian probability, alongside frequentist statistical significance, that ICIs were associated with reduced OS in patients with HNSCC with a PD-L1 CPS of less than 1. These subgroup-derived findings warrant validation and cautious use in this understudied population.
中文摘要:免疫检查点抑制剂(ICIs)被推荐用于复发/转移性头颈部鳞状细胞癌(HNSCC),包括程序性细胞死亡1配体1(PD-L1)联合阳性评分(CPS)小于1的肿瘤患者。然而,ICIs在该人群中的获益仍不确定。本研究旨在量化与标准非ICI治疗相比,ICIs在PD-L1 CPS小于1的HNSCC中与生存改善或降低相关的概率。系统检索了PubMed、Embase、Web of Science和ClinicalTrials.gov,检索时间从数据库建库至2026年1月11日。纳入比较基于ICI的方案与标准非ICI对照、并在PD-L1 CPS小于1亚组中报告结局的HNSCC 3期随机临床试验。研究遵循系统评价和meta分析首选报告条目(PRISMA)报告指南。贝叶斯随机效应meta分析估计了风险比(HR)及95%可信区间(CrI),并计算HR大于1.0(有利于对照)的后验概率,这是一种连续证据度量。频率学派随机效应meta分析也估计了HR及95%CI和P值,以评估统计学显著性。所有流程由至少2名评价员独立完成,分歧通过讨论或由资深研究者裁定解决。主要结局为总生存(OS),次要结局为无病生存(DFS)、无进展生存(PFS)和无事件生存(EFS)的复合终点。该meta分析纳入2018年至2025年的7项随机临床试验,涉及630例PD-L1 CPS小于1的肿瘤患者。在复发/转移场景(3项试验)中,贝叶斯OS的HR为1.42(95%CrI,0.93-2.06),HR超过1.0的后验概率为95.6%。频率学派HR为1.46(95%CI,1.17-1.83;P < .001)。在局部晚期场景(4项试验)中,DFS、PFS和EFS复合终点的贝叶斯HR为1.19(95%CrI,0.72-2.06),HR超过1.0的后验概率为76.8%。在所有试验中,贝叶斯HR为OS 1.43(95%CrI,0.97-2.07)(4项试验),DFS、PFS和EFS复合终点1.30(95%CrI,0.94-1.75)(6项试验),HR超过1.0的后验概率分别为96.2%和95.5%。频率学派HR分别为OS 1.47(95%CI,1.18-1.83)和DFS、PFS和EFS复合终点1.31(95%CI,1.02-1.69)。本系统评价和meta分析发现,高贝叶斯概率以及频率学派统计学显著性表明,ICIs与PD-L1 CPS小于1的HNSCC患者OS降低相关。这些来自亚组的发现需要在研究不足的人群中验证并谨慎使用。
The incidence of human papillomavirus type 16 (HPV16-positive) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) is rising. Approved therapies offer a durable response to a minority of patients. To determine the efficacy and safety of a therapeutic HPV16-targeted immunotherapy, PDS0101, in combination with pembrolizumab in participants with HPV16-positive R/M HNSCC, with separate evaluation of immune checkpoint inhibitor (ICI)-naive and ICI-resistant cohorts. VERSATILE-002 was a phase 2, open-label, multicenter nonrandomized clinical trial conducted at 26 oncology centers from March 29, 2021, to May 15, 2025, across the US, UK, and Ireland using the Simon 2-stage optimal design. Efficacy analyses were performed on modified intent-to-treat (mITT) population; safety analyses included all participants who received 1 or more doses. Eighty-eight participants with histologically confirmed R/M HPV16-positive HNSCC were enrolled, of whom 87 (98.9%) received treatment and composed the safety population. Seventy five (85.2%) were in the mITT population used for efficacy analyses, of whom 53 (70.7%) were ICI-naive with a programmed cell death ligand 1 combined positive score of 1 or greater and 22 (29.3%) were ICI-resistant. Pembrolizumab (200 mg, intravenously, every 3 weeks for up to 35 cycles) plus subcutaneous PDS0101 (5 scheduled doses per protocol). The primary end point was objective response rate (ORR) per the Response Evaluation Criteria in Solid Tumors, version 1.1, by a masked independent central reviewer. Secondary end points included progression-free survival (PFS), median overall survival (mOS), and safety, with exploratory end points of duration of response, disease control rate, and response rates by programmed cell death ligand 1 status. Of the 75 patients in the mITT population, the mean (SD) age was 64.0 (8.3) years; 4 individuals (5%) were female and 71 (95%) were male; and 2 individuals (3%) were Asian, 1 (1%) was Black, 5 (7%) were Hispanic, and 71 (95%) were White. Among 53 ICI-naive participants in the mITT cohort, ORR by the central reviewer was 34.0%, median PFS was 5.3 months (95% CI, 2.10-9.00), and mOS was 39.3 months (95% CI, 23.90 to not evaluable). Among 22 ICI-resistant patients in the mITT cohort, no objective responses were observed and the primary end point (ORR by central reviewer) was not met, but mOS was 14.8 months (95% CI, 8.50-26.00). The treatment was well tolerated, with 13.8% experiencing grade 3 or higher treatment-related adverse events. The results of this nonrandomized clinical trial suggest that PDS0101 plus pembrolizumab showed antitumor activity in ICI-naive HPV16-positive R/M HNSCC, with favorable safety, response rates, and survival outcomes. The findings support further evaluation in a first-line setting. ClinicalTrials.gov Identifier: NCT04260126.
中文摘要:人乳头瘤病毒16型(HPV16阳性)复发/转移性(R/M)头颈部鳞状细胞癌(HNSCC)的发病率正在上升。已获批疗法仅对少数患者产生持久缓解。旨在确定靶向HPV16的治疗性免疫疗法PDS0101联合帕博利珠单抗在HPV16阳性R/M HNSCC参与者中的疗效和安全性,并分别评估免疫检查点抑制剂(ICI)初治和ICI耐药队列。VERSATILE-002是一项2期、开放标签、多中心非随机临床试验,于2021年3月29日至2025年5月15日在美国、英国和爱尔兰的26个肿瘤中心开展,采用Simon两阶段最优设计。疗效分析在改良意向治疗(mITT)人群中进行;安全性分析纳入所有接受至少1剂治疗的参与者。共入组88例组织学确诊的R/M HPV16阳性HNSCC参与者,其中87例(98.9%)接受了治疗并构成安全性人群。75例(85.2%)进入用于疗效分析的mITT人群,其中53例(70.7%)为ICI初治且程序性细胞死亡配体1联合阳性评分≥1,22例(29.3%)为ICI耐药。帕博利珠单抗(200 mg,静脉给药,每3周一次,最多35个周期)联合皮下注射PDS0101(按方案计划5剂)。主要终点为由设盲的独立中心审阅者根据实体瘤疗效评价标准第1.1版评估的客观缓解率(ORR)。次要终点包括无进展生存期(PFS)、中位总生存期(mOS)和安全性,探索性终点包括缓解持续时间、疾病控制率以及按程序性细胞死亡配体1状态划分的缓解率。mITT人群的75例患者中,平均(SD)年龄为64.0(8.3)岁;4例(5%)为女性,71例(95%)为男性;2例(3%)为亚洲人,1例(1%)为黑人,5例(7%)为西班牙裔,71例(95%)为白人。在mITT队列的53例ICI初治参与者中,中心审阅者评估的ORR为34.0%,中位PFS为5.3个月(95% CI,2.10-9.00),mOS为39.3个月(95% CI,23.90至不可评估)。在mITT队列的22例ICI耐药患者中,未观察到客观缓解,主要终点(中心审阅者评估的ORR)未达到,但mOS为14.8个月(95% CI,8.50-26.00)。治疗耐受性良好,13.8%发生3级或以上治疗相关不良事件。这项非随机临床试验的结果提示,PDS0101联合帕博利珠单抗在ICI初治的HPV16阳性R/M HNSCC中显示出抗肿瘤活性,并具有有利的安全性、缓解率和生存结局。这些发现支持在一线治疗背景下进一步评估。ClinicalTrials.gov注册号:NCT04260126。
Separate phase III trials of the anti-B7-H3 antibody-drug conjugates tambotatug pelitecan and risvutatug rezetecan significantly improved overall survival, progression-free survival, and objective response rates compared with topotecan in patients with relapsed small-cell lung cancer. In a third trial, the combination of the investigational PD-L1 x VEGF-A bispecific antibody pumitamig plus the anti-B7-H3 ADC elfetabart drozuntecan showed encouraging early efficacy in SCLC across lines of therapy and doses. The studies were presented at the 2026 World Congress on Lung Cancer in Seoul, Republic of Korea.
中文摘要:两项针对抗B7-H3抗体药物偶联物tambotatug pelitecan和risvutatug rezetecan的独立III期试验显示,在复发小细胞肺癌患者中,与拓扑替康相比,这两种药物显著改善了总生存期、无进展生存期和客观缓解率。在第三项试验中,研究性PD-L1 x VEGF-A双特异性抗体pumitamig联合抗B7-H3抗体药物偶联物elfetabart drozuntecan在跨治疗线和跨剂量的SCLC中显示出令人鼓舞的早期疗效。这些研究在韩国首尔举行的2026年世界肺癌大会上公布。
The gut microbiome has been linked to immune checkpoint inhibitor (ICI) outcomes, but the temporal dynamics of microbial communities during treatment remain poorly characterised. To characterise gut microbiome trajectories during ICI therapy and evaluate whether on-treatment microbial states improve the identification and generalisability of pretreatment biomarker signatures. We performed a large prospective longitudinal shotgun metagenomic study of 315 patients with advanced primary liver cancer receiving ICI-based therapy, profiling 777 serial stool metagenomes collected at baseline and at approximately 3-month intervals on treatment. Responders (durable clinical benefit ≥6 months) contributed extended follow-up beyond 18 months. On-treatment windows were used for feature discovery; baseline-trained models were evaluated across all nine public ICI cohorts (n=1204). Responders showed higher baseline alpha diversity and distinct community structure. Longitudinal profiling revealed marked ecological remodelling during therapy in both response groups, characterised by reduced network connectivity, increased modularity and strong time point specificity of discriminatory species. Using the on-treatment contrast at ~6 months (T2) as a discovery window, we identified a 16-species panel. A baseline model built from this panel outperformed models based on baseline-only feature discovery and generalised across nine public ICI studies. The resulting gut microbiome-derived immunotherapy outcome score stratified overall and progression-free survival in the discovery cohort (HRs 0.49 and 0.44) and across multiple external datasets, including stable-disease subsets. The gut microbiome undergoes structured ecological remodelling during ICI therapy; on-treatment longitudinal windows improve pretreatment signature portability and support microbiome-guided stratification in immuno-oncology.
中文摘要:肠道微生物组与免疫检查点抑制剂(ICI)结局相关,但治疗期间微生物群落的时间动态仍表征不足。为刻画ICI治疗期间肠道微生物组轨迹,并评估治疗中微生物状态是否提高治疗前生物标志物特征的识别与可推广性。我们开展了一项大型前瞻性纵向鸟枪法宏基因组研究,纳入315例接受基于ICI治疗的晚期原发性肝癌患者,对基线和治疗期间约每3个月间隔采集的777份连续粪便宏基因组进行分析。应答者(持久临床获益≥6个月)提供了超过18个月的延长随访。治疗中窗口用于特征发现;基线训练的模型在全部九个公开ICI队列(n=1204)中评估。应答者显示更高的基线α多样性以及不同的群落结构。纵向分析显示,在两个应答组中,治疗期间均出现显著的生态重塑,其特征为网络连接性降低、模块性增加以及判别性物种具有强烈的时间点特异性。以约6个月时(T2)的治疗中对比作为发现窗口,我们识别出一个16个物种的组合。基于该组合构建的基线模型优于仅基于基线特征发现的模型,并在九项公开ICI研究中具有可推广性。由此得到的肠道微生物组来源的免疫治疗结局评分在发现队列中对总生存和无进展生存进行分层(HR分别为0.49和0.44),并在多个外部数据集中得到验证,包括疾病稳定亚组。肠道微生物组在ICI治疗期间经历结构化的生态重塑;治疗中纵向窗口提高了治疗前特征的可移植性,并支持免疫肿瘤学中基于微生物组的分层。
Brainstem gliomas, particularly H3K27M-mutant diffuse midline gliomas (DMGs), lack effective therapies owing to anatomic inaccessibility, intact blood-brain barrier, and treatment resistance. Conventional models have low establishment rates and fail to preserve the native tumor microenvironment, limiting translational study for this rare disease. Here, we established a patient-derived brainstem glioma organoid (BSGO) platform with high success, faithfully recapitulating parental tumor features. Multi-omics and functional assays revealed that DMGs maintain oligodendrocyte precursor cell (OPC) stemness by dysregulating ACTIVIN signaling. To overcome delivery barriers and target stemness, we conducted an intrathecal drug screening and identified triple intrathecal therapy (methotrexate + cytarabine + dexamethasone, TIT) as a potent regimen against DMGs. In DMG patients, organoid-avatar guided personalized therapy induced sustained responses, with TIT-associated reductions in OPC markers reliably tracked by cerebrospinal fluid (CSF) proteomic profiling. Together, our study provides an organoid-based platform for mechanistic investigation and personalized intrathecal therapy screening and proposes TIT as a promising translational strategy for DMG.
中文摘要:脑干胶质瘤,尤其是H3K27M突变型弥漫性中线胶质瘤(DMG),由于解剖位置难以到达、血脑屏障完整以及治疗耐药,缺乏有效疗法。传统模型建立率低,且无法保留原生肿瘤微环境,限制了这一罕见疾病的转化研究。在此,我们建立了一个患者来源的脑干胶质瘤类器官(BSGO)平台,成功率高,并忠实再现亲本肿瘤特征。多组学和功能实验显示,DMG通过ACTIVIN信号失调维持少突胶质前体细胞(OPC)干性。为克服递送障碍并靶向干性,我们进行了鞘内药物筛选,并确定了三联鞘内治疗(甲氨蝶呤+阿糖胞苷+地塞米松,TIT)是抗DMG的有效方案。在DMG患者中,类器官替身指导的个体化治疗诱导了持续缓解,TIT相关的OPC标志物减少可通过脑脊液(CSF)蛋白质组学分析可靠追踪。总之,我们的研究提供了一个基于类器官的平台,用于机制研究和个体化鞘内治疗筛选,并提出TIT作为DMG有前景的转化策略。
KRAS G12D mutations drive approximately 40% of pancreatic ductal adenocarcinoma (PDAC) cases and foster an immunosuppressive tumor microenvironment. This phase 1/2 trial (NCT06427239) evaluated HRS-4642, a selective KRAS G12D inhibitor, combined with the PD-L1 blockade adebrelimab in 48 pretreated patients with metastatic KRAS G12D-mutant PDAC. Dose escalation revealed no dose-limiting toxicities, establishing the recommended phase 2 dose (RP2D), and no treatment-related deaths occurred; hypercholesterolemia and anemia (each 50%) were the most common treatment-related adverse events. In the RP2D cohort (n = 37), the confirmed objective response rate was 43.2% (95% confidence interval [CI], 27.1-60.5), disease control rate was 81.1% (95% CI, 64.8-92.0), median duration of response was 6.9 months (95% CI, 4.8-8.6), median progression-free survival was 5.7 months (95% CI, 4.0-7.5), and median overall survival was 11.5 months (95% CI, 9.2-16.9). This chemotherapy-free regimen is tolerable and shows encouraging antitumor activity in refractory KRAS G12D-mutant PDAC, warranting further investigation.
中文摘要:KRAS G12D突变驱动约40%的胰腺导管腺癌(PDAC)病例,并促进免疫抑制性肿瘤微环境。这项1/2期试验(NCT06427239)评估了选择性KRAS G12D抑制剂HRS-4642联合PD-L1阻断剂adebrelimab在48例既往接受过治疗的转移性KRAS G12D突变PDAC患者中的疗效。剂量递增未发现剂量限制性毒性,确定了推荐的2期剂量(RP2D),且未发生治疗相关死亡;高胆固醇血症和贫血(各占50%)是最常见的治疗相关不良事件。在RP2D队列(n=37)中,确认的客观缓解率为43.2%(95%置信区间[CI],27.1-60.5),疾病控制率为81.1%(95% CI,64.8-92.0),中位缓解持续时间为6.9个月(95% CI,4.8-8.6),中位无进展生存期为5.7个月(95% CI,4.0-7.5),中位总生存期为11.5个月(95% CI,9.2-16.9)。这种无化疗方案耐受性良好,在难治性KRAS G12D突变PDAC中显示出令人鼓舞的抗肿瘤活性,值得进一步研究。
In this network meta-analysis (NMA), efficacy of first-line (1L) zolbetuximab and immune checkpoint inhibitors (ICIs) was compared across programmed death-ligand 1 [PD-(L)1] combined positive score (CPS) levels in patients with locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma in global trials. Studies evaluating zolbetuximab or ICIs plus chemotherapy as 1L treatments among adults with LA unresectable or mG/GEJ adenocarcinoma were included. A Bayesian fixed-effects NMA compared overall survival (OS) and progression-free survival (PFS) across treatments in PD-(L)1 CPS subgroups (CPS ≥1 to <5; ≥5 to <10; or ≥10). Because PD-(L)1 CPS is a biologically and clinically validated treatment effect modifier for ICIs, CPS-specific hazard ratios were used for ICIs but not zolbetuximab, which targets claudin 18 isoform 2 (CLDN18.2). Sensitivity analyses of PD-(L)1 CPS ≥10 leveraged patients with optimal zolbetuximab exposure-those who did not experience nausea/vomiting leading to inadequate dose exposure or discontinuation. Five regimens (zolbetuximab, pembrolizumab, tislelizumab, or nivolumab plus chemotherapy, and chemotherapy alone) were included. In PD-(L)1 CPS ≥1 to <5, zolbetuximab showed similar or numerically favorable OS and PFS versus ICIs. In PD-(L)1 CPS ≥5 to <10, zolbetuximab had numerically favorable OS and PFS versus ICIs. In PD-(L)1 CPS ≥10, ICIs had numerically favorable OS and PFS versus zolbetuximab. However, in sensitivity analyses, among patients with optimal zolbetuximab exposure, zolbetuximab showed similar OS and PFS to ICIs. These findings support a biomarker-informed treatment approach in human epidermal growth factor receptor 2 (HER2)-negative, CLDN18.2-positive advanced gastric/GEJ adenocarcinoma. In PD-(L)1 CPS ≥1 to <10, zolbetuximab plus chemotherapy demonstrated consistent efficacy and may represent a relevant option beyond PD-(L)1-driven selection. In CPS ≥10, zolbetuximab remained clinically meaningful, with efficacy comparable to select ICI-based regimens when exposure is optimized. Results should be interpreted cautiously given these are indirect comparisons and warrant confirmation in prospective studies.
中文摘要:在这项网络荟萃分析(NMA)中,我们在全球试验中比较了一线(1L)佐贝妥昔单抗和免疫检查点抑制剂(ICIs)在局部晚期(LA)不可切除或转移性胃或胃食管结合部(mG/GEJ)腺癌患者中按程序性死亡配体1[PD-(L)1]联合阳性分数(CPS)水平划分的疗效。纳入的研究评估了佐贝妥昔单抗或ICIs联合化疗作为成人LA不可切除或mG/GEJ腺癌1L治疗。采用贝叶斯固定效应NMA比较PD-(L)1 CPS亚组(CPS≥1至<5;≥5至<10;或≥10)中各治疗的总生存(OS)和无进展生存(PFS)。由于PD-(L)1 CPS是ICIs在生物学和临床上已验证的疗效修饰因素,因此对ICIs使用了CPS特异性风险比,但未对靶向claudin 18异构体2(CLDN18.2)的佐贝妥昔单抗使用。PD-(L)1 CPS≥10的敏感性分析利用了佐贝妥昔单抗最佳暴露的患者,即未发生导致剂量暴露不足或停药的恶心/呕吐的患者。共纳入5种方案(佐贝妥昔单抗、帕博利珠单抗、替雷利珠单抗或纳武利尤单抗联合化疗,以及单纯化疗)。在PD-(L)1 CPS≥1至<5中,佐贝妥昔单抗与ICIs相比OS和PFS相似或数值上更有利。在PD-(L)1 CPS≥5至<10中,佐贝妥昔单抗与ICIs相比OS和PFS数值上更有利。在PD-(L)1 CPS≥10中,ICIs与佐贝妥昔单抗相比OS和PFS数值上更有利。然而,在敏感性分析中,在佐贝妥昔单抗最佳暴露的患者中,佐贝妥昔单抗与ICIs相比OS和PFS相似。这些发现支持在人类表皮生长因子受体2(HER2)阴性、CLDN18.2阳性晚期胃/GEJ腺癌中采用基于生物标志物的治疗策略。在PD-(L)1 CPS≥1至<10中,佐贝妥昔单抗联合化疗显示出一致的疗效,可能代表超越PD-(L)1驱动选择的相关选择。在CPS≥10中,佐贝妥昔单抗仍具有临床意义,当暴露优化时其疗效与部分基于ICIs的方案相当。鉴于这些为间接比较,结果应谨慎解读,并需要在前瞻性研究中确认。
Chimeric antigen receptor T-cell (CAR-T) therapies are cellular immunotherapies that improve survival in patients with relapsed haematologic malignancies. However, their association with major adverse cardiovascular events (MACE) has received limited study, particularly in older adults. This study investigated the incidence of MACE, associated risk factors, and their impact on survival among older patients undergoing CAR-T in the USA. Medicare fee-for-service beneficiaries over 65 who received inpatient CAR-T therapy between 2018 and 2023 were included. Baseline characteristics were assessed during the 12 months preceding CAR-T. MACE were defined as a composite of acute heart failure (HF), cardiogenic shock, myocardial infarction, cardiac tamponade, ventricular arrhythmia, complete heart block, or stroke. Multivariable models were adjusted for demographics, malignancy type, and baseline cardiovascular comorbidities. Among 3292 patients receiving CAR-T, 191 (5.8%) had MACE. Most common events were acute HF (3.1%), followed by ischaemic (1.3%) and haemorrhagic stroke (1%). Pre-treatment atrial fibrillation/flutter [adjusted odds ratio (aOR) 1.52 (1.08-2.16)], cardiomyopathy [aOR 2.49 (1.75-3.54)], and cerebrovascular disease [aOR 2.40 (1.30-4.43)] were independently associated with MACE. In 2021-23, MACE were also associated with immune effector cell-associated neurotoxicity syndrome and higher-grade cytokine release syndrome. MACE were associated with higher in-hospital mortality [aOR 16.9 (11.0-26.1)] and 1-year mortality after discharge [adjusted hazard ratio 1.91 (1.46-2.49)]. In the largest national sample of older adults receiving CAR-T, MACE occurred in 5.8% of patients and were associated with increased in-hospital and 1-year mortality. Further investigation into preventive and mitigating measures is needed.
中文摘要:嵌合抗原受体T细胞(CAR-T)疗法是一种细胞免疫疗法,可提高复发性血液系统恶性肿瘤患者的生存率。然而,其与主要不良心血管事件(MACE)的关联研究有限,尤其是在老年人中。本研究调查了美国接受CAR-T治疗的老年患者中MACE的发生率、相关危险因素及其对生存的影响。纳入2018年至2023年间接受住院CAR-T治疗的65岁以上Medicare按服务收费受益人。在CAR-T治疗前12个月内评估基线特征。MACE定义为急性心力衰竭(HF)、心源性休克、心肌梗死、心脏压塞、室性心律失常、完全性心脏传导阻滞或卒中的复合终点。多变量模型对人口统计学、恶性肿瘤类型和基线心血管合并症进行了校正。在3292例接受CAR-T的患者中,191例(5.8%)发生MACE。最常见的事件是急性HF(3.1%),其次是缺血性卒中(1.3%)和出血性卒中(1%)。治疗前心房颤动/心房扑动[校正比值比(aOR)1.52(1.08-2.16)]、心肌病[aOR 2.49(1.75-3.54)]和脑血管疾病[aOR 2.40(1.30-4.43)]与MACE独立相关。在2021-23年,MACE还与免疫效应细胞相关神经毒性综合征和更高级别的细胞因子释放综合征相关。MACE与较高的院内死亡率[aOR 16.9(11.0-26.1)]和出院后1年死亡率[校正风险比1.91(1.46-2.49)]相关。在接受CAR-T治疗的老年人这一最大的全国样本中,5.8%的患者发生MACE,且与院内和1年死亡率增加相关。需要进一步研究预防和减轻措施。
基础研究 (30篇)
The acidic and immunosuppressive tumor microenvironment (TME) remarkably hampers the therapeutic efficacy of transcatheter arterial embolization (TAE) for hepatocellular carcinoma (HCC). Herein, uniform CaCO3 nanoparticles encapsulated nickel-alginate microspheres (CaNPs/Ni-Alg MSs) were engineered using a microfluidic device, serving as an immune-regulated embolic agent to amplify TAE treatment of HCC. CaNPs/Ni-Alg MSs could adsorb His-tagged interleukin-2 (IL-2) and enable sustained release through coordination interactions between the His-tag and Ni2 +, thereby reducing systemic cytokine elevation risk from IL-2 administration. IL-2-loaded microspheres (IL-2/CaNPs/Ni-Alg MSs) effectively neutralize intratumoral lactic acid (LA) via CaCO3, modulating the acidic TME. Proton neutralization restores IL-2 activity, enhancing T lymphocyte infiltration and proliferation. Additionally, lactate made available following acid neutralization may serve as a metabolic substrate, as supported by the calcium lactate and neutralization-mimicking experiments in vitro, contributing to CD8+ T-cell metabolic fitness. IL-2/CaNPs/Ni-Alg MSs could reprogram the TME into an immune-promoting milieu, synergizing with immune checkpoint blockade (ICB) therapy to suppress both primary and distant tumors. Not surprisingly, TAE with IL-2/CaNPs/Ni-Alg MSs combined with αPD-L1 achieved superior therapeutic efficacy without side effect in a rat orthotopic HCC model. Overall, this work presents a safe metabolism-reprogramming embolic strategy that repurposes LA to boost IL-2-mediated embolization-immunotherapy in HCC.
中文摘要:酸性和免疫抑制性肿瘤微环境(TME)显著削弱了经导管动脉栓塞(TAE)对肝细胞癌(HCC)的治疗效果。在此,本研究利用微流控装置构建了均匀的CaCO3纳米颗粒包封的镍-海藻酸盐微球(CaNPs/Ni-Alg MSs),作为免疫调节性栓塞剂以增强TAE对HCC的治疗。CaNPs/Ni-Alg MSs可吸附带His标签的白细胞介素-2(IL-2),并通过His标签与Ni2+之间的配位相互作用实现持续释放,从而降低IL-2给药引起的全身性细胞因子升高风险。载IL-2微球(IL-2/CaNPs/Ni-Alg MSs)通过CaCO3有效中和瘤内乳酸(LA),调节酸性TME。质子中和可恢复IL-2活性,增强T淋巴细胞浸润和增殖。此外,酸中和后释放的乳酸可能作为代谢底物,这一点得到体外乳酸钙和模拟中和实验的支持,有助于CD8+ T细胞的代谢适应性。IL-2/CaNPs/Ni-Alg MSs可将TME重编程为免疫促进性微环境,与免疫检查点阻断(ICB)治疗协同抑制原发瘤和远端瘤。不出所料,在大鼠原位HCC模型中,使用IL-2/CaNPs/Ni-Alg MSs进行TAE联合αPD-L1取得了更优疗效且无副作用。总体而言,这项工作提出了一种安全的代谢重编程栓塞策略,将LA重新利用以增强HCC中IL-2介导的栓塞-免疫治疗。
Despite the success of mRNA lipid nanoparticle therapeutics, bottlenecks persist in limited cellular expression and uncontrolled encapsulation and release kinetics. Here we introduce a microfluidics-based method, MIMAC (microfluidic integrated mRNA amplification circuit), that restructures preformed lipid nanoparticles by inserting a metabolic enhancing RNA to an internal peripheral compartment while relocating the therapeutic RNA towards the core. Rapid shear-mediated reorganization generates a defined peripheral-to-core RNA arrangement that enables sequential cytosolic availability: early release of the metabolic RNA elevates ATP levels up to 4.2-fold and enhances following translation of the therapeutic RNA. The approach is compatible with multiple nucleic acid types-including linear, circular and self-amplifying RNA and plasmid DNA-and with varied lipid formulations. In mice, the structured lipid nanoparticles improve a human papillomavirus cancer vaccine, suppressing tumour growth by 89.2% and increasing survival. Applied to SARS-CoV-2 vaccines, our method boosts antibody titres by 62.3- to 174.8-fold while maintaining potency at one-tenth the dose. A benchtop device produces 200 doses per hour, supporting scalable use.
中文摘要:尽管 mRNA 脂质纳米颗粒疗法取得了成功,但在细胞表达有限以及封装与释放动力学不可控方面仍存在瓶颈。在此,我们介绍一种基于微流控的方法,MIMAC(微流控集成 mRNA 放大回路),其通过将一种代谢增强 RNA 插入内部外周区室、同时将治疗性 RNA 重新定位至核心,来重构预形成的脂质纳米颗粒。快速的剪切介导重排产生明确的从外周至核心的 RNA 排列,从而实现顺序的胞质可用性:代谢 RNA 的早期释放使 ATP 水平提高至多 4.2 倍,并增强随后治疗性 RNA 的翻译。该方法与多种核酸类型兼容,包括线性、环状和自扩增 RNA 以及质粒 DNA,并且与多种脂质配方兼容。在小鼠中,这种结构化脂质纳米颗粒改善了人乳头瘤病毒癌症疫苗,使肿瘤生长抑制达 89.2% 并提高生存率。应用于 SARS-CoV-2 疫苗时,我们的方法使抗体滴度提高 62.3 至 174.8 倍,同时在十分之一剂量下仍保持效力。一台台式设备每小时可生产 200 剂,支持规模化使用。
Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor, for which radiotherapy constitutes the key component of standard comprehensive treatment; however, tumor relapse could inevitably arise from intrinsically radioresistant GBM subclones. Radiotherapy exerts biphasic regulatory effects on the tumor immune microenvironment (TIME), with transient activation followed by sustained immunosuppression. Nevertheless, it remains elusive how radioresistant GBM cells remodel such an immunosuppressive TIME to evade immune surveillance. Herein, integrative analyses encompassing clinical specimens, public single-cell RNA-seq datasets, orthotopic glioma models, primary CD8+ T cell co-culture systems, and tandem mass tag (TMT) proteomics indicated that CD81 was highly expressed in radioresistant GBM and governed GBM immune evasion. CD81-high tumor cells were surrounded by functionally exhausted CD8+ T cells, alongside immunosuppressive signature within neighboring myeloid and NK cells. CD81 depletion promoted selective macroautophagic/autophagic degradation of CD274/PD-L1, increased CD8+ T cell infiltration and cytotoxic activity, reduced M2-like tumor-associated macrophages, and suppressed intracranial tumor growth. Moreover, CD81-knockdown augmented the antitumor efficacy of anti-PDCD1/PD-1, yielding a pronounced survival benefit when combined with radiotherapy. Mechanistically, CD81 interacted with CD274 via its large extracellular loop (LEL) and recruited the deubiquitinase USP14 through its cytoplasmic C-terminal tail (CCT). This resultant ternary complex erased K63-linked ubiquitination at the K280 residue of CD274, thereby abolishing SQSTM1/p62-dependent recognition and subsequent autophagy-lysosomal degradation of CD274 to maintain its protein stability. Collectively, our work establishes CD81 as a pivotal bridge connecting radioresistance to immune escape via sustaining CD274 abundance in GBM, highlighting CD81 as a promising therapeutic target to optimize radioimmunotherapy.Abbreviations: BBB: blood-brain barrier; CTLs: cytotoxic T lymphocytes; CCK-8: cell counting kit-8; ELISA: enzyme-linked immunosorbent assay; GBM: glioblastoma; IHC: Immunohistochemistry; GZMB: granzyme B; MDSCs: myeloid-derived suppressor cells; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; OS: overall survival; PFA: paraformaldehyde; PLA: proximity ligation assay; PRF1: Perforin1; STR: short tandem repeat; SQSTM1: sequestosome 1; TMT: tandem mass tag; TMZ: temozolomide; TME: tumor microenvironment; TDEs: tumor-derived exosomes; Tregs: regulatory T cells; WT: wild type.
中文摘要:多形性胶质母细胞瘤(GBM)是侵袭性最强的原发性脑肿瘤,放疗是其标准综合治疗的关键组成部分;然而,肿瘤复发不可避免地源于内在耐放疗的GBM亚克隆。放疗对肿瘤免疫微环境(TIME)发挥双相调控作用,表现为短暂激活后持续免疫抑制。然而,耐放疗GBM细胞如何重塑这种免疫抑制性TIME以逃避免疫监视仍不清楚。在此,涵盖临床标本、公共单细胞RNA测序数据集、原位胶质瘤模型、原代CD8+ T细胞共培养体系以及串联质谱标签(TMT)蛋白质组学的整合分析表明,CD81在耐放疗GBM中高表达并主导GBM免疫逃逸。CD81高表达的肿瘤细胞周围环绕着功能耗竭的CD8+ T细胞,邻近髓系和NK细胞中也存在免疫抑制特征。CD81缺失促进CD274/PD-L1的选择性巨自噬/自噬降解,增加CD8+ T细胞浸润和细胞毒活性,减少M2样肿瘤相关巨噬细胞,并抑制颅内肿瘤生长。此外,CD81敲低增强了抗PDCD1/PD-1的抗肿瘤疗效,与放疗联合时产生显著的生存获益。机制上,CD81通过其大胞外环(LEL)与CD274相互作用,并通过其胞质C端尾(CCT)招募去泛素化酶USP14。由此形成的三元复合物消除了CD274 K280位点的K63连接泛素化,从而废除SQSTM1/p62依赖性识别以及随后的CD274自噬-溶酶体降解,以维持其蛋白稳定性。总之,我们的工作确立了CD81作为连接放疗抵抗与免疫逃逸的关键桥梁,其通过维持GBM中CD274丰度发挥作用,突出CD81作为优化放射免疫治疗的有前景的治疗靶点。缩写:BBB:血脑屏障;CTLs:细胞毒性T淋巴细胞;CCK-8:细胞计数试剂盒-8;ELISA:酶联免疫吸附测定;GBM:胶质母细胞瘤;IHC:免疫组织化学;GZMB:颗粒酶B;MDSCs:髓源性抑制细胞;MAP1LC3/LC3:微管相关蛋白1轻链3;OS:总生存期;PFA:多聚甲醛;PLA:邻位连接分析;PRF1:穿孔素1;STR:短串联重复序列;SQSTM1:sequestosome 1;TMT:串联质谱标签;TMZ:替莫唑胺;TME:肿瘤微环境;TDEs:肿瘤来源外泌体;Tregs:调节性T细胞;WT:野生型。
The cancer-immunity cycle begins with the death of cancer cells, making the mode of cell death a critical determinant of antitumor immune responses. Apoptosis, the predominant form of cell death in most tumors, is often immunologically silent and therefore provides limited support for effective antitumor immunity. By contrast, programmed necrosis promotes cancer immunosurveillance through membrane disruption and the release of immunostimulatory intracellular contents and inflammatory mediators that facilitate immune priming. However, therapeutic induction of these pathways remains challenging, as many cancers harbour molecular defence mechanisms that impair their execution, while tumor heterogeneity, immunosuppressive microenvironments and biological barriers further constrain therapeutic efficacy. In this context, nanomedicine offers a promising strategy for overcoming these limitations by enhancing tumor accumulation through the rational design of physicochemical properties. This Review discusses the immunological significance of programmed necrosis, with particular emphasis on the biological contexts governing its induction, and highlights recent advances in nanomedicines designed to trigger these pathways, including their mechanisms of action, translational challenges and future prospects for cancer immunotherapy.
中文摘要:癌症-免疫循环始于癌细胞死亡,因此细胞死亡方式成为抗肿瘤免疫应答的关键决定因素。凋亡是大多数肿瘤中主要的细胞死亡形式,通常具有免疫沉默性,因此对抗肿瘤免疫的有效支持有限。相比之下,程序性坏死通过膜破裂以及释放免疫刺激性胞内内容物和炎症介质促进免疫致敏,从而促进癌症免疫监视。然而,治疗性诱导这些通路仍具挑战性,因为许多癌症具有损害其执行的分子防御机制,而肿瘤异质性、免疫抑制微环境和生物屏障进一步限制治疗效果。在此背景下,纳米医学通过合理设计理化性质增强肿瘤蓄积,为克服这些局限提供了一种有前景的策略。本综述讨论程序性坏死的免疫学意义,尤其关注决定其诱导的生物学背景,并重点介绍旨在触发这些通路的纳米药物的最新进展,包括其作用机制、转化挑战以及用于癌症免疫治疗的未来前景。
Tumor-associated macrophages (TAMs) are a major component of the tumor microenvironment and exhibit remarkable functional plasticity, acting as either immunosuppressive cells that promote tumor progression or immunostimulatory cells that can support antitumor immunity, depending on the prevailing microenvironmental cues. These cells promote angiogenesis, metastasis, immune suppression, and therapy resistance. However, when appropriately reprogrammed, TAMs can directly kill or phagocytose cancer cells and/or activate antitumor T cell and natural killer cell responses. In this article, we review current therapeutic strategies targeting TAMs, including approaches directed against macrophage-associated receptors, signaling pathways, and epigenetic and metabolic regulators. We also discuss emerging TAM-targeted therapeutic modalities, including cytokine-based therapies, cell-based therapies, bispecific antibodies, macrophage-targeted nanoplatforms, and anti-TAM chimeric antigen receptor T-cell approaches, highlighting their potential to enhance antitumor immunity and improve clinical outcomes.
中文摘要:肿瘤相关巨噬细胞(TAMs)是肿瘤微环境的主要组成部分,并表现出显著的功能可塑性:根据所处微环境信号的不同,它们既可作为免疫抑制细胞促进肿瘤进展,也可作为免疫刺激细胞支持抗肿瘤免疫。这些细胞促进血管生成、转移、免疫抑制和治疗耐药。然而,当被适当地重编程后,TAMs 可直接杀伤或吞噬癌细胞,和/或激活抗肿瘤 T 细胞和自然杀伤细胞反应。在本文中,我们综述了当前靶向 TAMs 的治疗策略,包括针对巨噬细胞相关受体、信号通路以及表观遗传和代谢调节因子的方法。我们还讨论了新兴的 TAM 靶向治疗模式,包括基于细胞因子的疗法、细胞疗法、双特异性抗体、靶向巨噬细胞的纳米平台以及抗 TAM 嵌合抗原受体 T 细胞方法,并强调它们增强抗肿瘤免疫和改善临床结局的潜力。
Oncolytic viruses have pledged to combat cancer by causing immunogenic cell death of cancerous cells while priming cancer-specific immune responses. These outcomes have proven elusive in the clinic. Current-generation vectors rarely reach effective concentrations inside tumors when given intravenously, and consequently are limited to intratumoral administration. Even after direct tumor infusion, these therapies frequently fail to overcome local immunosuppression caused by inappropriate activation of transforming growth factor beta (TGF-β) signaling throughout the tumor microenvironment. VET3-TGI is a vaccinia virus that expresses the chemokine receptor C-X-C chemokine receptor 3 (CXCR3) in infected cells within the first hours after infection. Circulating cells infected in situ on intravenous infusion are driven to migrate to tumors that express cognate chemokines, thus delivering the virus to its target. Infected tumor cells subsequently secrete interleukin-12 (IL-12) and a soluble TGF-β inhibitor. Expression of CXCR3 from vaccinia virus boosted delivery of virus to tumors containing C-X-C motif chemokine 9 and C-X-C motif chemokine 10, which are known to be upregulated in many human cancers. VET3-TGI effectively combated tumor growth when administered intravenously as a single agent in multiple mouse tumor models. In these models, IL-12 provoked inflammation-driven antitumor activity from immune cells. This activity was strengthened by local TGF-β blockade, which crippled the ability of tumors to suppress the immune response. VET3-TGI demonstrates the efficacy of three different transgenes with distinct and complementary activities: CXCR3 for tumor targeting to enable intravenous delivery, a TGF-β inhibitor to disrupt immunosuppression, and IL-12 to promote antitumor immunity.
中文摘要:溶瘤病毒有望通过诱导癌细胞发生免疫原性细胞死亡并启动肿瘤特异性免疫应答来对抗癌症。然而这些效果在临床中一直难以实现。当前一代载体静脉给药时很少能在肿瘤内达到有效浓度,因此仅限于瘤内给药。即使直接向肿瘤内输注,这些疗法也常常无法克服由肿瘤微环境中转化生长因子β(TGF-β)信号异常激活所导致的局部免疫抑制。VET3-TGI是一种痘苗病毒,可在感染后最初数小时内使被感染细胞表达趋化因子受体C-X-C趋化因子受体3(CXCR3)。静脉输注后原位感染的循环细胞被驱动迁移至表达同源趋化因子的肿瘤,从而将病毒递送至靶标。被感染的肿瘤细胞随后分泌白细胞介素12(IL-12)和一种可溶性TGF-β抑制剂。痘苗病毒表达CXCR3可增强病毒向含有C-X-C基序趋化因子9和C-X-C基序趋化因子10的肿瘤的递送,而已知这两种趋化因子在多种人类癌症中上调。在多种小鼠肿瘤模型中,VET3-TGI作为单药静脉给药时可有效抑制肿瘤生长。在这些模型中,IL-12激发免疫细胞产生炎症驱动的抗肿瘤活性。局部TGF-β阻断增强了这种活性,削弱了肿瘤抑制免疫应答的能力。VET3-TGI证明了三种具有不同且互补活性的转基因的效力:CXCR3用于肿瘤靶向以实现静脉递送,TGF-β抑制剂用于破坏免疫抑制,IL-12用于促进抗肿瘤免疫。
NKG2A-HLA-E axis contributes to an immunosuppressive checkpoint network in hepatocellular carcinoma.
The immunosuppressive tumor microenvironment in hepatocellular carcinoma (HCC) limits the efficacy of current immunotherapies. The interplay between the emerging inhibitory receptor NKG2A and its activating counterpart NKG2C, both binding HLA-E, and its interaction with the PD-1-PD-L1 pathway in cancer remains unclear. This study aims to delineate the functional network formed by these pathways in shaping the immunosuppressive landscape of HCC. We analyzed public databases and performed immunohistochemistry on HCC tissues to assess HLA-E expression and prognostic relevance. Tumor-infiltrating lymphocytes from patient samples were examined by flow cytometry to evaluate the functional impact of NKG2A, NKG2C, and PD-1 expression on T and NK cells. Single-cell RNA and T cell receptor (TCR) sequencing were employed to characterize immune subset heterogeneity. Functional assays and mouse models were used to evaluate the effects of NKG2A and PD-1 blockade. In the absence of CD8+ T cell infiltration, elevated HLA-E expression in HCC tissue correlated with poorer overall survival in non-immunotherapy-treated patients. Conversely, in the presence of CD8+ T cells, high HLA-E expression was linked to an inflammatory tumor microenvironment characterized by IFN-γ-producing T cells, and increased major histocompatibility complex I, which was associated with improved patient response to immunotherapy. Tumor-infiltrating CD8+ T and NK cells from HCC patients upregulated NKG2A, conferring tissue-resident memory and tumor-reactive characteristics while simultaneously impairing cytotoxic function. Single-cell RNA and TCR sequencing revealed differential expression patterns of NKG2A, NKG2C, and PD-1 in different T and NK cell subsets, with NKG2A+ PD-1+ T cells relevant to antigen-specific clonal expansion. Mechanistically, the inhibitory effect mediated by the NKG2A-HLA-E axis contributed more prominently than the stimulatory role of the NKG2C-HLA-E axis in suppressing antitumor immunity. Furthermore, the NKG2A-HLA-E axis acted cooperatively with the PD-1-PD-L1 axis to promote CD8+ T cell dysfunction. Combined blockade of NKG2A and PD-1 enhanced the cytotoxic activity of tumor-infiltrating CD8+ T and NK cells, resulting in potent tumor eradication in vitro and in vivo, outperforming single-agent treatments. Our findings identify the NKG2A-HLA-E axis as an important immunoregulatory pathway associated with immune suppression in HCC and provide a rationale for further evaluation of combined NKG2A and PD-1 blockade strategies.
中文摘要:肝细胞癌(HCC)中的免疫抑制性肿瘤微环境限制了当前免疫治疗的疗效。新兴抑制性受体NKG2A与其激活型对应受体NKG2C(二者均结合HLA-E)之间的相互作用,以及其与PD-1-PD-L1通路在肿瘤中的交互关系,仍不清楚。本研究旨在阐明这些通路在塑造HCC免疫抑制格局中所形成的功能网络。我们分析了公共数据库,并对HCC组织进行免疫组化,以评估HLA-E表达及其预后相关性。通过流式细胞术检测患者样本中的肿瘤浸润淋巴细胞,以评估NKG2A、NKG2C和PD-1表达对T细胞和NK细胞的功能影响。采用单细胞RNA和T细胞受体(TCR)测序来刻画免疫亚群的异质性。利用功能实验和小鼠模型评估NKG2A和PD-1阻断的效果。在缺乏CD8+ T细胞浸润的情况下,HCC组织中HLA-E表达升高与非免疫治疗患者较差的总生存期相关。相反,在存在CD8+ T细胞时,高HLA-E表达与以产生IFN-γ的T细胞为特征的炎症性肿瘤微环境以及主要组织相容性复合体I增加相关,这与患者对免疫治疗应答改善相关。来自HCC患者的肿瘤浸润CD8+ T和NK细胞上调NKG2A,赋予其组织驻留记忆和肿瘤反应性特征,同时损害其细胞毒性功能。单细胞RNA和TCR测序揭示了NKG2A、NKG2C和PD-1在不同T细胞和NK细胞亚群中的差异表达模式,其中NKG2A+ PD-1+ T细胞与抗原特异性克隆扩增相关。机制上,NKG2A-HLA-E轴介导的抑制作用比NKG2C-HLA-E轴的刺激作用在抑制抗肿瘤免疫中更为突出。此外,NKG2A-HLA-E轴与PD-1-PD-L1轴协同促进CD8+ T细胞功能障碍。联合阻断NKG2A和PD-1增强了肿瘤浸润CD8+ T和NK细胞的细胞毒性活性,在体外和体内均导致强效的肿瘤清除,优于单药治疗。我们的发现将NKG2A-HLA-E轴确定为与HCC免疫抑制相关的重要免疫调节通路,并为进一步评估NKG2A和PD-1联合阻断策略提供了依据。
Cellular senescence is a common outcome of cytostatic and cytotoxic cancer therapies. While in some contexts therapy-induced senescence can drive tumor growth suppression and anti-tumor immunity through the senescence-associated secretory phenotype (SASP), in others it can promote metastatic progression and immune suppression. A systematic interrogation of the impact of different classes of therapy on heterogeneous senescent phenotypes is required to effectively apply these drugs in specific cancer contexts and to rationally design combination treatments. Using genetically-defined human and murine prostate cancer cell lines, we found that many classes of cancer therapeutics, including chemotherapies and targeted Aurora kinase and CDK inhibitors, could induce cellular senescence, with DNA-damaging agents mediating the most robust growth arrest and SASP. The SASP produced by chemotherapy-induced senescence, particularly with docetaxel, contained not only inflammatory factors that influence immune responses, but also ECM remodeling factors that facilitate tumor cell dissemination. Though docetaxel treatment could induce senescence and reduce tumor growth in syngeneic prostate cancer mouse models, it was not sufficient to activate anti-tumor immunity or slow metastatic dissemination. Senolytic therapies targeting the pro-survival BCL2 and IAP pathways upregulated after docetaxel-induced senescence effectively killed senescent tumor cells through multiple cell death pathways, remodeling the inflammatory SASP to repolarize myeloid phenotypes and potentiate CD8+ T cell activation to further block tumor growth and suppress metastasis. These results suggest that senolytic agents can enhance the immunogenicity and anti-metastatic potential of chemotherapy used for treating advanced prostate cancer patients.
中文摘要:细胞衰老是细胞抑制性和细胞毒性抗癌治疗的常见结果。在某些情况下,治疗诱导的衰老可通过衰老相关分泌表型(SASP)驱动肿瘤生长抑制和抗肿瘤免疫,但在另一些情况下,它可促进转移进展和免疫抑制。要有效地将这些药物应用于特定癌症背景并合理设计联合治疗,需要系统探究不同类别治疗对异质性衰老表型的影响。我们使用遗传学定义的人和小鼠前列腺癌细胞系发现,许多类别的抗癌治疗,包括化疗以及靶向Aurora激酶和CDK的抑制剂,均可诱导细胞衰老,其中DNA损伤剂介导最显著的生长停滞和SASP。化疗诱导衰老产生的SASP,尤其是多西他赛诱导的SASP,不仅含有影响免疫应答的炎性因子,还含有促进肿瘤细胞播散的ECM重塑因子。尽管多西他赛治疗可在同基因前列腺癌小鼠模型中诱导衰老并减少肿瘤生长,但不足以激活抗肿瘤免疫或减缓转移播散。靶向多西他赛诱导衰老后上调的促生存BCL2和IAP通路的衰老细胞清除疗法,可通过多种细胞死亡途径有效杀伤衰老肿瘤细胞,重塑炎性SASP以重极化髓系表型并增强CD8+ T细胞活化,从而进一步阻断肿瘤生长并抑制转移。这些结果提示,衰老细胞清除剂可增强用于治疗晚期前列腺癌患者的化疗的免疫原性和抗转移潜能。
The paradigm in the field of oncolytic virotherapy proposes that tumor cell killing by an oncolytic virus (OV) culminates in the priming of antitumor CD8+ T cells. However, this ignores the impact a highly immunodominant antiviral response against the OV has on the subdominant antitumor response, particularly regarding the naturally low affinity of tumor antigens to their cognate T cell receptors. To investigate this experimentally, we first studied the interaction between the two responses in B16 and MC38 tumor models both expressing ovalbumin (OVA). Contrary to the accepted paradigm, the inflammatory vesicular stomatitis virus (VSV) failed to expand OVA-specific T cells in vivo unless armed with tumor-associated antigen (TAA). In fact, treatment with the control VSV led to the ablation of antitumor T cells and a shift toward dysfunction as determined by the upregulation of markers including LAG3 and CD39 correlating with lower rates of survival. Combination with anti-PD-1 immune checkpoint blockade therapy significantly improved survival only when VSV expressed TAA. VSV expressing altered peptide ligand (APL) variants of tumor antigens, which evade mechanisms of central tolerance expanded near-self antigen specific T cells with the ability to cross react with tolerized tumor antigens, thus providing an antitumor effector population capable of proliferating in the presence of a potent antiviral response. Taken together, these findings offer a rational approach to OV design which preserves acute antitumor therapy provided by antiviral innate and T cell responses whilst promoting the induction of tumor-specific T cells.
中文摘要:溶瘤病毒治疗领域的范式提出,溶瘤病毒(OV)杀伤肿瘤细胞最终会启动抗肿瘤CD8+ T细胞。然而,这忽略了针对OV的高度免疫显性抗病毒反应对亚显性抗肿瘤反应的影响,尤其是肿瘤抗原与其同源T细胞受体天然低亲和力方面。为通过实验研究这一点,我们首先在均表达卵清蛋白(OVA)的B16和MC38肿瘤模型中研究两种反应之间的相互作用。与公认范式相反,炎症性水疱性口炎病毒(VSV)在体内未能扩增OVA特异性T细胞,除非其携带肿瘤相关抗原(TAA)。事实上,对照VSV治疗导致抗肿瘤T细胞消融,并转向功能障碍,这由LAG3和CD39等标志物上调所确定,并与较低的生存率相关。仅当VSV表达TAA时,与抗PD-1免疫检查点阻断疗法联用才显著改善生存。表达肿瘤抗原的改变肽配体(APL)变体的VSV可逃逸中枢耐受机制,扩增出能够与耐受化肿瘤抗原交叉反应的近自身抗原特异性T细胞,从而提供能够在强效抗病毒反应存在时增殖的抗肿瘤效应细胞群。综上所述,这些发现为OV设计提供了一种合理方法,该方法保留由抗病毒先天免疫和T细胞反应提供的急性抗肿瘤治疗作用,同时促进肿瘤特异性T细胞的诱导。
Pancreatic ductal adenocarcinoma (PDAC), the most common subtype of pancreatic cancer, is a deadly disease with a complex tumor microenvironment (TME). Cytotoxic combination chemotherapy treatments are the mainstay of PDAC therapy, but patients rapidly develop chemoresistance, highlighting the need to elucidate how chemotherapy alters the TME and whether these changes drive chemoresistance. Here, we examined matched pre- and post-treatment tissue specimens using single-cell RNA-sequencing and found near-universal enrichment after treatment of axonal guidance genes in cancer-associated fibroblasts (CAFs). These neural CAFs were enriched near sites of perineural invasion, coinciding with regions of increased tumor cell proliferation, and were enriched in tumor areas distant from nerves after chemotherapy. Metastatic recurrent lesions had the highest prevalence of neural CAFs versus primary tumors and untreated metastases. Neural CAFs showed elevated non-canonical WNT mediators and axonal guidance genes, which complemented matching cognate binding partners in tumor epithelial cells, suggesting a role in tumor-stroma crosstalk. Additionally, in vitro studies revealed enrichment of axonal guidance genes in patient-derived CAF lines upon exposure to chemotherapy or tumor cells. Altogether, these findings implicate fibroblast-derived axonal-guidance genes in promoting PDAC invasion and point to a promising therapeutic target for this disease.
中文摘要:胰腺导管腺癌(PDAC)是胰腺癌最常见的亚型,是一种致死性疾病,具有复杂的肿瘤微环境(TME)。细胞毒性联合化疗是PDAC治疗的主要手段,但患者很快出现化疗耐药,这凸显出需要阐明化疗如何改变TME以及这些变化是否驱动化疗耐药。在此,我们利用单细胞RNA测序检测了配对的治疗前和治疗后组织标本,发现治疗后癌症相关成纤维细胞(CAF)中轴突导向基因几乎普遍富集。这些神经性CAF富集于神经周围侵犯部位附近,与肿瘤细胞增殖增加区域重合,并且在化疗后富集于远离神经的肿瘤区域。与原发性肿瘤和未治疗的转移灶相比,转移性复发病灶中神经性CAF的比例最高。神经性CAF显示非经典WNT介质和轴突导向基因升高,这与肿瘤上皮细胞中匹配的同源结合配偶体互补,提示其在肿瘤-基质串扰中发挥作用。此外,体外研究显示,患者来源的CAF细胞系在暴露于化疗或肿瘤细胞后,轴突导向基因富集。总之,这些发现提示成纤维细胞来源的轴突导向基因可促进PDAC侵袭,并指出一个有前景的治疗靶点。
PD-1/PD-L1 blockade can produce durable tumor control, yet primary, adaptive, and acquired resistance remain common. Existing accounts often catalogue resistance by cellular compartment, obscuring the coordinated nature of tumor adaptation. Here, we introduce immune-pressure redistribution as a treatment-oriented framework that complements cancer immunoediting by asking where therapeutic immune pressure is diverted after checkpoint release. Resistance is organized into three coupled routes: transfer into tumor-intrinsic escape through antigen-presentation loss, interferon-response defects, oncogenic rewiring, and lineage plasticity; weakening through defective priming, terminal T-cell differentiation, compensatory checkpoints, metabolic constraint, and chronic cytokine signaling; and unloading into stromal, vascular, myeloid, regulatory, microbial, and systemic host compartments. We integrate clinically validated mechanisms with emerging evidence, including the temporal duality of interferon-JAK signaling, the role of tumor-draining lymph nodes in sustaining progenitor-exhausted T cells, and the limited translation of TIGIT, IDO1, TGF-β, and CSF-1R targeting. We further propose a biomarker-guided strategy that combines tumor visibility, immune-cell state, spatial architecture, systemic inflammation, and early treatment dynamics to identify the dominant resistance topology. This framework supports topology-matched combinations and adaptive sequencing rather than uniform escalation, with the aim of restoring productive immune pressure while limiting compensatory escape and toxicity.
中文摘要:PD-1/PD-L1 阻断可实现持久的肿瘤控制,但原发性、适应性和获得性耐药仍很常见。现有论述常按细胞区室对耐药进行分类,掩盖了肿瘤适应的协同性质。在此,我们提出「免疫压力再分布」这一以治疗为导向的框架,补充癌症免疫编辑,追问在检查点释放后治疗性免疫压力被转移至何处。耐药被归纳为三条相互耦合的路径:转移至肿瘤内在逃逸,通过抗原呈递缺失、干扰素应答缺陷、致癌重编程和谱系可塑性实现;减弱,通过启动缺陷、终末T细胞分化、代偿性检查点、代谢限制和慢性细胞因子信号实现;以及卸载至基质、血管、髓系、调节性、微生物和全身宿主区室。我们整合了临床验证的机制与新出现的证据,包括干扰素-JAK信号的时间双重性、肿瘤引流淋巴结在维持祖细胞耗竭T细胞中的作用,以及TIGIT、IDO1、TGF-β和CSF-1R靶向治疗有限的转化。我们进一步提出一种生物标志物指导的策略,结合肿瘤可见性、免疫细胞状态、空间结构、全身炎症和早期治疗动态,以识别主导的耐药拓扑。该框架支持拓扑匹配的联合治疗和适应性序贯治疗,而非统一升级,旨在恢复有效的免疫压力,同时限制代偿性逃逸和毒性。
Colorectal cancer liver metastasis (CRLM) represents a formidable clinical challenge, yet the metabolic mechanisms by which tumor cells dismantle hepatic immune surveillance and remodel the tumor microenvironment (TME) remain elusive. Here, integrating single-cell RNA sequencing (scRNA-seq), transcriptomic analysis, and mass cytometry (CyTOF), we uncover MAL2 as a key regulator of immune-metabolic crosstalk in CRLM. MAL2 is significantly upregulated and specifically enriched in malignant epithelial cells within liver metastatic lesions. Transcriptomic analysis demonstrates that MAL2 activates non-canonical NF-κB (ncNF-κB) signaling, directly driving FASN transcription, enhancing lipid droplet (LD) biogenesis and secretion, and promoting epithelial-mesenchymal transition (EMT). CyTOF-based immune mapping further indicates that these tumor-derived LDs, upon entering the metastatic microenvironment, selectively recruit PLIN2+ neutrophils and induce neutrophil extracellular traps (NETs), which entrap FABP1+ macrophages and forge an immunosuppressive niche that accelerates metastatic outgrowth. Conceptually, these LDs function as "Trojan horses," appearing as innocuous metabolic gifts while harboring hidden MAL2-driven signals. Once inside the liver, they "open the gates" by recruiting and reprogramming myeloid cells, ultimately dismantling immune defenses from within. Our study establishes MAL2-induced LDs as critical mediators of metastatic immune evasion and nominates the MAL2-ncNF-κB-FASN axis as a therapeutic vulnerability in CRLM.
中文摘要:结直肠癌肝转移(CRLM)是一项严峻的临床挑战,然而肿瘤细胞瓦解肝脏免疫监视并重塑肿瘤微环境(TME)的代谢机制仍不清楚。本研究整合单细胞RNA测序(scRNA-seq)、转录组分析和质谱流式(CyTOF),揭示MAL2是CRLM中免疫-代谢串扰的关键调控因子。MAL2显著上调,并特异性富集于肝转移病灶内的恶性上皮细胞中。转录组分析表明,MAL2激活非经典NF-κB(ncNF-κB)信号通路,直接驱动FASN转录,增强脂滴(LD)的生成与分泌,并促进上皮-间质转化(EMT)。基于CyTOF的免疫图谱进一步表明,这些肿瘤来源的脂滴进入转移微环境后,选择性招募PLIN2+中性粒细胞并诱导中性粒细胞胞外诱捕网(NETs),后者捕获FABP1+巨噬细胞,从而构建一个加速转移生长的免疫抑制微环境。从概念上讲,这些脂滴发挥「特洛伊木马」的作用,看似无害的代谢礼物,实则隐藏着由MAL2驱动的信号。一旦进入肝脏,它们便通过招募并重编程髓系细胞来「打开大门」,最终从内部瓦解免疫防御。本研究确立了MAL2诱导的脂滴是转移性免疫逃逸的关键介质,并提出MAL2-ncNF-κB-FASN轴是CRLM的一个治疗脆弱点。
In cancer, T-cell state strongly influences antitumor immunity and response to immunotherapy. High-parameter cytometry, single-cell transcriptomics, and multiomic profiling now resolve lineage identity, differentiation history, clonality, metabolic fitness, and tissue adaptation in parallel. These studies place naïve, activated, effector, memory, exhausted, and senescent T cells along continuous, context-dependent trajectories rather than within rigid subset boundaries. Their transitions are shaped by interacting transcriptional, epigenetic, signaling, and metabolic programs that integrate antigen strength, co-stimulation, and cytokines with cues from the tumor microenvironment. Within that microenvironment, suppressive myeloid, erythroid, and stromal populations, extracellular matrix (ECM) remodeling and spatial exclusion, nutrient competition, and tissue-specific conditioning impose a chronic stress that, together with sustained immune-checkpoint signaling, drives exhaustion and senescence and underlies immune evasion. This mechanistic view shifts the therapeutic question from how broadly to activate T cells to which states should be generated, preserved, or rescued. We organize dysfunctional T-cell states along five complementary dimensions: reversibility, antigen dependence, proliferative history, epigenetic fixation, and metabolic collapse. We then map precision cytokines, spatially restricted co-stimulation, metabolic interventions, epigenetic modulation, immune-checkpoint blockade, and genome engineering onto the state transitions they are intended to influence. This framework separates clinically established approaches from exploratory strategies and provides a testable basis for state-informed biomarker development and therapeutic design.
中文摘要:在癌症中,T细胞状态强烈影响抗肿瘤免疫和对免疫治疗的应答。高参数细胞术、单细胞转录组学和多组学分析现在能够并行解析谱系身份、分化历史、克隆性、代谢适应性和组织适应性。这些研究将初始、活化、效应、记忆、耗竭和衰老T细胞置于连续的、依赖情境的轨迹上,而非僵硬的亚群边界内。它们的转变由相互作用的转录、表观遗传、信号和代谢程序塑造,这些程序将抗原强度、共刺激和细胞因子与肿瘤微环境的线索整合起来。在该微环境中,抑制性髓系、红系和基质细胞群体、细胞外基质(ECM)重塑和空间排斥、营养竞争以及组织特异性条件化施加慢性应激,并与持续的免疫检查点信号一起驱动耗竭和衰老,构成免疫逃逸的基础。这一机制观点将治疗问题从应多大范围激活T细胞转变为应生成、保留或挽救哪些状态。我们沿五个互补维度组织功能失调的T细胞状态:可逆性、抗原依赖性、增殖历史、表观遗传固定和代谢崩溃。然后,我们将精准细胞因子、空间限制性共刺激、代谢干预、表观遗传调节、免疫检查点阻断和基因组工程映射到它们意图影响的状态转变上。该框架将临床已确立的方法与探索性策略区分开来,并为基于状态的生物标志物开发和治疗设计提供了可检验的基础。
Conventional fractionated radiotherapy (CFRT) remains a mainstay for many solid tumors, yet it often fails to elicit durable anti-tumor immunity. How CFRT engages tumor-cell programs to shape the immune microenvironment and determine therapeutic outcome remains unclear. Here we show in preclinical mouse models that CFRT is associated with increased tumor-cell HMGB1 relative to stereotactic body radiotherapy (SBRT), and that loss of tumor-cell HMGB1 eliminates the efficacy gap between the regimens. HMGB1 deficiency markedly restrains tumor progression under CFRT in immunocompetent, but not immunodeficient, hosts, accompanied by increased intratumoral CD8+ T cells and effector function. In esophageal squamous cell carcinoma (ESCC) specimens from patients receiving CFRT plus platinum-based chemotherapy, tumor-cell HMGB1 increases after treatment, and elevated pretreatment HMGB1 is associated with poor treatment response, reduced post-treatment CD8+ T-cell infiltration, and adverse outcomes. Mechanistically, HMGB1 restrains CFRT-induced CD8+ T-cell immunity through two convergent arms: CCL2-CCR2-dependent accumulation of suppressive monocytes and FUT8-linked regulation of PD-L1 fucosylation in tumor cells. TCF4 is linked to HMGB1-dependent induction of CCL2 and FUT8. Blocking CCL2 or inhibiting PD-L1 fucosylation restores CD8+ T-cell effector function and enhances CFRT efficacy, alone or in combination with anti-PD-1 therapy. Together, these findings identify a tumor-cell HMGB1 program that underpins CFRT-associated immune suppression and nominate actionable targets to improve CFRT-immunotherapy combinations.
中文摘要:常规分割放疗(CFRT)仍是许多实体瘤的主要治疗手段,但常无法引发持久抗肿瘤免疫。CFRT如何调动肿瘤细胞程序以塑造免疫微环境并决定治疗结局仍不清楚。在此,我们在临床前小鼠模型中显示,与立体定向体部放疗(SBRT)相比,CFRT与肿瘤细胞HMGB1升高相关,而肿瘤细胞HMGB1缺失消除了两种方案间的疗效差距。在免疫功能正常而非免疫缺陷宿主中,HMGB1缺陷显著抑制CFRT下的肿瘤进展,并伴随瘤内CD8+ T细胞及效应功能增加。在接受CFRT联合铂类化疗的食管鳞状细胞癌(ESCC)患者标本中,治疗后肿瘤细胞HMGB1升高,且治疗前HMGB1升高与治疗反应差、治疗后CD8+ T细胞浸润减少以及不良结局相关。机制上,HMGB1通过两条汇聚通路抑制CFRT诱导的CD8+ T细胞免疫:依赖CCL2-CCR2的抑制性单核细胞积聚,以及FUT8相关的肿瘤细胞PD-L1岩藻糖基化调控。TCF4与HMGB1依赖性的CCL2和FUT8诱导相关。阻断CCL2或抑制PD-L1岩藻糖基化可恢复CD8+ T细胞效应功能并增强CFRT疗效,单用或与抗PD-1治疗联合均如此。总之,这些发现鉴定了一个肿瘤细胞HMGB1程序,其支撑CFRT相关免疫抑制,并提出了可操作靶点以改善CFRT-免疫治疗联合方案。
Tertiary lymphoid structures (TLSs) are ectopic, organized immune aggregates forming in non-lymphoid tissues during chronic inflammation. Resembling secondary lymphoid organs (SLOs) architecturally and functionally, TLSs feature specialized stromal networks and compartmentalized immune cell zones. In autoimmunity, TLSs can perpetuate local immune activation, autoantibody production, and tissue damage, correlating with disease severity and progression. In the tumor microenvironment, TLSs are generally associated with enhanced anti-tumor immunity, improved patient survival, and better responses to immunotherapy, although their functional impact can vary across cancer types. This review systematically examines the structural and functional foundations of TLSs and dissects the mechanisms driving their formation in both autoimmune disorders and cancers. We critically evaluate the clinical correlations of TLSs with disease activity, progression, and patient outcomes. Furthermore, we summarize current methodologies for TLS detection and assess their diagnostic and prognostic utility in disease monitoring. Finally, we discuss emerging therapeutic strategies aimed at modulating TLSs formation or function. By synthesizing current knowledge, this review provides crucial insights into TLSs biology within autoimmunity and cancer, highlighting their potential as novel biomarkers and therapeutic targets, thereby advancing our understanding of disease mechanisms and treatment approaches.
中文摘要:三级淋巴结构(TLS)是在慢性炎症过程中于非淋巴组织中形成的异位、有组织的免疫聚集体。TLS在结构和功能上类似于次级淋巴器官(SLO),具有特化的基质网络和分区的免疫细胞区域。在自身免疫中,TLS可维持局部免疫激活、自身抗体产生和组织损伤,并与疾病严重程度和进展相关。在肿瘤微环境中,TLS通常与增强的抗肿瘤免疫、患者生存改善以及对免疫治疗更好的反应相关,尽管其功能影响可能因癌症类型而异。本综述系统探讨了TLS的结构和功能基础,并剖析了驱动其在自身免疫性疾病和癌症中形成的机制。我们批判性地评估了TLS与疾病活动度、进展及患者结局的临床相关性。此外,我们总结了当前TLS检测方法,并评估其在疾病监测中的诊断和预后价值。最后,我们讨论了旨在调节TLS形成或功能的新兴治疗策略。通过综合现有知识,本综述为自身免疫和癌症中的TLS生物学提供了关键见解,强调其作为新型生物标志物和治疗靶点的潜力,从而增进我们对疾病机制和治疗方法的理解。
Tertiary lymphoid structures (TLS), which form as tumor-localized lymphoid-like structures, play a critical role in enhancing immune responses and improving prognosis. However, native TLS is highly prone to developmental arrest within the tumor microenvironment (TME), and conventional free-circulating drugs suffer from significant drawbacks such as short half-lives and high systemic toxicity. Nanomedicines, with their advantages of spatiotemporally controlled release, deep physical penetration, and multi-target co-delivery, offer an engineered solution for reshaping the TME and inducing TLS formation. This article systematically summarizes engineered intervention strategies for nanomedicine-induced TLS formation across three key aspects: activating chemotactic networks to accelerate immune cell homing; targeting matrix reprogramming to induce high-endothelial microvessels for physical scaffold construction; and enhancing antigen cross-presentation to drive germinal center (GC) maturation. Furthermore, the paper explores in depth how nanomedicine-mediated TLS functions as an immunological hub, generating synergistic effects with existing immune checkpoint inhibitors, cellular therapies, and physical therapies. Finally, it analyzes the current barriers to clinical translation in this field and outlines a blueprint for future development. Through a multidisciplinary perspective, this paper provides theoretical guidance and a technical roadmap for the design and clinical application of next-generation precision immunotherapy nanomedicines.
中文摘要:三级淋巴结构(TLS)以肿瘤局部淋巴样结构的形式形成,在增强免疫应答和改善预后中发挥关键作用。然而,天然TLS在肿瘤微环境(TME)中极易发生发育停滞,且传统游离循环药物存在半衰期短、全身毒性高等显著缺陷。纳米药物具有时空可控释放、深度物理穿透和多靶点共递送等优势,为重塑TME并诱导TLS形成提供了一种工程化解决方案。本文从三个关键方面系统总结了纳米药物诱导TLS形成的工程化干预策略:激活趋化网络以加速免疫细胞归巢;靶向基质重编程以诱导高内皮微血管,从而构建物理支架;以及增强抗原交叉呈递以驱动生发中心(GC)成熟。此外,本文深入探讨了纳米药物介导的TLS如何作为免疫枢纽,与现有免疫检查点抑制剂、细胞疗法和物理疗法产生协同效应。最后,分析了该领域当前临床转化的障碍,并勾勒了未来发展的蓝图。通过多学科视角,本文为下一代精准免疫治疗纳米药物的设计与临床应用提供了理论指导和技术路线图。
Immunosuppressive tumor-associated macrophages (TAMs) create a barrier to effective antitumor immunity and promote therapeutic resistance. Reeducating TAMs to enhance their antitumor capabilities through phenotypic remodeling remains challenging. Here, we report a modular oncolytic herpesvirus platform, engineered with a PD-L1-specific chimeric receptor integrated into the viral envelope protein (CAR-oHSV). This design endows the virus with dual tropism, enabling it to target both tumor cells and TAMs within the tumor microenvironment. In virus-resistant tumor models, CAR-oHSV preferentially targets PD-L1+ TAMs and triggers a STING-dependent reprogramming into a CXCL9+ phenotype, enhancing their tumor antigen cross-presentation capability and inducing an endogenous antitumor T cell response. Furthermore, this platform can synergize with adoptive T cell therapy and immune checkpoint blockade therapy to overcome immunotherapy resistance. Collectively, our findings define a precision-oncolytic platform that dismantles TAM-mediated immunosuppression while amplifying adaptive immunity, offering a promising translational avenue for cancer immunotherapy.
中文摘要:免疫抑制性肿瘤相关巨噬细胞(TAM)会形成有效抗肿瘤免疫的屏障,并促进治疗耐药。通过表型重塑将TAM再教育以增强其抗肿瘤能力仍具挑战性。在此,我们报道了一种模块化溶瘤疱疹病毒平台,其将PD-L1特异性嵌合受体整合到病毒包膜蛋白中(CAR-oHSV)。该设计赋予病毒双重趋向性,使其能够靶向肿瘤微环境中的肿瘤细胞和TAM。在病毒抵抗性肿瘤模型中,CAR-oHSV优先靶向PD-L1+ TAM,并触发依赖STING的重编程,使其转变为CXCL9+表型,增强其肿瘤抗原交叉呈递能力,并诱导内源性抗肿瘤T细胞反应。此外,该平台可与过继性T细胞疗法和免疫检查点阻断疗法协同,以克服免疫治疗耐药。总体而言,我们的发现定义了一个精准溶瘤平台,既能瓦解TAM介导的免疫抑制,又能放大适应性免疫,为癌症免疫治疗提供了一条有前景的转化途径。
Metal ions are increasingly recognized as regulators of immune function, yet their application in cancer immunotherapy remains underexplored. Here, we identified cobalt ions (Co2+) as potent suppressors of IFN-γ-induced IDO1 expression through systematic screening of biologically relevant metal ions. Across multiple cancer cell lines, Co2+ notably reduced IDO1 expression and kynurenine production. Mechanistically, Co2+ destabilized IFNGR1 and inhibited IFN-γ-JAK-STAT1 signaling, thereby restoring kynurenine/tryptophan metabolic balance and alleviating immunosuppression of CD8+ T cell. These effects reprogrammed the immunosuppressive tumor microenvironment toward enhanced cytotoxic T cell activity. To minimize the toxicity associated with free Co2+, we developed ConaHA, a hyaluronic acid-based nanoparticle platform enabling sustained and tumor-targeted cobalt delivery. ConaHA enhanced cobalt-mediated immune checkpoint blockade in vivo, resulting in notably improved antitumor efficacy in subcutaneous Panc02, MC38, and B16F10 tumor models and KPC (LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre) models. Collectively, these findings reveal a previously unrecognized immunoregulatory role of Co2+ and establish a promising framework for metalloimmunotherapy through modulation of metal-immune signaling pathways.
中文摘要:金属离子日益被认为是免疫功能的调节因子,但其在癌症免疫治疗中的应用仍未被充分探索。在此,我们通过对生物学相关金属离子进行系统性筛选,发现钴离子(Co2+)是IFN-γ诱导的IDO1表达的有效抑制因子。在多种癌细胞系中,Co2+显著降低IDO1表达和犬尿氨酸生成。机制上,Co2+使IFNGR1不稳定并抑制IFN-γ-JAK-STAT1信号,从而恢复犬尿氨酸/色氨酸代谢平衡并减轻对CD8+ T细胞的免疫抑制。这些效应将免疫抑制性肿瘤微环境重编程为增强的细胞毒性T细胞活性。为尽量减少游离Co2+相关毒性,我们开发了ConaHA,一种基于透明质酸的纳米颗粒平台,能够实现持续且肿瘤靶向的钴递送。ConaHA在体内增强了钴介导的免疫检查点阻断,在皮下Panc02、MC38和B16F10肿瘤模型以及KPC(LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre)模型中显著改善抗肿瘤疗效。总之,这些发现揭示了Co2+此前未被认识的免疫调节作用,并建立了通过调节金属-免疫信号通路进行金属免疫治疗的有前景框架。
Tumor cells often evade immune pressure via metabolic reprogramming, yet the key metabolic regulators orchestrating this process remain incompletely defined. Here, using in vivo metabolic CRISPR screening under distinct immune pressures, we identified tumor cell-intrinsic solute carrier family 1 member 5 (SLC1A5) as a metabolic node that sustains an immunosuppressive tumor microenvironment. SLC1A5-mediated glutamine metabolism in tumor cells modulated CD8 T cell infiltration and effector function, reshaping tumor responses to immune checkpoint blockade therapy. Glucose deprivation up-regulated SLC1A5 isoforms in tumor cells, enhancing glutamine uptake and glutathione synthesis. This adaptation limited mitochondrial oxidative stress and cytosolic mitochondrial DNA release, thereby suppressing cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) activation, interferon-β production, and CD8 T cell antitumor responses. These findings define a glutamine-fueled metabolic program as a barrier to tumor immunogenicity, positioning SLC1A5 as a tumor-intrinsic metabolic regulator with potential therapeutic relevance.
中文摘要:肿瘤细胞常通过代谢重编程逃避免疫压力,但调控这一过程的关键代谢调节因子仍未完全明确。在此,我们利用在不同免疫压力下的体内代谢CRISPR筛选,发现肿瘤细胞内在的溶质载体家族1成员5(SLC1A5)是维持免疫抑制性肿瘤微环境的代谢节点。肿瘤细胞中SLC1A5介导的谷氨酰胺代谢调节CD8 T细胞浸润和效应功能,重塑肿瘤对免疫检查点阻断治疗的应答。葡萄糖剥夺上调肿瘤细胞中的SLC1A5亚型,增强谷氨酰胺摄取和谷胱甘肽合成。这种适应限制了线粒体氧化应激和胞质线粒体DNA释放,从而抑制环鸟苷酸-腺苷酸合成酶-干扰素基因刺激因子(cGAS-STING)激活、干扰素-β产生以及CD8 T细胞抗肿瘤反应。这些发现将谷氨酰胺驱动的代谢程序定义为肿瘤免疫原性的屏障,并将SLC1A5定位为具有潜在治疗相关性的肿瘤内在代谢调节因子。
Chimeric antigen receptor (CAR)-T cell therapy has emerged as a transformative cancer immunotherapy, employing genetic engineering to express CARs in patient T cells. CARs are composed of a single-chain variable fragment (scFv), hinge, transmembrane, and intracellular signaling domains. While scFv directly recognizes tumor-associated antigens, the hinge domain connects the scFv to intracellular signaling domains, determining the formation of immunological synapse (IS). Because IS is critical for CAR activation, optimizing hinge length is crucial for successful CAR-T cell therapy. Here, we developed a novel dimerization-dependent fluorescent protein (ddFP)-based IS biosensor, named CAR-D, to investigate hinge length effects on CAR activation. CAR-D consists of a CAR fused to ddFP-A and a ZAP70-tSH2 domain fused to ddFP-B. Upon CAR engagement with the target antigen, CAR phosphorylation recruits ZAP70-tSH2, triggering ddFP-A/ddFP-B dimerization and generating a fluorescent signal that reports CAR activation at the IS in real time. Using the CAR-D system, we assessed CARs with different hinge lengths targeting distinct epitopes of two tumor-associated antigens, mesothelin (MSLN) and HER2, and determined threshold hinge lengths for CAR activation. Our results revealed a strong correlation between threshold hinge length and the distance from scFv to the target epitope, implying that hinge length optimization is crucial for effective CAR-T cell therapy. Furthermore, the CAR-D system provides a valuable tool for predicting CAR efficacy and guiding future CAR engineering strategies.
中文摘要:嵌合抗原受体(CAR)-T细胞疗法已成为一种变革性的癌症免疫疗法,通过基因工程在患者T细胞中表达CAR。CAR由单链可变片段(scFv)、铰链区、跨膜区和胞内信号结构域组成。scFv直接识别肿瘤相关抗原,而铰链区将scFv连接到胞内信号结构域,决定免疫突触(IS)的形成。由于IS对CAR激活至关重要,优化铰链长度对于成功的CAR-T细胞疗法十分关键。在此,我们开发了一种新型的基于二聚化依赖型荧光蛋白(ddFP)的IS生物传感器,命名为CAR-D,用于研究铰链长度对CAR激活的影响。CAR-D由一个与ddFP-A融合的CAR和一个与ddFP-B融合的ZAP70-tSH2结构域组成。当CAR与靶抗原结合后,CAR磷酸化招募ZAP70-tSH2,触发ddFP-A/ddFP-B二聚化并产生荧光信号,从而实时报告IS处CAR的激活。利用CAR-D系统,我们评估了针对两种肿瘤相关抗原间皮素(MSLN)和HER2不同表位的不同铰链长度CAR,并确定了CAR激活的阈值铰链长度。我们的结果揭示了阈值铰链长度与scFv到靶表位距离之间的强相关性,提示铰链长度优化对于有效的CAR-T细胞疗法至关重要。此外,CAR-D系统为预测CAR疗效和指导未来CAR工程策略提供了有价值的工具。
B7-H3/CD276 is an emerging immunotherapy target in cancers. However, limited knowledge of B7-H3 signaling and its role in modulating the tumor microenvironment hinders the clinical application of B7-H3-targeting therapy. Here, we report that B7-H3 plays dual roles in regulating myeloid-derived suppressor cells (MDSCs) and cancer-associated fibroblasts (CAFs), thereby promoting tumor progression and therapy resistance, respectively. We comprehensively characterized a non-canonical function of B7-H3 that triggers MAPK signaling in monocytic MDSCs and induces cellular senescence. The senescent monocytic M-MDSCs secreted chemokines to recruit immunosuppressive granulocytic MDSCs. Genetic deletion or pharmacological inhibition of B7-H3/Cd276 reduced Gr-MDSCs and delayed tumor progression. Nevertheless, the secretory factor SPINK1 derived from MDSCs compensatorily activates EGFR/MEK/ERK signaling in CAFs and promotes their extracellular matrix remodeling features, dampening B7-H3-targeting immunotherapy. Combining the B7-H3 monoclonal antibody with the FDA-approved MEK inhibitor trametinib showed durable anti-tumor effects in preclinical models of castration-resistant prostate cancer by fully attenuating immunosuppressive mechanisms.
中文摘要:B7-H3/CD276是癌症中一种新兴的免疫治疗靶点。然而,对B7-H3信号及其在调节肿瘤微环境中作用的认识有限,阻碍了靶向B7-H3治疗的临床应用。在此,我们报道B7-H3在调节髓源性抑制细胞(MDSC)和癌症相关成纤维细胞(CAF)中发挥双重作用,分别促进肿瘤进展和治疗耐药。我们全面刻画了B7-H3的一种非经典功能,即其在单核细胞型MDSC中触发MAPK信号并诱导细胞衰老。衰老的单核细胞型M-MDSC分泌趋化因子,以募集免疫抑制性粒细胞型MDSC。B7-H3/Cd276的基因缺失或药理学抑制减少了Gr-MDSC并延缓了肿瘤进展。然而,来源于MDSC的分泌因子SPINK1代偿性激活CAF中的EGFR/MEK/ERK信号,并促进其细胞外基质重塑特征,从而削弱靶向B7-H3的免疫治疗。将B7-H3单克隆抗体与FDA批准的MEK抑制剂曲美替尼联合,在去势抵抗性前列腺癌的临床前模型中显示出持久的抗肿瘤效果,其完全减弱了免疫抑制机制。
Altered O-glycosylation is a hallmark of many adenocarcinomas and is often characterized by expression of the Tn antigen. However, the role of B cells in protection against Tn-expressing solid tumors remains poorly understood. We generated a colorectal tumor cell line (CMT93) lacking Cosmc, resulting in high Tn expression. Using mice with defined B-cell abnormalities, including deficiencies in B cells, IgM secretion, natural IgM, and B-cell receptor (BCR) repertoire diversity, we investigated the contribution of B cells and secreted antibody to immunity against Tn-expressing colorectal tumors. Cosmc-deficient tumors grew more rapidly than parental tumors, and IgM deposition was observed within tumors from wild-type mice, suggesting a potential role for antibody in antitumor defense. Tumor-reactive serum IgM, including Tn-reactive IgM, was present in naïve mice. B cell-deficient muMT, VHB1-8 transgenic mice with a restricted BCR repertoire, CD19-/- mice deficient in natural IgM, and μS-/- mice unable to secrete IgM, lacked tumor-reactive IgM and showed increased tumor burdens, suggesting a protective role for secreted tumor-reactive IgM. Lack of tumor-reactive IgM in VHB1-8 transgenic and μS-/- mice was associated with significant alterations in tumor-infiltrating leukocyte composition. Relative to wild-type mice, tumors from VHB1-8 transgenic and μS-/- mice exhibited significantly increased PD-L1hiLy6G+Ly6C-CD11b+ myeloid cells, but reduced B, T, and natural killer cells, along with reduced major histocompatibility complex class II expression on tumor-associated dendritic cells. Moreover, tumor draining lymph nodes from VHB1-8 transgenic and μS-/- mice showed significant reductions in antibody-secreting cells, including IgG+ plasmablasts, which corresponded with decreased IgM and IgG deposition on tumors. These findings support a role for B cells and secreted IgM in restraining the growth of Tn-expressing solid tumors and shaping antitumor immunity against tumors with aberrant O-glycosylation.
中文摘要:O-糖基化改变是许多腺癌的标志,常以Tn抗原表达为特征。然而,B细胞在抵御表达Tn的实体瘤中的作用仍知之甚少。我们构建了缺乏Cosmc的结直肠肿瘤细胞系CMT93,导致高Tn表达。利用具有明确B细胞异常的小鼠,包括B细胞缺陷、IgM分泌缺陷、天然IgM缺陷以及B细胞受体(BCR)库多样性缺陷,我们研究了B细胞和分泌型抗体对表达Tn的结直肠肿瘤免疫的贡献。Cosmc缺陷肿瘤比亲本肿瘤生长更快,并且在野生型小鼠的肿瘤内观察到IgM沉积,提示抗体可能在抗肿瘤防御中发挥作用。未免疫小鼠血清中存在肿瘤反应性IgM,包括Tn反应性IgM。B细胞缺陷的μMT小鼠、BCR库受限的VHB1-8转基因小鼠、天然IgM缺陷的CD19-/-小鼠以及无法分泌IgM的μS-/-小鼠均缺乏肿瘤反应性IgM,并表现出肿瘤负荷增加,提示分泌型肿瘤反应性IgM具有保护作用。VHB1-8转基因和μS-/-小鼠中缺乏肿瘤反应性IgM与肿瘤浸润白细胞组成的显著改变相关。与野生型小鼠相比,VHB1-8转基因和μS-/-小鼠的肿瘤中PD-L1高表达Ly6G+Ly6C−CD11b+髓系细胞显著增加,而B细胞、T细胞和自然杀伤细胞减少,同时肿瘤相关树突状细胞的主要组织相容性复合体II类表达降低。此外,VHB1-8转基因和μS-/-小鼠的肿瘤引流淋巴结中抗体分泌细胞显著减少,包括IgG+浆母细胞,这与肿瘤上IgM和IgG沉积减少相对应。这些发现支持B细胞和分泌型IgM在抑制表达Tn实体瘤生长以及塑造针对O-糖基化异常肿瘤的抗肿瘤免疫中发挥作用。
Loss-of-function mutations in Kelch-like ECH-associated protein 1 (KEAP1) frequently occur in lung adenocarcinoma and are associated with poor prognosis and limited benefit from immunotherapy. However, the mechanisms linking KEAP1 deficiency to immune evasion remain elusive. We combined clinical data analysis, in vivo tumor models, and in vitro co-culture systems to investigate how KEAP1 deficiency shapes dendritic cell (DC) biology and response to PD-1 blockade. Ferroptosis induction assays, damage-associated molecular patterns (DAMPs) quantification, cytokine profiling, and mechanistic interrogation of the FSP1-CoQ10 axis were performed to delineate pathways. KEAP1 mutations correlated with poor response to PD-1 blockade and reduced DC infiltration. In mice, KEAP1-deficient tumors exhibited accelerated growth and reduced DC and CD8+ T-cell infiltration, consistent with an immune-cold phenotype. Mechanistically, KEAP1 loss impaired DC function in vitro, as evidenced by reduced maturation, phagocytosis, and naïve CD8+ T-cell priming capacity. This defect was linked to two mechanisms. First, KEAP1-deficient tumor cells resisted ferroptosis and failed to release immunogenic DAMPs, including extracellular ATP, HMGB1, and calreticulin. Second, KEAP1 deficiency reprogrammed the cytokine secretion profile, with downregulation of CCL2, IL-6, CXCL1, and CXCL2, thereby diminishing DC recruitment and inflammatory signaling. Notably, inhibition of the FSP1-CoQ10 antioxidant axis restored ferroptosis-associated immunogenic cell death. Our study identifies KEAP1 deficiency as a driver of immune-cold tumor microenvironments and resistance to PD-1 blockade, acting through impaired ferroptosis-induced immunogenic cell death and disrupted DC function. Genetic FSP1 deletion restored ferroptosis-associated immunogenicity and DC activation in KEAP1-deficient cells, supporting FSP1 as a potential therapeutic target for further in vivo evaluation.
中文摘要:Kelch样ECH相关蛋白1(KEAP1)的功能缺失突变在肺腺癌中频繁发生,并与不良预后和免疫治疗获益有限相关。然而,KEAP1缺陷与免疫逃逸之间的联系机制仍不清楚。我们结合临床数据分析、体内肿瘤模型和体外共培养系统,研究KEAP1缺陷如何塑造树突状细胞(DC)生物学及对PD-1阻断的应答。我们进行了铁死亡诱导实验、损伤相关分子模式(DAMPs)定量、细胞因子谱分析以及FSP1-CoQ10轴的机制探究,以阐明相关通路。KEAP1突变与PD-1阻断应答不佳和DC浸润减少相关。在小鼠中,KEAP1缺陷肿瘤表现出加速生长,并伴有DC和CD8+ T细胞浸润减少,符合免疫冷表型。机制上,KEAP1缺失在体外损害DC功能,表现为成熟、吞噬和初始CD8+ T细胞致敏能力降低。这一缺陷与两种机制有关。第一,KEAP1缺陷肿瘤细胞抵抗铁死亡,未能释放免疫原性DAMPs,包括细胞外ATP、HMGB1和钙网蛋白。第二,KEAP1缺陷重编程了细胞因子分泌谱,CCL2、IL-6、CXCL1和CXCL2下调,从而削弱DC募集和炎症信号。值得注意的是,抑制FSP1-CoQ10抗氧化轴恢复了铁死亡相关的免疫原性细胞死亡。我们的研究确定KEAP1缺陷是通过损害铁死亡诱导的免疫原性细胞死亡和破坏DC功能,驱动免疫冷肿瘤微环境和对PD-1阻断耐药的驱动因素。在KEAP1缺陷细胞中,FSP1基因缺失恢复了铁死亡相关免疫原性和DC激活,支持FSP1作为潜在治疗靶点以供进一步体内评估。
Radiation induces immunosuppressive myeloid cells that drive therapeutic resistance and metastasis. We identify TET2 as a radiation-induced regulator of myeloid-derived suppressor cells whose expression correlates with poor outcomes in advanced lung cancer patients receiving radio-immunotherapy. Following radiotherapy, myeloid-specific Tet2 deletion suppresses tumor progression and redirects monocyte differentiation toward antigen-presenting myeloid-derived activating cells (MDACs), which augment antitumor T cell responses; spatiotemporal mapping shows that this fate program initiates rapidly in the bone marrow. Mechanistically, a radiation-responsive p53-TET2 axis decreases m5C on chromatin-associated RNAs (caRNAs), enforcing immunosuppressive chromatin compaction and silencing interferon signaling, whereas Tet2 loss restores chromatin accessibility and enhances CD8+ T cell cytotoxicity. Pharmacological TET2 inhibition recapitulates this phenotype and augments radiotherapy and PD-L1 blockade to control primary and metastatic tumors. These findings define MDACs as an immunogenic myeloid subset and establish myeloid reprogramming as a strategy to improve radiotherapy-immunotherapy outcomes.
中文摘要:放疗可诱导具有免疫抑制作用的髓系细胞,后者驱动治疗抵抗和转移。我们发现TET2是放疗诱导的髓源性抑制细胞调节因子,其表达与接受放疗-免疫治疗的晚期肺癌患者的不良结局相关。放疗后,髓系特异性Tet2缺失可抑制肿瘤进展,并将单核细胞分化重定向为抗原呈递型髓源性激活细胞(MDACs),后者增强抗肿瘤T细胞应答;时空图谱显示,这一命运程序在骨髓中迅速启动。机制上,放疗应答性p53-TET2轴降低染色质相关RNA(caRNAs)上的m5C,强化免疫抑制性染色质紧缩并沉默干扰素信号,而Tet2缺失可恢复染色质可及性并增强CD8+ T细胞细胞毒性。药理学抑制TET2可再现该表型,并增强放疗和PD-L1阻断对原发和转移性肿瘤的控制。这些发现将MDACs定义为一种免疫原性髓系亚群,并确立髓系重编程作为改善放疗-免疫治疗结局的策略。
Rapid protein turnover is essential for cellular stress adaptation. HUWE1 (HECT, UBA, and WWE domain containing 1), a large HECT-type E3 ligase, regulates many short-lived stress-responsive proteins, yet the mechanisms underlying its substrate selectivity remain unclear. Here, we reveal that HUWE1 functions as a ubiquitin chain amplifier that captures pre-ubiquitinated substrates and amplifies the degradation signal by assembling long ubiquitin chains containing K11-K48 branch points, a process regulated by its partners HUWE1-associated protein stress response 1 (HAPSTR1) and USP7 (ubiquitin-specific-processing protease 7). Structural and biochemical analyses show that HAPSTR1 engages HUWE1's ubiquitin-binding motifs to drive nuclear import and modulate substrate recruitment. A cryo-EM structure of the HUWE1-USP7 complex reveals a bidirectional regulatory mechanism: HUWE1 activates USP7's catalytic activity, while USP7 modulates HUWE1 conformational states. Global proteomic analyses demonstrate that this axis drives extensive remodeling of the short-lived nuclear proteome. These findings establish the HUWE1-HAPSTR1-USP7 complex as a key ubiquitin code modifier, providing a molecular rationale for HUWE1 dysregulation in neurodevelopmental disorders and cancer.
中文摘要:快速蛋白质周转对细胞应激适应至关重要。HUWE1(含HECT、UBA和WWE结构域蛋白1)是一种大型HECT型E3连接酶,调控许多短寿命的应激响应蛋白,但其底物选择性的机制尚不清楚。在此,我们揭示HUWE1作为一种泛素链放大器发挥作用,它捕获预先泛素化的底物,并通过组装含有K11-K48分支位点的长泛素链来放大降解信号,这一过程受其伙伴蛋白HAPSTR1(HUWE1相关蛋白应激响应1)和USP7(泛素特异性加工蛋白酶7)的调控。结构和生化分析表明,HAPSTR1与HUWE1的泛素结合基序结合,驱动其核输入并调节底物招募。HUWE1-USP7复合物的冷冻电镜结构揭示了一种双向调控机制:HUWE1激活USP7的催化活性,而USP7调节HUWE1的构象状态。全局蛋白质组学分析表明,该轴驱动短寿命核蛋白质组的广泛重塑。这些发现确立了HUWE1-HAPSTR1-USP7复合物作为关键泛素密码修饰因子的地位,为HUWE1在神经发育障碍和癌症中的失调提供了分子依据。
Dendritic cells (DCs) are professional orchestrators of the immune system, integrating environmental signals to initiate, modulate, and sustain antitumor immunity. Although their therapeutic potential extends beyond antigen delivery, most clinical strategies have used DCs primarily as cellular vaccines. Here, we propose that DCs should be viewed as programmable therapeutic cells whose functions can be rationally controlled, either in situ or ex vivo, through four variables: DC identity, antigenic input, anatomical site of action, and immune-instructive output. Together, these variables determine how DCs establish tissue-level immune circuits for tumor control. We further discuss how tumor-associated barriers determine DC programming requirements and how matching DC programs to these microenvironmental or systemic barriers may improve tumor control in patients with cancer.
中文摘要:树突状细胞(DC)是免疫系统的专业协调者,能整合环境信号以启动、调节并维持抗肿瘤免疫。尽管其治疗潜力不仅限于抗原递送,但大多数临床策略主要将DC用作细胞疫苗。在此,我们提出应将DC视为可编程的治疗性细胞,其功能可通过四个变量在原位或离体条件下被理性调控:DC身份、抗原输入、作用解剖部位以及免疫指导性输出。这些变量共同决定了DC如何建立组织水平的免疫回路以控制肿瘤。我们进一步讨论肿瘤相关屏障如何决定DC编程需求,以及将DC编程方案与这些微环境或全身性屏障相匹配可能如何改善癌症患者的肿瘤控制。
Human cancer cells and malignant tumours operate immune evasion machinery, which consists of a set of cross-linked biochemical pathways that suppress the activities of immune cells, such as cytotoxic T cells and natural killer cells. Recent evidence demonstrated that the immune evasion machinery operated by human cancer cells is self-sustaining. However, the mechanisms underlying self-regulation of cancer immune evasion networks remain to be understood. Here we report for the very first time that the cell surface receptor CD44 acts as an enhancer of immune evasion activity in human cancer cells rather than an immune checkpoint per se. Furthermore, upon interaction with galectin-9, CD44 was found to alter cell membrane potential and induce the secretion of TGF-β. Secreted TGF-β displays autocrine and paracrine activities following TGF-β receptor (TGFBR) engagement, which was shown to then activate the Smad3 transcriptional pathway. CD44 complexed to galectin-9 allosterically enhances activity of the TGFBR complex and this was shown to substantially amplify the expression of immune checkpoint proteins crucially associated with suppressing the anti-cancer activities of cytotoxic lymphoid cells. We also demonstrated that this is a fundamental pathway used by human embryos to prevent immune rejection and by innate immune cells to facilitate anti-bacterial innate immune response. Cancer cells and malignant tumours hijack and successfully adapt this fundamental pathway to escape immune surveillance and suppress anti-cancer immune reactions. As such, this autocrine loop allows for the self-regulation of immune evasion networks operated by cancer cells and can be considered as a promising target for highly efficient immunotherapy of cancer.
中文摘要:人类癌细胞和恶性肿瘤会运行免疫逃逸机制,该机制由一组相互交联的生化通路组成,可抑制免疫细胞(如细胞毒性T细胞和自然杀伤细胞)的活性。近期证据表明,人类癌细胞运行的免疫逃逸机制能够自我维持。然而,癌症免疫逃逸网络自我调控的机制仍有待理解。在此,我们首次报道,细胞表面受体CD44在人类癌细胞中发挥免疫逃逸活性增强因子的作用,而非本身作为免疫检查点。此外,CD44与galectin-9相互作用后,被发现可改变细胞膜电位并诱导TGF-β分泌。分泌的TGF-β在结合TGF-β受体(TGFBR)后表现出自分泌和旁分泌活性,随后被证明可激活Smad3转录通路。与galectin-9形成复合物的CD44通过变构方式增强TGFBR复合物的活性,且这被证明可显著放大与抑制细胞毒性淋巴样细胞抗癌活性密切相关的免疫检查点蛋白表达。我们还证明,这是人类胚胎用于防止免疫排斥以及先天免疫细胞用于促进抗细菌先天免疫应答的一条基础通路。癌细胞和恶性肿瘤劫持并成功适应这条基础通路,以逃避免疫监视并抑制抗癌免疫反应。因此,这种自分泌环使得癌细胞运行的免疫逃逸网络能够自我调控,并可被视为癌症高效免疫治疗的一个有前景的靶点。
Ovarian cancer (OC) remains a highly lethal malignancy characterised by diffuse peritoneal dissemination and frequent treatment resistance. Beyond tumor-intrinsic alterations and classical stromal support, the peripheral nervous system is emerging as an important component of the tumor microenvironment. Here, we develop an OC-focused framework of a nerve-dependent metastatic niche, integrating tumor-associated neural remodeling, subtype-specific neural signalling and neuro-immune crosstalk across disease progression. We outline the physiological basis of ovarian and tubo-ovarian innervation and examine how OC may co-opt peripheral neural programmes through neurotrophic factors, axon-guidance molecules and extracellular vesicle signalling. Particular emphasis is placed on sensory and adrenergic pathways implicated in angiogenesis, tumor-cell survival, invasion and immune regulation, while distinguishing OC-specific evidence from mechanisms established in other malignancies. We further consider how neural responsiveness may be reconfigured during peritoneal dissemination through interactions with ascitic, adipose, immune, stromal and mechanical niches. Finally, we discuss emerging neuro-targeted strategies, including receptor antagonism, neurotransmitter-synthesis inhibition, neural manipulation and AAV-enabled neuroengineering, and highlight the translational opportunities and current limitations of targeting nerve-tumor crosstalk in OC.
中文摘要:卵巢癌(OC)仍是高度致死性的恶性肿瘤,以弥漫性腹膜播散和频繁的治疗耐药为特征。除肿瘤内在改变和经典基质支持之外,外周神经系统正逐渐成为肿瘤微环境的重要组成部分。在此,我们提出一个以卵巢癌为核心的神经依赖性转移生态位框架,整合疾病进展过程中的肿瘤相关神经重塑、亚型特异性神经信号传导和神经-免疫串扰。我们概述卵巢及输卵管-卵巢神经支配的生理基础,并探讨卵巢癌如何可能通过神经营养因子、轴突导向分子和细胞外囊泡信号来劫持外周神经程序。特别关注与血管生成、肿瘤细胞存活、侵袭和免疫调节相关的感觉和肾上腺素能通路,同时区分卵巢癌特异性证据与其他恶性肿瘤中已确立的机制。我们进一步思考在腹膜播散过程中,神经反应性如何可能通过与腹水、脂肪、免疫、基质和力学生态位的相互作用而被重塑。最后,我们讨论新兴的神经靶向策略,包括受体拮抗、神经递质合成抑制、神经操控和AAV赋能的神经工程,并强调靶向卵巢癌中神经-肿瘤串扰的转化机遇与当前局限。
A major natural killer (NK) cell and CD8+ T cell checkpoint is mediated by the inhibitory receptor NKG2A/CD94 and its ligand, human leukocyte antigen E (HLA-E) complexed with nine-amino acid HLA-Ia leader sequence-derived peptides termed VL9 (HLA-E-VL9). Here, we used structure-based design and high-throughput library screening to generate high-affinity antibodies that block NKG2A/CD94 interactions. These antibodies enabled direct NK and CD8+ T cell cytotoxicity and mediated NK cell antibody-dependent cellular cytotoxicity (ADCC). Anti-HLA-E-VL9 antibodies enhanced human NK cell line NK-92 killing of HLA-E-VL9+ human tumors in mice, demonstrating checkpoint inhibition activity in vivo. Moreover, HLA-E-VL9 was found to be expressed on primary human CD4+ T cells infected with HIV in vitro, and its engagement by HLA-E-VL9 antibodies drove elimination of infected cells by NK cell-mediated ADCC. HLA-E-VL9 antibodies also enhanced the killing of HIV-infected cells by NKG2A/CD94+ CD8+ T cells targeting an HIV Rev-derived epitope that complexes with HLA-E. Therefore, anti-HLA-E-VL9 antibodies represent a candidate therapeutic approach to eliminating pathogenic target cells by enhancing both NK cell and CD8+ T cell function and by promoting ADCC.
中文摘要:自然杀伤(NK)细胞和CD8+ T细胞的一个主要检查点由抑制性受体NKG2A/CD94及其配体人类白细胞抗原E(HLA-E)介导,后者与源自HLA-Ia前导序列的九氨基酸肽VL9形成复合物(HLA-E-VL9)。在此,我们利用基于结构的设计和高通量文库筛选,生成了可阻断NKG2A/CD94相互作用的高亲和力抗体。这些抗体能够直接启动NK细胞和CD8+ T细胞的细胞毒性,并介导NK细胞抗体依赖性细胞毒性(ADCC)。抗HLA-E-VL9抗体增强了人NK细胞系NK-92对HLA-E-VL9+人肿瘤细胞在小鼠体内的杀伤,证明了其在体内的检查点抑制活性。此外,研究发现,在体外感染HIV的原代人CD4+ T细胞上表达HLA-E-VL9,而HLA-E-VL9抗体与其结合可驱动NK细胞介导的ADCC消除感染细胞。HLA-E-VL9抗体还增强了NKG2A/CD94+ CD8+ T细胞对感染细胞的杀伤,这些T细胞靶向一个与HLA-E形成复合物的HIV Rev来源表位。因此,抗HLA-E-VL9抗体代表了一种候选治疗策略,可通过增强NK细胞和CD8+ T细胞功能并促进ADCC来清除致病靶细胞。
Achieving tumor-specific delivery and sustained activation of both cytotoxic and immune-modulating agents remains a critical challenge in chemoimmunotherapy. Here, a bacterial platform was engineered to combine enzyme/prodrug chemotherapy with immunotherapy, in which tumor-homing Escherichia coli Nissle 1917 expressed cytosine deaminase to convert the prodrug 5-fluorocytosine into the cytotoxic drug 5-fluorouracil and concurrently produced an IL-15 superagonist and a PD-L1 blocking nanobody in tumors. This platform demonstrated potent antitumor effects in murine MC38 and B16-F10 solid tumor models. Mechanistic analyses showed that bacterial enzyme/prodrug therapy alone elicited both immune activation and compensatory immunosuppressive responses, whereas inclusion of IL-15 superagonist and PD-L1 blockade enhanced activation of antigen-presenting cells, T cells, and natural killer cells and attenuated immunosuppressive pathways. Abscopal and rechallenge experiments indicated that this bacterial chemoimmunotherapy strategy induces systemic antitumor immunity and durable immune memory. In summary, our approach integrates enzyme/prodrug therapy and immunotherapy into a single bacterial delivery system, overcoming key limitations of conventional therapies by providing a rationally designed framework for spatially controlled chemoimmunotherapy.
中文摘要:在化学免疫治疗中,实现肿瘤特异性递送以及细胞毒性和免疫调节药物的持续激活仍是一项关键挑战。在此,研究者构建了一种细菌平台,将酶/前药化疗与免疫治疗相结合:肿瘤归巢性大肠杆菌Nissle 1917表达胞嘧啶脱氨酶,将前药5-氟胞嘧啶转化为细胞毒性药物5-氟尿嘧啶,同时在肿瘤内产生IL-15超级激动剂和PD-L1阻断纳米抗体。该平台在小鼠MC38和B16-F10实体瘤模型中表现出强效抗肿瘤作用。机制分析显示,仅细菌酶/前药治疗即可引发免疫激活和代偿性免疫抑制反应,而加入IL-15超级激动剂和PD-L1阻断后,可增强抗原呈递细胞、T细胞和自然杀伤细胞的激活,并减弱免疫抑制通路。远隔效应和再激发实验表明,这种细菌化学免疫治疗策略可诱导全身性抗肿瘤免疫和持久免疫记忆。总之,本方法将酶/前药治疗和免疫治疗整合到单一细菌递送系统中,通过提供合理设计的空间控制化学免疫治疗框架,克服了传统治疗的关键局限。
3临床/流行病学 (20篇)
临床研究 (13篇)
The NHS-Galleri trial was a randomized controlled trial evaluating a multi-cancer early detection (MCED) test added to usual care. We reported elsewhere that the primary endpoint of a reduction in the incidence of stage III/IV cancer diagnoses in the intervention arm versus control arm was not met. Here we report prespecified secondary test performance endpoints among evaluable intervention arm participants across three annual screening rounds. These analyses were descriptive; there was no hypothesis testing. Participants aged 50-77 years (N = 142,250) were randomized 1:1 into intervention (MCED) or control arms. Intervention arm participants with positive MCED results were referred to National Health Service (NHS) standard-of-care pathways for diagnostic workup, with referrals informed by the predicted cancer signal origin (CSO). Positive test results were returned for 722 of 70,325 (1.03%), 518 of 64,498 (0.80%) and 561 of 62,323 (0.90%) participants in rounds 1-3, respectively. In aggregate, 937 participants had MCED-detected primary cancers. Respective by-round cancer detection rates were 0.60%, 0.40% and 0.41%; positive predictive values were 58.0% (419/722), 50.4% (261/518) and 45.8% (257/561); and negative predictive values were 98.98% (68,895/69,603), 98.90% (63,278/63,980) and 98.86% (61,058/61,762). Across rounds, specificity ranged from 99.50% to 99.60%; episode sensitivity ranged from 26.7% to 37.2% for all cancers and from 47.6% to 63.4% for 12 prespecified types; and CSO accuracy ranged from 91.1% to 93.6%. These data provide insights on the performance of the MCED test in population screening within the NHS setting. ClinicalTrials.gov: NCT05611632 ; ISRCTN: ISRCTN91431511 .
中文摘要:NHS-Galleri试验是一项随机对照试验,评估在常规诊疗基础上增加一种多癌种早期检测(MCED)测试。我们在其他文献中报告,干预组与对照组相比,在降低III/IV期癌症诊断发生率这一主要终点上未达到。本文报告在三个年度筛查轮次中可评估的干预组参与者的预设次要测试性能终点。这些分析为描述性分析;未进行假设检验。年龄50-77岁参与者(N=142,250)按1:1随机分配至干预组(MCED)或对照组。干预组中MCED结果阳性的参与者被转诊至英国国家医疗服务体系(NHS)标准诊疗路径进行诊断性检查,转诊参考预测的癌症信号来源(CSO)。第1-3轮分别有70,325名参与者中的722名(1.03%)、64,498名中的518名(0.80%)和62,323名中的561名(0.90%)返回阳性检测结果。总计937名参与者发现MCED检出的原发性癌症。按轮次分别,癌症检出率为0.60%、0.40%和0.41%;阳性预测值为58.0%(419/722)、50.4%(261/518)和45.8%(257/561);阴性预测值为98.98%(68,895/69,603)、98.90%(63,278/63,980)和98.86%(61,058/61,762)。跨轮次,特异性范围为99.50%至99.60%;对所有癌症,每轮灵敏度范围为26.7%至37.2%,对12种预设类型为47.6%至63.4%;CSO准确率范围为91.1%至93.6%。这些数据为在NHS环境中人群筛查中MCED测试的性能提供了见解。ClinicalTrials.gov:NCT05611632;ISRCTN:ISRCTN91431511。
Early cancer detection improves survival; however, most cancer types do not have guideline-recommended screening. We previously reported the first PATHFINDER study that established feasibility of cancer screening with a blood-based multi-cancer early detection (MCED) test that predicts cancer signal origin (CSO) to guide diagnostic workup. The prospective, interventional PATHFINDER 2 study expands clinical evidence for the MCED test by evaluating co-primary endpoints of MCED performance metrics and safety in participants aged 50 years or older without clinical suspicion of cancer. Performance measures included cancer detection rate, positive and negative predictive values, episode sensitivity, specificity and CSO prediction accuracy. Safety was evaluated in terms of number and type of invasive procedures performed and adverse events due to diagnostic testing, after 12 months of follow-up. Endpoints were analyzed descriptively; no hypothesis testing was performed. Between December 2021 and July 2024, 35,878 participants were enrolled. Among 32,007 performance-analyzable participants, cancer detection rate was 0.54% (95% confidence interval (CI): 0.47-0.63%), positive predictive value was 60.3% (95% CI: 54.5-65.8%), negative predictive value was 99.2% (95% CI: 99.1-99.3%) and specificity was 99.64% (95% CI: 99.57-99.70%). Episode sensitivity was 39.3% (95% CI: 34.9-44.0%; all cancers) and 69.8% (95% CI: 62.8-76.0%; prespecified 12-cancer subgroup). Positive and negative likelihood ratios were 108.9 (95% CI: 87.6-135.2) and 0.61 (95% CI: 0.56-0.66), respectively, and the number needed to screen to detect one cancer was 185 (95% CI: 159-215). CSO prediction accuracy was 91.3%. Among 35,335 safety-analyzable participants, 213 (0.6%) had invasive procedure(s) after a positive MCED test; 90.5% were nonsurgical. No serious study-related adverse events were reported by the time of this analysis. These results provide insights into performance and safety of the MCED test in an intended-use population. Randomized trials and longer follow-up are needed to assess the clinical utility of MCED tests. ClinicalTrials.gov identifier: NCT05155605 .
中文摘要:早期发现癌症可提高生存率;然而,大多数癌种没有指南推荐的筛查方法。我们先前报道了首个PATHFINDER研究,该研究确立了使用基于血液的多癌种早期检测(MCED)试验进行癌症筛查的可行性,该试验可预测癌症信号来源(CSO)以指导诊断性检查。这项前瞻性、干预性PATHFINDER 2研究通过评估MCED性能指标和安全性这两个共同主要终点,在50岁及以上、临床不怀疑癌症的参与者中扩展了MCED试验的临床证据。性能指标包括癌症检出率、阳性预测值和阴性预测值、发作期灵敏度、特异度和CSO预测准确性。安全性通过12个月随访后实施的侵入性操作数量和类型以及诊断性检测导致的不良事件进行评估。终点进行描述性分析;未进行假设检验。2021年12月至2024年7月期间,共入组35,878名参与者。在32,007名可进行性能分析的参与者中,癌症检出率为0.54%(95%置信区间(CI):0.47-0.63%),阳性预测值为60.3%(95% CI:54.5-65.8%),阴性预测值为99.2%(95% CI:99.1-99.3%),特异度为99.64%(95% CI:99.57-99.70%)。发作期灵敏度为39.3%(95% CI:34.9-44.0%;所有癌症)和69.8%(95% CI:62.8-76.0%;预先设定的12癌种子集)。阳性似然比和阴性似然比分别为108.9(95% CI:87.6-135.2)和0.61(95% CI:0.56-0.66),检出1例癌症所需筛查人数为185(95% CI:159-215)。CSO预测准确性为91.3%。在35,335名可进行安全性分析的参与者中,213名(0.6%)在MCED检测阳性后接受了侵入性操作;其中90.5%为非手术操作。截至本次分析时,未报告与研究相关的严重不良事件。这些结果为MCED试验在拟定使用人群中的性能和安全性提供了见解。需要随机试验和更长随访来评估MCED试验的临床效用。ClinicalTrials.gov标识符:NCT05155605。
In patients with Barrett oesophagus (BE), surveillance aims to detect dysplasia or oesophageal adenocarcinoma (EAC) early. Whether most asymptomatic patients undergoing endoscopic treatment are identified through surveillance remains uncertain. To assess the contribution of surveillance to the diagnosis of dysplasia and cancer. Patients in the Netherlands with curative treatment for BE-related dysplasia or EAC between 2008 and 2018 were identified from the Barrett Expert Center Registry for endoscopic therapy and the Cancer Registry for surgery or chemoradiotherapy. Endoscopy history was based on pathology reports, with at least one endoscopy with non-dysplastic BE 1-5 years before treatment. Primary endpoint was the proportion of patients with dysplasia or EAC with and without ('de novo patients') prior endoscopies. In total, 8914 patients were included: 90% (95% CI 89% to 91%; 8025/8914) presented de novo, while 10% (95% CI 9% to 11%; 889/8914) had prior endoscopies (mean of 4/IQR 2-7). Overall, 65% had stage ≥II disease, mostly in the de novo group (stage ≥II: 70% de novo vs 11% with prior endoscopy; p<0.001). Two-thirds of endoscopically treated patients (65% (95% CI 62% to 67%); 1283/1989) presented de novo and 97% (95% CI 97% to 98%; 6742/6925) with non-endoscopic therapy. Among those with prior endoscopy, a low rate of missed advanced neoplasia was observed (11%; 96/889). In this nationwide cohort, 90% of patients with Barrett-related dysplasia and cancer and 65% undergoing organ-preserving endoscopic treatment had not undergone prior endoscopy. This underscores the need to evaluate whether targeted, evidence-based screening strategies can improve early detection and patient outcomes.
中文摘要:在巴雷特食管(BE)患者中,监测旨在早期发现异型增生或食管腺癌(EAC)。大多数接受内镜治疗的无症状患者是否通过监测被发现仍不确定。本研究评估监测对异型增生和癌症诊断的贡献。从巴雷特专家中心内镜治疗登记处和癌症登记处(手术或放化疗)中识别2008年至2018年间在荷兰接受BE相关异型增生或EAC治愈性治疗的患者。内镜史基于病理报告,要求治疗前1至5年至少有一次显示非异型增生性BE的内镜检查。主要终点为有和无既往内镜检查的异型增生或EAC患者比例。共纳入8914例患者:90%(95% CI 89%至91%;8025/8914)为新发患者,而10%(95% CI 9%至11%;889/8914)有既往内镜检查(平均4次/四分位距2-7)。总体而言,65%为II期及以上疾病,主要见于新发组(II期及以上:新发组70% vs 有既往内镜组11%;p<0.001)。接受内镜治疗的患者中有三分之二(65%(95% CI 62%至67%);1283/1989)为新发,接受非内镜治疗的患者中该比例为97%(95% CI 97%至98%;6742/6925)。在有既往内镜检查者中,观察到漏诊进展期肿瘤的比例较低(11%;96/889)。在这个全国性队列中,90%的巴雷特相关异型增生和癌症患者以及65%接受保留器官内镜治疗的患者既往未接受内镜检查。这强调需要评估有针对性的、基于证据的筛查策略能否改善早期检测和患者结局。
Both symptoms and other aspects of health-related quality of life have been shown to be prognostic factors for cancer survival. Less is known about the association between distinct symptom subgroups and survival. Thus, this prospective study aimed to explore the possible association between symptom class membership during cancer treatment and long-term all-cause mortality, adjusting for known sociodemographic and clinical prognostic factors. Between 2008 and 2011, 534 patients with cancer were included in a study assessing self-reported symptoms during cancer treatment. Symptom class membership before initiation of new treatment was investigated and four subgroups were identified on the basis of the occurrence of symptoms [i.e. 'all low' (28% of all patients), 'all high' (28%), 'high psychological' (23%), and 'low psychological' (21%)]. In the present follow-up analysis, multivariate Cox proportional hazards regression models were used to estimate the strength of a possible association between symptom class membership and all-cause mortality by comparing the 'all high' subgroup with the three other subgroups 12-15 years after study inclusion. When adjusted for sociodemographic and clinical variables (i.e. sex, age, cancer diagnosis, and comorbidities), belonging to the 'all high' subgroup compared with the three other subgroups was associated with significantly higher mortality (hazard ratio 1.48, 95% confidence interval 1.14-1.94). The present study identified an association between symptom experience and long-term survival. This finding suggests that symptom class membership may be an important prognostic marker for identifying patients at increased risk of all-cause mortality.
中文摘要:症状以及健康相关生活质量的其他方面均已被证明是癌症生存的预后因素。对于不同症状亚组与生存之间的关联了解较少。因此,这项前瞻性研究旨在探讨癌症治疗期间症状类别归属与长期全因死亡率之间可能存在的关联,并校正已知的社会人口学和临床预后因素。2008年至2011年间,534例癌症患者被纳入一项评估癌症治疗期间自我报告症状的研究。研究调查了开始新治疗前的症状类别归属,并基于症状发生情况识别出四个亚组[即「全部低」(占所有患者的28%)、「全部高」(28%)、「高心理」(23%)和「低心理」(21%)]。在本随访分析中,采用多变量Cox比例风险回归模型,通过将「全部高」亚组与另外三个亚组进行比较,评估症状类别归属与全因死亡率之间可能关联的强度,随访时间为研究纳入后12至15年。当校正社会人口学和临床变量(即性别、年龄、癌症诊断和合并症)后,与另外三个亚组相比,属于「全部高」亚组与显著更高的死亡率相关(风险比1.48,95%置信区间1.14-1.94)。本研究发现了症状体验与长期生存之间的关联。这一发现提示,症状类别归属可能是识别全因死亡率风险增加患者的重要预后标志物。
Vector-borne and opportunistic viral infections continue to expand geographically and present with diverse mucocutaneous manifestations that may be unfamiliar to dermatologists. Recognition of these presentations may facilitate early diagnosis. Herein, we summarize the epidemiology, clinical presentation, diagnosis, management, outcomes, and prevention of dermatologically relevant vector-borne viruses and opportunistic viral infections. Most infections are managed supportively, although prompt recognition is essential to identify patients at risk for severe neurologic disease, congenital infection, chronic inflammatory arthritis, or malignancy. Advances in vector control, vaccination, antiretroviral therapy, and targeted treatments have improved prevention and outcomes.
中文摘要:虫媒和机会性病毒感染的地理分布持续扩大,并表现出多种皮肤黏膜表现,皮肤科医生可能对此不熟悉。识别这些表现可能有助于早期诊断。本文中,我们总结了与皮肤病学相关的虫媒病毒和机会性病毒感染的流行病学、临床表现、诊断、管理、结局和预防。大多数感染以支持治疗为主,但及时识别对于找出有重症神经系统疾病、先天性感染、慢性炎性关节炎或恶性肿瘤风险的患者至关重要。病媒控制、疫苗接种、抗逆转录病毒治疗和靶向治疗的进展改善了预防和结局。
Here, we investigate whether participation in a structured exercise program after initial diagnosis is linked to modified muscle and fat measurements, performance status, tumor characteristics, and, ultimately, overall survival (OS) in recurrent glioblastoma patients. Included in this study were 201 consecutive glioblastoma patients (isocitrate dehydrogenase 1 (IDH1) wildtype) diagnosed between 2010 and 2023 with available primary and recurrence imaging. Of these, 25 (12.4%) participated in a structured exercise program after diagnosis. Patient characteristics at primary diagnosis and at recurrence were collected and muscle, inter-/intramuscular adipose tissue (IMAT), and subcutaneous adipose tissue (SAT) compartments of the neck were quantified on initial and recurrence radiation simulation CT scans. Time-to-event analyses were then run for OS from recurrence. Participants in the exercise program had lower tumor volumes (p = 0.025) and better Eastern Cooperative Oncology Group (ECOG) scores (p = 0.016) at recurrence than non-participants despite no differences at initial diagnosis (p > 0.8 for both). Exercise program participants also demonstrated reduced development of sarcopenic adiposity (i.e., a decline in muscle and an increase in IMAT and SAT measurements) in univariable and multivariable analyses. Exercise program participation, tumor volume, ECOG score, and sarcopenic adiposity measures showed univariable associations with post-recurrence OS (p < 0.05). Tumor volume at recurrence and increase in sarcopenic adiposity during treatment retained significance in multivariable models (p < 0.01) while exercise program participation itself did not (p = 0.11). This exploratory retrospective observational cohort study comparing prospectively enrolled exercise program participants with non-participants finds a close interplay between exercise program participation, muscle and fat dynamics, performance status, and tumor volume, linking structured exercise to prognostically favorable changes in patient and tumor characteristics. While results encourage exercise in glioblastoma, prospective randomized trials are needed to substantiate findings.
中文摘要:在此,我们探讨初诊后参加结构化运动项目是否与复发性胶质母细胞瘤患者肌肉和脂肪测量值改变、体能状态、肿瘤特征以及最终总生存期(OS)相关。本研究纳入2010年至2023年间诊断且具有初诊和复发影像资料的201例连续胶质母细胞瘤患者(异柠檬酸脱氢酶1(IDH1)野生型)。其中25例(12.4%)在诊断后参加了结构化运动项目。收集初诊和复发时的患者特征,并在初次和复发放疗模拟CT扫描上量化颈部肌肉、肌间/肌内脂肪组织(IMAT)和皮下脂肪组织(SAT)分区。随后对复发后OS进行时间到事件分析。与未参加者相比,运动项目参加者在复发时肿瘤体积更小(p=0.025),美国东部肿瘤协作组(ECOG)评分更好(p=0.016),尽管初诊时两组无差异(二者p>0.8)。在单变量和多变量分析中,运动项目参加者还表现出少肌性肥胖(即肌肉减少以及IMAT和SAT测量值增加)的发生减少。运动项目参与、肿瘤体积、ECOG评分和少肌性肥胖指标与复发后OS存在单变量关联(p<0.05)。复发时肿瘤体积和治疗期间少肌性肥胖增加在多变量模型中保持显著性(p<0.01),而运动项目参与本身未保持显著性(p=0.11)。这项探索性回顾性观察性队列研究将前瞻性入组的运动项目参加者与未参加者进行比较,发现运动项目参与、肌肉和脂肪动态变化、体能状态和肿瘤体积之间存在密切相互作用,将结构化运动与患者和肿瘤特征中预后有利的变化联系起来。虽然结果鼓励在胶质母细胞瘤中开展运动,但仍需要前瞻性随机试验来证实这些发现。
Promoter DNA hypermethylation is a key epigenetic mechanism of gene silencing in cancer, yet the DNA hypermethylome of oral squamous cell carcinoma (OSCC) and its prognostic relevance remain poorly characterized. Here, we systematically identified and validated novel hypermethylated genes with prognostic significance in OSCC using a genome-wide discovery and multi-platform validation strategy. Candidate genes were first identified by pharmacologic demethylation combined with RNA sequencing across OSCC cell lines, then validated by quantitative RT-PCR, methylation-specific PCR, and bisulfite sequencing in OSCC cell lines, normal oral mucosa, and primary OSCC tumors, with independent confirmation in the TCGA-HNSC dataset. Immunohistochemistry confirmed protein-level silencing, and Kaplan-Meier survival analysis assessed prognostic significance across both cohorts. This pipeline identified five candidate genes, GPX3, ANG, CTGF, GPRC5B, and BAMBI, exhibiting cancer-specific promoter hypermethylation associated with transcriptional and protein silencing in OSCC. Validation in oral cavity tumor samples extracted from the TCGA-HNSC dataset confirmed tumor-specific hypermethylation and revealed significant inverse correlations between methylation and expression for GPX3, GPRC5B, and CTGF. Notably, CTGF hypermethylation was independently associated with poor overall survival in both cohorts (institutional cohort, p=0.03; oral tumor subset from TCGA-HNSC, p=0.01), and a combined ANG+CTGF methylation signature showed superior and reproducible prognostic performance across both platforms. Pathway analysis linked these genes to epithelial-mesenchymal transition and interferon response signaling. This study establishes the first validated DNA methylation biomarker panel for OSCC prognosis, identifying CTGF hypermethylation as a robust prognostic driver with translational potential for clinical risk stratification.
中文摘要:启动子DNA高甲基化是癌症中基因沉默的关键表观遗传机制,但口腔鳞状细胞癌(OSCC)的DNA高甲基化组及其预后相关性仍未被充分阐明。在此,我们采用全基因组发现和多平台验证策略,系统鉴定并验证了OSCC中具有预后意义的新型高甲基化基因。候选基因首先通过药物去甲基化联合RNA测序在OSCC细胞系中鉴定,随后在OSCC细胞系、正常口腔黏膜和原发性OSCC肿瘤中通过定量RT-PCR、甲基化特异性PCR和亚硫酸氢盐测序验证,并在TCGA-HNSC数据集中独立确认。免疫组织化学证实了蛋白水平沉默,Kaplan-Meier生存分析评估了两个队列中的预后意义。该流程鉴定出五个候选基因GPX3、ANG、CTGF、GPRC5B和BAMBI,它们在OSCC中表现出癌症特异性启动子高甲基化,并与转录和蛋白沉默相关。对从TCGA-HNSC数据集中提取的口腔肿瘤样本进行验证,证实了肿瘤特异性高甲基化,并揭示GPX3、GPRC5B和CTGF的甲基化与表达之间存在显著负相关。值得注意的是,CTGF高甲基化在两个队列中均与较差的总生存独立相关(机构队列,p=0.03;TCGA-HNSC的口腔肿瘤子集,p=0.01),并且ANG+CTGF联合甲基化特征在两个平台上均显示出更优且可重复的预后性能。通路分析将这些基因与上皮-间质转化和干扰素反应信号传导联系起来。本研究建立了首个经过验证的OSCC预后DNA甲基化生物标志物组合,确定CTGF高甲基化为强有力的预后驱动因素,具有用于临床风险分层的转化潜力。
Histological variation is a prognostic feature of metastatic urothelial cancer1-3, but its evolutionary trajectory remains poorly defined. We developed a metastatic bladder cancer rapid autopsy programme enriched in histological subtypes4 to profile individuals with terminal disease. Here by reconstructing the evolutionary histories of patient tumours, we show that metastasis-to-metastasis seeding is the dominant pattern of cancer spread and that increased polyclonal migration predicts poor prognosis. The burden, heterogeneity and timing of genomic alterations differ markedly among histological subtypes. Plasmacytoid and neuroendocrine variants develop early driver alterations associated with shorter survival. Mutational signature analyses and experimental models demonstrated that plasmacytoid tumours uniquely use the Fanconi anaemia pathway to mitigate chemotherapy-induced genomic scarring. Single-nucleus profiling revealed mixed cell states in histological subtypes and an association between transcriptional heterogeneity and patient survival. Characterization of the tumour microenvironment uncovered distinct immune states across subtypes, with plasmacytoid tumours exhibiting immune-inflamed profiles, whereas squamous tumours are predominantly immunosuppressive. Last, we demonstrate that post-mortem cell-free DNA captures genomic and transcriptional heterogeneity of the subtypes, which provides a potential strategy for noninvasive assessment of tumour identity and aggressiveness. Our results provide new insights into how tumour heterogeneity shapes the evolutionary history of disease progression in bladder cancer histological subtypes.
中文摘要:组织学变异是转移性尿路上皮癌的预后特征,但其演化轨迹仍鲜有明确界定。我们建立了一个富含组织学亚型的转移性膀胱癌快速尸检项目,以对终末期疾病患者进行特征分析。在此,通过重建患者肿瘤的演化史,我们表明转移灶至转移灶的种植是癌症扩散的主要模式,并且多克隆迁移增加预示不良预后。基因组改变的负荷、异质性和发生时间在不同组织学亚型之间差异显著。浆细胞样和神经内分泌变异型发生与较短生存相关的早期驱动改变。突变特征分析和实验模型表明,浆细胞样肿瘤独特地利用范可尼贫血通路来减轻化疗诱导的基因组瘢痕。单核分析揭示了组织学亚型中的混合细胞状态,以及转录异质性与患者生存之间的关联。对肿瘤微环境的表征揭示了不同亚型间存在不同的免疫状态,其中浆细胞样肿瘤表现出免疫炎症型特征,而鳞状肿瘤主要呈免疫抑制型。最后,我们证明死后游离DNA可捕获这些亚型的基因组和转录异质性,这为无创评估肿瘤身份和侵袭性提供了潜在策略。我们的结果为肿瘤异质性如何塑造膀胱癌组织学亚型疾病进展的演化史提供了新见解。
KEYNOTE-859 showed a favorable benefit-risk profile for pembrolizumab plus chemotherapy compared with placebo plus chemotherapy, regardless of programmed death-ligand 1 (PD-L1) status, in participants with untreated locally advanced or metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. Outcomes after a median study follow-up of 4.5 years are reported. Overall, 1579 participants were randomly assigned 1 : 1 to pembrolizumab 200 mg or placebo plus chemotherapy every 3 weeks for ≤35 cycles. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival, objective response rate, and duration of response, all per RECIST v1.1 by blinded independent central review, and safety. The median study follow-up was 54.8 months (Q1-Q3, 46.8-62.1) at data cut-off (27 September 2024). In the intention-to-treat population, the median OS was 12.9 months for pembrolizumab plus chemotherapy compared with 11.5 months for placebo plus chemotherapy [hazard ratio (HR) 0.78, 95% confidence interval (CI) 0.70-0.86]. Median OS was longer in the PD-L1 combined positive score (CPS) ≥1 (13.0 compared with 11.4 months; HR 0.74, 95% CI 0.66-0.84) and CPS ≥10 (15.8 compared with 11.8 months; HR 0.64, 95% CI 0.53-0.77) populations. Grade 3 or 4 treatment-related adverse events (AEs) occurred in 458 participants (58.3%) receiving pembrolizumab plus chemotherapy and 388 (49.3%) receiving placebo plus chemotherapy; grade 5 treatment-related AEs occurred in 8 participants (1.0%) and 16 participants (2.0%), respectively. Extended follow-up confirms that first-line pembrolizumab plus chemotherapy improves efficacy and maintains a manageable safety profile compared with placebo plus chemotherapy, regardless of PD-L1 status, supporting this combination as a first-line treatment option for locally advanced or metastatic HER2-negative gastric or GEJ adenocarcinoma.
中文摘要:KEYNOTE-859研究显示,在未经治疗的局部晚期或转移性人表皮生长因子受体2(HER2)阴性胃或胃食管结合部(GEJ)腺癌受试者中,无论程序性死亡配体1(PD-L1)状态如何,帕博利珠单抗联合化疗相较安慰剂联合化疗具有有利的获益-风险特征。本文报告中位研究随访4.5年后的结局。共1579例受试者按1:1随机分配接受帕博利珠单抗200 mg或安慰剂联合化疗,每3周一次,最多35个周期。主要终点为总生存期(OS)。次要终点包括无进展生存期、客观缓解率和缓解持续时间(均由盲态独立中心评审按RECIST v1.1评估)以及安全性。数据截止日期(2024年9月27日)时,中位研究随访时间为54.8个月(Q1-Q3,46.8-62.1)。在意向治疗人群中,帕博利珠单抗联合化疗的中位OS为12.9个月,而安慰剂联合化疗为11.5个月[风险比(HR)0.78,95%置信区间(CI)0.70-0.86]。在PD-L1联合阳性评分(CPS)≥1人群中,中位OS更长(13.0个月对11.4个月;HR 0.74,95% CI 0.66-0.84),在CPS≥10人群中亦更长(15.8个月对11.8个月;HR 0.64,95% CI 0.53-0.77)。接受帕博利珠单抗联合化疗的458例受试者(58.3%)和接受安慰剂联合化疗的388例受试者(49.3%)发生3级或4级治疗相关不良事件(AE);分别有8例(1.0%)和16例(2.0%)受试者发生5级治疗相关AE。延长随访证实,与安慰剂联合化疗相比,无论PD-L1状态如何,一线帕博利珠单抗联合化疗均可改善疗效并维持可控的安全性特征,支持该联合方案作为局部晚期或转移性HER2阴性胃或GEJ腺癌的一线治疗选择。
High-grade astrocytoma with piloid features (HGAP) is a recently defined tumor type that is not well-understood. Prognostic factors of clinical outcomes are not well-established. Methylation profiling was performed on tumor samples, many at the National Cancer Institute (NCI) Laboratory of Pathology, and others from publicly available sources. Methylation classifier scores of ≥ 0.90 to the HGAP class on the NCI-Bethesda classifier version 3 were included. Clinical features were collected from the medical record. Survival analyses were performed using the Kaplan-Meier and Cox-proportional hazards methods. The cohort comprised 421 patients. There were high rates of ATRX alteration (62%), CDKN2A/B homozygous loss (78%) and MGMT promoter methylation (53%). MAPK alterations were identified in 74% of evaluable samples. The median age was 46 years, and posterior fossa location was predominant (52%). The median overall survival (OS) was 88 months. Older age (p = 0.01) and the presence of an ATRX alteration (p = 0.04) were found to be negative prognostic factors. The presence of cystic features on magnetic resonance imaging (MRI) was found to be favorably prognostic (p = 0.01). Factors that were not significantly associated with prognosis included histologic high-grade features, CDKN2A/B homozygous deletion, MGMT promoter methylation, extent of resection, and presence of NF1 syndrome. This large cohort establishes relative frequencies of several important markers. Additionally, older age, the presence of an ATRX alteration, and cystic features on MRI were found to be prognostic. Our work may aid in optimizing treatment regimens for patients with this tumor type.
中文摘要:伴毛样特征的高级别星形细胞瘤(HGAP)是一种新近定义的肿瘤类型,目前尚未被充分了解,其临床结局的预后因素也尚未明确确立。研究对肿瘤样本进行了甲基化谱分析,其中许多样本来自美国国家癌症研究所(NCI)病理实验室,其他样本来自公开可获取的来源。纳入标准为在NCI-Bethesda分类器第3版中HGAP类别的甲基化分类器评分≥0.90。临床特征从病历中收集。使用Kaplan-Meier法和Cox比例风险模型进行生存分析。该队列包含421例患者。ATRX改变发生率较高(62%),CDKN2A/B纯合缺失发生率为78%,MGMT启动子甲基化发生率为53%。在可评估样本中,74%发现了MAPK改变。中位年龄为46岁,后颅窝部位占主导(52%)。中位总生存期(OS)为88个月。年龄较大(p=0.01)和存在ATRX改变(p=0.04)被发现为负向预后因素。磁共振成像(MRI)上存在囊性特征被发现为有利预后因素(p=0.01)。与预后无显著相关的因素包括组织学高级别特征、CDKN2A/B纯合缺失、MGMT启动子甲基化、切除范围以及NF1综合征的存在。该大型队列确立了若干重要标志物的相对频率。此外,年龄较大、存在ATRX改变以及MRI上的囊性特征被发现具有预后意义。我们的工作可能有助于优化该肿瘤类型患者的治疗方案。
Chronic inflammatory pouch disorders may affect up to 20% of patients within 5 years after ileal pouch-anal anastomosis and remains a major therapeutic challenge. Within this spectrum, chronic antibiotic-refractory pouchitis is associated with impaired quality of life, long-term pouch-related complications, and potential risk for pouch failure and excision. Current recommendations support the use of probiotics for primary and secondary prevention in selected patients. Increasingly, targeted advanced therapies, including biologics and small molecules approved for the treatment of ulcerative colitis and Crohn's disease, are being used to reduce antibiotic dependence and maintain disease control in patients with pouch inflammation. Vedolizumab is the only advanced therapy approved in Europe for chronic pouchitis, whereas evidence for tumor necrosis factor (TNF) antagonists, ustekinumab, and newer agents, such as interleukin (IL)-23p19 antagonists and Janus kinase (JAK) inhibitors is largely based on observational data from clinical practice and real-world experience. Fecal microbiota transplantation is biologically attractive but remains investigational, with early studies showing inconsistent efficacy. Dietary patterns may modify pouch inflammation; however, most evidence is observational. Overall, current management strategies for chronic pouchitis are limited by incomplete understanding of disease pathogenesis, and by persistent methodological gaps, including poorly standardized treatment outcomes and the lack of validated treat-to-target strategies for this population. Well designed prospective and controlled studies are needed to define appropriate antibiotic-sparing strategies, optimal treatment positioning, and long-term durability of response.
中文摘要:慢性炎症性储袋疾病可能在回肠储袋肛管吻合术后5年内影响多达20%的患者,并且仍是重大治疗挑战。在该疾病谱中,慢性抗生素难治性储袋炎与生活质量受损、长期储袋相关并发症以及储袋失败和切除的潜在风险相关。当前建议支持在特定患者中使用益生菌进行一级和二级预防。越来越多已获批用于治疗溃疡性结肠炎和克罗恩病的靶向先进治疗,包括生物制剂和小分子药物,正被用于减少抗生素依赖并维持储袋炎症患者的疾病控制。维得利珠单抗是欧洲唯一获批用于慢性储袋炎的先进治疗,而肿瘤坏死因子拮抗剂、乌司奴单抗以及较新药物如白细胞介素23p19拮抗剂和Janus激酶抑制剂的证据主要基于临床实践中的观察性数据和真实世界经验。粪菌移植在生物学上具有吸引力,但仍处于研究阶段,早期研究显示疗效不一致。饮食模式可能调节储袋炎症;然而,大多数证据为观察性证据。总体而言,当前慢性储袋炎的管理策略受到对疾病发病机制认识不完整以及持续存在的方法学缺口限制,包括治疗结局标准化不足以及该人群缺乏经过验证的达标治疗策略。需要设计良好的前瞻性对照研究来明确合适的减少抗生素使用策略、最佳治疗定位以及长期应答持久性。
Patients with cancer usually report limitations of their functional capacity, which may range from subclinical impairment of cardiopulmonary exercise reserve to poor quality of life with physical, cognitive, or psychosocial consequences. Exercise training is a potent multi-targeted approach to control pre-existing and new risk factors. Preliminary evidence shows that it is associated with a lower risk of cancer therapy-related cardiotoxicity and increased self-reported well-being in patients with cancer. Current evidence demonstrates that supervised exercise therapy, including high-intensity interval training, is safe and well-tolerated and reduces risk in subjects with cancer in the pre-, active-, and post-treatment settings. The present consensus document will discuss the role of exercise training in cardio-oncology, focusing on patients with cardiovascular diseases induced by cancer treatment and on those who received cardiotoxic therapies.
中文摘要:癌症患者通常报告其功能能力受限,这种受限范围可从亚临床的心肺运动储备受损,到伴有躯体、认知或心理社会后果的生活质量下降。运动训练是一种有效的多靶点方法,用于控制既存的和新出现的危险因素。初步证据显示,它与癌症患者中较低的癌症治疗相关心脏毒性风险以及自我报告幸福感的提高相关。当前证据表明,包括高强度间歇训练在内的监督下运动治疗是安全且耐受良好的,并可降低治疗前、治疗中和治疗后阶段癌症患者的风险。本共识文件将讨论运动训练在肿瘤心脏病学中的作用,重点关注由癌症治疗诱发心血管疾病的患者以及接受过心脏毒性治疗的患者。
Dyslipidaemia in cancer patients presents several challenges with increasing survival of cancer patients. Dyslipidaemia and cancer treatments both increase atherosclerotic cardiovascular disease (ASCVD) risk; yet, most risk prediction scores for ASCVD do not include important cancer factors and thus underestimate true ASCVD. Some cancer therapies cause transient elevations of low-density lipoprotein cholesterol or triglycerides, or reduction in high-density lipoprotein cholesterol, occasionally to extreme levels requiring specific treatment and monitoring strategies. A range of lipid-lowering therapies can be used in cancer patients to manage cholesterol and triglycerides but of these, reliable data only exist for statins and ezetimibe for managing low-density lipoprotein cholesterol, and fibrates and Omega 3 fish oils for hypertriglyceridaemia. There are no robust randomized controlled trials conducted in cancer patients for reduction of adverse cardiovascular events and therefore current recommendations have been extrapolated from non-cancer trials. Cancer survivors may require combination therapies; yet, trials of newer lipid-lowering therapies excluded cancer patients and hence safety and efficacy data are limited. The initiation of lipid-lowering therapy in cancer patients requires an integration of several factors, which includes a careful assessment of ASCVD risk, drug-drug interactions, side-effect profiles, and prognosis. Further work is required to personalize individualized risk scores for ASCVD in cancer patients and survivors and new trials and 'real-world' or registry data would inform these existing data gaps. Beyond lipid management, the putative role of therapies such for statins as cardioprotective agent for anthracycline chemotherapy open novel avenues for further research as survival from many cancers continues to improve.
中文摘要:随着癌症患者生存率不断提高,癌症患者的血脂异常带来了若干挑战。血脂异常和癌症治疗都会增加动脉粥样硬化性心血管疾病(ASCVD)风险;然而,大多数ASCVD风险预测评分并未纳入重要的癌症相关因素,因此低估了真实ASCVD风险。一些癌症治疗可引起低密度脂蛋白胆固醇或甘油三酯的短暂升高,或高密度脂蛋白胆固醇降低,偶尔达到需要特定治疗和监测策略的极端水平。癌症患者可使用一系列降脂治疗来管理胆固醇和甘油三酯,但其中只有他汀类药物和依折麦布用于管理低密度脂蛋白胆固醇,以及贝特类和Omega 3鱼油用于高甘油三酯血症,具有可靠数据。目前尚无在癌症患者中开展的旨在减少不良心血管事件的稳健随机对照试验,因此当前推荐意见是从非癌症试验外推而来。癌症幸存者可能需要联合治疗;然而,较新的降脂治疗试验排除了癌症患者,因此安全性和有效性数据有限。在癌症患者中启动降脂治疗需要整合多个因素,包括仔细评估ASCVD风险、药物-药物相互作用、副作用特征和预后。需要进一步工作来为癌症患者和幸存者制定个体化的ASCVD风险评分,新的试验以及「真实世界」或注册数据将有助于填补这些现有数据缺口。除血脂管理外,他汀类药物作为蒽环类化疗心脏保护剂的假定作用,随着许多癌症生存率持续改善,为未来研究开辟了新途径。
基础研究 (7篇)
ATP6AP1, a key accessory subunit of the vacuolar H+-ATPase (V-ATPase) complex responsible for organelle acidification, has emerged as a potential cancer driver. Numerous studies have shown that ATP6AP1 is significantly upregulated in breast cancer, and its high expression is associated with poor prognosis. However, the specific functions and underlying mechanisms of ATP6AP1 in breast cancer progression remain unclear. In the present study, ATP6AP1 was demonstrated to enhance the malignant phenotype of breast cancer cells by upregulating XIAP expression. YY1 was further identified as a novel transcription factor that regulates XIAP, and ATP6AP1 was shown to directly interact with YY1, thereby stabilizing YY1 protein levels and subsequently promoting XIAP expression. In addition, ATP6AP1 silencing markedly increased the sensitivity of breast cancer cells to paclitaxel. Through screening of an FDA-approved drug library, niclosamide was identified as a novel degrader of ATP6AP1. Niclosamide bound to ATP6AP1, reduced its protein stability, and consequently downregulated its expression. Moreover, niclosamide inhibited the proliferation, migration, and invasion of breast cancer cells while promoting apoptosis through targeted degradation of ATP6AP1. Furthermore, niclosamide significantly enhanced the sensitivity of breast cancer cells to paclitaxel by targeting the ATP6AP1-YY1-XIAP axis. Taken together, these findings demonstrated that ATP6AP1 promotes breast cancer progression through activation of the YY1-XIAP signaling axis. Niclosamide was also identified as a promising therapeutic agent targeting ATP6AP1, thereby providing a potential therapeutic strategy for breast cancer treatment.
中文摘要:ATP6AP1是负责细胞器酸化的液泡H+-ATP酶(V-ATPase)复合体的关键附属亚基,已成为潜在的癌症驱动因子。大量研究表明,ATP6AP1在乳腺癌中显著上调,且其高表达与不良预后相关。然而,ATP6AP1在乳腺癌进展中的具体功能及潜在机制仍不清楚。在本研究中,ATP6AP1被证明通过上调XIAP表达增强乳腺癌细胞的恶性表型。进一步发现YY1是调控XIAP的新型转录因子,并显示ATP6AP1可直接与YY1相互作用,从而稳定YY1蛋白水平,进而促进XIAP表达。此外,沉默ATP6AP1可显著增加乳腺癌细胞对紫杉醇的敏感性。通过筛选美国食品药品监督管理局批准的药物库,氯硝柳胺被鉴定为一种新型ATP6AP1降解剂。氯硝柳胺与ATP6AP1结合,降低其蛋白稳定性,从而下调其表达。此外,氯硝柳胺通过靶向降解ATP6AP1抑制乳腺癌细胞增殖、迁移和侵袭,同时促进凋亡。再者,氯硝柳胺通过靶向ATP6AP1-YY1-XIAP轴显著增强乳腺癌细胞对紫杉醇的敏感性。综上所述,这些发现表明ATP6AP1通过激活YY1-XIAP信号轴促进乳腺癌进展。氯硝柳胺也被鉴定为一种靶向ATP6AP1的有前景的治疗药物,从而为乳腺癌治疗提供了潜在的治疗策略。
Coffee is one of the most commonly consumed beverages in daily life, with caffeine being the major psychoactive component that acts against fatigue and drowsiness. Epidemiological studies have demonstrated the protective effect of coffee intake on colon cancer risk, recurrence and overall survival, but the detailed mechanisms are unclear. In this study, we identified an adenosine receptor (ADORA) as an important upstream receptor for the Hippo/YAP axis and found that caffeine competitively blocked the activation of ADORA, which subsequently inhibited colon cancer carcinogenesis and progression. Caffeine blocked the activation of ADORA1 and then promoted YAP phosphorylation and deactivation via the Gαi-cAMP/PKA-LATS axis. Interestingly, YAP could bind to the promoter region of ADORA1 and facilitate its transcription, resulting in the formation of a positive feedback loop between Hippo signalling and the adenosine receptor pathway. Our study revealed a novel positive feedback loop between the Hippo/YAP axis and adenosine signalling in colon cancer progression, while the tumour-suppressive function of caffeine provides more guidance for lifestyle intervention for cancer prevention and therapeutics.
中文摘要:咖啡是日常生活中最常饮用的饮料之一,咖啡因是其主要的心理活性成分,具有抗疲劳和抗困倦作用。流行病学研究表明,摄入咖啡对结肠癌风险、复发和总生存具有保护作用,但具体机制尚不清楚。在本研究中,我们发现一种腺苷受体(ADORA)是Hippo/YAP轴的重要上游受体,并发现咖啡因可竞争性阻断ADORA的激活,进而抑制结肠癌的发生和进展。咖啡因阻断ADORA1的激活,随后通过Gαi-cAMP/PKA-LATS轴促进YAP磷酸化和失活。有趣的是,YAP可结合ADORA1启动子区域并促进其转录,从而在Hippo信号通路和腺苷受体通路之间形成正反馈环路。我们的研究揭示了结肠癌进展中Hippo/YAP轴与腺苷信号之间的新型正反馈环路,而咖啡因的肿瘤抑制功能为癌症预防和治疗的生活方式干预提供了更多指导。
T-cell receptors (TCRs) recognize antigens, including cancer antigens, offering a promising avenue for immunological profiling and early detection. As cancer diagnostics increasingly shift towards less invasive methods, deep learning has emerged as a powerful tool in facilitating this transition. The identification of cancer-associated TCRs (caTCRs) from peripheral blood samples presents a compelling alternative to traditional biopsy-based approaches, enabling more scalable and non-invasive cancer screening. In this review, we examine twelve state-of-the-art caTCR detection frameworks, detailing their conceptual innovations and method workflows. We also perform a limited external benchmarking of a subset of publicly available pre-trained models on our own data and analyze their performance. We further discuss the biological and methodological constraints of caTCRs and their detection methods, and assess their ability to be adopted within clinical settings. By highlighting both recent advances and remaining limitations, this manuscript aims to provide a balanced perspective on the field and to inform future research towards more robust, interpretable, and clinically relevant caTCR-based diagnostic tools.
中文摘要:T细胞受体(TCR)可识别抗原,包括癌症抗原,为免疫学分析和早期检测提供了有前景的途径。随着癌症诊断日益向微创方法转变,深度学习已成为推动这一转变的有力工具。从外周血样本中识别癌症相关TCR(caTCR)为传统的基于活检的方法提供了一种有吸引力的替代方案,可实现更具可扩展性和非侵入性的癌症筛查。在这篇综述中,我们考察了十二种最先进的caTCR检测框架,详细介绍了其概念创新和方法流程。我们还对一部分公开可用的预训练模型在我们自己的数据上进行了有限的外部基准测试,并分析了其性能。我们进一步讨论了caTCR及其检测方法的生物学和方法学限制,并评估了其在临床环境中被采用的能力。通过强调近期进展和仍存在的局限性,本文旨在为该领域提供一个平衡的视角,并为未来研究提供信息,以开发更稳健、可解释且具有临床相关性的基于caTCR的诊断工具。
Pancreatic cancer (PC) is a highly aggressive and lethal malignancy with extremely poor patient survival rates. The lack of biomarkers and deep tissue detection barriers has presented long-standing and unsolved issues, severely hindering the early diagnosis of PC even in living rodent models. Here, we report a renal-clearable leucine aminopeptidase (LAP)-activatable fluorescence probe, overturning the probe's pharmacokinetics from the liver to kidney pathway (90% of the injection dosage). This strategy reduces interference in the liver and enables LAP as a biomarker for PC detection in murine models. After in situ response with LAP in the pancreas, renal-clearable fluorogenic fragments could be efficiently excreted into the urine, thus addressing the depth barriers of PC. Our strategy has resolved the lack of biomarkers and deep tissue detection barriers in early PC detection in murine models, which would greatly expand the bioanalytical toolbox for PC identification, further enabling the efficient screening of PC drugs at the animal level and the exploration of diagnostic methods for PC.
中文摘要:胰腺癌(PC)是一种高度侵袭性且致死性极强的恶性肿瘤,患者生存率极低。生物标志物缺乏以及深部组织检测屏障是长期存在且尚未解决的问题,严重阻碍了胰腺癌的早期诊断,即使在活体啮齿动物模型中也如此。在此,我们报道了一种可经肾脏清除的亮氨酸氨肽酶(LAP)激活型荧光探针,将该探针的药代动力学从肝脏途径逆转为肾脏途径(注射剂量的90%经肾清除)。该策略减少了肝脏干扰,并使LAP可作为小鼠模型中胰腺癌检测的生物标志物。在与胰腺内LAP发生原位响应后,可经肾脏清除的荧光片段能够有效排泄至尿液中,从而解决胰腺癌的深度检测屏障。我们的策略解决了小鼠模型早期胰腺癌检测中生物标志物缺乏和深部组织检测屏障的问题,将极大拓展用于胰腺癌识别的生物分析工具箱,进一步支持在动物层面高效筛选胰腺癌药物,并探索胰腺癌的诊断方法。
Pancreatic cancer is one of the most lethal digestive system malignancies worldwide, characterized by insidious onset, limited early detection approaches and extremely poor long-term prognosis. It comprises multiple histological subtypes, among which pancreatic ductal adenocarcinoma (PDAC) represents the most prevalent exocrine neoplasm and accounts for the vast majority of all pancreatic cancer cases. Perineural invasion (PNI) stands as one of the defining biological hallmarks of PDAC. Detected in 80%-100% of PDAC patients, PNI serves as an independent adverse prognostic factor that drives local recurrence, distant metastasis, and resistance to both chemotherapy and immunotherapy. Historically regarded as a passive route for tumor dissemination, PNI is now recognized as a complex, multicellular process involving bidirectional crosstalk between cancer cells, nerve fibers, stromal cells, and immune components within the tumor microenvironment. This review dissects the molecular mechanisms underlying neuro-tumor interactions and proposes a unified four-stage mechanistic model of PNI, encompassing mutual chemotaxis between tumors and nerves, adhesion and invasion at the tumor-nerve interface, extracellular matrix remodeling, and neural plasticity alterations. Notably, we define the perineural invasion microenvironment as a neuro-immune privileged sanctuary, and delineate its multicellular composition and pathological consequences based on current research advances. Furthermore, we summarize potential therapeutic strategies targeting the neuro-immune-tumor axis and ongoing clinical trials, discuss key translational challenges, and highlight the transformative applications of multi-omics technologies and artificial intelligence in PNI diagnosis, mechanistic discovery, and therapeutic optimization. This work provides a comprehensive theoretical framework for understanding PNI mechanisms and guides future translational research and precision therapy development for pancreatic cancer.
中文摘要:胰腺癌是全球范围内致死率最高的消化系统恶性肿瘤之一,其起病隐匿、早期检测手段有限,长期预后极差。胰腺癌包含多种组织学亚型,其中胰腺导管腺癌(PDAC)是最常见的外分泌肿瘤,占全部胰腺癌病例的绝大多数。神经周围侵犯(PNI)是PDAC的标志性生物学特征之一。PNI在80%至100%的PDAC患者中可被检出,是独立的不良预后因素,可驱动局部复发、远处转移以及对化疗和免疫治疗的耐药。历史上,PNI曾被视作肿瘤播散的被动途径,如今则被认为是一个复杂、涉及多种细胞的进程,涵盖癌细胞、神经纤维、基质细胞与肿瘤微环境中免疫组分之间的双向交互。本综述剖析了神经—肿瘤相互作用的分子机制,并提出统一的PNI四阶段机制模型,包括肿瘤与神经之间的相互趋化、肿瘤—神经界面的黏附与侵袭、细胞外基质重塑以及神经可塑性改变。值得关注的是,我们将神经周围侵犯微环境定义为神经免疫豁免龛,并基于当前研究进展阐述其多细胞组成与病理学后果。此外,我们总结了靶向神经—免疫—肿瘤轴的潜在治疗策略及正在开展的临床试验,讨论了关键的转化挑战,并强调多组学技术与人工智能在PNI诊断、机制发现及治疗优化中的变革性应用。本工作为理解PNI机制提供了全面的理论框架,并为胰腺癌未来的转化研究与精准治疗开发提供指导。
The field of reverse cardio-oncology examines how subclinical and overt cardiometabolic dysfunction-such as obesity-fuels breast cancer (BCa) risk and altered tumour biology through shared mechanisms such as chronic inflammation, hormonal dysregulation, and cellular senescence. Limitations of body mass index (BMI) have prompted the development of refined obesity phenotypes, including metabolically healthy vs unhealthy obesity and sarcopenic obesity that more accurately stratify BCa risk. Reverse cardio-oncology is conceptually distinguished from traditional cardio-oncology by focusing on how cardiometabolic impairment-even in the absence of manifest cardiovascular disease-increases BCa incidence and worsens prognosis. Within a common-soil framework, senescent adipose tissue is recognized as a key driver of breast tumour microenvironment remodelling through senescence-associated secretory phenotype (SASP), epigenetic reprogramming, and immunosenescence. Emerging translational strategies-including lifestyle modification, cardiometabolic therapies such as GLP-1 receptor agonists and SGLT2 inhibitors, and senolytic approaches-highlight opportunities to integrate cardiovascular and oncologic prevention and treatment in women with or at risk for BCa. Overall, this review synthesizes current knowledge on obesity's mechanistic links to BCa within a reverse cardio-oncology paradigm and provides a conceptual foundation for improved risk stratification and interdisciplinary clinical management.
中文摘要:反向心脏肿瘤学领域研究亚临床和显性的心脏代谢功能障碍——如肥胖——如何通过慢性炎症、激素失调和细胞衰老等共同机制促进乳腺癌(BCa)风险及肿瘤生物学改变。体重指数(BMI)的局限性促使人们提出更精细的肥胖表型,包括代谢健康型与代谢不健康型肥胖以及肌少症性肥胖,这些表型能更准确地对BCa风险进行分层。反向心脏肿瘤学在概念上有别于传统心脏肿瘤学,其关注点在于心脏代谢损害——即使没有明显心血管疾病——如何增加BCa发病率并恶化预后。在共同土壤框架下,衰老脂肪组织被认为是乳腺癌肿瘤微环境重塑的关键驱动因素,其通过衰老相关分泌表型(SASP)、表观遗传重编程和免疫衰老发挥作用。新兴的转化策略——包括生活方式干预、GLP-1受体激动剂和SGLT2抑制剂等心脏代谢治疗以及去衰老疗法——突显了在患有BCa或有BCa风险的女性中整合心血管与肿瘤预防和治疗的机会。总体而言,本综述在反向心脏肿瘤学范式内综合了当前关于肥胖与BCa机制联系的知识,并为改进风险分层和多学科临床管理提供了概念基础。
Breast cancer (BC)-related atrial fibrillation (AF) contributes to an overall poor prognosis and raises great concerns. However, beyond cancer treatment-related AF, it is unknown whether BC itself is sufficient to directly induce AF. This study aimed to explore the role of BC in the development of AF, focusing on the tumour itself rather than therapy-related cardiotoxicity. A retrospective analysis was conducted on 1224 female BC patients before therapy and 18 159 healthy female participants. The prevalence of AF was assessed, and markers of atrial remodelling, including P-wave indices on electrocardiogram (ECG), were measured. An orthotopic BC model was established by implanting E0771 cells to mammary fat pads of female C57BL/6 mice. An electrophysiological study was employed to assess atrial arrhythmia vulnerability. Masson's trichrome staining, coculture assays and molecular biological techniques were used to determine the mechanisms of BC-induced AF. BC patients (n = 1217) were individually matched 1:1 to non-cancer female controls (n = 1217) by propensity score matching. Even before treatment, BC patients had a significantly higher prevalence of AF (6.41%) than controls (0.90%). BC patients exhibited more marked atrial remodelling evaluated by abnormal P-wave terminal force in ECG lead V1 (7.37% vs 3.90%, P < .001), compared to non-cancer female controls. Similarly, BC mice, as well as mice administered with tumour-conditioned media or plasma from BC mice, developed atrial fibrosis and had increased AF susceptibility. After screening tumour-secreted factors, both BC patients with AF and BC mice displayed elevated levels of soluble ADAM10 (sADAM10) in tumour tissue and plasma. Moreover, sADAM10 promoted the cleavage of Ephrin B2 into soluble Ephrin B2 (sEphrin B2) in atrial cardiofibroblasts (ACFs), which then bound with EphB3 and EphB4 receptors and activated the atrial fibrosis pathway. Cardiac fibroblast-specific knockdown of Ephrin B2 suppressed AF development in BC mice. The plasma levels of sEphrin B2 were especially higher in pre-treatment breast cancer patients with AF compared to controls, in parallel with increasing sADAM10 levels (R2 = 0.67, P < .0001). The inhibition of tumour-originated sADAM10 with its specific inhibitor (GI254023X) or its shRNA attenuated atrial fibrosis and AF susceptibility in BC mice. BC patients before treatment present a significantly higher prevalence of AF and atrial remodelling, which correlate with elevated levels of tumour-originated sADAM10 and ACF-secreted sEphrin B2. Tumour-originated sADAM10 directly promotes AF pathogenesis by inducing atrial fibrosis, independent of cancer treatment. These findings imply that the inhibition of sADAM10 represents a potentially new therapeutic option for BC-associated AF.
中文摘要:乳腺癌(BC)相关的心房颤动(AF)会导致总体预后不良,并引起高度关注。然而,除癌症治疗相关AF之外,尚不清楚BC本身是否足以直接诱发AF。本研究旨在探讨BC在AF发生中的作用,重点关注肿瘤本身而非治疗相关心脏毒性。研究对1224例治疗前女性BC患者和18159名健康女性参与者进行了回顾性分析,评估AF患病率,并测量心房重构标志物,包括心电图(ECG)上的P波指数。通过将E0771细胞植入雌性C57BL/6小鼠乳腺脂肪垫建立原位BC模型。采用电生理研究评估心房心律失常易感性。使用Masson三色染色、共培养实验和分子生物学技术确定BC诱导AF的机制。BC患者(n=1217)通过倾向评分匹配与非癌症女性对照(n=1217)按1:1个体匹配。即使在治疗前,BC患者的AF患病率(6.41%)也显著高于对照(0.90%)。根据ECG V1导联P波终末电势异常评估,BC患者表现出比非癌症女性对照更明显的心房重构(7.37%与3.90%相比,P<0.001)。类似地,BC小鼠以及接受肿瘤条件培养基或BC小鼠血浆的小鼠均出现心房纤维化,并且AF易感性增加。在筛选肿瘤分泌因子后,伴有AF的BC患者和BC小鼠的肿瘤组织及血浆中可溶性ADAM10(sADAM10)水平均升高。此外,sADAM10促进心房心脏成纤维细胞(ACF)中的Ephrin B2裂解为可溶性Ephrin B2(sEphrin B2),后者随后与EphB3和EphB4受体结合并激活心房纤维化通路。心脏成纤维细胞特异性敲低Ephrin B2可抑制BC小鼠的AF发生。与对照相比,治疗前伴有AF的乳腺癌患者血浆sEphrin B2水平尤其更高,并与sADAM10水平升高相一致(R²=0.67,P<0.0001)。用特异性抑制剂(GI254023X)或其shRNA抑制肿瘤来源的sADAM10可减轻BC小鼠的心房纤维化和AF易感性。治疗前BC患者AF和心房重构患病率显著更高,这与肿瘤来源的sADAM10和ACF分泌的sEphrin B2水平升高相关。肿瘤来源的sADAM10通过诱导心房纤维化直接促进AF发病,且独立于癌症治疗。这些发现提示,抑制sADAM10可能是BC相关AF的一种潜在新治疗选择。
4消化系统肿瘤 (17篇)
临床研究 (5篇)
The absence of accurate, noninvasive, scalable screening tools keeps early esophageal cancer (EC) detection a global health challenge. Although noncontrast computed tomography (NC CT) is widely accessible, the esophagus is a hollow tubular structure prone to collapse and motion artifacts, making small early malignant lesions difficult to distinguish from normal tissue. Here we developed the Esophageal AI-Guided malignant Lesion Evaluation (EAGLE) model to detect precancerous lesions and cancer from chest NC CT, a task historically considered impossible. EAGLE was trained on 6,813 patients from two centers and validated across 12 centers in three countries involving 80,612 patients in opportunistic and population-based screening settings. For opportunistic screening on existing CT scans, multicenter external test cohorts (eight centers, n = 11,466) achieved 98.5% specificity, with 90.0% sensitivity for cancer and 52.5% for precancerous lesions; low-dose CT (LDCT) validation (two centers, n = 1,607) showed comparable performance, supporting EC screening through lung-cancer screening programs. Calibration in a real-world cohort (three centers, n = 35,402) reduced false positives by 72.7% while preserving sensitivity; prospective hospital validation (n = 17,446) achieved a 42.2% PPV, and real-world low-dose screening (n = 10,959) reached 99.94% specificity. EAGLE also detected precancerous lesions-in paired CT-endoscopy cohorts (two centers, n = 702), sensitivities were 65.0% for precancerous lesions and 78.4% for stage I EC at a higher-sensitivity operating point. Exploratory analyses of a prospectively enrolled cohort suggest that referring high-risk individuals for endoscopy could improve screening efficiency. In conclusion, EAGLE has the potential to serve as a scalable tool for early EC screening. Chictr.org.cn identifier: ChiCTR2300074806 .
中文摘要:缺乏准确、无创、可扩展的筛查工具,使早期食管癌(EC)检测仍是全球卫生挑战。尽管非增强计算机断层扫描(NC CT)广泛可及,但食管是易塌陷和产生运动伪影的中空管状结构,使小的早期恶性病变难以与正常组织区分。在此,我们开发了食管人工智能引导恶性病变评估(EAGLE)模型,用于从胸部 NC CT 中检测癌前病变和癌症,这一任务历史上被认为不可能。EAGLE 在来自两个中心的 6,813 例患者上训练,并在三个国家 12 个中心、涉及 80,612 例患者的机会性筛查和人群筛查场景中验证。对于在现有 CT 扫描上进行机会性筛查,多中心外部测试队列(8 个中心,n=11,466)达到 98.5% 特异性,癌症灵敏度为 90.0%,癌前病变灵敏度为 52.5%;低剂量 CT(LDCT)验证(2 个中心,n=1,607)显示性能相当,支持通过肺癌筛查项目进行 EC 筛查。在真实世界队列(3 个中心,n=35,402)中的校准将假阳性降低 72.7%,同时保持灵敏度;前瞻性医院验证(n=17,446)达到 42.2% 的 PPV,真实世界低剂量筛查(n=10,959)达到 99.94% 特异性。EAGLE 还在配对的 CT-内镜队列(2 个中心,n=702)中检测到癌前病变——在更高灵敏度操作点,癌前病变灵敏度为 65.0%,I 期 EC 为 78.4%。对前瞻性入组队列的探索性分析提示,将高风险个体转诊进行内镜检查可提高筛查效率。总之,EAGLE 有潜力作为早期 EC 筛查的可扩展工具。Chictr.org.cn 标识:ChiCTR2300074806。
Most individuals with steatotic liver disease (SLD) do not develop advanced liver disease. Multiple risk scores for SLD-associated cirrhosis and hepatocellular carcinoma (HCC) have been proposed, but their utility to inform decisions about surveillance for advanced liver disease is unknown. To compare the clinical utility of SLD risk scores for predicting cirrhosis and hepatocellular carcinoma in patients with noncirrhotic steatotic liver disease. This cohort study used data from the national US Veterans Affairs health system of adults with imaging-confirmed SLD without viral hepatitis or primary liver disease from 2008 and 2020. Nine clinical risk scores were calculated at the time of the first imaging results that demonstrated hepatic steatosis. Individuals were followed up until cirrhosis, HCC, death, or 6 months after last follow-up visit. Data were analyzed between November 1, 2025, and May 11, 2026. Nine risk scores evaluated for prediction of cirrhosis or HCC within 10 years were: (1) ALBI, albumin-bilirubin; (2) aMAP, age-male-albumin-bilirubin-platelet; (3) APRI, the aspartate aminotransferase-to-platelet ratio; (4) BARD, body mass index, age, alanine aminotransferase-to-aspartate aminotransferase ratio, and diabetes; (5) FIB-4, fibrosis-4 index; (6) NFS, nonalcoholic fatty liver disease fibrosis; (7) SAFE, steatosis-associated fibrosis estimator; and 2 additional scores. First diagnosis of cirrhosis and first diagnosis of HCC identified using VA and Medicare diagnosis codes and data from the VA Cancer Registry. Cox proportional hazards models were used to calculate time-dependent 10-year probabilities of each outcome predicted by 9 risk scores. Decision curves were generated for each outcome by calculating the net benefit, a weighted measure of true and false positives over a prespecified range of risk thresholds at which a clinician may reasonably recommend intervention. Nine risk scales were used to quantify the risk of cirrhosis or HCC within 10 years. The analysis included 853 131 patients (median [IQR] age, 61 [51-68] years; 62 168 females [7.3%] and 790 965 males [92.7%]) whose median (IQR) BMI was 31.3 (27.6-35.5) and 275 898 (32.3%) had diabetes; of these, 33 794 (3.96%) developed cirrhosis and 2978 (0.35%) developed HCC within 10 years. The FIB-4, APRI, and SAFE scores demonstrated the greatest discrimination of cirrhosis risk, while the SAFE, Tate, and FIB-4 scores demonstrated the greatest discrimination of HCC risk. The SAFE score demonstrated the greatest net benefit predicting cirrhosis. A score of 29.5 corresponded to a 10-year cirrhosis risk of 2.5% and yielded a net benefit of 0.019, or 1.9 additional individuals who develop cirrhosis per 100 individuals classified as at-risk patients. At a 0.25% 10-year risk of HCC, the SAFE score had a net benefit of 0.0016 (1.6 additional true positives per 1000 individuals). The findings of this cohort study show that the SAFE score may inform decisions to repeat screening for cirrhosis in patients with SLD. Clinical risk scores for HCC demonstrated minimal utility to inform HCC screening decisions for patients with noncirrhotic SLD.
中文摘要:大多数脂肪性肝病(SLD)患者不会发展为晚期肝病。已提出多种用于SLD相关肝硬化和肝细胞癌(HCC)的风险评分,但其在指导晚期肝病监测决策方面的效用尚不明确。比较SLD风险评分在非肝硬化脂肪性肝病患者中预测肝硬化和肝细胞癌的临床效用。这项队列研究使用了美国国家退伍军人事务部医疗系统2008年至2020年间影像学确诊SLD、无病毒性肝炎或原发性肝病的成人数据。在首次影像学结果显示肝脂肪变时计算了九种临床风险评分。个体随访至发生肝硬化、HCC、死亡或末次随访后6个月。数据分析时间为2025年11月1日至2026年5月11日。评估用于预测10年内肝硬化或HCC的九种风险评分为:(1)ALBI,白蛋白-胆红素;(2)aMAP,年龄-男性-白蛋白-胆红素-血小板;(3)APRI,天冬氨酸氨基转移酶与血小板比值;(4)BARD,体重指数、年龄、丙氨酸氨基转移酶与天冬氨酸氨基转移酶比值及糖尿病;(5)FIB-4,纤维化-4指数;(6)NFS,非酒精性脂肪性肝病纤维化评分;(7)SAFE,脂肪变性相关纤维化估算器;以及另外2种评分。采用VA和Medicare诊断代码以及VA癌症登记处数据确定首次肝硬化诊断和首次HCC诊断。使用Cox比例风险模型计算九种风险评分预测的各结局10年时依概率。通过计算净获益生成各结局的决策曲线;净获益是在预先设定的临床医生可能合理推荐干预的风险阈值范围内,对真阳性和假阳性的加权衡量。使用九种风险量表量化10年内肝硬化或HCC风险。分析纳入853 131例患者(中位[IQR]年龄,61[51-68]岁;62 168例女性[7.3%]和790 965例男性[92.7%]),其中位(IQR)BMI为31.3(27.6-35.5),275 898例(32.3%)患有糖尿病;其中,33 794例(3.96%)在10年内发生肝硬化,2978例(0.35%)发生HCC。FIB-4、APRI和SAFE评分对肝硬化风险的区分度最大,而SAFE、Tate和FIB-4评分对HCC风险的区分度最大。SAFE评分在预测肝硬化方面显示出最大净获益。29.5分对应10年肝硬化风险2.5%,净获益为0.019,即每100名被归类为风险患者的人中,额外有1.9人发生肝硬化。在10年HCC风险0.25%时,SAFE评分的净获益为0.0016(每1000人中额外1.6名真阳性)。这项队列研究的结果表明,SAFE评分可能有助于指导SLD患者重复筛查肝硬化的决策。HCC临床风险评分在指导非肝硬化SLD患者的HCC筛查决策方面效用极小。
Patients with immune tolerant (IT) chronic hepatitis B (CHB) have high viral loads, minimal inflammation and minimal fibrosis. Nevertheless, the benign nature of this phase and the need for antiviral therapy remain controversial. We explored the natural history of IT patients by assessing the risk of transition to immune active (IA) disease, fibrosis progression and hepatocellular carcinoma (HCC). This international multicentre study from the RADICAL consortium includes mono-infected patients with CHB from sites around the world. The IT-phase was strictly defined as persistently (1) hepatitis B e-antigen (HBeAg)-positive, (2) alanine aminotransferase (ALT) ≤40 U/L, (3) HBV DNA >7 log10 IU/mL and (4) F0-1 during the first year after baseline. We assessed the probabilities of transition to IA disease (ALT ≥50 U/L), the risk of significant fibrosis (≥F2) and HCC. In total, 951 IT patients were included with a median age of 33, 40% were male with a median follow-up of 13 years. Median ALT and HBV DNA at baseline were 25.5 U/L and 8.4 log10 IU/mL.The probability of transitioning to IA disease was 51%, 67% and 72% before 5 years, 10 years and 15 years. A high-normal ALT was associated with an increased risk of IA disease (subdistribution hazard ratio (sHR): 20-30 U/L: 1.744, p<0.001, sHR: >30U/L: 3.130, p<0.001). IT patients had a low risk of progression to significant fibrosis (15 years: 6.3%), and HCC (15 years: 1.1%). The majority of this large cohort of well-defined IT patients transition to IA disease within 5 years of follow-up, with the highest risk observed in those with a high-normal ALT, suggesting that these patients may benefit from either more frequent monitoring or pre-emptive therapy.
中文摘要:免疫耐受(IT)期慢性乙型肝炎(CHB)患者病毒载量高、炎症轻微且纤维化轻微。然而,该阶段的良性性质以及是否需要抗病毒治疗仍存争议。我们通过评估向免疫活动(IA)期疾病转变的风险、纤维化进展和肝细胞癌(HCC)风险,探讨IT患者的自然史。这项来自RADICAL联盟的国际多中心研究纳入全球多个中心感染单一CHB的患者。IT期严格定义为基线后第一年内持续满足:(1)乙型肝炎e抗原(HBeAg)阳性,(2)丙氨酸氨基转移酶(ALT)≤40 U/L,(3)HBV DNA >7 log10 IU/mL,(4)F0-1。我们评估了向IA期疾病转变(ALT ≥50 U/L)的概率、显著纤维化(≥F2)风险和HCC风险。共纳入951例IT患者,中位年龄33岁,40%为男性,中位随访13年。基线ALT和HBV DNA中位数分别为25.5 U/L和8.4 log10 IU/mL。向IA期疾病转变的概率在5年、10年和15年前分别为51%、67%和72%。高正常ALT与IA期疾病风险增加相关(亚分布风险比(sHR):20-30 U/L:1.744,p<0.001;sHR:>30 U/L:3.130,p<0.001)。IT患者进展为显著纤维化的风险低(15年:6.3%),HCC风险也低(15年:1.1%)。在这个定义明确的大型IT患者队列中,大多数患者在随访5年内转变为IA期疾病,高正常ALT者风险最高,提示这些患者可能从更频繁监测或抢先治疗中获益。
Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy, largely because early-stage symptoms are non-specific and diagnosis is often delayed. Although liquid biopsies (LBs) offer a promising non-invasive strategy for early detection, their clinical translation is hindered by substantial analytical limitations. This review examines the current landscape of nucleic acid-based liquid biopsy biomarkers for PDAC detection. We evaluate key limitations of established diagnostic methodologies, including next-generation sequencing (NGS) and droplet digital PCR (ddPCR). In complex biofluids, these approaches may be confounded by background signal and amplification artifacts, particularly when applied for the detection of ultra-rare targets. To address this diagnostic gap, we discuss the role of CRISPR-based biosensing and bioassay not as a replacement but as an additional specificity layer within existing diagnostic workflows. In this framework, CRISPR technologies can act as sequence-specific molecular filters that introduce an active post-amplification validation step. Although pre-analytical limitations remain to be fully characterized, integrating CRISPR into the diagnostic workflow may contribute to a rapid, cost-effective, and highly specific framework for the early detection of PDAC.
中文摘要:胰腺导管腺癌(PDAC)仍是一种高度致命的恶性肿瘤,主要因为早期症状不具特异性,且诊断常被延迟。尽管液体活检(LBs)为早期检测提供了一种有前景的非侵入性策略,但其临床转化受到显著分析局限性的阻碍。本综述探讨了用于PDAC检测的基于核酸的液体活检生物标志物的当前图景。我们评估了现有诊断方法的关键局限性,包括下一代测序(NGS)和微滴数字PCR(ddPCR)。在复杂生物流体中,这些方法可能受到背景信号和扩增伪影的干扰,尤其是在用于检测超罕见靶标时。为弥补这一诊断缺口,我们讨论了基于CRISPR的生物传感和生物测定在现有诊断工作流程中的作用,其并非作为替代,而是作为额外的特异性层。在这一框架中,CRISPR技术可作为序列特异性分子过滤器,引入主动的扩增后验证步骤。尽管分析前局限性仍有待充分表征,但将CRISPR整合到诊断工作流程中,可能有助于构建一个快速、成本效益高且高度特异的PDAC早期检测框架。
There is no clinically relevant blood-based assay for the detection of early-stage pancreatic ductal adenocarcinoma (PDAC), a solid malignancy characterized by poor outcomes. Here we developed, validated and tested a blood-based microRNA (miRNA) assay (which included hsa-miR-142-3p, hsa-miR-30c-5p, hsa-miR-335-5p, hsa-miR-340-5p, hsa-miR-200b-3p, hsa-miR-1260b, hsa-miR-145-3p, hsa-miR-145-5p, hsa-miR-429 and hsa-miR-200a-3p) and a composite score, PANXEON (PANcreatic cancer eXosome Early detectiON), that integrates the miRNA signature with carbohydrate antigen 19-9 for the detection of early-stage PDAC. We conducted an international, multicenter, observational, prospective biomarker study that involved 1,785 individuals with and without PDAC from four countries. The miRNA signature achieved an area under the receiver operating characteristic curve of 88.6% in the testing cohort, with a sensitivity of 83.8% for early-stage PDAC, while showing minimal cross-reactivity with other gastrointestinal cancers. In a cohort of 19 individuals, the miRNA signature levels decreased during neoadjuvant chemotherapy and after surgery and increased before disease recurrence. When combined with carbohydrate antigen 19-9 levels, this blood assay demonstrated a sensitivity of 86.8% for stage I-II PDAC, false-positive rates of 3.2% in low-risk controls and 15.6% in high-risk controls in the testing cohort. PANXEON demonstrates potential for detecting high-grade dysplasia in individuals with high-risk pancreatic cysts (64.3%). Collectively, we present a composite biomarker that may complement existing strategies for the detection of early-stage PDAC and warrants further large-scale prospective studies. ClinicalTrials.gov registration: NCT06388967 .
中文摘要:目前尚无临床适用的基于血液的检测方法用于早期胰腺导管腺癌(PDAC)的检测,这是一种预后较差的实体恶性肿瘤。在此,我们开发、验证并测试了一种基于血液的微小RNA(miRNA)检测方法(包括hsa-miR-142-3p、hsa-miR-30c-5p、hsa-miR-335-5p、hsa-miR-340-5p、hsa-miR-200b-3p、hsa-miR-1260b、hsa-miR-145-3p、hsa-miR-145-5p、hsa-miR-429和hsa-miR-200a-3p)以及一个复合评分PANXEON(PANcreatic cancer eXosome Early detectiON),该评分将miRNA特征与糖类抗原19-9整合,用于检测早期PDAC。我们开展了一项国际、多中心、观察性、前瞻性生物标志物研究,纳入了来自4个国家的1785例伴或不伴PDAC的个体。该miRNA特征在测试队列中达到88.6%的受试者工作特征曲线下面积,对早期PDAC的敏感性为83.8%,同时与其他胃肠道肿瘤的交叉反应极小。在一个19例个体的队列中,miRNA特征水平在新辅助化疗期间和手术后下降,并在疾病复发前升高。当与糖类抗原19-9水平联合时,该血液检测在测试队列中对I-II期PDAC的敏感性为86.8%,在低风险对照中的假阳性率为3.2%,在高风险对照中为15.6%。PANXEON在高风险胰腺囊肿个体中显示出检测高级别异型增生(64.3%)的潜力。总之,我们提出了一种复合生物标志物,可能补充现有早期PDAC检测策略,并值得进一步开展大规模前瞻性研究。ClinicalTrials.gov注册号:NCT06388967。
基础研究 (12篇)
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a highly aggressive phenotype and limited therapeutic options, primarily attributable to diagnostic delays and intrinsic chemotherapy resistance, thereby underscoring the critical need for the development of more effective therapeutic strategies. Tripterine (TP) is a natural compound with potent antitumor activity, but has shown limited clinical use due to its multi-organ toxicity. Here, we overcame this limitation by formulating TP into liposomes (TP-lipo). We evaluated the therapeutic potential of TP-lipo showing that TP-lipo exhibited antitumor activity in vitro (murine Pdx1-Cre/LSL-KrasG12D/+ /LSL-Trp53R172H/+ pancreatic cancer cells, KPC cells) and in vivo (PDAC mouse) models. TP-lipo reshaped the tumor immune microenvironment by promoting macrophage polarization toward the M1 phenotype, increasing the proportion of interferon-γ (IFN-γ)-secreting CD8+ T cells. In vitro, TP-lipo promoted IFN-γ and granzyme B production in CD8+ T cells, while TP-lipo-pretreated macrophages enhanced T-cell differentiation into cytotoxic T lymphocytes. Notably, combination therapy with TP-lipo and PD-1 antagonist exerted a synergistic antitumor effect and significantly prolonged median survival in PDAC-bearing mice. TP-lipo showed substantially lower toxicity than the free drug, highlighting its improved safety profile and therapeutic potential. Collectively, these findings suggest TP-lipo, particularly in combination with PD-1 blockade, as a promising therapeutic strategy for PDAC.
中文摘要:胰腺导管腺癌(PDAC)具有高度侵袭性表型和有限的治疗选择,主要归因于诊断延迟和内在化疗耐药,因此亟需开发更有效的治疗策略。雷公藤红素(Tripterine,TP)是一种具有强效抗肿瘤活性的天然化合物,但由于其多器官毒性,临床使用受限。在此,我们通过将TP制成脂质体(TP-lipo)克服了这一局限。我们评估了TP-lipo的治疗潜力,显示TP-lipo在体外(小鼠Pdx1-Cre/LSL-KrasG12D/+ /LSL-Trp53R172H/+胰腺癌细胞,KPC细胞)和体内(PDAC小鼠)模型中均表现出抗肿瘤活性。TP-lipo通过促进巨噬细胞向M1表型极化,增加分泌干扰素-γ(IFN-γ)的CD8+ T细胞比例,重塑了肿瘤免疫微环境。在体外,TP-lipo促进CD8+ T细胞产生IFN-γ和颗粒酶B,而经TP-lipo预处理的巨噬细胞增强T细胞分化为细胞毒性T淋巴细胞。值得注意的是,TP-lipo与PD-1拮抗剂联合治疗发挥了协同抗肿瘤作用,并显著延长了荷PDAC小鼠的中位生存期。TP-lipo的毒性明显低于游离药物,突显了其改善的安全性特征和治疗潜力。总之,这些发现表明TP-lipo,特别是与PD-1阻断联合,是PDAC的一种有前景的治疗策略。
Multiple strategies to target RAS are now available to treat pancreatic cancer. As pancreatic precancers also have KRAS mutations, these tools hold great promise for cancer interception.
中文摘要:目前已有多种靶向RAS的策略可用于治疗胰腺癌。由于胰腺癌前病变也存在KRAS突变,这些工具在癌症拦截方面具有巨大前景。
Repeated Phase 3 failures have framed proficient mismatch repair/microsatellite stable colorectal cancer as 'cold' and immunotherapy-resistant. We argue that this resistance is conditional, shaped by disease stage, metastatic anatomy, spatial immune architecture, and therapeutic mechanism. Recognizing these principles can guide patient selection, biomarker stratification, and drug development to realize immunotherapy's clinical potential.
中文摘要:反复出现的III期试验失败,使错配修复功能完整/微卫星稳定型结直肠癌被定义为「冷」肿瘤且对免疫治疗耐药。我们认为,这种耐药是有条件的,受疾病分期、转移解剖部位、空间免疫结构和治疗机制的影响。认识这些原则可指导患者选择、生物标志物分层和药物开发,从而实现免疫治疗的临床潜力。
The efficacy of photothermal therapy (PTT) mediated immunotherapy against tumor recurrence and metastasis is limited by inherent cellular thermoresistance and weak immune activation. To address this, we developed an accelerated immunomodulatory matrix reservoir (AIMR) integrating methylgermanane nanosheets (mGeNS) within an active Ca2 +-crosslinked alginate hydrogel. As an emerging 2D material, mGeNS exhibits exceptional drug-loading capacity and robust near-infrared (NIR) photothermal conversion (efficiency > 60%). Importantly, the hydrogel matrix effectively shields these biodegradable nanosheets from premature in vivo clearance. Upon NIR irradiation, localized hyperthermia softens the hydrogel, triggering the co-release of Ca2+ and an mGeNS-delivered immunogenic cell death (ICD) inducer (doxorubicin, DOX). This heat stimulation promotes intracellular Ca2+ influx, causing mitochondrial dysfunction that downregulates thermoprotective heat shock proteins (e.g., HSP70), thereby sensitizing tumor cells and amplifying PTT‑mediated endoplasmic reticulum stress. Such a synergistic strategy boosts ICD accompanied by the release of numerous damage-associated molecular patterns for dendritic cell maturation and CD8+ T cell activation. In murine bilateral tumor models, AIMR achieved > 80% local tumor suppression and a 2.43-fold increase in abscopal immune memory over 60 days compared to surgery alone. By synergizing novel 2D mGeNS with active thermosensitive hydrogel, AIMR provides a dual-organelle stress platform for durable photoimmunotherapy.
中文摘要:光热疗法(PTT)介导的免疫治疗对抗肿瘤复发和转移的疗效受到固有细胞耐热性和免疫激活较弱的限制。为此,我们开发了一种加速免疫调节基质储库(AIMR),将甲基锗烷纳米片(mGeNS)整合到活性Ca2+交联的海藻酸盐水凝胶中。作为一种新兴二维材料,mGeNS具有优异的载药能力和强大的近红外(NIR)光热转换能力(效率>60%)。重要的是,水凝胶基质可有效保护这些可生物降解纳米片免于在体内被过早清除。在NIR照射下,局部高温使水凝胶软化,触发Ca2+和mGeNS递送的免疫原性细胞死亡(ICD)诱导剂(多柔比星,DOX)共同释放。这种热刺激促进细胞内Ca2+内流,引起线粒体功能障碍,从而下调热保护性热休克蛋白(如HSP70),进而使肿瘤细胞增敏并放大PTT介导的内质网应激。这种协同策略增强ICD,并伴随大量损伤相关分子模式的释放,以促进树突状细胞成熟和CD8+ T细胞活化。在小鼠双侧肿瘤模型中,与单纯手术相比,AIMR在60天内实现>80%的局部肿瘤抑制以及2.43倍的远隔免疫记忆增加。通过将新型二维mGeNS与活性热敏水凝胶协同,AIMR为持久的光免疫治疗提供了一个双细胞器应激平台。
Ovarian and gastric cancers are associated with poor prognosis and derive limited benefit from current therapies, highlighting the need for novel immunotherapeutic approaches. The L1 cell adhesion molecule (L1CAM) is aberrantly expressed in several types of solid tumors and is associated with aggressive clinical behavior. This study aimed to develop and characterize optimized L1CAM-targeted chimeric antigen receptor-T (CAR-T) cells with improved efficacy and safety, using patient-derived preclinical models of ovarian and gastric cancer. L1CAM expression was assessed in tumor tissues from patients with ovarian cancer (OC;n=227) and gastric cancer (GC;n=132), followed by an analysis of its clinical impact. A panel of L1CAM-targeted CAR constructs incorporating distinct hinge and co-stimulatory domains was systematically evaluated. Functional activity was assessed by cytotoxicity and cytokine release assays using cancer cell lines and patient-derived tumor cells. Antitumor efficacy, persistence, and safety were evaluated in xenograft and patient-derived xenograft (PDX) models, including NanoLuc-based in vivo tracking of CAR-T cell distribution. High L1CAM expression correlated with aggressive clinicopathological features and adverse prognosis in patients with OC. Among the constructs tested, CAR-T cells incorporating an IgD/IgG1 hybrid hinge and dual CD28-ICOS co-stimulatory domains demonstrated the most potent antigen-specific activity. These cells exhibited enhanced cytotoxicity, robust interferon-γ production, and sustained functional activity. In vivo, optimized L1CAM CAR-T cells achieved complete tumor regression in OC PDX models and significant tumor suppression in GC models, with durable tumor control and CAR-T persistence. Intraperitoneal delivery further improved therapeutic efficacy and CAR-T cell localization compared with intravenous administration. Importantly, no evidence of neurotoxicity or systemic toxicity was observed, supporting a favorable safety profile. Optimized L1CAM-targeted CAR-T cells demonstrate potent, durable, and antigen-specific antitumor activity with a favorable safety profile in preclinical models of OC and GC. The combination of rational CAR design (CD28-ICOS signaling) and optimized delivery strategy provides a strong rationale for the clinical development of L1CAM-targeted CAR-T therapy, particularly in patients with L1CAM-positive solid tumors.
中文摘要:卵巢癌和胃癌预后较差,现有治疗获益有限,因此亟需新型免疫治疗策略。L1细胞黏附分子(L1CAM)在多种实体瘤中异常表达,并与侵袭性临床行为相关。本研究旨在利用卵巢癌和胃癌的患者来源临床前模型,开发并表征经优化的L1CAM靶向嵌合抗原受体T细胞(CAR-T),以提高疗效和安全性。研究评估了卵巢癌(OC;n=227)和胃癌(GC;n=132)患者肿瘤组织中的L1CAM表达,并分析其临床影响。随后系统评价了一组包含不同铰链和共刺激结构域的L1CAM靶向CAR构建体。使用癌细胞系和患者来源肿瘤细胞,通过细胞毒性和细胞因子释放试验评估功能活性。在异种移植和患者来源异种移植(PDX)模型中评估抗肿瘤疗效、持久性和安全性,包括基于NanoLuc的CAR-T细胞分布体内追踪。在OC患者中,高L1CAM表达与侵袭性临床病理特征和不良预后相关。在测试的构建体中,包含IgD/IgG1杂合铰链和双CD28-ICOS共刺激结构域的CAR-T细胞表现出最强的抗原特异性活性。这些细胞显示出增强的细胞毒性、稳健的干扰素-γ产生以及持续的功能活性。在体内,优化的L1CAM CAR-T细胞在OC PDX模型中实现肿瘤完全消退,在GC模型中显著抑制肿瘤,并具有持久的肿瘤控制和CAR-T持久性。与静脉给药相比,腹腔内递送进一步提高了治疗效果和CAR-T细胞定位。重要的是,未观察到神经毒性或全身毒性的证据,支持其良好的安全性。优化的L1CAM靶向CAR-T细胞在OC和GC临床前模型中表现出强效、持久且抗原特异性的抗肿瘤活性,并具有良好的安全性。合理的CAR设计(CD28-ICOS信号)与优化的递送策略相结合,为L1CAM靶向CAR-T疗法的临床开发提供了有力依据,尤其是在L1CAM阳性实体瘤患者中。
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most prevalent chronic liver disease worldwide, affecting approximately one-third of the global adult population, acting as the primary driver of cirrhosis and hepatocellular carcinoma. Despite its growing incidence and substantial clinical and socioeconomic toll, clinical treatment of MASLD remains severely limited by the absence of U.S. Food and Drug Administration (FDA)-approved pharmacotherapies, suboptimal hepatic targeting of existing agents, off-target adverse effects, and limited infiltration into the fibrotic hepatic microenvironment. Nanomedicine has emerged as a promising strategy to address these limitations and advance precision treatment for chronic liver diseases, yet a systematic review unifying the multifactorial pathogenesis of MASLD, rational target selection, and advanced nanoplatform development remains lacking. Herein, we systematically elaborate the multi-hit pathogenic cascade of MASLD, covering metabolic imbalance, oxidative and inflammatory injury, aberrant programmed cell death, inter-organ signaling crosstalk, and fibrogenic transformation, with a focus on recently identified mechanisms, including single-cell transcriptomic heterogeneity and epigenetic regulation. We further clinically translatable therapeutic targets, and comprehensively summarize the rational design, structure-activity relationships, hepatic targeted delivery strategies, therapeutic outcomes, and underlying molecular mechanisms of state-of-the-art nanosystems. Moreover, we evaluate preclinical achievements and dissect core translational obstacles and highlight future frontiers, including artificial intelligence-assisted nanodesign, theranostic integration, and oral liver-targeted nanosystems.
中文摘要:代谢功能障碍相关脂肪性肝病(MASLD)是全球最常见的慢性肝病,影响约三分之一的全球成年人口,是肝硬化和肝细胞癌的主要驱动因素。尽管其发病率不断上升,并造成沉重的临床和社会经济负担,MASLD的临床治疗仍严重受限,原因包括缺乏美国食品药品监督管理局(FDA)批准的药物疗法、现有药物肝脏靶向性欠佳、脱靶不良反应以及向纤维化肝脏微环境渗透有限。纳米医学已成为应对这些局限并推动慢性肝病精准治疗的有前景策略,然而,尚缺乏将MASLD多因素发病机制、合理靶点选择和先进纳米平台开发统一起来的系统性综述。在此,我们系统阐述MASLD的多重打击致病级联,涵盖代谢失衡、氧化与炎症损伤、异常程序性细胞死亡、器官间信号串扰和纤维化转化,并重点关注近期发现的机制,包括单细胞转录组异质性和表观遗传调控。我们进一步梳理具有临床转化潜力的治疗靶点,并全面总结最先进纳米系统的合理设计、构效关系、肝脏靶向递送策略、治疗结果及其潜在分子机制。此外,我们评估临床前成果,剖析核心转化障碍,并强调未来前沿方向,包括人工智能辅助纳米设计、诊疗一体化以及口服肝靶向纳米系统。
Inefficient clearance of tumor-associated cellular debris sustains chronic inflammation and reinforces tumor-promoting immune niches in the colorectal cancer (CRC), yet strategies to selectively enhance macrophage-mediated cellular debris clearance remain largely unexplored. Here, we engineered a dual-targeted oral nanoplatform based on probiotic-derived extracellular vesicles (EVs) for selective delivery of astaxanthin (AXT-EVs) to tumor-associated macrophages (TAMs) in inflamed colonic tissues. Following oral administration, AXT-EVs preferentially accumulated within TAMs and induced functional reprogramming toward enhanced inflammatory debris resolution. Internalized AXT downregulates bridging integrin 2 (BIN2), a previously unrecognized negative regulator of macrophage phagocytic remodeling, thereby restoring macrophage-mediated clearance of tumor-associated cellular debris and disrupting debris-driven inflammatory amplification. In murine CRC models, AXT-EVs significantly inhibited tumor progression, alleviated intestinal inflammation and restored epithelial barrier integrity. Our findings identify defective macrophage debris clearance as a therapeutically targetable driver of colorectal tumorigenesis and establish a probiotic nanovesicle-based strategy as an immune-modulating platform for restoring tissue clearance homeostasis.
中文摘要:肿瘤相关细胞碎片清除效率低下会维持慢性炎症,并强化结直肠癌(CRC)中促瘤免疫龛,然而选择性增强巨噬细胞介导的细胞碎片清除的策略仍基本未被探索。在此,我们构建了一种基于益生菌来源细胞外囊泡(EVs)的双靶向口服纳米平台,用于将虾青素(AXT-EVs)选择性递送至炎症结肠组织中的肿瘤相关巨噬细胞(TAMs)。口服给药后,AXT-EVs优先在TAMs内蓄积,并诱导其功能重编程,从而增强炎症性碎片的清除。内化的AXT下调桥接整合素2(BIN2)——一个此前未被认识的巨噬细胞吞噬重塑负调控因子,从而恢复巨噬细胞介导的肿瘤相关细胞碎片清除,并打断碎片驱动的炎症放大环路。在小鼠CRC模型中,AXT-EVs显著抑制肿瘤进展,减轻肠道炎症并恢复上皮屏障完整性。我们的发现将巨噬细胞碎片清除缺陷确定为结直肠肿瘤发生中可治疗干预的驱动因素,并确立了一种基于益生菌纳米囊泡的策略,作为恢复组织清除稳态的免疫调节平台。
Liver diseases are hepatic pathological changes caused by a variety of pathogenic factors, including viral hepatitis, alcoholic liver disease (ALD), metabolic dysfunction-associated steatotic liver disease (MASLD), cirrhosis, and hepatocellular carcinoma (HCC), etc. The characteristics of liver diseases are steatosis, hepatocyte ballooning, and immune cell infiltration. Among these immune cells, neutrophils are important immune cells in innate immunity. Under hepatic pathological conditions, neutrophils can produce neutrophil extracellular traps (NETs) under the stimulation of various factors, such as viral infections, metabolic disorders, toxic exposures, etc. Accumulating evidence has shown that NETs can interact with multiple signaling pathways and immune cells, regulate hepatic inflammatory responses, remodel the hepatic immune microenvironment, and promote the activation of hepatic stellate cells (HSCs). This review expounds the mechanism of NETs in various liver diseases, and the compounds or drugs that have been discovered or applied for the treatment of liver diseases by targeting NETs. This review enriches the pathogenesis of liver diseases and provides a theoretical basis and research directions for targeted therapeutic strategies.
中文摘要:肝脏疾病是由多种致病因素引起的肝脏病理改变,包括病毒性肝炎、酒精性肝病(ALD)、代谢功能障碍相关脂肪性肝病(MASLD)、肝硬化和肝细胞癌(HCC)等。肝脏疾病的特征为脂肪变性、肝细胞气球样变和免疫细胞浸润。在这些免疫细胞中,中性粒细胞是先天性免疫中的重要免疫细胞。在肝脏病理条件下,中性粒细胞可在病毒感染、代谢紊乱、毒性暴露等多种因素刺激下产生中性粒细胞胞外诱捕网(NETs)。越来越多证据表明,NETs可与多种信号通路和免疫细胞相互作用,调节肝脏炎症反应,重塑肝脏免疫微环境,并促进肝星状细胞(HSCs)活化。本综述阐述了NETs在多种肝脏疾病中的机制,以及已发现或应用于通过靶向NETs治疗肝脏疾病的化合物或药物。本综述丰富了肝脏疾病的发病机制,并为靶向治疗策略提供了理论基础和研究方向。
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of hepatocellular carcinoma (HCC), but how metabolic zonation drives regional transformation remains unclear. We identify sirtuin 2 (SIRT2) as a zonated cholesterol sensor that initiates reprogramming to drive MASLD-HCC. Lineage tracing establishes zone 1 hepatocytes as the cellular origin of tumors. SIRT2 overexpression in zone 1 triggers HCC, whereas its deletion prevents carcinogenesis by restoring cholesterol and bile acid metabolism and CD8+ T cell recruitment. Mechanistically, cholesterol binds and activates SIRT2, which deacetylates sterol carrier protein 2 (SCP2) at Lys546, thereby blocking peroxisome proliferator-activated receptor α (PPARα) recruitment to the Cyp7b1 promoter, suppressing alternative bile acid synthesis, and permitting 27-hydroxycholesterol accumulation. SIRT2 inhibition reverses this cascade in mice and human hepatic organoids. Patient specimens confirm zonal SIRT2 and cytochrome P450 7B1 (CYP7B1) dysregulation. Our findings establish spatially compartmentalized cholesterol sensing as a new regulatory layer and identify SIRT2 as a druggable target in liver cancer.
中文摘要:代谢功能障碍相关脂肪性肝病(MASLD)是肝细胞癌(HCC)的主要原因,但代谢分区如何驱动区域性转化仍不清楚。我们确定sirtuin 2(SIRT2)是一种分区化的胆固醇感受器,可启动重编程以驱动MASLD-HCC。谱系示踪证实1区肝细胞是肿瘤的细胞起源。1区SIRT2过表达可触发HCC,而其缺失可通过恢复胆固醇和胆汁酸代谢以及CD8+ T细胞募集来阻止癌变。机制上,胆固醇结合并激活SIRT2,后者使固醇载体蛋白2(SCP2)在Lys546位点去乙酰化,从而阻断过氧化物酶体增殖物激活受体α(PPARα)募集至Cyp7b1启动子,抑制替代性胆汁酸合成,并允许27-羟基胆固醇积累。在小鼠和人肝类器官中抑制SIRT2可逆转这一级联反应。患者标本证实了分区化的SIRT2和细胞色素P450 7B1(CYP7B1)失调。我们的发现确立了空间区室化的胆固醇感知作为一种新的调控层,并将SIRT2确定为肝癌中可成药的靶点。
``Single-cell and spatial atlases describe the healthy and diseased liver at high resolution, including lobular hepatocyte zonation, fibrotic macrophage-stellate niches, cholangiocyte reactions, immune remodeling, and hepatocellular carcinoma ecosystems. These maps show where cell states occur but do not, by themselves, predict whether liver injury will progress or how the liver will respond to an untested drug, toxicant, or genetic perturbation. In this review, we organize current approaches toward an AI Virtual Cell (AIVC) for the liver into three complementary modeling routes. Generative models represent cell states, dynamics and transport models infer state transitions, and pretrained or foundation models test whether learned representations transfer across donors, etiologies, disease stages, and platforms. Perturbation-response prediction serves as a cross-cutting assessment of whether these layers can predict responses to untested genetic, chemical, inflammatory, or metabolic interventions. Available evidence can be categorized as direct liver validation, liver-included benchmarks, general single-cell evidence, and conceptual applications. Published models demonstrate individual components, including atlas integration, inferred trajectories, transferable representations, and retrospective response programs. However, these models do not constitute a prospectively validated liver simulator. At minimum, evaluation should include donor-, etiology-, stage-, platform-, and perturbation-level hold-outs. Model performance should be reported using response direction, recovery of differentially expressed genes and rare states, and calibrated uncertainty. Claims about tissue- or function-level prediction additionally require independent spatial, histologic, metabolic, and functional readouts. Near-term use should prioritize experiment selection and hypothesis generation, whereas clinical decision support remains a longer-term objective.
中文摘要:单细胞与空间图谱以高分辨率描绘健康与患病肝脏,包括肝小叶肝细胞分区、纤维化巨噬细胞-星状细胞生态位、胆管细胞反应、免疫重塑和肝细胞癌生态系统。这些图谱显示了细胞状态发生的位置,但其本身并不能预测肝损伤是否会进展,也不能预测肝脏将如何对未经测试的药物、毒物或遗传扰动作出反应。在本综述中,我们将面向肝脏的人工智能虚拟细胞(AIVC)的当前方法组织为三条互补的建模路线。生成模型表征细胞状态,动力学与运输模型推断状态转换,预训练或基础模型检验所学表征能否跨供者、病因、疾病阶段和平台迁移。扰动响应预测作为一项交叉评估,检验这些层次能否预测对未经测试的遗传、化学、炎症或代谢干预的响应。现有证据可分为直接肝脏验证、纳入肝脏的基准测试、一般单细胞证据和概念性应用。已发表模型展示了各个单独组成部分,包括图谱整合、推断轨迹、可迁移表征和回顾性响应程序。然而,这些模型尚不构成经前瞻性验证的肝脏模拟器。至少,评估应包括供者、病因、阶段、平台和扰动层面的留出。模型性能应通过响应方向、差异表达基因和稀有状态的恢复情况以及校准的不确定性来报告。关于组织或功能层面预测的主张,还需要独立的空间、组织学、代谢和功能读出。近期应用应优先考虑实验选择和假设生成,而临床决策支持仍是较长期目标。
Cancer cells must deal with excessive reactive oxygen species (ROS) to survive severe hypoxia and anticancer therapy; however, anti-ROS mechanisms other than the well-known NFE2L2/NRF2 signaling pathway are poorly recognized. Here, we report a ROS scavenging mechanism mediated by HIF1α-KLF4-induced hemoglobin extraerythrocytically expressed in hepatocellular carcinoma (HCC). We found that the ROS pathway was aberrantly activated in HCC and was associated with hemoglobin upregulation, which independently predicts poor outcomes. Network analysis further identified heme binding as the top ROS-associated functional module, suggesting a previously unrecognized role of hemoglobin in maintaining redox homeostasis in HCC. Hemoglobin expression in cancer cells is transcriptionally controlled by HIF1α via KLF4 but not HIF2α or the recently identified KDM5A-KLF1 signaling. The upregulated hemoglobin counteracts the detrimental effects of oxidative stress by scavenging ROS, promoting sorafenib resistance, which could be effectively reversed by interfering with hemoglobin expression, leading to tumor suppression. Both in vitro and in vivo experiments consistently supported the functional importance of hemoglobin in regulating oxidative stress adaptation and therapeutic response. Overall, a previously unrecognized mechanism was identified for cancer cell survival under oxidative stress, where HIF1α-KLF4 signaling induces hemoglobin to scavenge ROS produced during hypoxia and anticancer therapy, providing a promising target of synthetic lethality for cancer therapeutics.
中文摘要:癌细胞必须应对过量的活性氧(ROS)才能在严重缺氧和抗癌治疗中存活;然而,除众所周知的NFE2L2/NRF2信号通路外,其他抗ROS机制仍知之甚少。在此,我们报道了一种由HIF1α-KLF4诱导的血红蛋白在肝细胞癌(HCC)中红细胞外表达所介导的ROS清除机制。我们发现ROS通路在HCC中异常激活,并与血红蛋白上调相关,而血红蛋白上调可独立预测不良结局。网络分析进一步确定血红素结合是最主要的ROS相关功能模块,提示血红蛋白在维持HCC氧化还原稳态中具有此前未被认识的作用。癌细胞中的血红蛋白表达由HIF1α通过KLF4转录控制,而非HIF2α或最近发现的KDM5A-KLF1信号。上调的血红蛋白通过清除ROS来抵消氧化应激的有害效应,促进索拉非尼耐药,而干扰血红蛋白表达可有效逆转这一耐药,导致肿瘤抑制。体外和体内实验均一致支持血红蛋白在调控氧化应激适应和治疗反应中的功能重要性。总体而言,我们发现了癌细胞在氧化应激下存活的一种此前未被认识的机制,其中HIF1α-KLF4信号诱导血红蛋白以清除缺氧和抗癌治疗过程中产生的ROS,为癌症治疗提供了一个有前景的合成致死靶点。
Adult neuronal survival underlies lifelong brain function, yet its sustaining mechanisms remain unclear. We identify a neurovascular survival axis at intracranial arteries in mice, where superior cervical ganglion (SCG) sympathetic terminals form synapse-like neurosmooth muscular junctions (NsMJs) with arterial smooth muscle cells (aSMCs) that secrete netrin-4 (Ntn4). Adult aSMC-restricted Ntn4 deletion selectively reduces rostral, intracranial-projecting (cerebrospinal fluid-traced) SCG neurons; the denervation of the intracranial arterial plexus follows soma loss. Local recombinant Ntn4 delivery to the SCG rescues these phenotypes. Ntn4 withdrawal engages a receptor-interacting serine/threonine kinase 1 (RIPK1)/mixed lineage kinase domain-like pseudokinase (MLKL)-linked, caspase-independent, non-inflammatory death program via deleted in colorectal cancer (DCC): unliganded DCC triggers neuronal loss, whereas Dcc knockout preserves vulnerable neurons. Arterial Ntn4 declines from young adulthood and precedes selective neuronal attrition before midlife; aSMC-targeted Ntn4 overexpression prevents this loss. Together, intracranial arteries provide a local, non-cell-autonomous trophic niche that maintains this adult sympathetic subset and becomes compromised as vascular Ntn4 output wanes with age.
中文摘要:成人神经元的存活是终生脑功能的基础,但其维持机制仍不清楚。我们在小鼠颅内动脉发现了一条神经血管生存轴,其中颈上神经节(SCG)交感神经末梢与动脉平滑肌细胞(aSMC)形成突触样神经平滑肌连接(NsMJs),而aSMC分泌netrin-4(Ntn4)。成人aSMC限制性Ntn4缺失选择性地减少吻侧、投射至颅内的(经脑脊液示踪)SCG神经元;颅内动脉丛的失神经支配随后于胞体丢失。向SCG局部递送重组Ntn4可挽救这些表型。Ntn4撤除通过结直肠癌缺失基因(DCC)启动一种与受体相互作用丝氨酸/苏氨酸激酶1(RIPK1)/混合谱系激酶结构域样假激酶(MLKL)相关、不依赖caspase且非炎性的死亡程序:未配体化的DCC触发神经元丢失,而Dcc敲除可保留易损神经元。动脉Ntn4从成年早期开始下降,并先于中年之前的选择性神经元丧失;靶向aSMC的Ntn4过表达可防止这种丢失。总之,颅内动脉提供了一个局部的、非细胞自主性的营养龛,维持这一成人交感神经亚群,并随着血管Ntn4输出随年龄减弱而受损。
5肿瘤基础/转化 (12篇)
基础研究 (12篇)
Ferroptosis, a regulated form of cell death driven by lipid peroxide accumulation, is crucial in tumor development and controlled by Glutathione Peroxidase 4 (GPX4). Targeting ferroptosis offers a promising cancer therapy approach but remains challenging. Here we show that Protein Arginine Methyltransferase 1 (PRMT1) is highly expressed in breast cancer and forms a transcriptional activation complex with Y-box binding protein 1 (YBX1). This complex binds the GPX4 promoter, suppressing ferroptosis and promoting breast cancer growth and metastasis. YBX1 recruits PRMT1 independently of its enzymatic activity, while PRMT1's methyltransferase function activates transcription via H4R3me2a modification. Combined treatment with MS023 (a type I PRMT inhibitor targeting PRMT1) and SU056 (a YBX1 inhibitor) synergistically decreases GPX4 expression, enhances ferroptosis, and suppresses tumor growth. These findings establish the PRMT1-YBX1-GPX4 axis as a previously unrecognized transcriptional regulatory module and a promising therapeutic target for breast cancer.
中文摘要:铁死亡是一种由脂质过氧化物积累驱动的调节性细胞死亡形式,在肿瘤发生发展中至关重要,并受谷胱甘肽过氧化物酶4(GPX4)调控。靶向铁死亡提供了一种有前景的癌症治疗策略,但仍具挑战性。本研究表明,蛋白精氨酸甲基转移酶1(PRMT1)在乳腺癌中高表达,并与Y-box结合蛋白1(YBX1)形成转录激活复合物。该复合物结合GPX4启动子,抑制铁死亡并促进乳腺癌生长和转移。YBX1以不依赖其酶活性的方式招募PRMT1,而PRMT1的甲基转移酶功能通过H4R3me2a修饰激活转录。联合使用MS023(一种靶向PRMT1的I型PRMT抑制剂)和SU056(一种YBX1抑制剂)可协同降低GPX4表达、增强铁死亡并抑制肿瘤生长。这些发现确立了PRMT1-YBX1-GPX4轴是一种此前未被认识的转录调控模块,并是乳腺癌一个有前景的治疗靶点。
Distant metastasis is the leading cause of death in colorectal cancer (CRC), and the gut vascular barrier (GVB) is the first obstacle to hematogenous spread. To investigate whether GVB function is directly influenced by metastasis-associated bacteria, we analyzed two cohorts comprising 20 healthy controls, 82 non-metastatic CRC patients, and 65 patients with liver or lung metastases. Multi-omics approaches (metagenomic sequencing and single-cell RNA sequencing) and gnotobiotic mouse models were employed to examine gut microbes that are linked to GVB disruption and metastasis. Patients with CRC liver metastasis exhibited impaired GVB and bacterial colonization at metastatic sites. Eggerthella lenta was enriched in patients with elevated expression of plasmalemmal vesicle-associated protein-1 (PV-1), a GVB injury marker, and its abundance was correlated with metastasis and recurrence. In vitro and in vivo, E. lenta compromised endothelial tight junction and GVB integrity, enhancing CRC cell migration and liver metastasis. Mechanistically, E. lenta adhered to endothelial cells and activated endoplasmic reticulum (ER) stress via a TLR4-dependent pathway, promoting autophagy and apoptosis. The knockdown of PERK attenuated ER stress, prevented autophagy and apoptosis, and downregulated the expression of ZO-1 and Claudin-5 induced by E. lenta. These findings highlight the clinical potential of microbiota-targeted strategies and PERK inhibition in the treatment of E. lenta-associated CRC metastasis.
中文摘要:远处转移是结直肠癌(CRC)死亡的首要原因,而肠道血管屏障(GVB)是血行播散的第一道障碍。为探究GVB功能是否直接受转移相关细菌影响,我们分析了两个队列,包括20名健康对照、82名非转移性CRC患者和65名肝或肺转移患者。采用多组学方法(宏基因组测序和单细胞RNA测序)及悉生小鼠模型,检查与GVB破坏和转移相关的肠道微生物。CRC肝转移患者表现出GVB受损和转移部位细菌定植。Eggerthella lenta在质膜囊泡相关蛋白-1(PV-1,一种GVB损伤标志物)表达升高的患者中富集,其丰度与转移和复发相关。在体外和体内,E. lenta损害内皮紧密连接和GVB完整性,增强CRC细胞迁移和肝转移。机制上,E. lenta黏附于内皮细胞,并通过TLR4依赖途径激活内质网(ER)应激,促进自噬和凋亡。敲低PERK可减弱ER应激,阻止自噬和凋亡,并下调由E. lenta诱导的ZO-1和Claudin-5表达。这些发现突显了微生物群靶向策略和PERK抑制在治疗E. lenta相关CRC转移中的临床潜力。
Poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) induce regressions and extend progression-free survival (PFS) in ovarian cancer, especially in tumors with BRCA1 or BRCA2 mutations that impair homologous recombination repair. While recent studies have clarified the key roles of BRCA1, BRCA2, and PARP1 in replication fork stability, the downstream mechanisms that mediate PARPi-induced cytotoxicity and resistance remain incompletely understood. Here we delineate cell fate outcomes following PARPi treatment in homologous recombination-deficient high-grade serous ovarian cancer and identify actionable pathways to overcome acquired resistance. Our findings reveal that PARPi-induced DNA damage simultaneously triggers apoptosis, which primarily occurs through the BAX/BAK-dependent intrinsic apoptotic pathway, while also driving cellular senescence, as manifested by the expression of senescence-associated β-galactosidase, CDKN1A upregulation and a senescence-associated secretory phenotype. Notably, the PARPi-induced senescent cells persist as resistance develops and exhibit multinucleation, a hallmark of nuclear atypia, both in vitro and in patient-derived xenografts (PDXs). Building on the observation that the anti-apoptotic protein BCLXL restrains pro-apoptotic BCL2 family members after PARPi treatment, we show that addition of the BCLXL inhibitor A-1155463 to PARPi therapy diminishes resistance in multiple high-grade serous ovarian cancer cell lines in vitro and significantly enhances PARPi-induced tumor response in a PDX model with acquired PARPi resistance in vivo. Overall, these preclinical findings strongly support the potential of combining BH3 mimetics with PARPis to treat resistant ovarian cancer.
中文摘要:聚(ADP-核糖)聚合酶(PARP)抑制剂(PARPi)可诱导卵巢癌肿瘤消退并延长无进展生存期(PFS),尤其是在BRCA1或BRCA2突变导致同源重组修复受损的肿瘤中。尽管近期研究已阐明BRCA1、BRCA2和PARP1在复制叉稳定性中的关键作用,但介导PARPi诱导的细胞毒性与耐药的下游机制仍不完全清楚。在此,我们描绘了同源重组缺陷型高级别浆液性卵巢癌中PARPi治疗后的细胞命运结局,并确定了克服获得性耐药的可干预通路。我们的研究发现,PARPi诱导的DNA损伤同时触发凋亡,凋亡主要通过BAX/BAK依赖的内在凋亡通路发生,同时还驱动细胞衰老,表现为衰老相关β-半乳糖苷酶表达、CDKN1A上调以及衰老相关分泌表型。值得注意的是,PARPi诱导的衰老细胞在耐药形成过程中持续存在,并在体外和患者来源异种移植(PDX)中均表现出多核化,这是核异型性的标志。基于抗凋亡蛋白BCLXL在PARPi治疗后抑制促凋亡BCL2家族成员的观察,我们显示将BCLXL抑制剂A-1155463加入PARPi治疗可在体外降低多种高级别浆液性卵巢癌细胞系的耐药性,并在体内显著增强PARPi对已获得PARPi耐药的PDX模型的肿瘤反应。总体而言,这些临床前发现有力支持将BH3模拟物与PARPi联合用于治疗耐药卵巢癌的潜力。
Ferroptosis is a regulated, iron-dependent form of cell death characterized by the unchecked peroxidation of polyunsaturated phospholipids and the collapse of cellular antioxidant defenses. Its therapeutic modulation has emerged as a promising strategy across a broad spectrum of diseases, particularly cancer, where ferroptosis induction offers opportunities to overcome apoptosis resistance and treatment tolerance. In this context, coordination chemistry provides a uniquely versatile platform for controlling intracellular redox processes, metal homeostasis, and radical reactivity, enabling the rational design of metal-based ferroptosis modulators. This review critically examines the rapidly expanding landscape of ferroptosis-inducing metal complexes derived from Fe, Cu, Mn, Co, Zn, Ga, Ru, Ir, Os, Pt, Au, and related elements for anticancer applications. We discuss how metal identity, oxidation state, coordination environment, and ligand architecture collectively govern redox reactivity, subcellular localization, biomolecular interactions, and catalytic reactive oxygen species generation. Particular emphasis is placed on the molecular mechanisms through which metallodrugs promote ferroptosis, including expansion of the labile iron pool (LIP), disruption of antioxidant defense pathways such as GPX4/GSH, ferroptosis suppressor protein 1 (FSP1)/coenzyme Q10 (CoQ10), and dihydroorotate dehydrogenase (DHODH), as well as initiation of lipid peroxidation through both non-enzymatic and enzyme-mediated processes. We further highlight the central role of ligand design in dictating ferroptotic activity. Soft sulfur-donor frameworks, including thiosemicarbazones and dithiocarbamates, facilitate Fe- and Cu-mediated redox cycling, whereas polypyridyl and macrocyclic scaffolds modulate metal-centered redox accessibility, kinetic stability, and intracellular trafficking. N-Heterocyclic carbene ligands provide an additional level of control by tuning metal-ligand electronic properties and exploiting the pronounced thiophilicity of Au(I) toward seleno- and thiol-containing proteins. Emerging strategies, including ionophore-based approaches, Trojan-horse iron-delivery approaches, and activatable metalloprodrug-based approaches, are also discussed as promising avenues for enhancing ferroptotic selectivity and efficacy. Finally, we outline key challenges that must be addressed to translate ferroptosis-inducing metallodrugs toward clinical application, including improving tumour selectivity, optimizing pharmacokinetic behaviour, understanding metal-specific toxicities, and establishing robust mechanistic biomarkers. Collectively, this review highlights how coordination chemistry can be leveraged to chemically programme ferroptotic susceptibility and positions metallodrug design as a powerful frontier in precision oncology.
中文摘要:铁死亡是一种受调控的、依赖铁的细胞死亡形式,其特征是多不饱和磷脂的失控过氧化以及细胞抗氧化防御的崩溃。对其治疗性调控已成为多种疾病尤其是癌症的一种有前景的策略,在癌症中诱导铁死亡为克服凋亡抵抗和治疗耐受提供了机会。在此背景下,配位化学提供了一个独特多功能的平台,用于控制细胞内氧化还原过程、金属稳态和自由基反应性,从而能够理性设计基于金属的铁死亡调节剂。本综述批判性地审视了由Fe、Cu、Mn、Co、Zn、Ga、Ru、Ir、Os、Pt、Au及相关元素衍生的、用于抗癌应用的铁死亡诱导金属配合物这一快速扩展的领域。我们讨论了金属身份、氧化态、配位环境和配体结构如何共同决定氧化还原反应性、亚细胞定位、生物分子相互作用以及催化性活性氧的产生。特别强调了金属药物促进铁死亡的分子机制,包括不稳定铁池(LIP)的扩大、抗氧化防御通路如GPX4/GSH、铁死亡抑制蛋白1(FSP1)/辅酶Q10(CoQ10)和二氢乳清酸脱氢酶(DHODH)的破坏,以及通过非酶促和酶介导过程启动脂质过氧化。我们进一步强调了配体设计在决定铁死亡活性中的核心作用。软硫供体框架,包括缩氨基硫脲和二硫代氨基甲酸酯,促进Fe和Cu介导的氧化还原循环,而多吡啶和大环支架调节金属中心的氧化还原可及性、动力学稳定性和细胞内转运。N-杂环卡宾配体通过调节金属-配体电子性质并利用Au(I)对含硒醇和硫醇蛋白的显著亲硫性,提供了额外水平的控制。还讨论了新兴策略,包括基于离子载体的方法、特洛伊木马铁递送方法和可激活金属前药方法,作为增强铁死亡选择性和疗效的有前景途径。最后,我们概述了将铁死亡诱导金属药物转化为临床应用必须解决的关键挑战,包括提高肿瘤选择性、优化药代动力学行为、理解金属特异性毒性以及建立稳健的机制生物标志物。总体而言,本综述强调了如何利用配位化学对铁死亡易感性进行化学编程,并将金属药物设计定位为精准肿瘤学中的一个强大前沿。
Endometriosis is a chronic, estrogen-dependent inflammatory disease that, despite its benign histology, displays several cancer-relevant features, including clonal expansion, somatic alteration-associated lesion evolution, tissue invasion, apoptosis resistance, immune evasion, angiogenesis, fibrosis, and metabolic adaptation. These features are particularly important in ovarian endometriosis, where recurrent hemorrhage, iron-driven oxidative stress, and chronic inflammatory remodeling may promote malignant transformation. This review examines endometriosis through an oncologic framework by integrating current evidence on disease initiation, clonal lesion evolution, and the peritoneal, ovarian, and deep-infiltrating microenvironments. We discuss how epithelial, stromal, immune, endothelial, mesothelial, and neural components cooperate to support lesion survival, dissemination, vascularization, fibrosis, neuroinflammation, and treatment resistance. Particular attention is given to cancer-associated molecular programs, including PI3K-AKT-mTOR, RAS-MAPK, WNT/β-catenin, hypoxia, oxidative-stress, inflammatory, and epigenetic signaling, and their relationship to endometriosis-associated ovarian cancer. We also critically evaluate animal models, organoids, three-dimensional scaffolds, and microfluidic systems for their ability to reproduce lesion heterogeneity, microenvironmental interactions, therapeutic responses, and malignant progression. Finally, we assess current and emerging therapeutic strategies, emphasizing non-hormonal interventions directed against inflammatory, immune, fibrotic, angiogenic, metabolic, and oncogenic vulnerabilities, together with biomarker-guided and fertility-sparing approaches. Viewing endometriosis as a cancer-relevant inflammatory and clonal disease may reveal actionable mechanisms for precision treatment and interception of endometriosis-associated malignancy.
中文摘要:子宫内膜异位症是一种慢性、雌激素依赖性炎症性疾病,尽管其组织学为良性,却表现出若干与癌症相关的特征,包括克隆性扩增、体细胞改变相关的病灶演化、组织侵袭、凋亡抵抗、免疫逃逸、血管生成、纤维化和代谢适应。这些特征在卵巢子宫内膜异位症中尤为重要,其中反复出血、铁驱动的氧化应激和慢性炎症重塑可能促进恶性转化。本综述通过肿瘤学框架审视子宫内膜异位症,整合了关于疾病起始、克隆性病灶演化以及腹膜、卵巢和深部浸润微环境的最新证据。我们讨论上皮、基质、免疫、内皮、间皮和神经成分如何协同支持病灶存活、播散、血管化、纤维化、神经炎症和治疗抵抗。尤其关注癌症相关分子程序,包括 PI3K-AKT-mTOR、RAS-MAPK、WNT/β-catenin、缺氧、氧化应激、炎症和表观遗传信号,及其与子宫内膜异位症相关卵巢癌的关系。我们还批判性评估动物模型、类器官、三维支架和微流控系统在重现病灶异质性、微环境相互作用、治疗反应和恶性进展方面的能力。最后,我们评估当前和新兴的治疗策略,强调针对炎症、免疫、纤维化、血管生成、代谢和致癌脆弱性的非激素干预,以及生物标志物指导和保留生育力的方法。将子宫内膜异位症视为一种与癌症相关的炎症性和克隆性疾病,可能揭示用于精准治疗和拦截子宫内膜异位症相关恶性肿瘤的可干预机制。
Ovarian cancer (OC) is a prevalent gynecological malignancy, with cisplatin (CDDP) serving as the cornerstone of its clinical management. However, the disease progression or recurrence attributable to CDDP resistance has become a major cause of the poor prognosis in OC. Beyond endogenous genetic or epigenetic drivers, the potential contribution of environmental exposure to CDDP resistance in OC remains an enigma. Bisphenol A (BPA), a prototypical environmental endocrine disruptor, has garnered widespread attention due to its pro-carcinogenic effects across various human malignancies. Nevertheless, the latent association between BPA exposure and clinical prognosis of OC has not yet been established. Our current work demonstrated that exposure to environmentally relevant doses of BPA significantly augmented CDDP resistance in human OC cells, which was primarily attributable to AKT-mediated attenuation of DNA damage and apoptosis induced by CDDP. Bioinformatics analysis of a transcriptomic microarray from BPA-exposed OC cells identified DDIT4 as a critical differentially expressed gene involved in BPA-driven CDDP resistance. Mechanistically, estrogen receptor α (ERα), a direct target of BPA dependent activation of a non-canonical DDIT4-mTOR-AKT signaling served as the key molecular event underlying BPA-driven CDDP resistance. Notably, ERα/DDIT4 expression exhibited prominent clinical significance in the prognosis of OC-high ERα/DDIT4 expression was associated with a poor prognosis in patients receiving CDDP treatment, and CDDP treatment failed to hold a tangible clinical benefit in those with high ERα/DDIT4 expression. Overall, our current work advances the understanding of the chemical carcinogenic effects of BPA from a unique perspective of the poor prognosis in OC, and also delivers a novel mechanistic insight into BPA-driven chemoresistance, which might contribute to the identification of promising prognostic biomarkers or chemosensitization targets for environmental exposure-driven OC.
中文摘要:卵巢癌(OC)是一种常见的妇科恶性肿瘤,顺铂(CDDP)是其临床治疗的基石。然而,由CDDP耐药导致的疾病进展或复发已成为OC预后不良的主要原因。除内源性遗传或表观遗传驱动因素外,环境暴露对OC中CDDP耐药的潜在贡献仍是一个谜。双酚A(BPA)是一种典型的环境内分泌干扰物,因其在多种人类恶性肿瘤中的促癌作用而受到广泛关注。然而,BPA暴露与OC临床预后之间的潜在关联尚未确立。我们目前的工作表明,暴露于环境相关剂量的BPA可显著增强人OC细胞对CDDP的耐药性,这主要归因于AKT介导的对CDDP诱导的DNA损伤和细胞凋亡的减弱。对BPA暴露OC细胞的转录组微阵列进行生物信息学分析,鉴定出DDIT4是参与BPA驱动CDDP耐药的关键差异表达基因。在机制上,雌激素受体α(ERα)作为BPA依赖性激活非经典DDIT4-mTOR-AKT信号通路的直接靶点,是BPA驱动CDDP耐药的关键分子事件。值得注意的是,ERα/DDIT4表达在OC预后中具有显著的临床意义——高ERα/DDIT4表达与接受CDDP治疗患者的不良预后相关,而在ERα/DDIT4高表达者中,CDDP治疗未能带来切实的临床获益。总体而言,我们目前的工作从OC预后不良这一独特视角推进了对BPA化学致癌效应的理解,也为BPA驱动的化疗耐药提供了新的机制见解,这可能有助于识别环境暴露驱动OC的有前景的预后生物标志物或化疗增敏靶点。
Chromosomal instability (CIN) refers to a high rate of chromosome segregation errors during consecutive cell divisions and is a hallmark of cancers with aggressive behavior and poor prognosis. Cancer cells exhibiting CIN may acquire both numerical (N-CIN) and structural (S-CIN) chromosome alterations, namely by chromosome mis-segregation and DNA replication/repair defects, respectively. Importantly, these processes are tightly interconnected: mis-segregating chromosomes are prone to DNA damage, while DNA replication or repair defects can, in turn, promote chromosome mis-segregation. Consequently, CIN emerges as a consequence of these intertwined occurrences. CIN can confer survival advantages to cancer cells by enhancing their adaptation abilities, promoting intratumor heterogeneity, therapy resistance and acquisition of metastatic potential. In contrast, induction of CIN in healthy cells typically compromises cellular fitness and viability, triggering senescence and apoptosis. Therefore, cancer cells develop specific adaptation capabilities that allow them to tolerate CIN, often becoming dependent on specific CIN tolerance pathways. Elucidating the molecular circuits underlying CIN and clarifying the basis of its multifaceted roles in cancer will deepen our understanding of tumorigenesis and reveal therapeutically exploitable vulnerabilities in chromosomally unstable cancers. Here, we provide an integrated perspective on the principal sources of CIN, newly identified CIN-specific dependencies and vulnerabilities and how CIN impacts genome integrity. We discuss emerging evidence on the potential influence of CIN on tumor evolution or regression, including the CIN paradox. We further highlight how integrating this novel information with emerging diagnostic technologies that allow quantitative, qualitative and spatiotemporal characterization of CIN within tumors is reshaping our ability to define CIN at the single-tumor level, opening new avenues for targeted therapeutic strategies.
中文摘要:染色体不稳定性(CIN)是指在连续细胞分裂过程中染色体分离错误发生率较高,是侵袭性强、预后差癌症的一个标志。表现出CIN的癌细胞可能分别通过染色体错误分离和DNA复制/修复缺陷获得数值型(N-CIN)和结构型(S-CIN)染色体改变。重要的是,这些过程紧密相互关联:错误分离的染色体易发生DNA损伤,而DNA复制或修复缺陷反过来又可促进染色体错误分离。因此,CIN是这些相互交织事件的结果。CIN可通过增强癌细胞的适应能力、促进瘤内异质性、治疗耐药和获得转移潜能,赋予癌细胞生存优势。相反,在健康细胞中诱导CIN通常会损害细胞适应度和存活力,触发衰老和凋亡。因此,癌细胞发展出特定的适应能力以耐受CIN,并常常依赖特定的CIN耐受通路。阐明CIN背后的分子回路并明确其在癌症中多面性作用的基础,将加深我们对肿瘤发生的理解,并揭示染色体不稳定癌症中可用于治疗的脆弱性。在此,我们提供关于CIN主要来源、新发现的CIN特异性依赖和脆弱性以及CIN如何影响基因组完整性的整合视角。我们讨论关于CIN对肿瘤进化或消退潜在影响的新兴证据,包括CIN悖论。我们进一步强调,如何将这些新信息与新兴诊断技术相结合,这些技术允许对肿瘤内CIN进行定量、定性和时空特征描述,正在重塑我们在单肿瘤水平定义CIN的能力,为靶向治疗策略开辟新途径。
Mutant isocitrate dehydrogenase 1 (mIDH1) catalyzes 2-hydroxyglutarate (2HG) production which leads to epigenetic reprogramming in astrocytomas with tumor protein p53 (TP53)/α-thalassemia/mental retardation, X-linked (ATRX) loss. RNA-sequencing, single-cell RNA-sequencing, and Chromatin Immunoprecipitation sequencing (ChIP-seq) followed by bioinformatics analysis shows that human and mouse mIDH1 gliomas exhibit downregulated gene ontologies (GOs) related to mitochondrial metabolism and upregulated autophagy-related GOs. Decreased mitochondrial metabolism is accompanied by decreased glycolysis, rendering autophagy as a source of energy in mIDH1 gliomas. Mutant IDH1 glioma cells exhibit increased expression of autophagy-related proteins and enhanced microtubule-associated protein 1 light chain 3 (LC3) I/II conversion, indicating augmented autophagy. Inhibiting autophagy in vivo by administration of synthetic protein nanoparticles (SPNPs) encapsulating autophagy related gene 7 (ATG7) silencing RNA sensitizes mIDH1 glioma cells to radiation, resulting in tumor regression, long-term survival, and immunological memory. This work uncovers autophagy as a critical pathway for survival in mIDH1 gliomas and its inhibition elicits radiosensitivity in vitro in human and mouse mIDH1 glioma cells, and in vivo in mIDH1 models.
中文摘要:突变型异柠檬酸脱氢酶1(mIDH1)催化2-羟基戊二酸(2HG)生成,从而在伴有肿瘤蛋白p53(TP53)/α-地中海贫血/智力发育迟缓X连锁(ATRX)缺失的星形细胞瘤中导致表观遗传重编程。RNA测序、单细胞RNA测序和染色质免疫沉淀测序(ChIP-seq)及后续生物信息学分析显示,人和小鼠mIDH1胶质瘤中与线粒体代谢相关的基因本体(GO)下调,而自噬相关GO上调。线粒体代谢降低伴随糖酵解降低,使自噬成为mIDH1胶质瘤的能量来源。突变型IDH1胶质瘤细胞自噬相关蛋白表达增加,微管相关蛋白1轻链3(LC3)I/II转化增强,表明自噬增强。通过给予封装自噬相关基因7(ATG7)沉默RNA的合成蛋白纳米颗粒(SPNP)在体内抑制自噬,可使mIDH1胶质瘤细胞对放射增敏,导致肿瘤消退、长期生存和免疫记忆。该工作揭示自噬是mIDH1胶质瘤存活的关键通路,抑制自噬可在人和小鼠mIDH1胶质瘤细胞体外以及mIDH1模型体内诱导放射敏感性。
Chemoresistance, often driven by aberrant transcriptional and epigenetic mechanisms, remains a significant barrier to effective colon cancer therapy. This study introduces a dendrimer-based proteolysis-targeting chimera (PROTAC) system, JTP, generated by conjugation of polyamidoamine (PAMAM-G4) dendrimer with 4-hydroxythalidomide (an E3 ligase recruiter) and JQ1 carboxylic acid (a BRD4 inhibitor). The multivalent dendrimer scaffold increases local surface ligand density, promotes endocytic uptake and endosomal escape, and facilitates cytosolic engagement of BRD4 for proteasome-mediated degradation. In vitro, JTP effectively increased the chemosensitivity of CT26 colon cancer cells to chemotherapy, particularly to irinotecan, leading to enhanced DNA damage, cell cycle arrest in the S and G2/M phases, and apoptosis, as well as a synergistic reduction in oncoprotein expression. In vivo studies in orthotopic colon cancer-bearing mice demonstrated a prominent antitumor effect of JTP in combination with irinotecan, yielding marked inhibition of tumors and metastases and promoting long-term survival, with toxicity within a well-tolerated range. The in vivo studies also demonstrated the robust effects of JTP on reducing the expression of TFEB, c-Myc, β-catenin, Bcl-2, VEGFR2, IL-1β, TNF-α, HIF-1α, and vimentin by BRD4 elimination in tumor tissues. These findings demonstrate that combining JTP with epigenetic modulation offers an effective strategy to promote chemotherapeutic effects in colon cancer.
中文摘要:化疗耐药常由异常转录和表观遗传机制驱动,仍是有效治疗结肠癌的重大障碍。本研究介绍了一种基于树状大分子的蛋白水解靶向嵌合体(PROTAC)系统JTP,其通过将聚酰胺-胺(PAMAM-G4)树状大分子与4-羟基沙利度胺(一种E3连接酶招募剂)和JQ1羧酸(一种BRD4抑制剂)偶联而生成。多价树状大分子支架增加了局部表面配体密度,促进内吞摄取和内体逃逸,并促进BRD4进入胞质以进行蛋白酶体介导的降解。在体外,JTP有效提高了CT26结肠癌细胞对化疗的敏感性,尤其是对伊立替康,导致DNA损伤增强、S期和G2/M期细胞周期阻滞和凋亡,并协同降低癌蛋白表达。在体内研究中,原位结肠癌荷瘤小鼠显示JTP与伊立替康联合具有显著抗肿瘤作用,明显抑制肿瘤和转移并促进长期生存,且毒性在良好耐受范围内。体内研究还表明,JTP通过消除肿瘤组织中的BRD4,对降低TFEB、c-Myc、β-catenin、Bcl-2、VEGFR2、IL-1β、TNF-α、HIF-1α和波形蛋白的表达具有强大作用。这些发现表明,将JTP与表观遗传调控相结合,为促进结肠癌化疗效果提供了一种有效策略。
Doxorubicin's clinical utility is constrained by cumulative toxicities, including a significantly underestimated hepatotoxicity. As the primary metabolic hub, the liver accumulates doxorubicin via active transport, leading to mitochondrial crisis through quinone redox cycling and concurrent blockade of mitophagic flux. This drives hepatocytes toward synchronized regulated cell death, prominently featuring ferroptosis and pyroptosis. The injury is amplified by hepatic immune remodeling, characterized by Kupffer cell depletion and the formation of neutrophil extracellular traps. Furthermore, a proposed epigenetic component, driven by DNA hypomethylation and histone acetylation imbalances, may contribute to persistent hepatic dysfunction. By integrating these multidimensional mechanisms, this review evaluates forward-looking strategies, highlighting the potential of natural products, intelligent nanodelivery systems, and repurposed drugs to achieve hepatoprotection while critically addressing the inherent challenge of avoiding tumor protection.
中文摘要:多柔比星的临床应用受到累积毒性的限制,其中肝毒性被显著低估。肝脏作为主要代谢中枢,可通过主动转运蓄积多柔比星,经由醌类氧化还原循环并同时阻断线粒体自噬流,导致线粒体危机。这促使肝细胞发生同步化的调节性细胞死亡,以铁死亡和细胞焦亡尤为突出。肝免疫重塑会放大损伤,其特征为库普弗细胞耗竭和中性粒细胞胞外诱捕网形成。此外,由DNA低甲基化和组蛋白乙酰化失衡驱动的表观遗传成分可能促成持续性肝功能障碍。通过整合这些多维机制,本综述评估了前瞻性策略,强调天然产物、智能纳米递送系统和老药新用实现肝保护并批判性应对避免肿瘤保护的固有挑战。
Multidrug resistance (MDR) remains a major challenge in cancer treatment. MDR has been explained by single-gene mechanisms, such as overexpression of ATP-binding cassette (ABC) transporters, drug-target mutations, activation of bypass signaling pathways, and increased DNA repair. However, these mechanisms alone are insufficient to explain the heterogeneity, reversibility, temporal evolution, and environmental dependence of drug resistance observed in clinical settings. Increasing evidence suggests that MDR is better viewed as a complex and evolving biological phenomenon rather than the result of isolated molecular events. This shift in perspective presents both challenges and opportunities for drug development. Future strategies will therefore require dynamic and mechanism-informed approaches that integrate rational drug combinations with sequential, intermittent, or adaptive treatment according to the evolving resistance state. In this review, we propose a conceptual shift from conventional MDR models toward systemic adaptive resistance. We review classical drug resistance, including drug uptake/efflux, compensatory pathway activation, and apoptosis evasion. We explore non-genetic drug resistance, such as drug-tolerant persisters (DTPs), epithelial-mesenchymal transition (EMT), cancer stem cell (CSC) plasticity, and related factors. Then, we discuss the interaction between these mechanisms, and how their coordinated effects contribute to tumor persistence and the evolution of MDR. Finally, we evaluate barriers in translational medicine and emerging pharmacological strategies, including longitudinal molecular monitoring and artificial intelligence (AI) -assisted drug resistance prediction.
中文摘要:多药耐药(MDR)仍是癌症治疗中的主要挑战。MDR曾被解释为单基因机制,例如ATP结合盒(ABC)转运蛋白过表达、药物靶点突变、旁路信号通路激活以及DNA修复增强。然而,这些机制本身不足以解释临床中所观察到的耐药异质性、可逆性、时间演化以及对环境的依赖性。越来越多的证据表明,多药耐药更适合被视作一种复杂且不断演化的生物学现象,而非孤立分子事件的结果。这一视角转变既为药物研发带来挑战,也带来机遇。因此,未来策略需要动态且基于机制的方法,将合理的药物联合与序贯、间歇或适应性治疗相结合,以根据不断演变的耐药状态进行调整。在本综述中,我们提出从传统MDR模型向系统性适应性耐药的概念转变。我们回顾经典耐药机制,包括药物摄取/外排、代偿性通路激活和凋亡逃避。我们探讨非遗传性耐药,如耐药持留细胞(DTPs)、上皮-间质转化(EMT)、癌症干细胞(CSC)可塑性及相关因素。随后,我们讨论这些机制之间的相互作用,以及它们的协同效应如何促进肿瘤持续存在和MDR的演化。最后,我们评估转化医学中的障碍以及新兴药理学策略,包括纵向分子监测和人工智能(AI)辅助的耐药预测。
Ferroptosis is an iron-dependent form of regulated cell death driven by lipid peroxidation; however, how selective autophagy regulates ferroptotic sensitivity remains incompletely understood. Here, we identify RAB8A as a selective autophagic substrate and negative regulator of ferroptosis. Quantitative proteomic analyses reveal that ferroptotic stress induces ATG5- and ATG7-dependent degradation of RAB8A. Mechanistically, ferroptotic stimuli induce RNF126-dependent polyubiquitination of RAB8A and subsequent SQSTM1-mediated autophagic degradation. Functionally, loss of RAB8A sensitizes cancer cells to ferroptosis, whereas expression of the degradation-resistant active mutant RAB8AQ67L suppresses ferroptotic cell death. RAB8A interacts with TFRC and facilitates stress-induced redistribution of TFRC from the plasma membrane toward endolysosomal compartments. RAB8A deficiency impairs TFRC clearance, enhances transferrin-dependent iron uptake, and increases intracellular Fe2+ accumulation and lipid peroxidation. In fibrosarcoma and pancreatic cancer xenograft models, RAB8A depletion enhances the antitumor efficacy of ferroptosis-inducing therapy. Clinically, RAB8A is upregulated and associated with poor prognosis and ferroptosis resistance in pancreatic cancer. Collectively, these findings establish an autophagy-RAB8A-TFRC axis that regulates ferroptotic sensitivity.Abbreviations: BCA: bicinchoninic acid; BSA: bovine serum albumin; CCK-8: cellcounting kit-8; Co-IP: co-immunoprecipitation; DMSO: dimethylsulfoxide; ELISA: enzyme-linked immunosorbent assay; FBS: fetalbovine serum; HRP: horseradish peroxidase; IP: immunoprecipitation;LC-MS/MS: liquid chromatography-tandem mass spectrometry; MDA:malondialdehyde; MEF: mouse embryonic fibroblast; PBS:phosphate-buffered saline; PBS-T: PBS containing Tween-20; PI:propidium iodide; PVDF: polyvinylidene difluoride; qPCR: quantitativereal-time polymerase chain reaction; SDS: sodium dodecyl sulfate;STR: short tandem repeat; TBA: thiobarbituric acid; TBST:Tris-buffered saline containing Tween-20; TMT: tandem mass tag; WT:wild type.
中文摘要:铁死亡是一种由脂质过氧化驱动的铁依赖性调节性细胞死亡形式;然而,选择性自噬如何调控铁死亡敏感性仍不完全清楚。在此,我们将RAB8A鉴定为选择性自噬底物和铁死亡的负调控因子。定量蛋白质组学分析显示,铁死亡应激诱导ATG5和ATG7依赖性的RAB8A降解。机制上,铁死亡刺激诱导RNF126依赖性的RAB8A多泛素化以及随后的SQSTM1介导的自噬降解。功能上,RAB8A缺失使癌细胞对铁死亡敏感,而表达抗降解的活性突变体RAB8AQ67L则抑制铁死亡性细胞死亡。RAB8A与TFRC相互作用,并促进应激诱导的TFRC从质膜向内涵体-溶酶体区室重新分布。RAB8A缺乏会损害TFRC清除,增强转铁蛋白依赖性铁摄取,并增加细胞内Fe2+积累和脂质过氧化。在纤维肉瘤和胰腺癌异种移植模型中,RAB8A耗竭增强了铁死亡诱导疗法的抗肿瘤疗效。临床上,RAB8A在胰腺癌中上调,并与不良预后和铁死亡抵抗相关。总之,这些发现确立了调节铁死亡敏感性的自噬-RAB8A-TFRC轴。缩写:BCA:二辛可宁酸;BSA:牛血清白蛋白;CCK-8:细胞计数试剂盒-8;Co-IP:共免疫沉淀;DMSO:二甲基亚砜;ELISA:酶联免疫吸附测定;FBS:胎牛血清;HRP:辣根过氧化物酶;IP:免疫沉淀;LC-MS/MS:液相色谱-串联质谱;MDA:丙二醛;MEF:小鼠胚胎成纤维细胞;PBS:磷酸盐缓冲液;PBS-T:含Tween-20的PBS;PI:碘化丙啶;PVDF:聚偏二氟乙烯;qPCR:定量实时聚合酶链反应;SDS:十二烷基硫酸钠;STR:短串联重复序列;TBA:硫代巴比妥酸;TBST:含Tween-20的Tris缓冲盐溶液;TMT:串联质量标签;WT:野生型。
6其他实体瘤 (8篇)
临床研究 (2篇)
To evaluate the outcomes of a stepwise multimodal treatment approach for conjunctival melanocytic lesions ranging from low-grade conjunctival melanocytic intraepithelial lesion (LG-CMIL) through high-grade CMIL (HG-CMIL) to invasive conjunctival melanoma (iCoM) and to propose a practical management framework. Retrospective, single-centre cohort study. Patients diagnosed with LG-CMIL, HG-CMIL, or iCoM and managed at the Liverpool Ocular Oncology Centre between January 2015 and April 2025 were included. A sequential stepwise strategy was employed, comprising surgical excision or incisional biopsy, topical chemotherapy (mitomycin C, 5-fluorouracil, or interferon alpha-2b), and adjuvant Ruthenium-106 plaque brachytherapy or proton beam radiotherapy when indicated, selected according to histopathological grade and clinical growth pattern (focal versus diffuse). Kaplan-Meier survival analysis and Cox proportional hazards regression identified prognostic factors for recurrence and metastasis. Local recurrence was the primary endpoint; metastatic disease and residual pigmentation after primary therapy were the secondary endpoints. Among 165 eyes, including 39 LG-CMIL, 39 HG-CMIL, and 87 iCoM cases, HG-CMIL demonstrated the highest recurrence rate (24.3%; 9 eyes) and the earliest recurrence events (median 8.2 months), whereas LG-CMIL showed the lowest recurrence risk (11.1%; 4 eyes). Metastatic disease occurred exclusively in iCoM (11.4%; 8 eyes), accounting for 16.7% of deaths in the cohort. Non-bulbar involvement (HR 2.76, p=0.014) and residual pigmentation (HR 2.77, p=0.024) independently predicted local recurrence, while ulcerative features (HR 15.08, p=0.001), non-bulbar involvement (HR 7.28, p=0.015) and increased tumour thickness (HR 2.15, p=0.030) were associated with metastatic spread. A tailored sequential multimodal approach achieved satisfactory local disease control, with local recurrence being primarily driven by non-bulbar involvement and residual pigmentation after primary therapy, while metastatic spread was strongly associated with ulcerative features, followed by non-bulbar involvement and tumour thickness.
中文摘要:评估针对结膜黑色素细胞性病变(从低级别结膜黑色素细胞性上皮内病变(LG-CMIL)经高级别CMIL(HG-CMIL)至侵袭性结膜黑色素瘤(iCoM))的阶梯式多模式治疗方法的结局,并提出实用的管理框架。回顾性单中心队列研究。纳入2015年1月至2025年4月在利物浦眼科肿瘤中心诊治、诊断为LG-CMIL、HG-CMIL或iCoM的患者。采用序贯阶梯式策略,包括手术切除或切开活检、局部化疗(丝裂霉素C、5-氟尿嘧啶或干扰素α-2b),并在有指征时辅以钌-106敷贴近距离放疗或质子束放疗,具体根据组织病理学分级和临床生长模式(局灶性与弥漫性)选择。Kaplan-Meier生存分析和Cox比例风险回归确定了复发和转移的预后因素。局部复发为主要终点;转移性疾病和初次治疗后的残留色素沉着为次要终点。在165只眼中,包括39例LG-CMIL、39例HG-CMIL和87例iCoM,HG-CMIL的复发率最高(24.3%;9只眼),复发事件最早(中位8.2个月),而LG-CMIL的复发风险最低(11.1%;4只眼)。转移性疾病仅发生于iCoM(11.4%;8只眼),占该队列死亡的16.7%。非球结膜受累(HR 2.76,p=0.014)和残留色素沉着(HR 2.77,p=0.024)独立预测局部复发,而溃疡性特征(HR 15.08,p=0.001)、非球结膜受累(HR 7.28,p=0.015)和肿瘤厚度增加(HR 2.15,p=0.030)与转移扩散相关。量身定制的序贯多模式治疗实现了满意的局部疾病控制,局部复发主要由非球结膜受累和初次治疗后的残留色素沉着驱动,而转移扩散与溃疡性特征强烈相关,其次为非球结膜受累和肿瘤厚度。
Osteosarcoma is a malignant bone tumor for which diagnosis is critical to patient prognosis. MicroRNA-588 is downregulated in osteosarcoma, highlighting its potential as a diagnostic biomarker. However, its low abundance in body fluids makes sensitive detection difficult. This study presents a label-free reflective optical fiber surface plasmon resonance (SPR) biosensor with optimized probe immobilization for ultrasensitive miRNA-588 detection in serum. The sensor utilizes plasmonic coupling between a gold film and gold nanoparticles to enhance the SPR response. By incorporating an A15 anchor and a T5 spacer into a single oligonucleotide, the A15T5 probe promotes a more upright presentation of the recognition sequence while simplifying interface construction. Among the configurations evaluated, the A15T5 probe showed the best performance for miRNA-588 detection. The biosensor exhibits a wide detection range from 10-15 to 10-7 M, with a low detection limit (LOD) of 1.12 × 10-17 M, along with good stability and repeatability. In clinical sample testing, the sensor achieved an area under the receiver operating characteristic (ROC) curve of 0.95 and showed greater diagnostic discrimination than serum alkaline phosphatase in the evaluated cohort. This platform enables high-sensitivity detection of trace biomarkers, supporting the diagnosis of major diseases.
中文摘要:骨肉瘤是一种恶性骨肿瘤,其诊断对患者预后至关重要。MicroRNA-588在骨肉瘤中下调,突显其作为诊断生物标志物的潜力。然而,其在体液中的低丰度使灵敏检测变得困难。本研究提出了一种无标记反射式光纤表面等离子体共振(SPR)生物传感器,通过优化探针固定,用于血清中miRNA-588的超灵敏检测。该传感器利用金膜与金纳米颗粒之间的等离子体耦合来增强SPR响应。通过将A15锚定序列和T5间隔序列整合到单个寡核苷酸中,A15T5探针促进了识别序列更直立地呈现,同时简化了界面构建。在评估的构型中,A15T5探针对miRNA-588检测表现出最佳性能。该生物传感器具有从10^-15至10^-7 M的宽检测范围,低检测限(LOD)为1.12 × 10^-17 M,并具有良好的稳定性和重复性。在临床样本测试中,该传感器在评估队列中实现了0.95的受试者工作特征(ROC)曲线下面积,并显示出比血清碱性磷酸酶更强的诊断区分能力。该平台能够高灵敏度检测痕量生物标志物,支持重大疾病的诊断。
基础研究 (6篇)
CD4+ T cells orchestrate adaptive immunity and strategies that enable their genetic reprogramming hold promise for treating cancer, immune dysregulation and infectious diseases such as HIV. However, current T cell engineering approaches rely heavily on ex vivo manipulation, which is labor-intensive, costly, and can alter cell phenotypes. Lipid nanoparticles (LNPs) offer a scalable nonviral alternative, yet conventional formulations show minimal interaction with lymphocytes and are rapidly cleared by the liver. In this study, we develop a modular DBCO-azide click-chemistry approach to functionalize LNPs with a high-affinity CD4 nanobody, enabling precise CD4 receptor-directed delivery to human CD4+ T cells. Optimized CD4-targeted LNPs transfect up to 48% of non-activated CD4+ T cells within a PBMC co-culture, the highest efficiency reported so far through LNP transfection. Moreover, they successfully deliver CRISPR-Cas9 components to activated CD4+ T cells and achieve up to 32% gene editing. In humanized NSG-SGM3 mice, CD4-targeted LNPs selectively associate with and transfect circulating and bone marrow-resident human CD4+ T cells while showing minimal off-target activity in murine cells. These results establish CD4-nanobody LNPs as a versatile platform for targeted mRNA and gene-editing delivery, with broad potential for cancer immunotherapy, T cell reprogramming, and HIV cure strategies.
中文摘要:CD4+ T细胞协调适应性免疫,使能够对其进行基因重编程的策略有望用于治疗癌症、免疫失调以及HIV等感染性疾病。然而,当前的T细胞工程方法严重依赖体外操作,这劳动密集、成本高昂,并可能改变细胞表型。脂质纳米颗粒(LNPs)提供了一种可规模化的非病毒替代方案,但传统制剂与淋巴细胞的相互作用极少,并会被肝脏快速清除。在本研究中,我们开发了一种模块化的DBCO-叠氮点击化学方法,用高亲和力CD4纳米抗体对LNPs进行功能化,从而实现对人类CD4+ T细胞的精确CD4受体导向递送。优化后的CD4靶向LNPs在PBMC共培养体系中可转染高达48%的未活化CD4+ T细胞,这是目前通过LNP转染报道的最高效率。此外,它们成功将CRISPR-Cas9组分递送至活化的CD4+ T细胞,并实现高达32%的基因编辑。在人源化NSG-SGM3小鼠中,CD4靶向LNPs选择性结合并转染循环中及骨髓驻留的人类CD4+ T细胞,同时对小鼠细胞的脱靶活性极低。这些结果确立了CD4纳米抗体LNPs作为一个多功能的靶向mRNA和基因编辑递送平台,在癌症免疫治疗、T细胞重编程和HIV治愈策略方面具有广泛潜力。
Peptide receptor radionuclide therapy (PRRT) with ¹⁷⁷Lu-DOTATATE improves outcomes in neuroendocrine tumors (NETs), yet durable disease control remains limited in progressive pancreatic NET (pNET) and higher-grade disease. Combinations that enhance PRRT efficacy may be advantageous. As sunitinib has radiosensitizing and immunomodulatory effects, we explored the clinical activity and mechanistic basis of combining sunitinib with PRRT. Combination treatment with ¹⁷⁷Lu-DOTATATE (1-3 cycles; 7.4 GBq per cycle) and sunitinib at 37.5 mg/day was well tolerated and effective in a pilot group of heavily pretreated pNET patients with progressive disease. Treatment response was assessed by ⁶⁸Ga-DOTATOC PET/CT and serum tumor markers (CgA, NSE). Mechanistic studies were performed in QGP-1 pNET cells using proliferation and apoptosis assays, cell-cycle analysis, and immunogenic cell death (ICD) markers. Combination therapy was well tolerated and induced marked responses: three patients achieved near-complete responses and two partial responses on post-therapy ⁶⁸Ga-DOTATOC PET/CT. In vitro, ¹⁷⁷Lu-DOTATATE and sunitinib showed bidirectional sensitization: low-dose sunitinib reduced the LD50 of ¹⁷⁷Lu-DOTATATE, and low-activity ¹⁷⁷Lu-DOTATATE reduced the LD50 of sunitinib. ¹⁷⁷Lu-DOTATATE induced dose-dependent PARP cleavage and S/G2-M arrest; however, sunitinib shifted cell death toward late apoptosis/necrosis. The combination produced a more-than-additive increase in calreticulin exposure on the tumor cell surface and enhanced HMGB1 but not interleukin- 1ß- or interleukin-18-release compared with either monotherapy, indicating immunogenic late apoptosis/necrosis, without canonical inflammasome activation. Intermittent sunitinib combined with ¹⁷⁷Lu-DOTATATE PRRT demonstrated encouraging activity in progressive pNET. The mechanism of synergy in vitro was enhanced ICD, suggesting that immune responses contribute to the synergy in vivo.
中文摘要:使用¹⁷⁷Lu-DOTATATE的肽受体放射性核素治疗(PRRT)可改善神经内分泌肿瘤(NET)的结局,但在进展性胰腺NET(pNET)和更高级别疾病中,持久疾病控制仍然有限。能够增强PRRT疗效的联合方案可能具有优势。由于舒尼替尼具有放射增敏和免疫调节作用,我们探讨了舒尼替尼与PRRT联合的临床活性和机制基础。¹⁷⁷Lu-DOTATATE(1-3个周期;每周期7.4 GBq)与舒尼替尼37.5 mg/日联合治疗在一组经过大量预处理且疾病进展的pNET患者中耐受良好并有效。治疗反应通过⁶⁸Ga-DOTATOC PET/CT和血清肿瘤标志物(CgA、NSE)评估。在QGP-1 pNET细胞中,通过增殖和凋亡试验、细胞周期分析以及免疫原性细胞死亡(ICD)标志物进行了机制研究。联合治疗耐受良好并诱导了显著反应:治疗后⁶⁸Ga-DOTATOC PET/CT显示3例患者达到接近完全反应,2例达到部分反应。体外实验中,¹⁷⁷Lu-DOTATATE和舒尼替尼表现出双向增敏:低剂量舒尼替尼降低了¹⁷⁷Lu-DOTATATE的LD50,低活度¹⁷⁷Lu-DOTATATE降低了舒尼替尼的LD50。¹⁷⁷Lu-DOTATATE诱导剂量依赖性PARP切割和S/G2-M期阻滞;然而,舒尼替尼将细胞死亡转向晚期凋亡/坏死。与任一单药治疗相比,联合治疗使肿瘤细胞表面钙网蛋白暴露出现超过相加的增加,并增强HMGB1释放,但不增强白细胞介素-1β或白细胞介素-18释放,表明发生了免疫原性晚期凋亡/坏死,而没有经典炎症小体激活。间歇性舒尼替尼联合¹⁷⁷Lu-DOTATATE PRRT在进展性pNET中显示出令人鼓舞的活性。体外协同机制是增强的ICD,提示免疫反应参与了体内协同作用。
Microfluidic devices are valuable tools for live imaging. However, widespread adoption of microfluidic-based screening methods has been limited by the complexity of the existing techniques. Here, we introduce a user-friendly, high-throughput, and high-resolution automated imaging system for C. elegans. We demonstrate the system's capabilities in an RNA interference (RNAi) screen, combined with neural network-based phenotypic scoring. We evaluated the effects of RNAi targeting 193 candidate genes on anchor cell (AC) invasion, a model for basement membrane (BM) breaching that shares similarities with tumor cell invasion during cancer metastasis. Over 40,000 animals were imaged at subcellular resolution and scored using a custom neural network classifier with an accuracy of over 92%. The screen identified 41 of 52 genes previously known to control AC invasion, along with 51 additional regulators of invasion. This automated imaging and classification system enables researchers to perform forward mutagenesis, RNAi, and drug screens in C. elegans with much greater speed and higher resolution than previously possible.
中文摘要:微流控设备是活体成像的有力工具。然而,现有技术的复杂性限制了基于微流控的筛选方法的广泛采用。在此,我们介绍一种用户友好、高通量、高分辨率的秀丽隐杆线虫自动化成像系统。我们在RNA干扰(RNAi)筛选中展示了该系统的能力,并结合基于神经网络的表型评分。我们评估了靶向193个候选基因的RNAi对锚定细胞(AC)侵袭的影响,AC侵袭是基底膜(BM)突破的模型,与癌症转移中的肿瘤细胞侵袭具有相似性。以亚细胞分辨率对超过40,000只动物进行了成像,并使用定制的神经网络分类器进行评分,准确率超过92%。该筛选识别出52个已知控制AC侵袭的基因中的41个,以及另外51个侵袭调控因子。这种自动化成像和分类系统使研究人员能够以比以往更快的速度和更高的分辨率在秀丽隐杆线虫中进行正向诱变、RNAi和药物筛选。
Traditional two-dimensional (2D) cell cultures fail to capture the structural, mechanical, and biochemical complexity of living tissues, prompting a major paradigm shift toward three-dimensional (3D) cell culture models. 3D systems faithfully replicate in vivo physiological architectures, dynamic cell-to-cell contacts, and extracellular matrix (ECM) interactions, bridging a critical gap in preclinical studies by predicting human therapeutic responses more accurately. This review explores the technological evolution from simple multicellular tumor spheroids to sophisticated microphysiological networks. Scaffold-free methods-including the hanging drop, low-adherent plates, magnetic levitation, and dynamic bioreactors-efficiently recreate the pathophysiological oxygen, nutrient, and metabolic gradients characteristic of solid tumor zonation and drug-resistance pathways. Conversely, scaffold-based systems leverage hydrogels, synthetic polymers, and decellularized matrices to dissect the biomechanics of matrix stiffness and mechanotransduction. At a higher tier of biological fidelity, patient-derived organoids preserve cellular heterogeneity, native tissue polarity, and accurate patient-specific mutational profiles, serving as critical pipelines for personalized medicine and precision drug screening. Furthermore, the integration of advanced microfluidic technologies has facilitated the engineering of tumor-, organ-, and multi-organ body-on-a-chip platforms. These microphysiological systems reconstruct dynamic fluid flow, functional tissue-vascular interfaces, physiological barriers (such as the blood-brain barrier), and systemic pharmacokinetic/pharmacodynamic (ADME) drug profiles. Beyond deepening mechanistic insights into oncology, these interconnected 3D models provide highly ethical, predictive, and cost-effective alternatives to animal experimentation in strict alignment with the 3Rs principles. Ultimately, these complementary 3D culture technologies are transforming oncology into a highly predictive, patient-tailored discipline.
中文摘要:传统二维(2D)细胞培养无法捕捉活体组织的结构、力学和生化复杂性,促使研究范式向三维(3D)细胞培养模型发生重大转变。3D 系统可忠实再现体内生理结构、动态细胞间接触以及细胞外基质(ECM)相互作用,通过更准确地预测人体治疗反应,弥合了临床前研究中的关键缺口。本综述探讨了从简单的多细胞肿瘤球体到复杂微生理网络的技术演进。无支架方法——包括悬滴法、低黏附培养板、磁悬浮和动态生物反应器——能够高效重建实体瘤分区及耐药通路所特有的病理生理性氧、营养和代谢梯度。相反,基于支架的系统利用水凝胶、合成聚合物和脱细胞基质来剖析基质硬度与机械转导的生物力学。在更高层次的生物学保真度上,患者来源类器官保留了细胞异质性、天然组织极性和准确的患者特异性突变谱,可作为个性化医疗和精准药物筛选的关键流程。此外,先进微流控技术的整合促进了肿瘤、器官和多器官芯片机体平台的工程化。这些微生理系统重建了动态流体流动、功能性组织-血管界面、生理屏障(如血脑屏障)以及系统性药代动力学/药效动力学(ADME)药物特征。除了加深肿瘤学机制认识外,这些相互连接的 3D 模型还提供了高度符合伦理、具预测性且成本效益高的动物实验替代方案,严格契合 3R 原则。最终,这些互补的 3D 培养技术正在将肿瘤学转变为一门高度预测、以患者为中心的学科。
Single-molecule localization microscopy (SMLM) enables visualization of chromatin architecture at nanoscale resolution. However, high-performance DNA probes suitable for SMLM in both live cells and tissues remain limited. We developed Hoechst-6-Carboxytetramethylrhodamine (6-TAMRA) derivative (HoT) probes-rhodamine-based derivatives conjugated to a Hoechst moiety-through structural fine-tuning of rhodamine spirocyclization. HoTs are self-assembling, auto-blinking probes with excellent photostability and high temporal resolution. They permeate live cells, enabling long-term, real-time nanoscopic chromatin imaging in live and fixed cells and in tissue sections. In live cells, we identified nanoscale features in the 3D organization of chromatin and quantified DNA fiber kinetics at high resolution. We quantified DNA compaction in single cells within retinal and colon cancer sections. OligoSTORM (stochastic optical reconstruction microscopy)-labeled gene loci can be visualized and measured within their HoT-labeled chromatin footprints. Our work provides powerful tools for investigating chromatin structure and functions in living cells and tissues, with applications ranging from cancer diagnosis to retinal regeneration.
中文摘要:单分子定位显微镜(SMLM)能够在纳米级分辨率下可视化染色质结构。然而,适用于活细胞和组织中SMLM的高性能DNA探针仍然有限。我们通过对罗丹明螺环化进行结构精细调控,开发了Hoechst-6-羧基四甲基罗丹明(6-TAMRA)衍生物(HoT)探针,即与Hoechst基团偶联的罗丹明类衍生物。HoT是自组装、自发闪烁的探针,具有优异的光稳定性和高时间分辨率。它们可渗透活细胞,从而能够在活细胞、固定细胞以及组织切片中实现长期、实时的纳米级染色质成像。在活细胞中,我们识别了染色质三维组织中的纳米级特征,并高分辨率定量了DNA纤维动力学。我们定量了视网膜癌和结肠癌切片中单细胞内的DNA压缩程度。OligoSTORM(随机光学重建显微镜)标记的基因位点可以在其HoT标记的染色质足迹内被可视化和测量。我们的工作为研究活细胞和组织中的染色质结构与功能提供了强大工具,其应用范围从癌症诊断到视网膜再生。
Fibroblasts are central components of the intestinal microenvironment and can acquire a myofibroblast phenotype through fibroblast-to-myofibroblast transition (FMT), a process linked to increased tissue mechanosensitivity and active extracellular matrix (ECM) remodeling. In this way, FMT participates in normal intestinal homeostasis and repair, but it can also contribute to fibrosis and tumor-associated stromal remodeling when sustained. More importantly, FMT is not a passive process but an active reprogramming event in response to physiological demands or pathological conditions. Its regulation is highly complicated by the temporal and spatial coordination of various intestinal cell types, ultimately determining disease onset and progression. In this context, targeting cellular interaction networks and remodeling the pathological microenvironment may provide opportunities to limit or redirect disease-associated stromal remodeling. In this review, we summarize the key intercellular dialogs that regulate FMT during the onset and progression of intestinal disorders and further analyze their regulatory mechanisms. Moreover, we discuss emerging therapies targeting cellular interaction networks to provide a new framework and research focus for treating inflammatory bowel disease (IBD), intestinal fibrosis, and related tumors.
中文摘要:成纤维细胞是肠道微环境的核心组成部分,可通过成纤维细胞向肌成纤维细胞转化(FMT)获得肌成纤维细胞表型,这一过程与组织机械敏感性增加和细胞外基质(ECM)主动重塑相关。通过这种方式,FMT参与正常肠道稳态与修复,但若持续存在,也可促进纤维化及肿瘤相关基质重塑。更重要的是,FMT并非被动过程,而是响应生理需求或病理条件的主动重编程事件。其调控因多种肠道细胞类型在时间和空间上的协调而高度复杂,最终决定疾病的发生与进展。在此背景下,靶向细胞相互作用网络并重塑病理微环境,可能为限制或重定向疾病相关基质重塑提供机会。在本综述中,我们总结了在肠道疾病发生和进展过程中调控FMT的关键细胞间对话,并进一步分析其调控机制。此外,我们讨论了靶向细胞相互作用网络的新兴疗法,为治疗炎症性肠病(IBD)、肠道纤维化及相关肿瘤提供新的框架和研究重点。
7肺癌 (8篇)
临床研究 (7篇)
Peripheral pulmonary lesions (PPLs) are difficult to access bronchoscopically due to their distal location. Although robotic, electromagnetic navigation, and fluoroscopy-guided systems have been developed, inconsistent study designs have limited direct comparison of their diagnostic performance. This study aimed to compare the diagnostic performance and lesion-specific advantages of robotic bronchoscopy system (RBS), electromagnetic navigation bronchoscopy(ENB), and fluoroscopy bronchoscopy(FB) for PPLs. In this multicenter, prospective, parallel-controlled trial, consecutive patients with suspected PPLs from 7 centers were assigned to the RBS, ENB or FB groups according to a predefined cyclic sequence for biopsy between 2019 and 2023. Subgroup analyses of diagnostic yield were performed according to lesion characteristics. Machine-learning models and a web-based platform were developed for clinical evaluation. A total of 270 patients were included, with 90 patients in each group. RBS achieved a higher overall diagnostic yield than ENB and FB (87.8%, 83.3% and 63.3%, respectively; P < 0.001). Strict diagnostic yield was also highest in the RBS group (81.1% vs 61.1% and 47.8%; P < 0.001). In the subgroup analysis, RBS performed better for 15-30 mm lesions and lesions within 15 mm of the pleura (P < 0.005), whereas ENB showed a diagnostic yield comparable to RBS for malignant, larger and solid lesions. Navigation and biopsy success rates in the RBS group were 100%, with more precise trajectories and lower displacement than the other two techniques (P < 0.001). Based on lesion characteristics, internally developed models (all AUC > 0.96) were integrated into a visualization platform to estimate the technique-specific diagnostic success for individualized PPLs. This multicenter study demonstrates that RBS, ENB and FB have distinct diagnostic advantages across different PPL subgroups. RBS showed better diagnostic performance in selected challenging lesions, whereas ENB achieved comparable performance in malignant, solid, or larger lesions. The image-based prediction platforms may further support individualized selection of transbronchial navigation strategies for PPL or lung cancer diagnosis.
中文摘要:周围型肺病变(PPLs)因其位置偏远,经支气管镜难以到达。尽管机器人、电磁导航和透视引导系统已得到发展,但研究设计不一致限制了对其诊断效能的直接比较。本研究旨在比较机器人支气管镜系统(RBS)、电磁导航支气管镜(ENB)和透视支气管镜(FB)对PPLs的诊断效能及病灶特异性优势。在这项多中心、前瞻性、平行对照试验中,2019年至2023年间,来自7个中心的连续疑似PPLs患者按预定义循环顺序分配至RBS、ENB或FB组接受活检。根据病灶特征进行了诊断率亚组分析。开发了机器学习模型和基于网络的平台用于临床评估。共纳入270例患者,每组90例。RBS的总体诊断率高于ENB和FB(分别为87.8%、83.3%和63.3%;P < 0.001)。严格诊断率在RBS组也最高(81.1% vs 61.1%和47.8%;P < 0.001)。在亚组分析中,RBS对15-30 mm病灶及距胸膜15 mm以内的病灶表现更好(P < 0.005),而ENB对恶性、较大和实性病灶的诊断率与RBS相当。RBS组的导航和活检成功率均为100%,且轨迹比另外两种技术更精确、位移更小(P < 0.001)。基于病灶特征,将内部开发的模型(所有AUC > 0.96)整合到可视化平台中,以估计个体化PPLs的特定技术诊断成功可能性。这项多中心研究表明,RBS、ENB和FB在不同PPL亚组中具有不同的诊断优势。RBS在选定的挑战性病灶中表现出更好的诊断效能,而ENB在恶性、实性或较大病灶中达到相当的诊断效能。基于影像的预测平台可能进一步支持为PPL或肺癌诊断个体化选择经支气管导航策略。
The phase III ADVANCE study prospectively assessed a chemotherapy-free strategy combining aumolertinib with definitive radiotherapy (RT) in patients with unresectable stage III non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations (ChiCTR.org: ChiCTR2000040590). Participants were assigned in a 1:1 ratio to either the experimental arm (110 mg daily aulomertinib plus RT) or the control arm (cisplatin/pemetrexed with RT). The primary endpoint was progression-free survival (PFS). Planned enrollment was 98 patients to detect a hazard ratio (HR) of 0.5. A protocol-prespecified real-world cohort (n = 125) was used for validation. 43 eligible patients were randomized (24 experimental, 19 control). The trial was terminated early following the prespecified interim analysis because of loss of equipoise in an open-label setting, slow accrual, and a large observed PFS difference. At a median follow-up of 25.5 months, the experimental arm had significantly longer PFS (median 34.0 vs. 7.4 months; HR 0.15; P < 0.001). Median overall survival (OS) was not reached vs. 30.5 months (HR = 0.32; P = 0.09). Neutropenia and nausea were more frequent in the control arm; quality of life favored the experimental arm. These findings were supported by real-world validation (n = 125, median follow-up 32.7 months), in which EGFR tyrosine kinase inhibitors (TKIs) + RT and TKIs+cCRT showed similar outcomes, both superior to cCRT (P < 0.001) (ClinicalTrials.gov: NCT04304638). The ADVANCE trial establishes a novel chemo-free strategy incorporating TKI and RT, which prolongs PFS and demonstrates promising OS in unresectable stage III EGFR-mutant NSCLC versus cCRT.
中文摘要:III期ADVANCE研究前瞻性评估了在携带表皮生长因子受体(EGFR)突变、不可切除的III期非小细胞肺癌(NSCLC)患者中,将阿美替尼与根治性放疗(RT)联合的无化疗策略(ChiCTR.org:ChiCTR2000040590)。受试者按1:1比例分配至试验组(阿美替尼110 mg每日一次联合RT)或对照组(顺铂/培美曲塞联合RT)。主要终点为无进展生存期(PFS)。计划入组98例患者,以检测风险比(HR)为0.5的差异。方案预设的真实世界队列(n=125)用于验证。43例符合条件患者被随机分组(试验组24例,对照组19例)。因开放标签环境下均势丧失、入组缓慢以及观察到的PFS差异较大,该试验在预设中期分析后提前终止。中位随访25.5个月时,试验组PFS显著更长(中位34.0个月 vs. 7.4个月;HR 0.15;P<0.001)。中位总生存期(OS)未达到 vs. 30.5个月(HR=0.32;P=0.09)。中性粒细胞减少和恶心在对照组更常见;生活质量以试验组更优。这些发现得到真实世界验证(n=125,中位随访32.7个月)的支持,其中EGFR酪氨酸激酶抑制剂(TKIs)+RT与TKIs+同步化放疗(cCRT)显示出相似结局,两者均优于cCRT(P<0.001)(ClinicalTrials.gov:NCT04304638)。ADVANCE试验确立了一种结合TKI与RT的新型无化疗策略,与cCRT相比,该策略在不可切除的III期EGFR突变NSCLC中延长了PFS并显示出有前景的OS。
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, but can cause serious immune-related adverse events, with pneumonitis (ICI-P) being among the most severe. Early identification of high-risk patients before ICI initiation is critical for close monitoring, timely intervention, and optimizing outcomes. To develop and validate a deep learning foundation model to predict ICI-P from baseline CT scans in patients with lung cancer. We designed the Checkpoint-Inhibitor Pneumonitis Hazard EstimatoR (CIPHER), a deep learning-powered foundation model combining contrastive learning with a transformer-based masked autoencoder to predict ICI-P from baseline CT scans in patients with lung cancer. Using self-supervised learning, CIPHER was pretrained on 590,284 CT slices from 2,500 patients with non-small cell lung cancer (NSCLC) to learn representations of heterogeneous lung parenchyma. Following pretraining, CIPHER was adapted to the internal MD Anderson Cancer Center NSCLC immunotherapy cohort of 347 patients, of whom 33 developed adjudicated ICI-P. Fine-tuning was performed using 254 non-ICI-P patients only, and a held-out internal validation set of 93 patients, including 33 ICI-P cases and 60 non-ICI-P controls, was reserved for evaluation. CIPHER was benchmarked against clinical, radiomics, and ensemble comparator models and externally validated in an independent Johns Hopkins NSCLC cohort of 116 patients, including 20 ICI-P cases and 96 non-ICI-P controls. In our internal immunotherapy cohort, CIPHER consistently distinguished patients at elevated risk of ICI-P from those without the event, with area under the curves (AUCs) ranging from 0.77 to 0.85. In head-to-head benchmarking, CIPHER achieved an AUC of 0.83, outperforming the clinical, radiomics and ensemble models. In the external validation cohort, CIPHER maintained high performance (AUC=0.83; balanced accuracy=81.7%), exceeding the radiomics model (DeLong p=0.0318) and demonstrating superior specificity without sacrificing sensitivity. By contrast, the radiomics model, despite high sensitivity (85.0%), showed markedly lower specificity (45.8%). Confusion matrix analyses confirmed CIPHER's robust classification, correctly identifying 80 of 96 non-ICI-P cases and 16 of 20 ICI-P cases. We developed and externally validated CIPHER, a CT-based imaging biomarker for pretreatment ICI-P risk stratification in NSCLC. CIPHER shows promise as a non-invasive tool for ICI-P risk assessment but warrants prospective validation before clinical translation.
中文摘要:免疫检查点抑制剂(ICI)已革新肿瘤治疗,但可引起严重的免疫相关不良事件,其中肺炎(ICI-P)是最严重的事件之一。在开始ICI治疗前早期识别高风险患者,对于密切监测、及时干预和优化结局至关重要。为开发和验证一种深度学习基础模型,以根据肺癌患者的基线CT扫描预测ICI-P。我们设计了Checkpoint-Inhibitor Pneumonitis Hazard EstimatoR(CIPHER),这是一种由深度学习驱动的基础模型,将对比学习与基于Transformer的掩码自编码器相结合,以根据肺癌患者的基线CT扫描预测ICI-P。通过自监督学习,CIPHER在来自2500例非小细胞肺癌(NSCLC)患者的590284张CT切片上进行预训练,以学习异质性肺实质的表征。预训练后,CIPHER在MD Anderson癌症中心347例NSCLC免疫治疗患者的内部队列中进行适配,其中33例发生经判定的ICI-P。微调仅使用254例非ICI-P患者进行,并保留一个由93例患者组成的内部门验证集用于评估,其中包括33例ICI-P病例和60例非ICI-P对照。CIPHER与临床、放射组学和集成对照模型进行了基准比较,并在一个独立的Johns Hopkins NSCLC外部队列中进行了外部验证,该队列包括116例患者,其中20例ICI-P病例和96例非ICI-P对照。在我们的内部免疫治疗队列中,CIPHER一致地区分出ICI-P风险升高的患者与未发生该事件的患者,曲线下面积(AUC)范围为0.77至0.85。在头对头基准比较中,CIPHER达到AUC 0.83,优于临床、放射组学和集成模型。在外部验证队列中,CIPHER保持高性能(AUC=0.83;平衡准确率=81.7%),超过放射组学模型(DeLong p=0.0318),并在不牺牲灵敏度的情况下表现出更优的特异度。相比之下,放射组学模型尽管灵敏度高(85.0%),但特异度明显较低(45.8%)。混淆矩阵分析证实CIPHER分类稳健,正确识别出96例非ICI-P病例中的80例和20例ICI-P病例中的16例。我们开发并对CIPHER进行了外部验证,CIPHER是一种基于CT的影像生物标志物,用于NSCLC治疗前ICI-P风险分层。CIPHER有望作为ICI-P风险评估的无创工具,但在临床转化前仍需前瞻性验证。
Presented at the 2026 World Conference on Lung Cancer, two phase III trials-PAPILLON and REZILIENT3-established amivantamab and zipalertinib combination therapies as effective first-line strategies for advanced NSCLC with EGFR exon 20 insertions, with significantly improved progression-free survival, although high crossover rates prevented them demonstrating an overall survival benefit. Separately, HARMONi-2 showed that the bispecific antibody ivonescimab improved overall survival versus pembrolizumab in PD-L1-positive NSCLC, supporting its use as standard of care in China while larger global trials continue.
中文摘要:在2026年世界肺癌大会上公布的两项III期试验——PAPILLON与REZILIENT3——确立了amivantamab与zipalertinib联合疗法作为EGFR外显子20插入突变晚期非小细胞肺癌有效的一线治疗策略,显著改善了无进展生存期,但因交叉率较高而未能显示总生存获益。另外,HARMONi-2研究显示,双特异性抗体ivonescimab在PD-L1阳性非小细胞肺癌中较帕博利珠单抗改善了总生存,支持其在中国作为标准治疗使用,而更大规模的全球性试验仍在继续。
Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) is recommended for patients receiving chemotherapy with a high risk of febrile neutropenia (FN), but its use remains suboptimal in patients receiving intermediate-risk regimens who have additional risk factors, for whom secondary prophylaxis (SPx) is commonly used despite limited prospective evidence comparing the two approaches. This study evaluated efbemalenograstim alfa (EFBGα), a novel Fc fusion G-CSF, as primary or secondary prophylaxis for chemotherapy-induced neutropenia (CIN) in patients with non-small-cell lung cancer (NSCLC) receiving intermediate-risk FN regimens who have additional risk factors. This multicenter, randomized phase II trial enrolled chemotherapy-naïve patients with stage IIIB/IV NSCLC scheduled for platinum-taxane chemotherapy. Patients were randomized 2:1 to either primary prophylaxis (EFBGα 20 mg at 48 ± 4 h after each cycle) or secondary prophylaxis (given only after grade 3-4 neutropenia). The primary endpoint was the cycle 1 incidence of grade 3-4 neutropenia. A total of 102 patients were enrolled between February 2024 and December 2025, of whom 96 were included in the analysis: 63 in the primary prophylaxis group and 33 in the secondary prophylaxis group. In cycle 1, the incidence of grade 3-4 neutropenia was lower with primary prophylaxis than with secondary prophylaxis [20.6%, 95% confidence interval (CI) 11.5%-32.7% vs. 57.6%, 95% CI 39.2%-74.5%; risk difference -36.9%, 95% CI -52.4% to -16.1%; P < 0.001]. The median duration of grade 3-4 neutropenia was comparable between the groups (P = 0.144). Cycle 1 FN incidence was 1.6% in the primary and 6.1% in the secondary prophylaxis group. Treatment-related adverse events were mostly grade 1-2, with pain-related events (7.0%) being the most common. EFBGα exhibited promising efficacy and tolerability for CIN prophylaxis in patients with NSCLC and additional risk factors who are receiving intermediate-risk chemotherapy (IRC). The results support its use in both primary and secondary prophylactic strategies, and earlier initiation was associated with better CIN control.
中文摘要:对于接受发热性中性粒细胞减少症(FN)高风险化疗的患者,推荐使用粒细胞集落刺激因子(G-CSF)进行一级预防,但在接受中危方案且具有其他危险因素的患者中,其使用仍不理想;尽管比较两种方法的前瞻性证据有限,这些患者常接受二级预防(SPx)。本研究评估了efbemalenograstim alfa(EFBGα),一种新型Fc融合G-CSF,在接受中危FN方案且具有其他危险因素的非小细胞肺癌(NSCLC)患者中,作为化疗引起的中性粒细胞减少症(CIN)一级或二级预防的作用。这项多中心、随机II期试验入组了计划接受铂类-紫杉烷化疗的初治IIIB/IV期NSCLC患者。患者按2:1随机分配至一级预防(每周期后48±4小时给予EFBGα 20 mg)或二级预防(仅在发生3-4级中性粒细胞减少后给予)。主要终点是第1周期3-4级中性粒细胞减少的发生率。2024年2月至2025年12月共入组102例患者,其中96例纳入分析:一级预防组63例,二级预防组33例。在第1周期,一级预防组3-4级中性粒细胞减少的发生率低于二级预防组[20.6%,95%置信区间(CI)11.5%-32.7% vs. 57.6%,95% CI 39.2%-74.5%;风险差-36.9%,95% CI -52.4%至-16.1%;P < 0.001]。两组3-4级中性粒细胞减少的中位持续时间相当(P = 0.144)。第1周期FN发生率在一级预防组为1.6%,二级预防组为6.1%。治疗相关不良事件大多为1-2级,其中疼痛相关事件(7.0%)最常见。EFBGα在接受中危化疗(IRC)且具有其他危险因素的NSCLC患者中用于CIN预防显示出有希望的疗效和耐受性。结果支持其用于一级和二级预防策略,且更早开始与更好的CIN控制相关。
Serological detection of lung cancer biomarkers is critical for early diagnosis. However, existing technologies often lack the sensitivity required for clinical applications. Here, we report a fluorescence electrochemical impedance microscopy (F-EIM), a biosensor based on monolayer WS2, which is a label-free imaging technique that provides an ultrasensitive platform for detecting lung cancer biomarkers in complex clinical serum samples of patients. This unique approach enables optical imaging of the local surface charge distribution of atomically thin materials. As a proof of concept, leveraging the charge-sensitive fluorescence of monolayer WS2, the F-EIM biosensor successfully detects small-cell lung cancer biomarkers, including carcinoembryonic antigen (CEA), progastrin-releasing peptide (ProGRP), and neuron-specific enolase (NSE), with limits of detection of 2.16-7.04 ✕10-16 mg/mL. Clinical serological tests with 30 clinical samples confirmed the platform's high sensitivity and specificity. This rapid, highly sensitive, and accurate F-EIM biosensor holds significant promise as a point-of-care diagnostic tool, offering a practical solution to current challenges in cancer detection.
中文摘要:肺癌生物标志物的血清学检测对于早期诊断至关重要。然而,现有技术往往缺乏临床应用所需的灵敏度。在此,我们报道了一种基于单层WS2的荧光电化学阻抗显微镜(F-EIM)生物传感器,这是一种无标记成像技术,为检测患者复杂临床血清样本中的肺癌生物标志物提供了超灵敏平台。这一独特方法能够对原子级薄材料的局部表面电荷分布进行光学成像。作为概念验证,利用单层WS2的电荷敏感荧光,F-EIM生物传感器成功检测了小细胞肺癌生物标志物,包括癌胚抗原(CEA)、胃泌素释放肽前体(ProGRP)和神经元特异性烯醇化酶(NSE),检测限为2.16-7.04×10^-16 mg/mL。使用30份临床样本进行的临床血清学检测证实了该平台的高灵敏度和高特异性。这种快速、高灵敏且准确的F-EIM生物传感器有望成为即时诊断工具,为当前癌症检测中的挑战提供实用解决方案。
A rare inherited EGFR mutation took root in Southern Appalachia after being carried to the United States by European settlers in the 1700s. Mapping the distribution of this germline EGFRT790M variant could help clinicians identify people at elevated risk of lung cancer and target them for genetic testing and closer surveillance.
中文摘要:一种罕见的遗传性EGFR突变在18世纪由欧洲定居者带到美国后,在阿巴拉契亚南部扎根。绘制这种生殖系EGFR T790M变异的分布图,可帮助临床医生识别肺癌高风险人群,并将其作为基因检测和更密切监测的目标对象。
基础研究 (1篇)
In this issue of Cancer Cell, Ng et al. characterize and leverage cytotoxic γδ T cells in small cell lung cancer to overcome unsuccessful checkpoint blockade immunotherapy. Engaging Vδ2+ cells with a bispecific T cell engager (BiTE) bypasses the challenge of low MHC-I expression and ineffective CD8+ T cells.
中文摘要:在本期《Cancer Cell》中,Ng等人对小细胞肺癌中的细胞毒性γδ T细胞进行了表征并加以利用,以克服免疫检查点阻断免疫治疗未能成功的问题。通过双特异性T细胞衔接器(BiTE)招募Vδ2+细胞,绕过了MHC-I低表达以及CD8+ T细胞无效的难题。
8乳腺癌 (7篇)
临床研究 (3篇)
To systematically review and investigate the dose-response (DR) relationship of aerobic exercise (AE), resistance exercise (RE) and combined (COMB) exercise programmes on cancer-related fatigue, lean mass, physical function and muscle strength in women with breast cancer during and following primary treatment. Systematic review with DR network meta-analysis (DR-NMA; CRD42023491118). CINAHL, Embase, LILACS, PubMed, SciELO, SPORTDiscus and Web of Science were searched from inception to 10 January 2024, with an updated search in April 2025. Randomised controlled trials evaluating COMB, RE or AE in women with breast cancer on the four specified outcomes. 64 trials (n=5156) were included. COMB was the most effective modality for improving fatigue and lean mass, and RE was the most effective for improving physical function and muscle strength. The smallest effective doses of COMB associated with significant changes in fatigue (standardised mean differences (SMD) 0.23 (95% CI 0.18 to 0.28)) and lean mass (SMD 0.30 (95% CI 0.22 to 0.38)) were 18 and 11 metabolic equivalents per week (METs.min/week), respectively. For RE, about 7-8 METs.min/week produced significant improvements in physical function (SMD 0.23 (95% CI 0.15 to 0.30)) and strength (SMD 0.24 (95% CI 0.20 to 0.29)). Fatigue benefits (SMD 0.58 (95% CI 0.46 to 0.69)) plateaued at ~1428 METs.min/week for COMB, whereas no plateau was observed for lean mass or strength across the evaluated dose range, with effects increasing throughout the available dose range. COMB and RE were the most effective interventions across outcomes in women with breast cancer. Benefits for the outcomes assessed in this systematic review with DR-NMA were achieved with exercise doses as low as 10-40 min/week. CRD42023491118.
中文摘要:系统综述并探讨有氧运动(AE)、抗阻运动(RE)及联合运动(COMB)方案对乳腺癌女性在初始治疗期间及治疗后的癌因性疲乏、瘦体重、身体功能和肌肉力量的剂量-反应(DR)关系。系统综述与DR网状Meta分析(DR-NMA;CRD42023491118)。检索CINAHL、Embase、LILACS、PubMed、SciELO、SPORTDiscus和Web of Science,自建库至2024年1月10日,并于2025年4月更新检索。纳入评估COMB、RE或AE对乳腺癌女性上述四项结局的随机对照试验。共纳入64项试验(n=5156)。COMB是改善疲乏和瘦体重最有效的运动方式,RE是改善身体功能和肌肉力量最有效的运动方式。与疲乏(标准化均数差(SMD)0.23(95% CI 0.18至0.28))和瘦体重(SMD 0.30(95% CI 0.22至0.38))显著变化相关的最小有效COMB剂量分别为每周18和11代谢当量分钟(METs.min/week)。对于RE,约每周7-8 METs.min/week可使身体功能(SMD 0.23(95% CI 0.15至0.30))和力量(SMD 0.24(95% CI 0.20至0.29))显著改善。疲乏获益(SMD 0.58(95% CI 0.46至0.69))在COMB约1428 METs.min/week时达到平台期,而瘦体重或力量在评估剂量范围内未观察到平台期,效应在整个可用剂量范围内持续增加。COMB和RE是乳腺癌女性各项结局中最有效的干预措施。在本项采用DR-NMA的系统综述中,所评估结局的获益可在低至每周10-40分钟的运动剂量下实现。CRD42023491118。
This systematic review and meta-analysis included 34 studies encompassing 983 438 adult cancer survivors and evaluated the performance of both general-population and cancer-specific cardiovascular risk-prediction models across vascular events, cancer therapy-related cardiac dysfunction or heart failure, arrhythmias, and composite cardiovascular event outcomes. In total, 27 unique risk scores were assessed. Approximately one-third of model-outcome evaluations demonstrated acceptable-to-good discrimination, defined as an area under the curve of ≥0.70. Among general-population models, four risk scores demonstrated acceptable-to-good discrimination for vascular events, three models were acceptable for CTRCD/heart failure, and two models for arrhythmias. The New Zealand CVD score was the only composite outcome model with an AUC ≥0.70. Cancer-specific scores, such as HFA-ICOS and the Ezaz score, showed high specificity for selected outcomes and may support rule-in decisions, although their lower sensitivity limits use for ruling out risk of CTRCD/heart failure. In our subgroup analysis, model performance varied by cancer type, with more consistent discrimination in breast cancer cohorts and substantially poorer performance in survivors of haematologic malignancies, indicating limited transportability across cancer populations. In summary, these findings provide a comprehensive overview of available cardiovascular risk-prediction tools and may assist clinicians in selecting appropriate models for primary cardiovascular prevention in cancer survivors while highlighting the need for exposure-aware, externally validated models tailored to specific cancer populations.
中文摘要:这项系统综述和荟萃分析纳入34项研究、共983 438例成人癌症生存者,评估了普通人群和癌症特异性心血管风险预测模型在血管事件、癌症治疗相关心功能障碍或心力衰竭、心律失常以及复合心血管事件结局中的表现。共评估了27个独立风险评分。约三分之一的模型-结局评价显示出可接受至良好的区分度,定义为曲线下面积≥0.70。在普通人群模型中,有4个风险评分对血管事件表现出可接受至良好的区分度,3个模型对癌症治疗相关心功能障碍/心力衰竭可接受,2个模型对心律失常可接受。新西兰CVD评分是唯一一个曲线下面积≥0.70的复合结局模型。癌症特异性评分,如HFA-ICOS和Ezaz评分,对选定结局表现出高特异度,可能支持「纳入」决策,但其敏感度较低,限制了用于排除癌症治疗相关心功能障碍/心力衰竭风险。在我们的亚组分析中,模型表现因癌症类型而异,乳腺癌队列中的区分度更一致,而血液系统恶性肿瘤生存者中的表现显著较差,表明其在不同癌症人群间的可迁移性有限。总之,这些发现全面概述了可用的心血管风险预测工具,可能有助于临床医生为癌症生存者的心血管一级预防选择合适的模型,同时强调需要针对特定癌症人群、关注暴露因素并经过外部验证的模型。
The objective of this study was to define the relationships between the circulating proteome and metabolome with cardiac structure and function in patients with breast cancer receiving cardiotoxic therapies. Proteomics and metabolomics profiling was performed in a longitudinal, prospective cohort study of breast cancer patients receiving anthracyclines and/or trastuzumab, using the Olink Explore 3072 platform and rapid liquid chromatography-mass spectrometry, respectively. Multivariable linear mixed-effect models evaluated the contemporaneous (same visit) and lagged (subsequent visit) associations between repeated measures of individual proteins or metabolites with quantitative echocardiographic measures of cardiac structure [left ventricular (LV) mass and left atrial volume index] and function [LV ejection fraction (LVEF), longitudinal and circumferential strain, E/e', and ventricular-arterial coupling]. Cox regression and pathway enrichment analyses were conducted for biomarkers demonstrating significant associations with cardiac function. Across 547 breast cancer participants (median age 50 years), 203 unique proteins and 16 unique metabolites were significantly associated with measures of cardiac structure and function in contemporaneous and lagged analyses. Notably, cathepsin C was associated with LVEF [false discovery rate (FDR), P = .017], longitudinal strain (FDR, P = .046), left atrial volume index (FDR, P = .035), and incident cardiac dysfunction, defined by an LVEF decline ≥10% to <50% (hazard ratio .61, 95% confidence interval .41, .90). The 147 proteins associated with cardiac function were enriched in biological processes reflective of protein deubiquitination, protein modification by small protein removal, macromolecule catabolic processes, and global metabolic pathways. Individual metabolites significantly associated with cardiac function (LVEF, longitudinal strain) included n-acetylglutamine, aspartic acid, acetylasparagine, alanyl-alanine, and prolyl-glycine (FDR, P-value < .001), and belonged to amino acids and derivatives and peptides. These findings provide translational insights into cancer therapy-related cardiac dysfunction and remodelling and identify potential new biomarkers of cardiotoxicity. There is an important need for validation of these findings and a deeper understanding of the biology of these biomarkers.
中文摘要:本研究旨在明确接受心脏毒性治疗的乳腺癌患者中循环蛋白质组和代谢组与心脏结构和功能之间的关系。研究在一项前瞻性纵向队列中对接受蒽环类药物和/或曲妥珠单抗治疗的乳腺癌患者进行了蛋白质组学和代谢组学分析,分别使用Olink Explore 3072平台和快速液相色谱-质谱联用技术。采用多变量线性混合效应模型评估个体蛋白质或代谢物的重复测量值与心脏结构和功能的超声心动图定量指标之间的同期(同一次访视)和滞后(后续访视)关联;心脏结构指标包括左心室质量和左心房容积指数,功能指标包括左心室射血分数、纵向应变和圆周应变、E/e'以及心室-动脉耦联。对与心脏功能显著相关的生物标志物进行Cox回归和通路富集分析。在547名乳腺癌参与者(中位年龄50岁)中,203种独特蛋白质和16种独特代谢物在同期和滞后分析中与心脏结构和功能指标显著相关。值得注意的是,组织蛋白酶C与左心室射血分数(错误发现率,P = .017)、纵向应变(FDR,P = .046)、左心房容积指数(FDR,P = .035)以及新发心脏功能障碍相关;新发心脏功能障碍定义为左心室射血分数下降≥10%至<50%(风险比0.61,95%置信区间0.41,0.90)。与心脏功能相关的147种蛋白质富集于反映蛋白质去泛素化、通过小蛋白去除进行的蛋白质修饰、大分子分解代谢过程以及整体代谢通路的生物学过程。与心脏功能(左心室射血分数、纵向应变)显著相关的单个代谢物包括N-乙酰谷氨酰胺、天冬氨酸、乙酰天冬酰胺、丙氨酰-丙氨酸和脯氨酰-甘氨酸(FDR,P值< .001),属于氨基酸及其衍生物和肽类。这些发现为癌症治疗相关的心脏功能障碍和重构提供了转化见解,并确定了潜在的心脏毒性新生物标志物。十分有必要验证这些发现并更深入地理解这些生物标志物的生物学机制。
基础研究 (4篇)
Breast cancer progression to visceral organs such as the lung and liver is associated with poor prognosis. Yet, these organs have diverse cellular microenvironments that may differentially influence cancer cell behavior. Here, we show that breast cancer metastases differ in their capacity for secondary seeding: the liver fosters metastasis-promoting properties and boosts secondary spread, whereas the lung restricts these processes, favoring local growth. Using patient data and rapid autopsy tissues, mouse models with barcode-mediated tracing, niche-labeling technology, and single-cell analysis of tumor cells and their direct microenvironment, we dissect the cellular and molecular microenvironmental factors underlying this differential behavior. Mechanistically, we identify BMP2-producing endothelial cells as critical players within the liver metastatic niche, enhancing metastasis-to-metastasis dissemination. Targeting the BMP2 signaling axis suppresses secondary spread of liver-derived breast cancer lesions. Altogether, we reveal site-specific behavior of lung and liver metastases in breast cancer, highlighting microenvironmental mechanisms and therapeutic opportunities for intervention.
中文摘要:乳腺癌进展至肺和肝等内脏器官与不良预后相关。然而,这些器官具有多样的细胞微环境,可能对癌细胞行为产生不同影响。在此,我们表明乳腺癌转移灶的二次播散能力存在差异:肝脏促进转移促进性特性并增强二次播散,而肺则限制这些过程,更有利于局部生长。利用患者数据和快速尸检组织、条形码介导示踪的小鼠模型、微环境标记技术,以及对肿瘤细胞及其直接微环境的单细胞分析,我们剖析了导致这种差异行为的细胞和分子微环境因素。在机制上,我们发现产生BMP2的内皮细胞是肝脏转移微环境中的关键参与者,可增强转移至转移的播散。靶向BMP2信号轴可抑制肝源性乳腺癌病灶的二次播散。总之,我们揭示了乳腺癌中肺和肝转移的位点特异性行为,突出了微环境机制及干预的治疗机会。
Most Triple Negative Breast Cancers (TNBCs) are p53 mutant high-grade invasive ductal carcinomas with a basal-like transcriptional programme. A large proportion of TNBCs also have mutation signatures indicating defective homologous recombination (HR) DNA repair. While HR deficiency is mutagenic and oncogenic, it can also compromise cell fitness. Here, we show that BLBCs harbouring the recurrent 9p21.3-9p24 amplicon, and particularly those that are HR-defective, overexpress PUM3 (Pumilio RNA binding family member 3). PUM3 inhibition is also synthetic lethal in tumour cells that overexpress PUM3 including those that have BRCA1/BRCA2 defects. Mechanistically, PUM3 suppresses transcription-mediated replicative stress and R-loop accumulation, thereby preventing DNA damage that would normally require RAD51-mediated repair. Transcription/replication collisions are commonly resolved by topoisomerase TOP1; without PUM3, TOP1 DNA chromatin localisation is impaired, revealing one mechanism by which PUM3 limits replication stress. PUM3 is therefore required for the continued fitness of a BLBC subset, allowing tolerance of HR deficiency's deleterious effects.
中文摘要:大多数三阴性乳腺癌(TNBC)是p53突变的高级别浸润性导管癌,具有基底样转录程序。很大一部分TNBC还带有提示同源重组(HR)DNA修复缺陷的突变特征。HR缺陷虽具有致突变性和致癌性,但也会损害细胞适应性。本研究表明,携带复发性9p21.3-9p24扩增子的基底样乳腺癌(BLBC),尤其是其中HR缺陷者,过表达PUM3(Pumilio RNA结合家族成员3)。在过表达PUM3的肿瘤细胞(包括具有BRCA1/BRCA2缺陷者)中,抑制PUM3也表现出合成致死效应。从机制上看,PUM3抑制转录介导的复制应激和R环积聚,从而防止通常需要RAD51介导修复的DNA损伤。转录/复制冲突通常由拓扑异构酶TOP1解决;在缺乏PUM3的情况下,TOP1在DNA染色质上的定位受损,这揭示了PUM3限制复制应激的一种机制。因此,PUM3是BLBC某一亚群维持适应性的必需因子,使其能够耐受HR缺陷带来的有害效应。
Triple-negative breast cancer (TNBC) remains a formidable clinical challenge owing to its aggressive metastatic behavior and the absence of well-defined therapeutic molecular targets. Although photodynamic therapy (PDT) holds immense promise, its efficacy is often limited by the aggregation-caused quenching (ACQ) of conventional photosensitizers and the restricted tissue penetration of visible excitation light. To address these limitations, we developed DBC, an AIE-active photosensitizer featuring a highly twisted, sterically hindered molecular architecture. This structural design endows DBC with an exceptionally large two-photon absorption (TPA) cross-section, enabling high-contrast deep-tissue imaging and efficient phototherapy under near-infrared (NIR) excitation. Consequently, DBC efficiently generates reactive oxygen species (ROS) through both Type I and Type II photochemical pathways, ensuring potent photodynamic activity under diverse microenvironmental conditions. Mechanistically, DBC preferentially localizes to the ER and mitochondria. Upon light irradiation, the localized ROS burst induces severe organelle stress and synergistically triggers PANoptosis, a hybrid programmed cell death pathway integrating apoptosis, necroptosis, and pyroptosis. Concurrently, mitochondrial damage and ER stress promote mitochondrial DNA leakage and immunogenic cell death (ICD), leading to the activation of the cGAS-STING innate immune signaling pathway. The resulting production of type I interferons and pro-inflammatory cytokines remodels the tumor microenvironment by converting immunologically "cold" tumors into "hot" tumors, thereby enhancing antitumor immune activation. Collectively, the coordinated induction of PANoptosis, ICD, and cGAS-STING signaling establishes a self-reinforcing antitumor immune response, ultimately eliciting robust local tumor eradication and systemic therapeutic efficacy against TNBC. STATEMENT OF SIGNIFICANCE: This study addresses triple-negative breast cancer (TNBC) treatment by developing a photosensitizer, DBC, with a multiple-twist molecular architecture. Unlike traditional agents limited by shallow light penetration and quenching aggregation, DBC features exceptional near-infrared two-photon absorption for precise, deep-tissue photodynamic therapy. Mechanistically, it targeted both the endoplasmic reticulum and mitochondria to trigger PANoptosis, a coordinated programmed cell death mode. Furthermore, DBC acts as a cGAS-STING agonist to remodel the tumor microenvironment, effectively converting "cold" tumors into "hot" immunogenic ones. These findings bridge photophysical molecular design with advanced tumor immunotherapy, offering broader readers an impactful paradigm for engineering multi-functional biomaterials to combat aggressive cancers.
中文摘要:三阴性乳腺癌(TNBC)因其侵袭性转移行为和缺乏明确治疗分子靶点,仍是严峻的临床挑战。尽管光动力治疗(PDT)具有巨大前景,但其疗效常受传统光敏剂聚集导致猝灭(ACQ)以及可见激发光组织穿透受限的制约。为解决这些局限,我们开发了DBC,一种具有高度扭曲、位阻化分子结构的聚集诱导发光(AIE)活性光敏剂。该结构设计赋予DBC异常大的双光子吸收(TPA)截面,使其能够在近红外(NIR)激发下实现高对比度深部组织成像和高效光治疗。因此,DBC可通过I型和II型光化学途径高效产生活性氧(ROS),确保在不同微环境条件下均具有强光动力活性。机制上,DBC优先定位于内质网和线粒体。光照后,局部ROS爆发诱导严重细胞器应激,并协同触发泛凋亡(PANoptosis),这是一种整合凋亡、坏死性凋亡和焦亡的混合程序性细胞死亡途径。同时,线粒体损伤和内质网应激促进线粒体DNA泄漏和免疫原性细胞死亡(ICD),从而激活cGAS-STING天然免疫信号通路。由此产生的I型干扰素和促炎细胞因子通过将免疫「冷」肿瘤转化为「热」肿瘤来重塑肿瘤微环境,进而增强抗肿瘤免疫激活。总体而言,泛凋亡、ICD和cGAS-STING信号的协同诱导建立了自我强化的抗肿瘤免疫应答,最终实现对TNBC的强效局部肿瘤清除和全身治疗疗效。意义声明:本研究通过开发具有多重扭曲分子结构的光敏剂DBC,针对三阴性乳腺癌(TNBC)治疗。与传统受限于浅表光穿透和猝灭聚集的制剂不同,DBC具有优异的近红外双光子吸收能力,可用于精准、深部组织光动力治疗。机制上,它同时靶向内质网和线粒体以触发泛凋亡这一协调的程序性细胞死亡模式。此外,DBC作为cGAS-STING激动剂重塑肿瘤微环境,有效将「冷」肿瘤转化为「热」免疫原性肿瘤。这些发现将光物理分子设计与先进肿瘤免疫治疗相连接,为更广泛读者提供了一个有影响力的范式,即工程化多功能生物材料以对抗侵袭性癌症。
Cigarette smoking and nicotine exposure promote breast cancer progression and poor outcomes by aberrantly activating nicotinic acetylcholine receptors (nAChRs), with α9-nAChR serving as a key oncogenic driver, especially in triple-negative breast cancer (TNBC). However, effective therapeutic strategies that directly target α9-nAChR remain limited. In this study, we engineered an antigen comprising the extracellular loops of α9-nAChR (α9CLP) and used mouse immunization followed by phage display to isolate an α9CLP-specific single-chain variable fragment (scFv) antibody, mCLPS1. The dominant clone mCLPS1 showed specific binding to α9-nAChR and was further engineered into an Fc-fusion antibody (mCLPS1-Fc) and an anti-mPEG bi-specific antibody (mCLPS1/anti-mPEG BsAb) to improve its affinity and therapeutic potential. The mCLPS1/anti-mPEG BsAb significantly enhanced the therapeutic efficacy of mPEGylated liposomal doxorubicin (LD) in targeting α9-nAChR-positive breast cancer. In TNBC patient-derived xenograft (PDX) models, mCLPS1-Fc markedly inhibited tumor growth, mitigated nicotine-induced tumor acceleration, and enhanced docetaxel's antitumor efficacy. Preliminary tolerability assessments of mCLPS1/anti-mPEG BsAb and mCLPS1 Fc antibody administration in non-human primates, cynomolgus macaque (Macaca fascicularis). did not reveal neuromuscular toxicity, myasthenia gravis-like symptoms, hematologic abnormalities, or overt organ injury within the observation period, supporting a favorable short-term tolerability profile under the tested conditions. In summary, this study identifies α9-nAChR as a key molecular target in nicotine-induced tumor progression and highlights α9-nAChR-specific antibodies as promising targeted therapeutic candidates for TNBC, particularly in patients with a history of nicotine exposure.
中文摘要:吸烟和尼古丁暴露通过异常激活烟碱性乙酰胆碱受体(nAChR)促进乳腺癌进展并导致不良预后,其中α9-nAChR是关键致癌驱动因子,在三阴性乳腺癌(TNBC)中尤为突出。然而,直接靶向α9-nAChR的有效治疗策略仍然有限。本研究构建了包含α9-nAChR胞外环的抗原(α9CLP),并采用小鼠免疫结合噬菌体展示技术分离出α9CLP特异性单链可变区抗体(scFv)mCLPS1。优势克隆mCLPS1显示出对α9-nAChR的特异性结合,随后被进一步改造为Fc融合抗体(mCLPS1-Fc)和抗mPEG双特异性抗体(mCLPS1/anti-mPEG BsAb),以提高其亲和力和治疗潜力。mCLPS1/anti-mPEG BsAb显著增强了mPEG化脂质体多柔比星(LD)靶向α9-nAChR阳性乳腺癌的治疗效果。在TNBC患者来源异种移植(PDX)模型中,mCLPS1-Fc明显抑制肿瘤生长,减轻尼古丁诱导的肿瘤加速生长,并增强多西他赛的抗肿瘤疗效。对mCLPS1/anti-mPEG BsAb和mCLPS1 Fc抗体在非人灵长类食蟹猴(Macaca fascicularis)中的给药进行初步耐受性评估,在观察期内未发现神经肌肉毒性、类重症肌无力症状、血液学异常或明显器官损伤,支持在所测试条件下具有良好的短期耐受性。总之,本研究确认α9-nAChR是尼古丁诱导肿瘤进展的关键分子靶点,并提示α9-nAChR特异性抗体是TNBC(尤其是有尼古丁暴露史的患者)有前景的靶向治疗候选药物。
9神经系统肿瘤 (4篇)
基础研究 (4篇)
Glioblastoma is the most common malignant primary intracranial tumor, characterized by high invasiveness, rapid progression, and poor sensitivity to radiotherapy and chemotherapy. Given the limited efficacy of current treatments, novel therapeutic strategies are urgently needed. Astrocytes play pivotal roles in glioma initiation and progression by promoting tumor proliferation, invasion, therapeutic resistance, and immune evasion. Reactive astrocytes are increasingly recognized as dynamic, heterogeneous cell states rather than fixed subtypes. This review discusses representative astrocyte programs linked to immune modulation, tumor support, and therapy response, including TRAIL-associated, STAT3/CHI3L1-related, and PDGFR-β-associated phenotypes. Furthermore, the study describes emerging astrocyte-targeted strategies, such as blocking pro-tumor cytokine signaling, disrupting astrocyte-glioma communication, inhibiting extracellular vesicle transfer, and modulating immunosuppressive astrocyte states. Targeting tumor-associated astrocytes may offer new strategies to counter glioblastoma progression, immune escape, and therapeutic resistance.
中文摘要:胶质母细胞瘤是最常见的恶性原发性颅内肿瘤,具有高侵袭性、快速进展以及对放化疗敏感性差的特点。鉴于当前治疗疗效有限,迫切需要新的治疗策略。星形胶质细胞通过促进肿瘤增殖、侵袭、治疗耐药和免疫逃逸,在胶质瘤的发生和进展中发挥关键作用。反应性星形胶质细胞日益被认为是一种动态、异质性的细胞状态,而非固定的亚型。本综述讨论了与免疫调节、肿瘤支持和治疗反应相关的代表性星形胶质细胞程序,包括TRAIL相关、STAT3/CHI3L1相关以及PDGFR-β相关表型。此外,本研究描述了新兴的靶向星形胶质细胞的策略,如阻断促肿瘤细胞因子信号传导、破坏星形胶质细胞与胶质瘤之间的通讯、抑制细胞外囊泡转移以及调节免疫抑制性星形胶质细胞状态。靶向肿瘤相关星形胶质细胞可能为对抗胶质母细胞瘤进展、免疫逃逸和治疗耐药提供新策略。
Diffuse intrinsic pontine glioma (DIPG) is a devastating pediatric brain tumor with limited treatment options. Emerging evidence indicates infiltration of tumor-associated macrophages (TAMs) within tumor sites, accompanied by an immunosuppressive tumor microenvironment (TME). However, the mechanisms underlying macrophage recruitment and communication between TAMs and other cellular compartments within brain tumors remain poorly understood. Bulk RNA sequencing of 26 DIPG autopsy specimens with matched normal brain tissue, single-cell RNA sequencing data from eight DIPG patients integrated with public pediatric high-grade glioma (pHGG) datasets, and in vitro transwell and flow cytometry assays collectively indicated that DIPG tumors actively recruit monocytes through chemokine-mediated mechanisms. The chemokine expression of tumor cells is driven by a mesenchymal-like (MES-like) lineage state rather than histone mutations, as evidenced by significant correlation between MES-like lineage scores and chemokine expression scores across 46 pHGG cell lines. CellChat analysis predicted APP-CD74 signaling as a prominent tumor cell-TAM interaction pathway, supported by immunofluorescence validation. Notably, APP expression was significantly reduced in DIPG tumor tissues compared with normal brain tissue at both the RNA and protein levels. Recombinant APP stimulation of THP-1-derived macrophages induced a robust proinflammatory response, including upregulation of M1-like markers, enrichment of interferon-related pathways, and elevated secretion of inflammatory cytokines. Collectively, these findings suggest that reduced APP expression in tumor may contribute to a non-inflammatory TAM phenotype and an immunosuppressive microenvironment. Furthermore, protein modeling and docking analyses identified the APP-CD74 binding interface, providing a structural basis for therapeutic targeting.
中文摘要:弥漫性内生性桥脑胶质瘤(DIPG)是一种治疗选择有限的毁灭性儿童脑肿瘤。新出现的证据表明,肿瘤部位存在肿瘤相关巨噬细胞(TAM)浸润,并伴随免疫抑制性肿瘤微环境(TME)。然而,脑肿瘤内巨噬细胞募集机制以及TAM与其他细胞区室之间的通讯仍知之甚少。对26例DIPG尸检标本及匹配的正常脑组织进行批量RNA测序、整合8例DIPG患者的单细胞RNA测序数据与公开的儿童高级别胶质瘤(pHGG)数据集,并结合体外Transwell和流式细胞术检测,共同表明DIPG肿瘤通过趋化因子介导的机制主动募集单核细胞。肿瘤细胞的趋化因子表达由间充质样(MES样)谱系状态驱动,而非组蛋白突变,46个pHGG细胞系中间充质样谱系评分与趋化因子表达评分之间的显著相关性证明了这一点。CellChat分析预测APP-CD74信号是一种突出的肿瘤细胞-TAM相互作用通路,并得到免疫荧光验证的支持。值得注意的是,与正常脑组织相比,DIPG肿瘤组织中APP在RNA和蛋白水平均显著降低。重组APP刺激THP-1来源的巨噬细胞可诱导强烈的促炎反应,包括M1样标志物上调、干扰素相关通路富集以及炎性细胞因子分泌升高。总体而言,这些发现提示,肿瘤中APP表达降低可能促成非炎性TAM表型和免疫抑制性微环境。此外,蛋白建模和对接分析识别了APP-CD74结合界面,为治疗靶向提供了结构基础。
Oligodendroglioma is a primary central nervous system tumor classified by the presence of isocitrate dehydrogenase (IDH) mutations and codeletion of 1p/19q. A lack of faithful preclinical model systems for this disease has limited progress in understanding the biology of this genetically unique subtype of adult diffuse-type glioma and in developing new effective therapies. To address this unmet need, we sought to establish a mouse model that faithfully recapitulates the genetic and phenotypic features of human IDH-mutant 1p/19q-codeleted oligodendroglioma. We performed in utero electroporation to introduce distinct combinations of genetic alterations and evaluated their potential to form tumors. Resulting tumors were characterized by histology, metabolite profiling, RNA-sequencing and single-cell RNA sequencing. We identified co-expression of IDH1R132H and PIK3CAE545K together with loss of Cic, Fubp1 and Cdkn2a (termed OligoCdkn2a) as the optimal genetic combination to drive fully penetrant tumors that histologically resemble human grade II/III IDH-mutant 1p/19q-codeleted oligodendroglioma. Substituting Cdkn2a loss with Trp53 deletion decreased latency and shifted tumors toward high-grade astrocytoma histology. OligoCdkn2a tumors displayed metabolic and transcriptional changes associated with IDH and CIC mutations, and single-cell sequencing identified a bias towards oligodendrocyte differentiation compared to an IDH wild-type glioblastoma mouse model. To our knowledge, OligoCdkn2a tumors represent the first autochthonous, genetically engineered mouse model to recapitulate the genetic, histological and transcriptional features of human IDH-mutant 1p/19q-codeleted oligodendrogliomas. This model will provide a valuable platform to further dissect mechanisms of tumorigenesis and test novel therapeutic strategies for this molecularly distinct glioma subtype.
中文摘要:少突胶质细胞瘤是一种原发性中枢神经系统肿瘤,其分类依据为存在异柠檬酸脱氢酶(IDH)突变和1p/19q共缺失。缺乏忠实地模拟该疾病的临床前模型系统,限制了在理解这一遗传学上独特的成人弥漫型胶质瘤亚型生物学以及开发新的有效疗法方面的进展。为解决这一未满足的需求,我们试图建立一个能够忠实再现人IDH突变型1p/19q共缺失少突胶质细胞瘤遗传和表型特征的小鼠模型。我们通过子宫内电穿孔引入不同的遗传改变组合,并评估其形成肿瘤的潜力。由此产生的肿瘤通过组织学、代谢物谱分析、RNA测序和单细胞RNA测序进行表征。我们发现IDH1R132H和PIK3CAE545K共表达,同时伴有Cic、Fubp1和Cdkn2a缺失(称为OligoCdkn2a),是驱动完全外显肿瘤的最佳遗传组合,这些肿瘤在组织学上类似于人II/III级IDH突变型1p/19q共缺失少突胶质细胞瘤。用Trp53缺失替代Cdkn2a缺失缩短了潜伏期,并使肿瘤向高级别星形细胞瘤组织学转变。OligoCdkn2a肿瘤显示出与IDH和CIC突变相关的代谢和转录改变,单细胞测序发现,与IDH野生型胶质母细胞瘤小鼠模型相比,其偏向少突胶质细胞分化。据我们所知,OligoCdkn2a肿瘤是首个能够再现人IDH突变型1p/19q共缺失少突胶质细胞瘤遗传、组织学和转录特征的自体发生基因工程小鼠模型。该模型将为进一步剖析肿瘤发生机制和测试针对这一分子上独特的胶质瘤亚型的新治疗策略提供宝贵平台。
Glioblastoma remains highly aggressive, with limited treatment response and poor prognosis. Tissue biopsy (TB) is invasive and fail to capture tumor heterogeneity or temporal dynamics. Liquid biopsy (LB) provides a noninvasive alternative for real-time monitoring via circulating biomarkers, including cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles (EVs) in plasma, cerebrospinal fluid (CSF), urine, and saliva. This review advances beyond prior biomarker catalogs by delivering a quantitative technology scorecard comparing cfDNA-, CTC-, and EV-based platforms in terms of sensitivity, clinical actionability, cost, and scalability. We introduce a multimodal decision matrix and an artificial intelligence (AI)-driven fusion pipeline integrating fragmentomics, EV proteomics, and CTC transcriptomics to enhance minimal residual disease detection and guide precision neuro-oncology.
中文摘要:胶质母细胞瘤仍然具有高度侵袭性,治疗反应有限且预后不良。组织活检(TB)具有侵入性,且无法捕捉肿瘤异质性或时间动态变化。液体活检(LB)通过循环生物标志物提供了一种非侵入性的实时监测替代方案,这些标志物包括血浆、脑脊液(CSF)、尿液和唾液中的游离DNA(cfDNA)、循环肿瘤DNA(ctDNA)、循环肿瘤细胞(CTCs)和细胞外囊泡(EVs)。本综述超越了以往生物标志物目录,提供了一个定量技术评分卡,从灵敏度、临床可操作性、成本和可扩展性方面比较基于cfDNA、CTC和EV的平台。我们引入了一个多模态决策矩阵和一个人工智能(AI)驱动的融合流程,整合片段组学、EV蛋白质组学和CTC转录组学,以增强微小残留病检测并指导精准神经肿瘤学。
10泌尿生殖肿瘤 (1篇)
基础研究 (1篇)
Herein, a novel noble-metal nanomaterial in the shape of a cracker (AuAgPt NTCs) was synthesized. The nanoparticles exhibit outstanding Surface-enhanced Raman spectroscopy (SERS) performance (enhancement factor: 1.09 × 107) due to the tip effect of the triangular structure and edge protrusion, and plasmonic coupling from its surface pores. Based on the excellent optical properties of AuAgPt NTCs and the dissociation of nanoparticles from magnetic beads induced by hyaluronidase (HAase) hydrolysis, a dual-mode biosensor for HAase detection was developed. In SERS mode, a tungsten disulfide film was used as the SERS substrate, enhancing the biosensor's SERS performance by approximately 45.6 ± 2.3% via chemical enhancement. SERS detection of HAase activity was achieved over the range 0.001 to 100 U·mL-1, with a limit of detection (LOD) of 0.0001 U·mL-1. In colorimetric mode, the protrusions on the edges and surface pores of the AuAgPt NTCs increase the effective interaction area between light and the nanoparticles, enhancing the extinction capacity of individual particles. Therefore, this biosensor achieves detection performance comparable to that of chemical catalytic methods without the use of chemical reagents. HAase activity was detected within the range of 10 to 100 U·mL-1, with an LOD of 3.9 U·mL-1. This greatly simplifies the workflow. Furthermore, an image analysis software (Bladder Guardian) was designed for rapid tiered screening of HAase activity, achieving an accuracy rate of 93.8 ± 2.6%. In summary, this study provides a novel tool for multidimensional detection of BC urinary biomarker HAase activity.
中文摘要:本文合成了一种新型饼干状贵金属纳米材料(AuAgPt NTCs)。由于三角形结构的尖端效应和边缘凸起,以及其表面孔产生的等离激元耦合,该纳米颗粒表现出优异的表面增强拉曼光谱(SERS)性能(增强因子:1.09 × 10^7)。基于AuAgPt NTCs优异的光学性质以及透明质酸酶(HAase)水解诱导纳米颗粒从磁珠上解离,研制了一种用于HAase检测的双模式生物传感器。在SERS模式中,采用二硫化钨薄膜作为SERS基底,通过化学增强使生物传感器的SERS性能提高约45.6 ± 2.3%。在0.001至100 U·mL-1范围内实现了对HAase活性的SERS检测,检出限(LOD)为0.0001 U·mL-1。在比色模式中,AuAgPt NTCs边缘的凸起和表面孔增加了光与纳米颗粒之间的有效相互作用面积,增强了个体颗粒的消光能力。因此,该生物传感器无需使用化学试剂即可达到与化学催化方法相当的检测性能。HAase活性检测范围为10至100 U·mL-1,LOD为3.9 U·mL-1。这大大简化了工作流程。此外,还设计了一款图像分析软件(Bladder Guardian),用于快速分层筛查HAase活性,准确率达到93.8 ± 2.6%。总之,本研究为多维检测膀胱癌(BC)尿液生物标志物HAase活性提供了一种新工具。
11其他 (4篇)
基础研究 (4篇)
Correction for 'Planar rotor-enabled quenching-resistant NIR-II fluorophores for high-contrast bioimaging and efficient cancer phototheranostics' by Weilong Chen et al., Mater. Horiz., 2026, 13, 6665-6678, https://doi.org/10.1039/d6mh00067c.
中文摘要:对Weilong Chen等人发表的「Planar rotor-enabled quenching-resistant NIR-II fluorophores for high-contrast bioimaging and efficient cancer phototheranostics」一文进行更正,Mater. Horiz., 2026, 13, 6665-6678, https://doi.org/10.1039/d6mh00067c。
The ATR-ATRIP complex regulates the DNA replication stress and is targeted in cancer therapy, but the molecular mechanisms of its activation and inhibition have remained unclear. Here, we present high-resolution cryo-electron microscopy structures of the human ATR-ATRIP complex in distinct functional states, including two ATPγS-bound precatalytic states, a Chk1-bound catalytic state, a TopBP1-bound activated catalytic state and four inhibitor-bound states with gartisertib, berzosertib, ceralasertib and elimusertib. These structures show that ATPγS binding alone can prime the ATR kinase catalytic center for catalysis and position Chk1 without major conformational rearrangements. TopBP1 engages the ATR-ATRIP HEAT-repeat scaffold to reorganize the dimer into a near-symmetric conformation that promotes ATR-ATRIP autophosphorylation and efficient Chk1 phosphorylation. Notably, the phosphorylated ATR-ATRIP complex remains active toward Chk1 after TopBP1 dissociation while adopting an asymmetric conformation, indicating that catalytic activity is compatible with both near-symmetric and asymmetric conformations. In addition, inhibitor-bound structures reveal how potent and selective ATR inhibition is achieved through multipocket engagement and exploitation of active-site conformational plasticity. Together, our findings provide a structural framework for understanding multiple routes of ATR activation and inhibition, offering insights for developing next-generation ATR-targeted cancer therapies.
中文摘要:ATR-ATRIP复合物调控DNA复制应激,是癌症治疗的靶点,但其激活和抑制的分子机制仍不清楚。在此,我们展示了人源ATR-ATRIP复合物在不同功能状态下的高分辨率冷冻电镜结构,包括两个结合ATPγS的预催化状态、一个结合Chk1的催化状态、一个结合TopBP1的激活催化状态,以及四个分别结合gartisertib、berzosertib、ceralasertib和elimusertib的抑制剂结合状态。这些结构显示,仅ATPγS结合即可使ATR激酶催化中心具备催化能力,并在无需重大构象重排的情况下定位Chk1。TopBP1与ATR-ATRIP的HEAT重复支架结合,使二聚体重组为近似对称的构象,从而促进ATR-ATRIP自磷酸化和高效的Chk1磷酸化。值得注意的是,在TopBP1解离后,磷酸化的ATR-ATRIP复合物仍对Chk1保持活性,同时采取不对称构象,表明催化活性与近似对称和不对称构象均相容。此外,抑制剂结合结构揭示了如何通过多口袋结合和利用活性位点构象可塑性实现强效且选择性的ATR抑制。总之,我们的发现为理解ATR激活和抑制的多种途径提供了结构框架,为开发下一代ATR靶向癌症疗法提供了见解。
Volume-regulated anion channels, which are activated in response to hypotonicity, are heteromers composed of LRRC8 family members. They consist of the obligatory subunit LRRC8A and at least another paralog that determines their substrate preference. Here we investigate heteromeric assemblies composed of LRRC8A and D subunits, the latter of which confer permeability to amino acids, osmolytes and anti-cancer drugs. Using patch-clamp electrophysiology, we show that LRRC8A/D channels are reversibly activated by cell swelling and that their response is modulated by sybodies targeting the A subunits, which either potentiate or repress channel activity. Structures of the LRRC8A/D channel in complex with the inhibitory sybody Sb1 define the channel stoichiometry of four A and two D subunits, with Sb1 stabilizing the A subunits in a similar closed channel conformation as found in homomeric LRRC8A assemblies. In LRRC8A/D heteromers, the two D subunits weaken the arrangement of A subunits and thus enhance the activation properties of the channel. This channel conformation is strongly perturbed upon binding of the potentiating sybody Sb4, which disrupts the packing of the cytoplasmic domains linking their mobility to pore opening.
中文摘要:容积调节性阴离子通道在低渗刺激下被激活,是由LRRC8家族成员组成的异聚体。它们由必需的亚基LRRC8A和至少另一种旁系同源亚基组成,后者决定其底物偏好。本研究探讨由LRRC8A和D亚基组成的异聚体组装,其中D亚基赋予通道对氨基酸、渗透质和抗癌药物的通透性。利用膜片钳电生理学,我们发现LRRC8A/D通道可被细胞肿胀可逆激活,并且其反应受靶向A亚基的sybody调节,这些sybody可增强或抑制通道活性。抑制性sybody Sb1与LRRC8A/D通道复合物的结构确定了通道的化学计量为四个A亚基和两个D亚基,其中Sb1将A亚基稳定在与同聚LRRC8A组装中发现的相似的闭合通道构象。在LRRC8A/D异聚体中,两个D亚基削弱A亚基的排列,从而增强通道的激活特性。当增强性sybody Sb4结合时,该通道构象受到强烈扰动,Sb4破坏胞质结构域的堆积,而这些结构域将其运动性与孔道开放联系起来。
The immune system balances protective immunity against pathogens with tolerance to self and selected foreign antigens. Emerging evidence identifies erythropoietin (EPO) as a systemic immunoregulatory signal that links physiological stress to immune adaptation. Beyond its canonical role in erythropoiesis, EPO-EPO receptor (EPOR) signaling reprograms specialized myeloid cells, including macrophages and type 1 conventional dendritic cells (cDC1s), promoting efferocytosis, inflammatory restraint, and maturation-associated cDC1 fate. Through these mechanisms, EPO shapes antigen-specific T-cell responses across transplantation and cancer. We propose that the EPO-EPOR axis functions as a systemic regulator of immune adaptation through myeloid-cellprogramming.
中文摘要:免疫系统在针对病原体的保护性免疫与对自身及所选外来抗原的耐受之间维持平衡。新出现的证据表明,促红细胞生成素(EPO)是一种系统性免疫调节信号,将生理应激与免疫适应联系起来。除了其在红细胞生成中的经典作用外,EPO-EPO受体(EPOR)信号可重编程特化的髓系细胞,包括巨噬细胞和1型经典树突状细胞(cDC1),促进胞葬作用、炎症抑制以及成熟相关的cDC1命运。通过这些机制,EPO在移植和癌症中塑造抗原特异性T细胞应答。我们提出,EPO-EPOR轴通过髓系细胞编程发挥免疫适应的系统性调节因子作用。